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I. Abstract 
Background: Tackling severe acute malnutrition (SAM) is a global health priority. Whilst SAM-
related mortality is well described, little is known about long-term effects on survivors. Given 
extensive evidence from developed countries that early nutritional insults have enduring 
detrimental effects, particularly heightened risk of non-communicable disease (NCD) in 
adulthood, it is plausible that SAM survivors could share some of these traits. Applying the 
DOHaD (Developmental Origins of Health and Disease) concept to a novel group, this study 
aimed to explore the long-term impacts of SAM on growth, body composition, and functional 
outcomes. 
 
Methods and Findings: From August 2013 to February 2014 I followed-up the 352/1024 
Malawian children who were still alive following SAM treatment in 2006-2007, comparing them 
to siblings and age/sex matched community controls. Compared to community controls, SAM-
survivors had significantly lower height-for-age z-score (HAZ) (-0.4, CI -0.2 to -0.6) and limb 
length (-2.0cm, CI -1.0 to -3.0) although there was evidence of some catch-up growth. They also 
had smaller mid-upper arm, calf and hip circumferences and less lean mass. Functional deficits 
included: weaker hand-grip (-1.68kg, CI -0.9 to -2.4) and fewer minutes completed of an exercise 
test (-1.59 minutes, CI -1.0 to -2.5). There was no statistically significant impact on lung function, 
skinfold thickness, sitting height and head circumference. 
 
Conclusions: These results show that there are long-term implications of an episode of SAM in 
the areas of growth, body composition, and physical function. Most notable are deficits in HAZ, 
lean mass, grip strength, and preservation of sitting height and head circumference at the expense 
of leg length, a pattern consistent with ‘thrifty growth’ which is associated with increased future 
cardiometabolic disease risk. Some catch-up of linear growth has occurred, suggesting that 
interventions post-“first 1000 days” could still be effective. Children who experienced SAM at an 
older age had greater detrimental effects, emphasising the need for early intervention and better 
prevention. Further follow-up is required to establish the full impact of puberty, and societal 
transition such as greater access to high fat/sugar diets. Intervention studies are also needed to 
determine whether earlier SAM treatment, improved post-SAM care such as nutrition 
supplementation and/or physical fitness interventions, could minimise or reverse some of these 
long-term effects.  
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Chapter 1: Introduction  
 
This chapter introduces severe acute malnutrition and some of the main concepts which justify my 
exploration of its potential long-term effects. I also introduce each of the four outcomes of interest 
for this PhD under individual subheading: growth, body composition, physical activity and lung 
function. The latter half of the chapter presents the scope of the study, the study hypotheses and 
the objectives.  
 
1.1 Background 
1.1.1 Severe Acute Malnutrition 
Undernutrition is a major public health problem in developing countries and is recognised as an 
underlying factor in 45% of all child deaths[1]. Undernutrition can be chronic, acute, moderate or 
severe. Severe Acute Malnutrition (SAM) specifically affects more than 19 million children under 
5 and causes more than 1 million child deaths each year[1, 2]. The diagnosis of malnutrition is 
based on measurement of body size (anthropometry) and clinical signs. SAM is currently defined 
as: 
• having a low weight-for-height (<-3 z scores of the WHO 2006 international growth 
standard) 
• or a low mid upper arm circumference (MUAC) (<115 mm) 
• or presence of oedematous malnutrition (also known as Kwashiorkor)[3].  
It is important to recognise that acute malnutrition is distinct from chronic malnutrition, which is 
defined as having a low height-for-age (<-3 z scores of the WHO standard) and is also known as 
stunting. 
SAM, previously known as “protein-energy malnutrition” and with a variety of changing case 
definitions, has always been associated with high mortality. The majority of SAM-related 
research and programming has therefore traditionally focused on preventing SAM deaths[4]. 
However, in the last decade important strides have been made in the battle to curb child mortality; 
major advances in treating SAM [5] as well as many other child health interventions and social 
changes, have contributed to reductions in child mortality from the 10.8 million deaths per year 
estimated by the first Lancet Child Survival Series in 2003[6] to 6.3 million in 2013[7]. Increases 
in child survival has led policy and programmes across many fields of child health to focus more 
on preserving the quality of life and maximising child development, as well as reducing 
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mortality[2, 8]. This same shift in focus has contributed to the creation of an international 
malnutrition movement called Scaling Up Nutrition (SUN) which aims to prevent the long-term 
and irreversible impacts of malnutrition on intellectual, physical and social development, as well 
as increase GDP (Gross Domestic Product)  in developing countries and reduce the burden on 
healthcare systems (http://scalingupnutrition.org/). These are all long-term and wider 
consequences of malnutrition, and much of the focus of the SUN campaign is on reducing 
stunting, known to have enduring detrimental effects. 
The long-term effects of an episode of acute malnutrition are far less explored and therefore not a 
current focus for policy makers and programme implementers. For example, neither the 
Millennium Development Goals (MDGs) nor the new Sustainable Development Goals (SDGs) 
mention mitigation of the long-term effects of SAM. The SDGs do however mention targets for 
reducing wasting, stunting, and addressing premature mortality from non-communicable diseases, 
all areas neglected by the MDGs[9]. With SAM research focusing on mortality reduction and 
research for improving long-term outcomes of malnutrition focusing on stunting, research 
considering the long-term outcomes of SAM has fallen through the gap between these two 
priorities. As global child mortality falls, the long-term effects of SAM are becoming increasingly 
important. A recent major campaign  called “Generation Nutrition” emphasises this need to look 
at “long term health effects” of SAM in point 8 of its10 point plan to end acute malnutrition[10]. 
For SAM programmes and policies to effectively achieve this, and in order to tackle all aspects of 
malnutrition, more evidence regarding the long-term effects of SAM is urgently needed.  
 
1.1.1.1 SAM Pathophysiology 
Understanding the pathophysiology of SAM is integral when considering the possible long-term 
consequences. SAM encompasses 2 related disorders: marasmus and kwashiorkor; it is also 
possible to have a combination of both known as marasmic-kwashiorkor. The term marasmus is 
derived from the Greek word marasmos, which means withering or wasting. The term 
kwashiorkor is taken from the Kwa language of Ghana and means "the sickness of the weaning” 
or “the deposed child”, first used by Williams in 1933[11]. Marasmus is characterised by a loss of 
muscle mass assessed by anthropometry; weight-for-height and mid-upper arm circumference 
(MUAC) are the measures currently recommended by the WHO[12]. MUAC as a independent 
measure of wasting has only been widely accepted relatively recently, following an expert 
meeting in 2005[3]. However MUAC has been utilised as a valid measure of wasting for some 
time; for example the QUAC (Quaker Arm Circumference) stick which was a measure of MUAC 
for height, was first used in Nigeria in the 1960’s[13]. Kwashiorkor is characterised by the 
presence of bilateral oedema starting at the feet and progressing up the body as severity increases. 
4 
	
It was previously thought that marasmus was the result of inadequate energy intake whereas 
kwashiorkor was the result of inadequate protein specifically[14]. However this has since been 
disproved as evidence has shown that children with kwashiorkor do not ingest any less protein 
than children with marasmus and oedema dissipates while children are being fed low protein 
diets[15, 16]. The exact difference between causes of marasmus vs kwashiorkor has yet to be 
elucidated. Prevalence of kwashiorkor is thought to be highest in central and southern Africa[17]; 
it is particularly high in Malawi where the majority of SAM cases present with oedema[18].   
 
In both marasmus and kwashiorkor normal physiology is disturbed by a process called ‘reductive 
adaptation’. This process involves catabolizing tissue reserves of carbohydrate, fat, and protein , 
and reducing activity of all physiological and metabolic body systems in order to adapt to a lack 
of nutrients[19]. Physical activity and growth are reduced and the basal metabolic rate is slowed. 
This process is initially beneficial, allowing maintenance of homeostasis though reduced energy 
demands however the resultant metabolic changes become progressively more dangerous[20]. 
The number and function of sodium-potassium (Na-K) pumps in cell membranes is reduced 
resulting in sodium leakage into cells and loss of potassium out of the cells and into the urine. The 
function of all the major organs is also impaired: the kidneys are less able to excrete the extra 
sodium; cardiac muscle is atrophied and hypokalaemia also contributes to reduced cardiac 
function. Glucose stores in the liver are depleted and gluconeogenesis impaired. Nutrient 
digestion and absorption is impaired by villous atrophy, minimized production of acid and 
enzymes, and decreased intestinal muscle function, which can compound the lack of nutrients 
available[19]. The immune and inflammatory systems also become impaired, resulting in 
vulnerability to infections; pneumonia, TB, enteric infections and malaria are common 
complications in SAM patients[20, 21].  
 
Understanding these changes in physiological function is very important in the management of 
SAM treatment; therapeutic decisions that are life-saving in a well-nourished child can be 
potentially fatal in a child with SAM. Due to the atrophied cardiac muscle and increase in body 
sodium, children with SAM are very sensitive to increases in circulatory volume. Their 
metabolism also cannot cope with high levels of protein whilst in a state of reductive adaptation 
hence feeding treatment must start with a low protein, low energy, and high micronutrient food. 
Children are not expected to gain weight until after metabolic equilibrium has been reobtained; 
this “stabilisation phase” is then followed by “recovery phase” where patients can be provided 
with high quantities of energy, protein and the right balance of macro and micronutrients to 
promote tissue growth and weight gain[20]. The WHO recommends “ten steps” within these 
phases in order to best manage children with SAM; steps one to six focus on managing the 
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changes in physiological function seem in SAM children: hypoglycaemia, hypothermia, 
dehydration, electrolyte imbalance, infection and micronutrient deficiencies[22]. The ‘reductive 
adaptation”, the concurrent infections and the treatment process could all have implications for 
long-term outcomes following SAM, particularly during a time of fast development such as the 
first few years of life.   
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1.1.1.2 Causes of SAM 
Understanding some of the causes of SAM may also have relevance to the possible resultant long-
term effects. The underlying causes can be complex, involving not only nutrition but other health 
factors, agriculture, seasonality, maternal health, culture and socioeconomic factors. Malnutrition, 
chronic and acute, may result from a combination of inadequate nutrient intake, increased losses 
(diarrhoeal episodes, vomiting) and increased energy expenditure (usually due to infections). 
Acute malnutrition often presents around the time of weaning (hence kwashiorkor translates as 
“weaning sickness”) because it is a critical period when breast milk no longer provides adequate 
calories for growth but weaning foods may be nutritionally incomplete and also a source of 
infection[19]. 
We now know that nutrition and infection have a cyclical relationship[23], both playing an 
important role in SAM. It is often difficult to determine the exact sequence of events in any one 
child as malnutrition and infection coexist with one increasing susceptibility to the other. Factors 
therefore that contribute to either poor diet and/or infection can be underlying causes of SAM. 
These factors can range from immediate causes such as diarrheal infection to high-level “basic” 
causes such as national resources and international economic structures, as described in the 
UNICEF conceptual framework (Figure 1).  
	
	
Figure 1: UNICEF conceptual framework for causes of undernutrition[24] 
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Besides the increased energy expenditure, anorexia and direct losses that accompany enteric 
infection, there is growing appreciations that these infections impair intestinal absorption which 
may be contributing to a substantial portion of global malnutrition[25]. The lumen of the 
gastrointestinal tract is lined by a single layer of cells: the epithelium. Malnutrition and diarrhoea 
result in damage to the lumen epithelial cells which can hamper absorption and makes them 
susceptible to infection; this can then lead to further malnutrition and enteric infections. This is 
thought to be another element to the infection-malnutrition cycle; it could also be an important 
consideration for SAM survivors who may have even poorer nutrient absorption than other 
children as a result. A recent high-profile study found evidence that gut microbiome of SAM 
survivors remain suboptimal or “immature”, even after full weight recovery[26]. The researchers 
suggested that these immature gut microbiomes may result in long-term implications such as	
stunted growth, cognitive delays, and weakened immune system.    
   
1.1.2 Early Life Nutrition and Long-term Health 
“The devil has put a penalty on all things we enjoy in life. Either we suffer in health or we 
suffer in soul or we get fat.”  - Albert Einstein 
As our understanding of SAM physiology and intestinal infections has increased, SAM treatment 
has improved resulting in a striking reduction of mortality among children with SAM[27]. Whilst 
the focus on nutrition research in developing countries has so far focused on how best to meet 
nutritional needs and bringing down mortality rates, nutrition research in developed countries has 
shifted to understanding the effects of nutrition on long term health. 
There is now a large evidence base linking early life nutrition and adult health, particularly non-
communicable diseases (NCDs) in adult life. Some of the earliest evidence linking nutrition and 
long-term health came from animal models, when in 1933 it was found that restricting diets of 
rats in early life resulted in increased life span[28]. The concept began to attract a lot more 
attention following the 1995 publication of a key theory based on human evidence linking low 
birth weight (LBW) and coronary heart disease in adulthood: Foetal Origins of Adult Disease 
hypothesis, also known as The Thrifty Phenotype hypothesis [29, 30]. LBW is most commonly 
defined as an infant weighing less than 2500g at birth[31]. The theory proposes that 
environmental factors in utero such as malnutrition can result in metabolic adaptations which may 
favour immediate survival but that program future propensity to adult diseases. Strong evidence 
now links early life nutrition to risk of diabetes, obesity, hypertension, dyslipidemia, 
cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD) and asthma[32, 
33]. The majority of this evidence focuses on prenatal nutrition, generally using LBW as a 
measure of prenatal undernutrition. There have however been a few acute historical famines 
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which have enabled researchers to link prenatal undernutrition with later health outcomes without 
the need to define malnutrition as LBW. 
1.1.2.1 Using “Natural experiments” to Link Early Nutrition to Later Health 
Studying historic famines in developed countries allows for retrospective cohorts diminishing the 
need to follow-up a group of individuals over many decades. These studies have tended to take 
place in developed countries where individuals are otherwise healthy and subsequently well-
nourished, reducing the number of confounding factors.  One key example of a “natural 
experiment” is the Dutch famine and its resultant studies. These studies used a cohort of adults 
known to be in utero during the time of the Dutch famine. This famine was specific in both timing 
and location as it resulted from a food shortage due to a blockade by Allied forces during World 
War II. Studies of this cohort have linked in-utero nutrition to impaired glucose tolerance, 
hypercholesterolaemia, raised blood pressure and obesity. These studies even allowed for analysis 
of the nutritional deficiency and resultant adult outcome to be linked to specific gestational 
periods[34]. 
Another key series of famine studies comes from those exposed to the siege of Leningrad by 
German troops, also during World War II. This siege lasted from September 1941 to January 
1944 resulting in an acute food shortage and severe malnutrition. It is estimated that the average 
daily ration per person during the most severe period of the siege was around 300 kilocalories and 
contained virtually no protein[35]. However, in contrast to results from the Dutch Famine, 
survivors of the siege of Leningrad exposed to famine either in utero or infancy did not have 
significantly different insulin concentration, fasting glucose, blood pressure, or concentration of 
lipids or coagulation factors than unexposed controls[35]. There was however evidence that 
endothelial damage was raised in the subjects exposed to intrauterine malnutrition. It has been 
suggested that these survivors were not affected in the same way as survivors of the Dutch 
Famine because they remained relatively poor and undernourished even after the siege had 
finished, whereas the Dutch Famine survivors quickly reverted to a higher socioeconomic state 
and were therefore exposed to a larger contrast in nutrition conditions[36].  
 
A third example of famine exposure and later health comes from the 1959–1961 Chinese Famine, 
the largest in human history. A number of interrelated factors including drought, industrialisation 
and the social structure of the “Great Leap Forward” resulting in decreased incentives for food 
production, and a delayed response to the food shortage by the authorities all contributed to the 
famine which caused millions of deaths[36]. Studies using extensive government health records 
have found that foetal exposure to the famine was associated with increased risks of overweight, 
schizophrenia and hyperglycaemia in adult life [36-38]. As well as foetal exposure, studies have 
considered the long-term outcomes of those exposed to the famine during early and late 
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childhood; results suggest that postnatal exposure during the first 3 years of life reduces adult 
height and increases adult BMI, risk of hypertension and possibly risk of hyperglycaemia[36, 38]. 
Evidence for the long-term impacts of postnatal nutritional insults may be most relevant for SAM 
survivors as the majority of SAM cases are between the ages of 18 months and 3 years.  
 
One final example, also very relevant as it is from an African context, is a study of those exposed 
to the famine in Biafra during the Nigerian civil war (1967–1970)[39]. Forty years later, this 
study found that foetal-infant exposure to this famine was associated with elevated BP, increased 
waist circumference, and increased risk of systolic hypertension, impaired glucose tolerance, and 
overweight, as compared to people born after the famine. Although the study did not have access 
birth weight data and was unable to separate the effects of foetal and infant famine, the results are 
highly suggestive of potential adverse consequences in SAM survivors across the continent.  
	
1.1.2.2 Postnatal Nutrition and Long-term Health 
Besides evidence from the Chinese Famine, there are some other examples of studies showing the 
long-term effects of postnatal nutrition. These include evidence of the protective benefits of 
breastfeeding and studies reporting the negative consequences of rapid weight gain in the first few 
months of life[40, 41]. In fact, some now argue that much of the detrimental effects of LBW 
could actually be attributed to the rapid postnatal catch up growth experienced by LBW 
infants[42]. As this evidence has widened the window of plasticity in which nutritional insults can 
occur, the theory previously known as the “foetal origins of adult disease” hypothesis  is now 
commonly known and accepted as the Developmental Origins of Health and Disease (DOHaD) 
theory[43]. Table 1 summarises the literature on human studies linking early nutritional insults to 
later health, highlighting not only the plethora of outcomes but the complexity of when, how, and 
what. The evidence linking rapid weight gain to detrimental adult health may also be relevant for 
SAM survivors who experience rapid weight gain during treatment. Rapid weight gain is 
currently used as a measure of SAM treatment performance but may not be consistent with 
optimal longer-term health outcomes. There is need for more evidence during SAM treatment 
regarding the type of weight gain undertaken at this time and resultant body composition changes. 
Although this study will not be able to decipher whether the undernutrition or the subsequent 
rapid weight gain is the cause of any adverse long-term outcomes, this is something which can be 
considered by future studies and could have great implications for how SAM is treated in the 
future.   
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Trait Influenced  
(Human studies only) 
Nature and Timing of nutritional 
insult/ nutrition choice  
Reference 
Cardiovascular risk (inc. 
Atherosclerosis) 
Prenatal growth retardation  
Rapid infant catch-up  
Formula-feeding 
Barker 1995[29]; Huxley 2007[44]; 
Forsen 1999[45]; Leon 1998[46]; 
Singhal 2004[47] & 2004[41] 
Hypertension  Prenatal growth retardation  
Rapid infant catch-up  
Formula-feeding 
Early postnatal diet quality 
Martin 2005[48]; Lawlor 2005[49]; 
Brion 2008[50]; Ekelund 2007[51]; 
Gennser 1988[52] Huang 2010 [38]  
Glucose intolerance/insulin 
sensitivity/ diabetes  
Prenatal growth retardation  
Rapid infant catch-up  
Formula-feeding 
Owen 2006[53]; Hales 1991[54];  
Ravelli 1998[55]; Soto 2003[56] 
Skeletal muscle development Prenatal micronutrient deficiency  Iannotti 2008[57] 
Cognitive Function Early postnatal diet quality 
SAM 
Smithers 2012[58]; Golley 2013[59]; 
Grantham-McGregor 1994[60] 
Obesity  Prenatal growth retardation  
Rapid infant catch-up  
Early postnatal diet quality 
Ravelli 1975[61] & 1999[62]; Lucas 
1999[42]; Singhal 2004[41]; Harder 
2005[63]; Schack-Nielsen 2010[64]; 
Owen 2005[65] 
Dyslipidaemia / HDL Cholesterol Prenatal growth retardation 
Rapid infant catch-up 
Formula-feeding 
Owen 2002[66]; Wells 2007[67]; 
Fagerberg 2004[68]; Singhal 2004[41] 
Endothelial dysfunction  Rapid infant catch-up Singhal 2004[47] 
BMI / Abdominal adiposity Prenatal growth retardation 
Rapid infant catch-up 
Early Postnatal diet quality 
Fagerberg 2004[68]; Ibanez 2008[69]; 
Kensara 2005[70]; Singhal 2010[71]; 
Meyerkort 2012[72] 
COPD / Asthma  Prenatal growth retardation Barker 1991[73]; Svanes 2010[74] 
Schizophrenia  Prenatal famine exposure  St Clair 2005[37]; Hoek 1998[75] 
Table 1: Summary of the evidence and references from human studies linking early nutritional insults to 
later health, including a list of long-term outcomes as well as the nature and timing of the insult/ choice 
	
1.1.2.3 Mechanisms and “The window of Plasticity” 
The mechanisms underlying DOHaD are currently not clear. Current theories include premature 
telomere shortening, disruption of organ function which affects hormone secretions, increases in 
the number or size of fat cells, alterations in adipose tissue function; and/or disturbances in 
regulation of appetite caused by central nervous system dysfunction [76]. Another theory is the 
“capacity-load” model which pins the mechanism on organ size and lean mass levels; if the 
growth of organs is hampered during early life and an individual gains weight in adulthood 
thereby increasing their metabolic load, their capacity is insufficient making them susceptible to 
NCDs[77]. The mechanisms have been difficult to define due to the long gap between exposure 
and outcome, with timing, the multitude of confounders, and selection bias making conclusions 
problematic [78]. Identification of the mechanism(s) controlling this link between early nutrition 
and adult health will likely aid in further defining the window of plasticity, explain how both low 
and high birthweight are associated with NCDs and finally help in designing interventions. We 
currently know that the “window of plasticity” starts in utero and continues into the first few 
months of life, and potentially beyond. Phenotypic plasticity is defined as the ability of a single 
genotype to produce more than one alternative form of morphology, physiological state, and/or 
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behaviour in response to environmental conditions[79]. The window for developmental 
phenotypic plasticity is finite; plant and animal studies have shown that the window for 
phenotypic adaption to the environment varies greatly across species and can either be very 
narrow or very wide[80, 81]. How large the window is in humans is not known; as humans are 
born at a relatively advanced state in development, it could be that phenotypic plasticity largely 
stops around early infancy and that the adaptions seen in LBW babies are not relevant to SAM 
children. However, we do know that a large portion of growth and development happens after 
birth; hence it could be that infants suffering from SAM are subject to phenotypic adaptation. This 
study aims to add evidence to DOHaD in a completely new patient group, as well as help to 
define the extent of the “window of plasticity” for DOHaD in human children. 
1.1.2.4 DOHaD in Developing Countries  
The study will also contribute to the currently limited evidence for DOHaD in developing 
countries, as the majority of studies in this area have so far been conducted in developed nations. 
The implications of DOHaD for developing countries are just beginning to be more widely 
discussed[82]. Nutrition research and interventions in developing countries have largely focused 
on preventing and treating undernutrition, which remains an important problem, however it is 
now becoming clear that NCDs are also of top priority for global public health. In 2008 80% of 
the 36 million deaths caused by CVD, diabetes, cancer and COPD occurred in low and middle-
income countries[83]. The effects of early life nutrition in developing countries with reference to 
NCDs in adulthood is therefore of high importance.  
Besides foetal and infant nutrition, there has been significant research in developing countries into 
the long-term effects of chronic undernutrition in childhood (stunting) on intellectual ability, 
economic productivity, reproductive health and some chronic diseases. However, again, the 
biological mechanisms behind these links are not clear and the complicated web of co-
determinants is difficult to unpick. Additionally, there is evidence that stunting and foetal 
nutrition are intertwined[84], so is it stunting which results in poor adult health and productivity? 
Or is this on the causal pathway of low birth weight and/or maternal undernutrition? This picture 
becomes even more complicated when considering the links between SAM and stunting. The 
relationship between weight-for-height and height-for-age are still not fully understood and the 
evidence so far has been inconsistent depending on the type of data being considered (i.e. 
population or individual level; cross-sectional or longitudinal)[85]. 
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1.1.3 Long-term Effects of SAM 
Few studies have explored the long-term effects of SAM specifically. One recent study conducted 
a literature review on the long-term outcomes of SAM patients and found eight existing 
papers[86]. Most of these studies followed-up children for between 6 and 18 months after 
discharge, including a paper which describes the one-year follow-up of the cohort being used in 
this study[87]. This initial follow-up of 1024 children admitted to “Moyo” Nutrition ward in 
Blantyre, Malawi in 2006 and 2007[88] found that 23% (238) died during the inpatient phase of 
treatment; a further 8% (84) died in the first 90 days following original admission; and at 1 year 
post-discharge only 45% were reliably reported to still be alive. The “FuSAM” 1 year follow-up 
also found that, using the NCHS 1978 growth reference, mean weight-for-age z-score (WAZ) was 
significantly lower for cases than sibling controls, as was mean height-for-age z-score (HAZ). 
Very few studies have gone on to follow up ex-SAM children for longer than 18 months, 
particularly using the current definitions of SAM and since the onset of the HIV pandemic [89, 
90]. One relatively recent study from India in 1999 followed up SAM survivors ranging from 1 
and 7 years post-discharge and compared their growth to that of their siblings. Interestingly, they 
found SAM-survivors to be in better health than their siblings which could be explained by 
“survivor bias”[91]. Survivor bias will also be an important consideration for this study as we 
already know that 42% (427/1024) of the case children had died by 1 year post-discharge. HIV 
will also be a pertinent consideration in this study as 49% (445/904) of the original case group 
were known to be HIV positive. The HIV positive group may also be particularly susceptible to 
survivor bias as of those children known to have died by 1 year post-discharge, 70% (298/427) 
were known to be HIV positive.  
The focus of malnutrition interventions and research in developing countries has very much been 
focused on children less than 2 years old, and this has been galvanised in the past few years by the 
“thousand days” concept which states that the optimal “window of opportunity” for preventing 
long-term consequences of malnutrition is in the first 1000 days of life (conception to 2 years) 
(www.thousanddays.org)[92]. This catchy concept has gained considerable political backing and 
investment. Some are concerned that the success of this campaign may have resulted in the view 
that interventions outside of this window are unlikely to have any effect[93]. There is some 
evidence that stunting can be partially or fully reversed during adolescence, and there is an effort 
being made to dub this the “second window of opportunity” lest it be forgotten[93, 94]. With 
regard to SAM, first the long-term effects need to be established in order to determine where the 
windows of opportunity for prevention and reversal might lie.  
Based on strong evidence, largely from developed countries, that nutrition in prenatal and early 
post-natal life can affect long-term health, particularly NCDs, it is conceivable that SAM may 
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have adverse long-term effects. NCDs are increasingly becoming a burden in developing 
countries, including Malawi, and it is thought that traditional risk factors, such as smoking, 
obesity, high salt intake, sedentary lifestyle and pollution, may not fully explain the rapid increase 
in the NCD epidemic and the early onset of disease in sub-Saharan Africa. Other unique factors 
specific to the region, such as high levels of child undernutrition, are now also thought to be 
important[95]. However there is currently no research to support this. This study is an exploratory 
start at filling this research gap.    
1.1.4 Study Outcomes: Growth, Body Composition, Physical Function and Lung Function 
1.1.4.1 Scope of the study  
Based on current evidence about DOHaD, the long term effects of SAM are likely to be changes 
in growth, body composition, and organ function and metabolism, which may contribute to an 
increased risk of NCDs in adulthood. As this is an exploratory study, it aimed to look at a large 
variety of potential adverse outcomes including some of the immediate changes as well as early 
risk signs for NCDs. However, every study must have its limits and my PhD also had to have 
limits. This PhD therefore focuses on the most fundamental long-term outcomes, namely growth 
and body composition, which enable a detailed description of the child’s current phenotype. I also 
wanted to take these outcomes one step further to consider if these were having an effect on the 
child’s everyday function, namely physical activity, muscle strength, physical capacity, and lung 
function. Both the phenotypic and functional outcomes all have potential implications for NCDs 
in adulthood, which was another important consideration. 
 
Beyond my PhD, the larger study that I was working on also considered various aspects of the 
other major body systems: lipid profile, endocrine function, cognitive function, and 
cardiovascular function. Each of these areas could be large studies in themselves; hence I decided 
to leave these out of my PhD as it would not be possible to adequately discuss them all. This 
study focused on whether there are long-term effects of SAM and what they might be, it did not 
intend to establish which mechanisms are responsible for these effects; that is the role of future 
research.  
The rest of this section explores some of the evidence specific to the long-term outcomes being 
assessed in this study (growth, body composition, physical function and lung function) and begins 
to make hypotheses based on this evidence, starting with growth.    
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1.1.4.2 Long-term Effects of Nutrition on Growth Outcomes 
Growth is an important determinant of both short- and long-term health and quality of life[84, 
96]. In 2006, Kerac et al. conducted a 1 year follow-up of SAM survivors discharged from the 
Nutrition Rehabilitation Unit (NRU) in Blantyre, Malawi, and found that not only had a large 
proportion (10%) of those discharged as cured since died, but the height-for-age of survivors 
remained very low. Mean HAZ of survivors was -3.37 (or -2.97 based on NCHS growth 
reference) compared to 2010 DHS mean HAZ -1.8 in Malawian children <5 [97, 98]. Stunting has 
known long-term adverse effects including reduced earning capacity, lower cognitive function 
and poor outcomes during child birth, as well as adverse inter-generational effects[84].The 
relationship between wasting and stunting is currently poorly understood; SAM is usually 
considered to be a short-term response to inadequate food or a result of acute infectious disease, 
whereas stunting is considered to be a gradual response to chronic poor diet or repeated 
infections[85, 99]. There is a large variety of conflicting results from cohort and cross-sectional 
studies exploring if and how much SAM contributes to stunting [100-105]. Findings from the 1 
year follow-up of this cohort suggested that SAM survivors are at greater risk of stunting in the 
short-term; I will explore the prevalence of stunting in SAM survivors 7 years post-discharge.  
 
Although stunting has known adverse outcomes, whether stunted children can reverse this 
affliction has also been studied with mixed results[103, 104]. Catch-up growth in children who 
remain in the same environment with minimal change in diet and prevalence of infections is 
thought to be difficult; infections can result in wasting as well as loss of linear growth, and 
insufficient food means there is little opportunity for catch-up [84, 94]. Two well-known cohort 
studies have presented conflicting evidence with regard to catch-up growth in stunted children; 
Adair et al., found stunted Filipino children were able to catch-up a significant amount of their 
HAZ by adolescence without intervention, whereas Martorell et al,. found that a Guatemalan 
cohort remained as stunted by late adolescence as they were in early childhood [103, 106]. More 
specific to this cohort, a study in India followed-up two groups of SAM survivors: those 
discharged 1-3 years ago and those discharged 5-7 years ago, and found large improvements in 
weight-for-age in both groups but only found improvements in height-for-age in those children 
discharged 5 -7 years ago[91]. This could therefore be true for our cohort, who exhibited no 
catch-up in HAZ by 1 year post-discharge but could have had some catch-up growth by 7 years 
post-discharge. Remarkably, the India follow-up study also found that weigh-for-height was 
actually lower in the sibling controls than SAM survivors; they hypothesised that this is due to 
survivor bias. Kerac at al., did not find this pattern at the 1 year follow-up[97], but it is something 
which needs to be kept in mind when interpreting the results of this follow-up. It is also worth 
mentioning the value of control groups in assessing both stunting and catch-up growth. Deficits or 
improvements in HAZ compared to a global reference could merely reflect changes in isolated 
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household or community environments whereas comparing HAZ and change in HAZ to local 
control groups allows for these factors and makes a stronger scientific argument for the specific 
influences of SAM.    
 
Another consideration is the age at which catch-up growth is likely to occur. The majority of our 
cohort were admitted with SAM when they were between 1 and 3 years old, and they are now 
between the ages of 8 and 11 years. Some cohort studies have concluded that although catch-up 
growth does not occur in childhood, it can occur in adolescence [93, 99, 107]. One study found 
that further growth faltering can occur throughout childhood [108]. Due to the large mixture of 
evidence, I conservatively hypothesise that SAM survivors will remain significantly more stunted 
than their sibling and community controls, and that their growth velocity between 1 year and 7 
years post-discharge will be similar to their sibling controls, not accelerated. In order for this 
group to catch-up to their community or family “norm” they would need to grow on a steeper 
growth trajectory. There is some evidence to suggest that this catch–up growth is more likely to 
occur in adolescence rather than in childhood. This is biologically plausible as most tissues, 
besides neuronal tissues, still have considerable growth and development to undergo between 24 
months and adulthood, particularly musculoskeletal tissue which, as a proportion of total growth, 
slows from ages 4 to 12 years, and then increases rapidly during adolescence (Figure 2)[93, 109].  
 
Besides linear growth, Figure 2 and other existing data suggest that SAM survivors will not have 
significantly different head circumference to controls as the majority of head growth has already 
occurred by the age of 2 years, before the SAM insult occurred in many. Additionally, based on 
Hales and Barker’s original “Thrifty Phenotype” hypothesis and the concept of “grow now, pay 
later”, core organ function and vital growth is preserved in times of limited resources at the 
expense of some less vital areas of growth and development. This suggests brain growth and head 
circumference are likely to be preserved in all but the most extreme cases of malnutrition, as 
evidence from LBW infants and undernourished children has shown [30, 40, 110, 111].  
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Figure 2: Differential timing of growth of major body systems from birth to 18 years in humans. Source:  
Prentice et al.[93] 
 
An area of “less vital” growth which may be compromised during a period of limited resources 
such as SAM is limb length. Human stature is made up of approximately 50% legs, and 50% 
trunk and head but there is existing evidence to suggest that early life insults may reduce leg 
length resulting in disproportioned bodies[112, 113]. There are several theories about exactly 
which tissues in the legs are affected and why. One theory states that the further from the heart the 
tissue, the less of a priority it is for growth[114, 115]. Another theory states that those tissues 
which grow the fastest are the most effected during an episode of illness or malnutrition and legs, 
especially the tibia, are growing the fastest in relation to other body segments between birth and 7 
years [112]. Leitch (1951) was the first to propose that a ratio of leg length to total stature could 
be a good indicator of early life nutrition [116]. Leg length has since been associated with length 
of breastfeeding, iodine deficiency, socioeconomic status and maternal smoking [117-122]. 
Having disproportionately shorter legs has also been found to have considerable consequences on 
adult health, such as higher risk of overweight, coronary heart disease, high blood pressure and 
diabetes [121, 123, 124]. Sitting height to height ratio has been found to be associated with 
overweight, coronary heart disease and diabetes in adulthood[121, 123]. In a developing county 
context, one study found that chronic undernutrition resulting in stunting did not result in 
disproportioned sitting height ratio[125]. This study therefore hypothesises that SAM survivors 
will have relatively shorter legs than control children due to the acute insult suffered by SAM 
survivors, opposed to the chronic undernutrition likely suffered by some controls.  
17 
	
1.1.4.3 Long-term Effects of Nutrition on Body Composition Outcomes 
Besides impacts of long-term growth, an insult such as malnutrition during a critical time in 
development can also result in altered body composition in later life[67]. The “Thrifty Phenotype” 
hypothesis (one theory under the relatively new “DOHaD” umbrella) postulates that if resources 
are limited during early development this induces an adaptive response which is protective at that 
time and increases chances of immediate survival. A now dated theory was that in most cases, 
after the insult had passed, survivors were exposed to adequate or excess resources, resulting in 
rapid catch-up growth and a mismatch of phenotypic adaption and actual environment[126, 127]. 
Although we now know that those exposed to poor nutrition in early life do worse in all adult 
environments, including famine[128], it may still hold true that the phenotypic adaptations which 
were protective in early life become a disadvantage later on. This may explain the strong evidence 
linking rapid catch-up growth following prenatal malnutrition with greater chances of obesity in 
both childhood and adulthood, as well as altered ratios of lean and fat mass[67, 129] however the 
exact mechanism for this is not currently known. Barker suggested that the adaptive phenotype 
during undernutrition favours fat storage, particularly on the core body where resources are 
needed for vital organ function and development, and this phenotype continues post-
malnutrition[29].  
Body composition is a measure of the amount and distribution of fat and fat-free mass in the 
body, as well as the body’s general size and shape. Not only the amount of fat, but the positioning 
of fat is of great importance to health, particularly NCDs in adulthood. Central fat on the waist 
and core body is detrimental to health, whereas peripheral fat on the hips and limbs is protective 
against some health problems [130-132]. Storage of fat on the core body can lead to an increase in 
fatty acids being released into the blood stream and therefore increased blood pressure, more 
insulin resistance and higher serum cholesterol. This also leads to an increased synthesis of 
triglycerides and very-low-density lipoprotein (VLDL) secretion by the liver, which is associated 
with CVD risk[133, 134]. The adverse effects of increased core fat storage may even be 
compounded for those with early undernutrition as organ and body size are likely to be smaller 
and therefore less able to cope with increased metabolic load. Metabolic load can be defined as 
the amount of tissue making demands on organs as well as things that challenge fuel homeostasis 
in other ways such as sedentary behaviour and smoking[67]. In other words, those with early 
nutritional insults are more likely to accumulate core fat due to phenotypic adaptions and are also 
more likely to have reduced “metabolic capacity” due to their smaller/damaged organs. This 
however does not explain the U-shaped relationship seen with birth weight and obesity where 
both low and high birth weights are associated with later obesity and subsequent NCDs[135].      
So far, evidence has been found linking an increased proportion of core body fat and related 
NCDs to both prenatal and postnatal nutritional insults; namely LBW, preterm births, rapid 
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weight gain in infancy, and formula milk feeding. This study aims to assess whether SAM in 
childhood can also be added to the list of early nutritional insults which affect later body 
composition. I hypothesise that SAM survivors will have less peripheral fat and more central 
adiposity than community and sibling controls. I do not expect cases or controls to have large 
amounts of fat as the majority are known to come from very low socioeconomic environments, 
however evidence shows that a person does not need to have a lot of fat to suffer the adverse 
consequences of altered body composition[136]. India has the highest incidence of diabetes in the 
world, and Indian diabetic patients have been described as “thin but fat”, meaning they are thin 
because they have low BMI, short height for age and low levels of lean mass, but fat because they 
have higher waist hip ratios, higher central subcutaneous fat levels and higher body fat 
percentages than non-diabetic Indians[136]. This pattern of “thin but fat” seems like a realistic 
expectation for the SAM survivors in this study. I also hypothesise that not only will SAM 
survivors have less peripheral fat than controls, they will have less peripheral lean mass than 
controls; both peripheral fat and peripheral lean mass are thought to be protective against NCDs 
in adulthood[67, 131]. Iannotti et al [57] for example found that calf circumference was 
significantly larger in infants whose mothers were treated with zinc during pregnancy than in 
controls. The study suggested that this could be due to the disruption of skeletal muscle fibre 
development during foetal development due to insufficient resources. This mechanism could also 
apply to children who suffered SAM in the first few years of life. I will measure calf and hip 
circumferences to assess peripheral mass, and also skinfold thickness on biceps and triceps to 
assess peripheral, subcutaneous fat.    
1.1.4.4 Long-term Effects of Nutrition on Physical Function Outcomes 
When exploring the long-term effects of a nutritional insult, such as SAM, I felt it was important 
to not only consider anthropometric and clinical markers, but also functional ones. 
Anthropometric and clinical markers don’t always translate into functional impact. Exploring 
functional outcomes allows us to assess long-term effects which have direct bearing on a person’s 
everyday life. Functional outcomes which may have been affected by a nutritional insult include 
physical function and lung function. Lung function is discussed in the next section. Physical 
function is a broad term that can be used to refer to strength, fitness, mobility, balance, 
coordination and flexibility[137]. For the purpose of this study physical function refers only to 
muscle strength and physical fitness, as these are the areas most relevant to SAM-survivors, as 
well as having important implications for chronic diseases in adulthood and major implications 
for productivity and earning-potential[96, 138].  
	
One of the most relevant and widely studied indicators of physical function is physical activity. 
Physical activity has been highlighted as an indicator of overall well-being in children and a 
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possible determinant, as well as output, of both their cognitive and motor development[139, 140]. 
It is also associated with better immunity and survival[96]. There have been studies which have 
found physical activity in SAM patients and SAM-recovering patients to be lower than other 
hospitalised children[141]. It is hypothesised that this is due to the need to balance energy 
requirements, either due to lack of calories, or spending more calories on weight-gain. There have 
also been a limited number of studies of physical activity in stunted children and teenagers, that 
have found mixed results [142, 143]. One study found that levels of physical activity of school 
aged children are unaffected by nutrition levels, whereas another found evidence that stunted pre-
school children have lower physical activity than well-nourished ones [144, 145]. One hypothesis 
is that school-aged children are more subject to peer-pressure and therefore use their energy on 
physical activity, leaving less available for linear growth[144]. No studies to my knowledge have 
considered physical activity in SAM survivors several years post-discharge. There is mixed 
evidence regarding the long-term effects of prenatal malnutrition on physical activity, with both 
high birth weight and LBW being associated with low physical activity in later life[146, 147]. 
However, in these cases the inactivity is also associated with obesity, and whether obesity causes 
inactivity or inactivity causes obesity is not clear[148]. Based on evidence that LBW and some 
stunted children have reduced physical activity, SAM-survivors may also have this impairment. 
Hence, this study will assess physical activity in SAM survivors using accelerometers. A large 
variety of methods have been used in previous studies to assess physical activity, such as heart 
rate monitoring, questionnaires and observation of activity levels, however none of these are 
considered particularly accurate[149]. The doubly labelled water (DLW) technique is considered 
the gold standard for measuring energy expenditure under free-living conditions, however the 
Actigraph accelerometer has been proven to correlate well with DLW energy expenditure, hence 
for feasibility and logistical ease, this method was used in this study[149].  
 
Physical capacity, also known as exercise capacity, is another important indicator of physical 
function. An individual’s capacity for exercise is measured by their ability to endure exercise 
and/or the maximum workload achieved during the exercise period. Physical capacity provides 
information on the functioning of several body systems, including circulation, cardiovascular, 
pulmonary, muscle action and neural function; small deficits in one or some of these areas may 
only be observed during strenuous effort such as exercise[150]. The gold standard test of physical 
capacity is a Cardio-pulmonary Exercise Test (CPET) which measures electrocardiology (ECG), 
blood pressure, oxygen saturation and expired gases using a facemask during exercise on a cycle 
ergometer. However the availability of specialist laboratory facilities, equipment and trained staff 
to undertake CPET testing is not feasible in many places, hence many opt to use a variety of other 
“field-friendly” exercise tests[151]. Studies looking at physical activity often also consider 
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physical capacity; hence the evidence is similar to that mentioned above. There is evidence that 
underweight adults (low weight for age and/or weight for height) have reduced physical capacity, 
which is usually discussed in relation to capacity to work and productivity. Causality of this 
association has been implied by improvements seen in work capacity following weight-gain [152, 
153]. Changes in body composition, such as increase in lean mass, are also associated with greater 
physical capacity and physical activity[154]. 
 
One study has also considered the long-term effects of chronic malnutrition on physical capacity 
by studying teenage boys in India (age 14-17, n=96) who had low HAZ at the age of 5 years. 
Physical capacity was measured as heart rate at a known level of physical exercise on a bike 
ergometer. They found a correlation between anthropometry at 5 years and that at 14-17 years. 
Physical capacity was correlated with current weight and height, as well as physical activity levels 
measured by observation over 2 days. Weight was particularly relevant for both physical capacity 
and physical activity, accounting for 64% (p < 0.00 1) of variance in physical capacity. Boys who 
were stunted at age 5 had lower physical activity and had a higher heart rate to achieve the same 
work capacity as other boys[155]. However, as malnourished children continued to be 
malnourished teenagers, this study could not conclude whether malnutrition in childhood affects 
physical function beside reduction in body size (i.e. if weight and height catch-up, is physical 
capacity still impaired?). Some studies proposed that the physical capacity of undernourished 
children, when expressed as a function of weight, or adjusted for height, approach or even surpass 
performances by European children, suggesting that deficiencies are directly as a result of weight 
and height limitations[156, 157]. Evidence from Chinese Famine survivors found those exposed 
to famine both prenatally and postnatally were significantly more stunted and had reduced work 
capacity resulting in lower economic outcomes. Work capacity was measured as total and home 
gardening hours worked; and agrarian, farm, and home gardening income. Effects were 
substantial; annual per capita agrarian income was reduced by 33% in famine survivors compared 
to controls[158].  
 
The third and final measure of physical function to be considered is muscle strength. Muscle 
strength is clearly relevant to SAM as acute malnutrition results in loss of muscle (i.e. wasting). 
Whether muscle weakness persists several years after recovery from SAM has not yet been 
studied. The most common measure of muscle function is hand grip strength which is simple, 
non-invasive and a good marker of muscle strength of upper extremities. Hand grip strength is 
associated with both short and long-term morbidity and mortality, and is often used as an 
indicator of current nutritional status in hospitalised adults as it is easy to measure and muscle 
function reacts early to nutritional deprivation[159]. As well as nutritional status, muscle strength 
is likely to be related to lean mass quantity and quality, particular lean mass on the arms, quantity 
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of which can be measured by arm muscle area (AMA)[142]. Muscle strength is also likely to be 
linked to levels of physical activity.  One study which looked at hand grip strength and AMA, as 
well as physical activity and physical capacity in relation to malnutrition, is by Benefice et al., 
(1992). 100 children aged 9-14 years were recruited in rural Senegal; those with WAZ <-1 were 
categorised as wasted. Wasted children were found to have lower AMA, ran slower, jumped less 
far and had weaker hand grip strength, however there was no difference in normal physical 
activity. HAZ also had a moderate influence on AMA and grip strength[142]. Although physical 
activity was unaffected by HAZ and WAZ in this study, it is important to note that it was 
measured by monitoring heart rate over 6 hours; heart rate can be influenced by infection, 
anaemia and emotions, therefore may not be an accurate reflection of physical activity.   
 
The evidence described above tells us that both undernutrition and stunting can affect physical 
function; however we do not know whether an episode of SAM 7 years previous can have 
enduring effects in this area. Mechanisms which could link SAM with long-term deficits in 
physical function include lack of catch up growth since the episode, altered body composition 
and/or impaired muscle development. Weight, height and body composition have all been 
implicated as important for physical function; if SAM survivors are stunted and have a lower 
proportion of lean mass, as I have hypothesised, this could have subsequent implications for 
physical function. Equally, if the “thrifty phenotype” hypothesis has affected SAM survivors and 
resources have been prioritised to core body growth rather than limbs, this could result in less 
muscle mass on arms and legs, long after recovery. Lastly, Iannotti et al., hypothesised that 
prenatal nutrition could affect skeletal muscle fibre development which would have lasting effects 
on muscle mass[57]; this could also affect SAM survivors as muscle development occurs not only 
prenatally, but cell proliferation of the musculoskeletal system also undergoes rapid development 
between 2-4 years of age[109]. Disruption of muscle development could have long-term 
implications for physical function.  
 
I hypothesise that compared to controls, SAM survivors have lower levels of physical activity, 
lower physical capacity during an exercise test and weaker hand grip strength. If one or all of 
these are true, this could have serious implications for NCDs in later life, as well as motor and 
cognitive development during younger years. Exploring the link between SAM and physical 
activity could contribute evidence towards a pathway linking changes in growth and body 
composition to an immediate functional output, and may be a possible link between early SAM 
and NCDs in later life. Although this study may not give us all these answers, establishing 
whether there is a link between SAM and later physical activity is a good starting place for future 
research.  
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1.1.4.5 Long-term Effects of Nutrition on Lung Function Outcomes 
Lung function is another functional output, besides physical activity and muscle strength, which 
may have been affected by SAM in the first few years of life. It is not just cigarette smoking that 
causes adult lung disease, there is growing appreciation that the origins of some adult lung disease 
arise in early life [32, 160]. Not only could SAM affect lung function in childhood, but it could 
predispose individuals to developing chronic respiratory diseases in adulthood, as both asthma 
and COPD are pivotal elements to the DOHaD theory. Lung disease is a growing public health 
problem with COPD predicted to become the fourth largest cause of mortality by 2030 and the 
global burden of asthma predicted to rise as high as 300 million people worldwide[161, 162]. 
Evidence contributing towards the understanding of all the determinants of lung diseases in 
developing countries, both in childhood and adulthood, will aid in the design of holistic public 
health interventions.  
Normal lung development begins in the 4th week of gestation and continues for the first few years 
of infancy[32]. From 16 to 27 weeks gestation the peripheral airways form and grow and the 
blood-gas barrier thins. Adults have between 300 and 600 million alveoli; alveologenesis begins 
at around 29 weeks gestation and is thought to continue until between 2 and 4 years of age, 
although there is no certainty about when alveoli cease to multiply [163, 164]. After birth, lung 
size increases with body size and there is a 30-fold increase in lung volume and a 20-fold increase 
in gas-exchanging surface area from birth to maturity[32]. An insult to growth and development 
during any of these time periods could feasibly damage lung function. 
Many physiological and epidemiological studies, as well as animal studies, have shown that 
insults during intrauterine growth or early postnatal life are associated with decreased lung 
function and increased susceptibility to respiratory disease in childhood and later life [165-169]. 
There is already strong evidence that prenatal conditions, such as maternal smoking, prematurity, 
and LBW, are risk factors for later COPD [49, 74, 170]. Postnatal risk factors for which there is 
evidence of long term respiratory consequences include formula milk feeding, vitamin A, D or E 
deficiency, exposure to environmental pollutants and respiratory infections in childhood [32, 74]. 
One study concluded that the impact of some postnatal risk factors on adult lung health is as large 
as that of heavy smoking, and that an increased focus on these risk factors in early life could 
contribute to the prevention of COPD [74]. A recent literature review in The Lancet outlines pre- 
and postnatal early risk factors associated with adult COPD in more detail[160]. 	  
The specific aspects of lung function which can be affected by early risk factors have been 
described by several studies. A recent study found that school age children who were very LBW 
have lower expiratory volumes, and a greater portion of air remaining in the lungs after exhale 
(residual volume) than normal birth weight infants, which may be explained by collapse of the 
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small airways during exhalation due to a loss of lung elastic recoil and impaired alveolar function. 
Disruption of alveolar development due to adverse uterine conditions could feasibly result in a 
reduction in the number of alveolar attachments, and this is associated with a reduction in lung 
elastic recoil[171]. Balinotti et al. reported that very premature infants compared with controls 
born at term had significantly lower pulmonary diffusing capacity; again, it is suggested that a 
disruption to alveolar development could be the cause of this as it can result in a reduction in gas-
exchange surface area[172]. Based on evidence such as these described as well as on the theory of 
lung development stages, I hypothesise that an episode of severe acute malnutrition in early 
childhood could result in children having reduced lung function. This could be due to fewer 
alveoli, thicker blood-air barrier, reduced lung weight, and/or impaired alveolar function although 
the mechanism will not be assessed in this study. I also hypothesise that those who suffered with 
SAM in early childhood (i.e. before 2 years) are likely to have more of an impairment than those 
who have SAM later as the majority of alveoli development happens before this time. However, it 
is possible for SAM sufferers of all ages to have long-term implications as it has recently been 
postulated that alveoli might continue to increase in size, number and complexity through to 
adolescence and even adulthood [173]. Although this postulation widens the potential period of 
vulnerability, it also offers exciting prospects in terms of recovery from early insults. If a deficit 
in lung function is seen in this cohort of SAM survivors, it could be possible, as with growth, that 
adolescence is a key time for intervention in order to reverse some of the long-term effects of 
SAM. 
As with the other outcomes explored by this study, very few studies have explored the effects of 
post-natal undernutrition specifically on long-term lung function. One recent study considered 
women who were exposed to the 1944-45 Dutch famine between the ages of 0 and 21years and 
found that risk of hospitalization from obstructive airways disease, COPD and asthma in adult life 
was increased[174]. Risk of hospitalization from asthma was 112% higher among severely famine 
exposed women compared to unexposed; risk of hospitalization for obstructive airways disease 
was 57% higher. By separating analysis into ever-smokers and never-smokers, this study suggests 
that women exposed to famine in early life are more sensitive to the toxic effects of smoking. This 
could be an important consideration for developing countries who could be suffering a higher 
burden of chronic lung diseases due to the combination of smoking and undernutrition in 
childhood. Interestingly, the Dutch famine study found no difference in outcome between the 
different ages at which children were exposed to famine (0-21 years), despite the majority of lung 
development taking place in infancy and early childhood. This study does however have some 
methodological issues: recall bias, passive smoking was not controlled for, and there was a large 
loss-to-follow up. Another study, although using dated undernutrition and lung function 
parameters, found that wasted school children in India have worse expiratory flow rates than other 
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Indian children, but stunted children have largely unaffected flow rates[175]. Ong et al., found a 
similar correlation between wasting (low MUAC) and spirometry outcomes in another study of 
Indian children [176]. Finally, another study found observational evidence suggesting that 
children (5-18 years) of the Fulani tribe, who are more stunted and underweight than other 
Nigerian children, have significantly worse lung function outcomes than other Nigerian children. 
They suggest that the diminished lung function in the Fulani group could be attributed to 
respiratory muscle weakness or an overall deficit in energy, rather than disrupted alveolar 
development [177]. Neither the India studies nor the Nigeria study consider children who were 
malnourished in early childhood and their long term outcomes, they focus on children who are 
malnourished at school age and malnourished at the time of testing.    
There is a need for more human evidence regarding the long term lung function outcomes of 
postnatal undernutrition. Particularly lacking is any evidence regarding the long-term effect of a 
SAM episode on lung function. This study aims to add to this currently limited evidence; I 
hypothesis that compared to controls, SAM survivors will have impaired lung function. I also 
hypothesise that younger SAM sufferers will having greater lung function impairment due to a 
greater disruption to lung development.  
	
	
25 
	
1.2  Hypotheses, Aims and Objectives 
 
1.2.1 Aim and Objectives 
The aim is to explore long-term (7 year) outcomes of severe acute malnutrition on growth, body 
composition, and functional outcomes in children. 
Using a longitudinal cohort study design with sibling and community controls for comparison, the 
study objectives are: 
1. To quantify the effects of an episode of SAM on growth and nutritional status 7 years 
post-discharge 
2. To quantify the effect of an episode of SAM on body composition 7 years post-discharge 
3. To quantify the effect of an episode of SAM on functional outcomes 7 years post-
discharge, specifically: 
a) Physical activity 
b) Physical capacity during an exercise test 
c) Muscle strength 
d) Lung function 
4. To quantify the effects of age at admission, severity of stunting and wasting at admission, 
time taken to recover, and presence of oedema at admission on each of the long-term 
outcomes.  
1.2.2 Hypotheses 
1. Compared to controls, SAM survivors have impaired linear growth (specifically (a) HAZ 
(b) shorter leg length) but (c) preserved head circumference 
2. Compared to sibling controls, linear growth velocity is continuing at normal rates 
resulting in no catch-up growth since 1 year post-discharge.  
3. Compared to controls, SAM survivors have an altered body composition, specifically (a) 
greater proportion of central fat to peripheral fat, (b) a lower magnitude of lean mass. 
4. Compared to controls, SAM survivors have (a) lower levels of physical activity, (b) lower 
physical capacity during an exercise test and (c) weaker hand grip strength. 
5. Compared to controls, SAM survivors have impaired lung function (namely reduced 
Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC) and/or 
FEV1/FVC ratio z scores). Additionally, those who suffered SAM at a younger age (<2 
years) have greater lung function impairments.  
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2 Chapter 2: Settings, Participants and General Methods 
 
This chapter will summarise the setting, subjects, equipment and overarching methodologies for 
conducting the study. As this thesis is divided into 4 areas of exploration: growth, body 
composition, physical activity and lung function; methods specific to these areas will be presented 
in the relevant chapter.   
 
 
 
 
2.1 Study Design 
ChroSAM (Chronic Disease Outcomes following Severe Acute Malnutrition study) is a 
longitudinal cohort study with the late addition of sibling and community controls. The cohort 
originally included all patients admitted to “MOYO House” nutrition ward, Queen Elizabeth 
Central Hospital, Blantyre, Malawi, from 12th July 2006 to 9th March 2007. The original cohort 
was for the “PRONUT” study, a Randomised Control Trial (RCT) of pre/probiotics whose main 
finding was no effect on treatment outcomes[88]. This was followed by “FuSAM”, an 
observational study at 1-year post-discharge[97]. This study (named “ChroSAM”) builds on these 
previous studies, using already extensive baseline data for case children and the addition of 
sibling and community children as controls (2 controls per case child). Due to some debate 
regarding the most appropriate control group for nutrition follow-up studies[89, 178], this 
research will use both sibling and community controls. This should help distinguish between 
some of the community, household and genetic confounders. This is the biggest and most 
comprehensive nutrition cohort available in Malawi, and likely one of the biggest in the region. 
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2.2 Setting 
The research described in this thesis is set in Blantyre District in Malawi. Malawi is a densely 
populated, landlocked country in southeast Africa. It has a national population of 16.8 million 
people, ranking it among one of the world’s most densely populated countries. It has a GDP 
(nominal) per capita of USD$226, ranked the lowest in the world by most estimations[179]. 
Around 80% of the population live in rural areas and agriculture accounts of one third of GDP. 
The performance of the tobacco sector is key to short-term growth as tobacco accounts for more 
than half of exports. The economy depends on substantial inflows of economic assistance from 
the IMF, the World Bank, and individual donor nations, although much of this ceased in 2014 due 
to allegations of corruption. Population health, although improving, is still lagging behind much 
of the world with a national life expectance of 59.9 years and infant mortality of 48 per 1000 live 
births. 10.8% of adults have HIV, which is the 9th highest country prevalence in the world[180]. 
Additionally, 13.8% of children under 5 are underweight and 4% suffer from SAM[98]. The 
number of children affected by SAM regularly peaks during the rainy season (also called the 
‘hungry’ season) when many families have to ration what little food is left over from last year’s 
harvest, plus prevalence of malaria and diarrhoea is high, resulting in many children already 
suffering from chronic undernutrition, slipping into acute malnutrition.  
Blantyre is Malawi’s second largest city, with the population representing a 5.1% share of the 
national population[181]. The last official population data was collected in 2008 when the 
population of Blantyre stood at 661,256 people, with a growth rate of 2.8%. The city is estimated 
to have 1,068,681 inhabitants in 2015. There are also 338,047 people estimated in “rural 
Blantyre”. Over 65% of the city’s population lives in informal settlements which occupy about 23 
percent of the land in Blantyre. The average population density in 2008 was 3,006 per square 
kilometre[181]. 	
Blantyre has 18 government-run health centres and 1 government-run hospital: Queen Elizabeth 
Central Hospital (QECH), which is the largest referral hospital in the country and also the 
teaching hospital for the national College of Medicine. Besides these, the health system also has 3 
private hospitals, many private clinics, clinics run by NGOs and religious organisations, and 
numerous traditional healers. “Moyo” nutrition ward (here after referred to as Moyo ward) is 
located in the paediatric department at QECH and is one of 3 nutritional rehabilitation units 
(NRU) in Blantyre District. Moyo means “life” in Chichewa, Malawi’s national language. Since 
the full roll-out of Community Management of Acute Malnutrition (CMAM) in Blantyre in 2008, 
case numbers have dropped considerable at Moyo ward and the characteristics of cases has also 
changed. Presently, the majority of cases are referred from health centres or other wards, and 
almost all cases have complications in addition to SAM. Cases of SAM without complications are 
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treated by CMAM programmes at health centre level. QECH and Moyo ward are part of the 
government health system and therefore all treatment is provided free of charge. 
 
Between 2006 when the baseline data for this cohort was collected and this current follow-up in 
2013-14, both the national and international guidelines for treatment and management of SAM 
have changed considerably. In 2003, Malawi was pioneering the development of CMAM and 
Moyo ward in particular was key in developing and validating a new, locally-manufactured 
Ready-to-use Therapeutic Food (RUTF)[182, 183]. In 2006, cases were being treated on the ward 
with RUTF (which replaced F100 milk in transition phase in 2005) and rehabilitation was 
conducted in an outpatient manner, with children returning to Moyo ward for review and RUTF 
collection. As of 2008, a full CMAM programme began, which meant many of the cases 
previously being treated at Moyo ward began being treated by health centres using an outpatient 
model, and those children who were treated on Moyo ward continue their rehabilitation in a 
CMAM programme post-discharge, without returning to the ward for review. Considering these 
changes have taken place over the course of the cohort, it is important to outline which admission 
criteria and treatment strategy was applied to this cohort in the following section. 
 
 
Image 1: Map of Africa with Malawi highlighted, and image of mothers sitting outside “Moyo ward” 
nutrition rehabilitation centre at Queen Elizabeth Central Hospital in Blantyre, Malawi.  
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2.3 Study Participants 
2.3.1 Eligibility Criteria: 
• All children admitted to ‘Moyo’ ward from 12th July 2006 to 9th March 2007 (“case”) and 
• A sibling closest in age to a “case” child and	
• A child living in the same community as a “case” child, who is also the same age (within 
12 months) and gender as a “case” child 	
• All control children must be older than 4 years of age and younger than 15.9 years of age, 
for better comparison between the groups  
• Children must have fully informed consent from a parent or guardian, and assent if they 
are older than 13. 	
• Children should be living in locations that can be visited from Blantyre in a day-trip (this 
therefore excludes those who have moved to Lilongwe, Mzuzu and areas beyond 
Mangochi).   
• Children should be located within a maximum of two attempts of searching for them 
2.3.2 SAM Admission Criteria and Treatment 
All “case” children in this study were admitted to Moyo ward with SAM. The Moyo ward 
admission criteria, following Malawi National Guidelines[184] and consistent with international 
guidelines[185] at that time, for the case definition of SAM were: 
 
• Weight-for-height <70% of median (NCHS reference) 
or 
• Mid-Upper Arm Circumference (MUAC) <11cm 
or 
• Kwashiorkor (oedematous malnutrition)  
CMAM was started in Blantyre district in 2008, so the distinction into complicated or 
uncomplicated SAM was not applicable. All patients identified as having SAM were admitted for 
initial inpatient treatment. Children presenting at QECH were first assessed for weight and 
clinical issues at A&E, and then referred to Moyo ward if suspected of SAM. Children were 
sometimes also referred from other wards following stabilisation of other clinical issues. Once at 
Moyo ward, children underwent more thorough anthropometric (weight, length and MUAC) and 
clinical assessment, and nutritional and clinical treatments began.  
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Nutritional treatment followed the standard 3-stage approach: 
I. Stabilisation Phase: Children were fed F75 therapeutic milk every 3 hours, including 
throughout the night. The quantity of milk was determined based on the child’s weight 
using standard charts from the Malawi National Guidelines[184].  
II. Transition Phase: to progress to this phase, children should show clinical improvements 
and return of appetite, as indicated by easily finishing all F75 milk prescribed in 
Stabilisation phase.  At this phase, RUTF was introduced to the diet, consistent with the 
then-new CMAM guidelines[186]. 200 kcal energy, per kg body weight, per day was 
prescribed in the form of RUTF, in addition to the F75 milk ration. This ensured that 
children who were not ready or not able to finish the ration of RUTF would still receive 
enough calories as F75 was still provided.  
III. Rehabilitation Phase: When easily eating at least ¾ of the RUTF ration, the child was 
deemed to have an active appetite and could therefore move into Rehabilitation Phase, 
provided they were also clinically well. This meant that they could be discharged for 
treatment at home at the next opportunity (discharges from the ward took place twice per 
week). They were provided with a 2-week ration of RUTF, F75 was stopped, and other 
foods and fluids were allowed. Children returned to Moyo ward after 2 weeks to pick up 
further rations and receive a clinical assessment. For children in this cohort, transport 
money was reimbursed in order to minimise defaulting.  
Children were discharged from Moyo “OTP” (outpatient treatment programme) following 2 
consecutive visits at or above target weight of 80% median weight-for-height. Minimum time on 
the Moyo OTP was therefore 4 weeks. Maximum time was 10 weeks; if the child had not reached 
and maintained their target weight after this time, they were deemed a “nutritional failure” and 
referred elsewhere. Common referrals from Moyo OTP were to HIV and disability services. All 
patients discharged from Moyo OTP were referred to their nearest supplementary feeding centre 
for a further 4 months supplementary feeds (using corn-soy blend) in order to minimise the 
chances of relapse. These were located at health centres distributed throughout the district.  
 
HIV testing and treatment was also an important part of Moyo ward treatment procedure. HIV 
prevalence on Moyo ward at the time of recruitment (2006) was over 40% (ref FUSAM or 
Markos PhD). An opt-out policy of HIV testing and counselling was offered to all patients in 
order to facilitate timely referral to HIV treatment services. HIV seropositive patients were treated 
according to national protocols; referral for antiretroviral (ARV) medication was based on clinical 
staging criteria and CD4 count if available. An ARV waiting list in 2006 meant that additional 
ARV therapy rarely started during inpatient phase of nutrition treatment. All HIV positive patients 
were started on long term co-trimoxazole prophylaxis as soon as diagnosed. 
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2.3.3 PRONUT and FuSAM Studies 
The cohort which forms the “case” children for this study was initially created for recruitment of 
participants into two previous studies: PRONUT study and FUSAM study[88, 97]. See Figure 3 
for summary flow-chart of previous studies. PRONUT was a randomised, double-blinded, 
placebo-controlled trial exploring the effects of a pre/probiotic (Synbiotic2000 Forte™) on 
treatment outcomes in children affected by SAM, which took place in 2006 and 2007. The study 
found no difference in nutritional or clinical outcomes between the intervention and control 
groups. This meant that the control and intervention groups could be merged into one cohort, and 
the group was then studied as a whole during the FuSAM study.   
 
Figure 3: Flow diagram outlining the 3 studies using the Malawi SAM cohort 
 
FuSAM aimed to describe long-term outcomes following SAM and identify key mortality risks 
factors. The study followed-up all children thought to be alive at 1 year post-discharge; it found 
that 10% of the cohort died between discharge and 1 year post-discharge, and Cox regression 
identified HIV, low weight-for-height, low MUAC and low weight-for-age as major risk factors 
for death (p<0.001) 
 
The majority of “case” children in this study have previously taken part in both PRONUT and 
FUSAM studies, although not all. Those families that declined to take part in the PRONUT and/or 
FUSAM were still approached for this research. Additionally, those children who could not be 
located during FUSAM study where still searched for during this research, with some success. 
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Although PRONUT and FuSAM concluded that there was no significant effect of synbiotics on 
nutritional or clinical outcomes, PRONUT study post-hoc analysis did observe a reduction in 
outpatient mortality amongst the synbiotic intervention group. For this reason, this study 
(ChroSAM) will assess for any long-term differences between intervention and control groups 
among the case children before any further analysis.    
 
 
2.3.4 Locating Participants  
Each case child (i.e. all ward admissions from 12th July 2006 to 9th March 2007) has a paper file 
which is stored in chronological order by date of admission (Image 2). If the child died on the 
ward or was found to have died at the one-year follow-up (FUSAM), these folders are red and 
orange respectively, and were not included in this study. In order to locate study participants, 
blocks of 50 files were sorted into geographical regions using the verbal map in the file, starting 
from the first admissions in July 2006. The “verbal maps” in the files where first collected during 
ward admission, for PRONUT study. The maps describe how to find the child’s home, as 
provided by the carer of the child, and usually refer to prominent landmarks such as towns, 
schools and churches, and usually include prominent people in the community who can direct the 
study team. Here is an example of a typical, fictional “verbal map”: 
“Soon after Phalula town centre on the main road to Lilongwe, there is a right turn 
where they sell Makala (charcoal). Take this road, cross the bridge and look for Chigdi 
primary school on your left. Take the road behind the school and continue until you reach 
Kasamba maize mill. There ask for Chapola plot. This family also go by the name 
Tiyesembo.” 
Taking of effective maps was aided by a large scale, physical map held on the ward which 
enabled staff and carers to identify local landmarks on route to the patient’s home. Some maps 
were updated during the FUSAM 1-year follow-up with additional details. A few files do not have 
a verbal map, if the family defaulted from the ward before it was collected, or if the family 
declined to provide it. Some files have GPS coordinates so the location can be looked up using 
Google Earth. Each geographical area was then visited with the aim of locating 2 – 3 cohort 
children per day. When these 50 files have been visited, the next 50 are selected and sorted. 
Ideally, the children would be visited in exact order of admission, however the need to group the 
children by geographical area in blocks of 50 files is necessary in order to minimise travel time 
and maximise resources. Two of the study nurses were part of the team who worked on PRONUT 
and FUSAM, so they were familiar with some of the locations and communities, despite there 
being a 6-year gap since the previous follow-up.  
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Image 2: case children’s files stored in chronological order by admission date; blue files were last known to 
be alive, red died during admission, orange died post-discharge and yellow declined to take part in 
“PRONUT” study. The image on the right shows that each file has a label with the patient name and study 
ID number 
Once the case child was found, the sibling control could also be identified and located. In order to 
locate the community control child using random selection, a bottle was spun at the house of the 
case child and the study team walk in that direction. They enquire at all houses in that direction 
until a child of same age and gender as the case child, who’s family are willing to consent, is 
found. If the area was particularly rural, it was necessary to ask the case family if they know of a 
suitable community control child, and in these cases a note was made on the file that this was 
‘convenience selection’. If a household member was found but the child was not at home, this 
child can still be recruited and invited to a hospital appointment. 
2.3.5 Informed Consent Process 
Once the family of a case child has been located, the main carer was identified and the study 
explained to him or her using the standardized information sheet. In most cases, the main carer 
was female, and informed consent sought from her in order to enrol her child (see English copies 
of the information sheet and consent form in Appendix 1). Additional consent from the male head 
of the household and the village chief was sought if possible, as this allowed the female carer and 
child to take part in the study in the confidence that she is supported by her family and community 
leaders. If all parties understood the information sheet and were happy to participate, the carer 
signed the consent form. If the child was 13 years or older, assent from the child was additionally 
sought before proceeding. If the carer was illiterate, there was an impartial witness to help the 
carer in the consent process, ensuring that the consent form had been correctly read to and 
understood by the consent-giver. Once consent was given, the data collection began with 
questionnaires and anthropometry at the child’s home. A hospital appointment date was then 
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given to the family for data collection to continue at the hospital. If the family and/or child did not 
want to consent after the study had been fully explained, then a note was made on the child’s file 
and they were not approached again.    
For sibling controls, if the child was 13 years or older, they had to assent to take part.  If the 
subject was 18 years or older, they were able to fully consent or decline for themselves without 
the input from their guardian. If the child was older than 13 and did not assent, then I asked the 
sibling next closest in age to take part. If the case child had no living siblings, or none willing to 
consent, then no sibling control was enrolled.  
For community controls the same information and consent process took place as with the case 
family. If the family and/or child did not want to consent after the study had been explained to 
them, another appropriate household was sought. On a few occasions, in small villages, no 
appropriate child that was willing to consent could be found.  
On most occasions, at the request of the carer, the study team made a visit to the child’s school in 
order to seek permission from the head teacher for the child to miss a day of school in order to 
participate in the research. In some cases, if the school was far away or if it was not open that day, 
a letter for the head teacher was given to the carer to provide to the school as an explanation for 
the child’s absence (see letter in Appendix 2).  
2.4 Ethical Approval:  
Conditional ethical approval was granted for the research project as a whole by Malawi College of 
Medicine Research and Ethics Committee (COMREC) in 2013, and fully granted in 2014 (see 
Appendix 3 for letters from COMREC and the approval certificate).  Additionally, Ethical 
approval was granted by University College London (UCL) Research Ethics Committee in 2013 
(see Appendix 4 for letters of approval from UCL).   
2.5 Sample Size 
The sample size was determined by the number of survivors from the original cohort and the 
number which we are able to find and recruit. Prior to data collection I estimated our sample size 
to be around 960 children (400 cases, 320 sibling controls, 240 community controls) based on 
success rate of the 1-year follow up[97]. For each of the main variables I conducted sample size 
calculations to assess whether these numbers were adequate for detecting a significant difference, 
powered at 90%; these calculations are presented in relevant method sections in following 
chapters. Statistical power is the likelihood of detecting an effect if one does exist. Greater power 
reduces the chance of a type II error.  As HIV is a key confounder across all outcomes, it was 
desirable for the target sample size to be greater than that required for simple analysis in order to 
allow for analysis of subgroups. In reality, I recruited 320 cases, 217 siblings and 184 community 
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controls; slightly below expected but still adequate for majority of analyses. It is also important to 
note that one major goal of this project was to inform sample size calculations of future 
intervention studies; hence the inflexibility of our sample size for this study was not a major 
concern. 
 
2.6 Data Collection Overview 
The families and children in this study participated in a wide variety of tests and measurements. 
Not all of these variables are included in this PhD but they are relevant to other sub-studies, and 
all relate to the long-term effects of acute malnutrition. Those questionnaires and measurements 
which are not included in this PhD are highlighted in grey.  
Field Measurements (at the child’s home): 
1. Questionnaires  
a. Basic information and general health 
b. Socioeconomic status (SES) 
c. Domestic violence  
d. Maternal mental health  
e. Family health 
f. UNICEF Disability screening 
g. DUREL Faith views  
2. Basic anthropometry 
3. Family anthropometry (all siblings and both parents) 
4. Accelerometers fitted 
Hospital Measurements: 
The following measurements took place if/when the children attended their hospital appointment, 
previously arranged at their home. The whole battery of assessments took around 5 hours, and 
generally took place in the exact order listed: 
1. Accelerometers collected 
2. Blood drawn (full blood count, lipid profile, HbA1c, metabolomics, and fasting glucose) 
3. Oral glucose tolerance test – subset of 100 children 
4. Saliva collection for salivary cortisol 
5. Remaining anthropometry 
6. Skinfold thicknesses 
7. Bioelectrical impedance analysis (BIA) 
8. Blood pressure and oxygen saturation 
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9. Maternal blood pressure 
10. Handgrip strength 
11. Spirometry 
12. MRI scan – subset of 50 case children 
13. CANTAB cognitive test 
14. iStep exercise test 
15. Retina photos 
 
2.6.1 Staff Training 
The research team consisted of 2 full-time nurses and 4 full-time field workers, plus some 
assistance from the 5 nurses who work on the malnutrition ward. All full-time staff members were 
trained on all aspects of data collection, however, some team members became specialised in 
certain tests in order to aid with consistency of testing. For example all members of the team were 
trained in conducting spirometry yet the majority of tests were conducted by me or 2 of the field 
workers.   
Intensive training of study staff, including myself, was required for each of the measurements. For 
spirometry, I received 2 weeks intensive training at UCL PORTEX Unit, Great Ormond Street 
Children’s Hospital. I and the Chichewa-speaking team also went out on a field trip with the 
Blantyre Health Study (BHS), who were conducting spirometry in adults in Malawi, in order to 
get some tips on how best to explain the process in Chichewa.  
All team members, including myself, were required to attend and pass a ‘Good Clinical Practice’ 
(GCP) course, which covered topics such as ethical research procedures and the informed consent 
process. During training on specific questionnaires, the whole team explored the pilot data 
collection forms and questionnaires and had the opportunity to feedback suggestions for 
amendments. Study staff training was conducted from March - July 2013. Refresher training then 
took place in January 2014, and further refresher training took place in April 2014, as a new team 
member joined the group. 
For anthropometry, following training by the Nutrition research department at Institute for Child 
Health, a “Standardization session” took place whereby each team member had to measure 10 
pilot children twice. This allows for comparison of intra-operator and inter-operator differences, 
and highlighted which measurements needed improvement or more training. The greatest intra 
and inter –operator differences occurred on hip circumference and waist circumference measures. 
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2.6.1.1 Anthropometry Standardisation Session Results 
Following training, I conducted an anthropometry “standardisation session” with the aim of 
extensively practicing the measurements as well as identifying inaccuracies with specific 
measurements or individual team members. This process involved 8 children whose 
anthropometry was measured twice by each trained data collector. The session took place at our 
data collection room in the hospital; children between the ages of 6 and 11 were recruited from 
siblings of hospital admissions or children of nursing staff, they were not part of the ChroSAM 
study. The children were stationed around the room and the data collectors were split into pairs to 
move systematically from child to child conducting their measurements.  This circuit was 
repeated after lunch so that each data collector measured each child twice. Anthropometric 
measures conducted were height, MUAC, bicep and waist skinfold thickness, head and waist 
circumference and chest width. These measures were selected to ensure practice with the whole 
range of equipment. Weight was not included as digital scales have negligible intra- and inter-
operator error.   
The intra-observer technical error of measurements (TEM) were calculated and compared (Table 
2)[187]. TEM is calculated by finding the deviation between an operator’s individual measures, 
squaring it, summing this for all the children measured, dividing this by number of children x 2, 
and then finding the square root, as shown in this equation:  
TEM= !!!!!  
Where  !! = summation of deviations raised to the second power, n = number of children 
measured, i=the number of deviations 
The accuracy for each measurement (rather than each individual operator) was considered using 
the mean standard deviation (SD) between all operators across each child (also presented in Table 
2). The “gold standard” intra-observer TEM is also presented in Table 2; this is the TEM of the 
expert anthropologists conducting the training for WHO Multicentre Growth Reference 
study[187]. Consulting the results of this exercise and discussing them with the team allowed for 
identification of those needing more training on specific measurements, for example  Operator 2 
and MUAC. I also identified waist skinfold thickness and waist circumference as measurements 
with high SD where extra care is required when taking measurements.  
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 n 
(children) 
Height  MUAC Bicep 
skinfold 
Waist 
skinfold 
Head 
circ 
Waist 
circ 
Chest 
width 
Operator 
1 TEM 
8 0.47cm 2.06mm 0.23mm 1.56mm 0.28cm 1.71cm 0.59cm 
Operator 
2 TEM 
8 0.38cm 6.95mm 1.19mm 2.12mm 0.38cm 0.93cm 1.08cm 
Operator 
3 TEM 
8 0.39cm 1.22mm 1.16mm 1.38mm 0.19cm 1.55cm 0.38cm 
Operator 
4 TEM 
9 0.38cm 1.66mm 0.23mm 1.68mm 0.31cm 1.53cm 0.66cm 
Operator 
5 TEM 
9 0.60cm 2.35mm 0.83mm 0.79mm 0.34cm 1.02cm 0.30cm 
Gold 
standard 
TEM[187] 
10 0.23cm 1.70mm 0.40mm 
(tricep) \ 
0.12cm 
\ \ 
Mean SD 
across 
children 
9 0.57cm 1.70mm 0.84mm 1.90mm 0.69cm 1.21cm 0.62cm 
Table 2: Intra-observer technical error of measurement (TEM) for anthropometry standardisation session 
conducted during ChroSAM team training, as well as “Gold Standard” TEM from WHO Multicentre 
Reference Study and mean standard deviation (SD) between operators across each child.  
2.6.2 Pilot Phase 
The pilot phase of this study took place in July 2013 with 10 case children from the actual cohort 
plus controls (timing of all study phases can be seen in Gantt chart in Appendix 5). This process 
informed many details of the study logistics, such as the need to approach fathers and chiefs for 
consent in addition to female carers. This phase also informed the average cost of transport 
required by study families and the need to carry petty cash on field visits as not being able to 
access transport money prior to travel was identified as a barrier to attending study appointments.  
I also learnt how long the hospital appointment takes, and saw the need to provide both a snack 
and lunch to the participants. The ‘incentive package’ was also discussed with the pilot 
participants and was found to be appropriate and acceptable.  
During the pilot phase I also learnt that some of the participants did not like the accelerometers 
being red in colour, and I further learnt that spray painting them yellow was less convincing than 
a full explanation of their function!  All other tests were deemed ‘acceptable’ to participants and 
their families, except the blood test which sometimes prevented people attending their 
appointments. The need to stress that all aspects of the research are optional, especially the blood 
test, was noted by the study team. The pilot phase also refined some of the Chichewa translation 
of the questionnaires and amended some of the skip-logic. 
2.6.3 Data Recording and Management 
The majority of data recording took place on Samsung Galaxy mobile phone devices using open-
access ODK-based open-platform software called “CommCare ODK” (www.commcarhq.org). 
During the pilot phase and very beginning of the study, paper forms were used and these were 
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entered into the CommCare database using the mobile phones retrospectively (paper versions of 
forms can be seen in Appendix 6). Once I had correctly programmed the software, we used 
mobile phones to enter data at the point of collection, without the need for paper. I visited a 
research project run by Institute of Global Health (UCL) in Machinji, Malawi that was using 
CommCare software in order to learn about its application in the field. This electronic data 
collection method misses out the step of data entry at a later date which saves time and reduces 
the probability of data entry errors. The phones also have the benefit of on-the-spot calculations 
for anthropometry, particularly quality control of anthropometry measures, and ensure that the 
correct skip-logic is applied, with no relevant questions left blank. In order to keep track of which 
forms were completed in the field and which needed to be done at the hospital appointment, we 
use one paper form known as the ‘Master Checklist’ which required the team member to tick 
which forms they have completed. This paper form also had space for free-text notes, which are 
not as easy to enter using the mobile phones. Lastly the paper form had space for adding further 
details to the child’s address or adding a new address so that the next follow-up which might take 
place is not reliant on access to the CommCare database for this information. Some data, such as 
blood test results, spirometry traces, CANTAB cognitive test scores and retina photos were stored 
on specially designed databases, rather than on CommCare.  
 
 
Image 3: Photo of mobiles phones used for data collection and screen showing CommCare software 
highlighting an error during data entry 
 
All data for each child was checked by me at the end of each week, before allowing the paper file 
to be returned to the filing cupboards. On occasion, children would be revisited at their home to 
gather missing data or clarify anomalous data. Any amendments needed to the data where 
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recorded as an instruction in a STATA do. file. Any clinical issues which arose during data 
collection were highlighted at the checking stage and the child invited to see the relevant 
clinician. The spirometry database was downloaded once per month, I conducted initial quality 
control conducted and then sent the data to the lung function department at Great Ormond Street 
Hospital (GOSH) for checking of queries and random checking of a further 40% of the 
spirograms. Following this, each spirometry database was exported into Microsoft Excel and 
compiled into one master spirometry database. The GOSH expert was blinded to the case/control 
status of the results. In general, the data collectors were not blinded to study group status due to 
lack of an adequate system which would allow for blinding but not allow potential errors in data 
recording; due to human resource limitations, all data collectors worked on all aspects of 
recruitment and data entry therefore could not be blinded.  
At the end data collection, the majority of the data, which was on the CommCare database, was 
imported into STATA12 and the correction do. file run. After checking all the ID numbers for 
errors, the spirometry database was also imported into STATA12 and merged based on the ID 
number. Selected relevant data from the PRONUT and FUSAM database was also merged based 
on ID numbers to create one long database, where each child has their own row of data.     
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2.6.4 Demographic Questionnaires 
The questionnaires were usually administered at the children’s homes; in exceptions they took 
place at the hospital appointment. The questionnaires, all administered in Chichewa language by 
the trained field team, can be seen in Appendix 7 (English and Chichewa versions). These 
questionnaires were developed based on those used in the “FuSAM” 1-year follow up study and 
adapted following consultation with the UCL research team, other researchers at Malawi-
Liverpool Wellcome Trust in Blantyre, some members of the field team and relevant experts in 
specific areas. The following four demographic questionnaires where asked: 
• Questionnaire A: Basic information  
Includes age, sex, alive/dead/sick, birth order, school achievement, and questions 
about hospital & outpatient visits, SAM admissions, history of TB, asthma, 
pneumonia, and HIV status. Questions are based on similar questionnaire for FuSAM 
study for continuity  
• Questionnaire D: Family Characteristics  
Includes parent’s marital status, occupation, literacy and education based on FuSAM 
questionnaire, as well as questions about domestic violence and social welfare based 
on Malawi DHS and select questions from Multidimensional Scale of Perceived 
Social Support (MSPSS) previously translated and validated in Malawi[188, 189]   
• Questionnaire E: Household and SES 
Includes questions about household assets and water and sanitation facilities, based 
on Malawi DHS, as well as questions about tobacco and cooking smoke in the home 
adapted from the American Thoracic Society’s ATS-DLD-78C respiratory 
questionnaire 
• Questionnaire K: Family health 
Includes maternal and paternal HIV status and general health, and history of SAM in 
all of the non-study siblings, based on a similar questionnaire from FuSAM study for 
continuity     
2.6.5 Maternal Mental Health SRQ 
This questionnaire (Appendix 8) was asked to the main female carer of the study child, most 
commonly the mother. The 20-item yes/no Self-Reporting Questionnaire (SRQ) was designed by 
WHO to identify common mental disorders such as depression,	 anxiety,	 and	 somatic	manifestations	of	distress	 in	 the	community[190].	 It	has	been	translated	and	validated	 for	use	in	many	developing	countries	including	Malawi,	where	a	cut-off	score	of	7	or	higher	is	recommended	 for	 identifying	 mental	 distress.	 For	 our	 study,	 this	 questionnaire	 was	administered	by	a	senior	nurse	who	had	previous	experience	using	it;	carers	scoring	more	
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than	12	or	 showing	signs	of	 suicide	 intent	were	 referred	 to	 routine	psychiatry	 services	at	QECH.		
2.6.6 Disability Screening Questionnaire 
Developed by the Washington Group on Disability Statistics in collaboration with UNICEF, this 
questionnaire was designed to be efficiently nested into larger surveys in order to collect broad 
information of disabilities in the community, as well as being a standardise tool for disability 
screening across all countries[191]. It includes questions on six core functional domains: seeing, 
hearing, walking, cognition, self-care and communication (see Appendix 9). I used this 
questionnaire to attain information on potential confounders as well as assess differences in 
disabilities across cases and control groups. 
2.6.7 Assessing HIV Status 
HIV status is an important variable as it is potentially a major confounder for many of the main 
study outcomes. HIV status was assessed firstly by ascertaining whether the participant had ever 
had a HIV test, followed by proof of the results of that test, usually in the form of a stamp in the 
individual’s “Health Passport” (Data Collection Form A). If no test had been taken or no proofs of 
results were available, the participant was offered a HIV test during the hospital appointment. 
Many case children had proof of their status in their health passports as this is a routine test upon 
hospital admission; however a large proportion of community controls, sibling controls and 
parents had never been tested. If consent was given, the HIV test was administered by a field 
worker or nurse with a valid Ministry of Health HIV testing and counselling certificate, following 
National protocol. This involves two rapid tests, Detemine™ as a screening test and Uni-Gold™ 
as a confirmatory test; all results were delivered in a private place with appropriate counselling. 
For those who did not know their status and did not consent to a HIV test, HIV status was 
recorded as “unknown”.  
 
2.6.8 Assessing Puberty 
As the children were already undergoing a long day of obtrusive tests and time was short, I 
decided not to rank puberty by Tanner stage or other physical assessment[192]. Puberty was 
simply recorded as yes/no/don’t know by asking the guardian or individual if the child has started 
puberty yet. The cultural understanding of onset of puberty for girls is start of menarche; for boys 
voice breaking was suggested to carers as a sign of the onset of puberty. This was a rough guide 
in order to avoid invasive examination (Data Collection Form A).  
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2.6.9 Gestures of Thanks/Incentives 
All families who attended the hospital appointment were given refreshments, a mid-morning 
snack, a hot lunch, reimbursement of the transport costs and a small incentive package worth 
approximately USD$2.50. This included soap, sugar, salt, matches, pencils, pencil sharpener and 
school exercise books. The children were also provided with stickers, lollipops and entertainment 
after various assessments; we tried to make the process as fun as possible for the children 
involved and their accompanying siblings.   
 
2.6.10 Quality Control Systems: 
Repeat Measures:  
Anthropometry is notoriously difficult to measure accurately if repeat measures are not taken to 
ensure quality. Therefore, for all the anthropometric measures in this study (except weight), a 
quality control system which involves two members of the trained study team taking independent 
readings, based on that used in the WHO Multicentre Growth Reference Study, was used[193]. 
The mobile phone data collection devices were designed so that each of the two staff members 
entered their anthropometric measure, without knowing what the other had entered. The device 
then informed the operators whether or not the two readings were within the acceptable range. If 
the two measurements were similar enough, then the team moved on to the next measurement; if 
the readings were outside of the maximum allowed difference then both operators had to repeat 
the measures. If the team repeated the measurements 3 times and were still not within the allowed 
difference, then a third team member was asked to take a measurement. The team could not 
proceed to the next question until they had two readings within the acceptable range. The final 
value used in the results was the average of the final pair of readings. The WHO Multicentre 
Growth Reference Study found that large differences owing to reading or recording errors were 
resolved by using this method[193]. The maximum allowable difference for acceptable precision 
was developed by the WHO Multicentre Growth Reference Study based on the TEM obtained in 
their initial standardization session conducted in Brazil, which predicts a range that will only 
require re-measurement 5% of the time. The WHO study decided to widen the allowable range for 
skinfold thickness to 2mm because this was the measure which the participants found most 
uncomfortable[193]. Following my own standardization session I decided that we would decrease 
this maximum allowable difference for skinfold thickness readings to 0.5mm as this would still 
allow for a low percentage of repeat readings. Weight was not re-measured as digital scales have 
negligible intra- and inter-operator error when measuring older children. See Table 3 for 
maximum acceptable differences for each reading. 
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Measurement Maximum 
allowable 
difference 
Standing Height 0.7 cm 
Sitting Height 0.5 cm 
Head Circumference 0.5 cm 
Mid-upper arm circumference 
(MUAC) 
0.5 cm 
Waist circumference 0.5 cm 
Hip circumference 0.5 cm 
Calf circumference 0.5 cm 
Chest circumference 0.5 cm 
Chest width 0.5 cm 
Chest depth 0.5 cm 
Knee Height 0.5 cm  
Skinfold thickness –left bicep 0.5 mm 
Skinfold thickness –left tricep 0.5 mm 
Skinfold thickness –left subscapular 0.5 mm 
Skinfold thickness –left suprailiac 0.5 mm 
Table 3: Maximum allowable differences between measurements conducted by independent data 
collectors; a quality control system developed by WHO Multicentre Reference Study.  
 
Questionnaires were also repeated for 10% of participants as a quality control check. 10% of 
carers who had answered the study questionnaires during the field visit were asked the 
questionnaires a second time during the hospital visit, in order to assess intra-participant validity, 
and inter-operator validity (see results of questionnaire data quality in Chapter 3). Similarly, BIA 
readings were taken twice, one immediately after the other, in order to pick up any random errors 
on the part of the device, and additionally, a 10% of participants had their BIA reading taken 
again at least 2 hours after the first pair of readings, in order to validate quality of the readings, 
particular at different points on the same day (see results of BIA data quality in Chapter 5).  
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Validity question: During the pilot, field staff were concerned that some mothers did not fully 
understand all the questions in the questionnaires, particularly the disability screen questionnaire, 
or they didn’t respond truthfully due to lack of interest. I therefore added a validity question at the 
end of some questionnaires, for the interviewer only, asking their opinion on the validity of the 
responses: 
 
“In your opinion, are the responses to this questionnaire valid?”  YES/NO  
 
“If NO, why not?  
1. Respondent didn’t understand the questions 
2. Didn’t pay attention 
3. Lack of motivation 
4. Impatient and restless 
5. Negative attitude toward the interviewer 
6. Interview interrupted” 
 
 
Age: Age is a key variable, particularly for calculating anthropometric and spirometric z scores. It 
is well known that age and date of birth can be poorly recorded, or poorly remembered by carers 
in many countries. Therefore, in order to minimise error, the carer was asked the child’s date of 
birth, and the mobile phone data collection device calculated the child’s age in years. The carer 
was then asked to confirm if this age was correct; inconsistencies or errors could therefore be 
immediately identified and further details could be asked to determine the child’s true date of 
birth.   
 
Calibration: Each instrument was calibrated according to the manufacturer’s instructions. The 
following equipment was calibrated daily: Weighing scales using 5kg reference weight, 
Stadiometer and Body Callipers using 1m wooden stick, Skinfold Callipers using 4mm wooden 
cube, Spirometer by blocking airflow and therefore registering zero flow, and lastly BIA 
Quadscan machine using a metal calibrator provided by the manufacturer.   
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2.7 Data Analysis 
2.7.1 Potential Confounders 
Much controversy exists regarding proper methods for the selection of variables in confounder 
control. Many authors condemn any use of significance testing, some encourage such testing, and 
others propose a mixed approach[194]. This study used a mixed method. I deduced potential 
confounders from reading related literature and then creating conceptual frameworks/causal 
pathways  for each of the main outcomes being assessed. A confounder is a third variable which is 
associated with both the outcome and the exposure and can distort the magnitude of the 
relationship between the two factors of interest if it is not properly accounted for. Whether this 
“third variable” has an association with the outcome of interest can be assessed with regression 
analysis; however statisticians advise that I cannot rely on statistical significance alone[195]. 
Choosing which confounders need adjusting for should be based on biological plausibility 
initially, followed by statistical significance testing. Selected potential confounders were included 
in the regression model, where available. See Figure 4 Error! Reference source not found.for 
conceptual frameworks identifying potential confounders for each major outcome.  
One potential confounder (or effect-modifier) which could affect all of the outcomes of interest in 
this study is HIV status. HIV is associated with the exposure (SAM): infections associated with 
HIV result in higher calorific demand resulting in a greater likelihood of all types of 
undernutrition; and HIV and resultant infections are associated with the outcomes: poor growth, 
dyslipidaemia, poor lung function, weaker muscle strength and lower physical activity levels[196-
199]. As HIV is so closely linked to both SAM and some of the outcomes studied, not only has it 
been included in the regression models, but I have also conducted stratified analysis in order to 
observe the effects of SAM without the influence of HIV. Ideally, I would have liked to assess the 
effects of SAM with HIV as well by comparing HIV positive cases to HIV positive controls; 
however the sample size for HIV positive controls was very small.  
Birth weight is also a potentially important confounder or effect-modifier. As discussed in the 
Chapter 1, many studies have found LBW to be associated with stunting, adverse body 
composition, poor lung function, and other risk signs of chronic diseases[32, 67]. LBW infants are 
also more likely to suffer from malnutrition[200]. Unfortunately, this is one of the major potential 
confounders which cannot be adjusted for in this study as accurate birth weights for participants 
are not known. Although at present most infants in Malawi are born in a health facility and their 
birth weight recorded, this was not the case when our study participants were born, and in 
instances where it was recorded, these documents have since been lost. A rough idea of birth 
weight was collected for case children at admission by asking mothers in the child was born 
normal weight, small or very small; this can be assessed as a predictor of outcomes in case 
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children and will therefore give some idea of the importance of birth weight on long-term 
outcomes, but this variable is not available for control children hence we cannot know if LBW is 
more prevalent among cases than controls.  
HIV status, age, sex, and socio-economic status (SES) are included as potential confounders in all 
regression analyses in this study, regardless of statistical significance, as it is highly plausible that 
these variables are associated with all outcomes, independent of the exposure (SAM). Although 
controls were “matched” to cases by some variables (i.e. community controls were matched on 
age and sex; sibling controls were matched on “household environment”, SES and genetic 
potential) these factors still require adjusting for during analysis as the matching process can 
create an association between the outcome (i.e. SAM) and a matched criteria (e.g. age) when there 
was no association before the matching was conducted[201]. Additionally, as analysis is not 
“matched” the differences in mean age, sex and SES between the groups will need adjusting for.  
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Figure 4b 
	
Figure 4a 
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Figure 4: Conceptual frameworks for each of the four hypotheses in this study linking SAM with outcomes 
7 years later including potential confounders; (4a) SAM leads to stunting, particularly shorter legs (4b) 
SAM leads to dyslipidemia (4c) SAM leads to lower levels of physical activity (4d) SAM leads to poor 
long-term lung function.   
Figure 4c 
Figure 4d 
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2.7.2 Linear Regression Analysis 
Linear regression is a statistical technique for modelling the relationship between a dependant 
variable (y) and one or more explanatory variables (x), with the assumption that it is linear. It can 
be used to predict variable y based on x, or to identify and quantify the relationship between y and 
x. In this study, I largely use multiple linear regression analysis to identify and quantify the 
relationship between an outcome such as stunting and the explanatory variable “study group” (i.e. 
case/sibling/community control), as well as including potential confounders in the model as 
additional explanatory variables. Linear regression analysis requires the dependant y variable to 
be normally distributed, which is the case for most of the outcomes of interest. Normal 
distribution was determined using a skewedness value between -1 and 1. For skewed outcomes, 
the variable is transformed into a log-normal distribution for analysis. All analyses for this study 
were conducted using Stata12 software (StataCorp LP, USA).       
As cases and controls were matched in certain variables at recruitment, “matched” analysis was 
considered. There is an argument that matched case-control studies should always be analysed in 
a matched format, however if there is no problem of sparse data, unconditional analysis is a better 
option as it often improves precision and avoids the need to exclude unmatched cases[201].  This 
study is not a case-control study as that would mean recruiting at the point of the outcome (e.g. 
stunting) and analysing retrospective risk factors (i.e. did they have SAM in the past or not?). This 
is a prospective cohort study with the addition of “unexposed” control groups hence matching of 
cases and those in the “unexposed” groups was primarily to reduce the range and breadth of 
potential confounders rather than with the intention of conducting matched analysis[202].  
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2.7.3 Principle Component Analysis (PCA) 
I used principle component analysis (PCA) to create wealth scores based on asset data. PCA is a 
multivariate statistical technique that allows linear transformation of many variables into fewer, 
uncorrelated variables which represent the majority of the information in the original data set[203, 
204]. It is commonly used for transforming asset data collected via DHS variables into an asset 
score which is indicative of socio-economic status [205]. This score cannot be used to compare 
one population with another, unless the exact same variables are used, however it is useful in this 
study for comparing socio-economic status between the study groups and adjusting for intra-
sample variability in SES. Although PCA analysis gives us an idea of wealth at a household level, 
it does not allow us to differentiate how resources are allocated within the household. The 
variables included in my PCA for creation of a wealth score, which was then cut into quintiles, 
are listed in Table 4 below. Quintile 1 has the lowest socio-economic status and quintile 5 the 
highest. As wealth and stunting are closely associated in almost all societies, a graph plotting the 
relationship between these two factors was used to test the accuracy of PCA-created wealth 
quintiles (Appendix 10)[206, 207].  
 
Questions included in PCA analysis 
In the dwelling is there electricity? 
In the dwelling is there a bicycle? 
In the dwelling, is there a motorbike? 
In the dwelling, is there a car? 
In the dwelling, is there a koloboyi? (basic lamp) 
In the dwelling, is there a paraffin lamp? 
In the dwelling, is there an oxcart? 
In the dwelling, is there a TV? 
In the dwelling, is there a mobile phone? 
In the dwelling, is there a telephone (landline)? 
In the dwelling, is there a bed with a mattress? 
In the dwelling, is there a sofa? 
In the dwelling, is there a table and chair? 
In the dwelling, is there a refrigerator? 
Do any members on the household own a watch? 
Do members of the household work their own agricultural land? 
Do any members of your household have a bank account? 
What is the principle household source of drinking water? 
What is the principle type of roofing in your dwelling? 
What is the principle type of toilet facility used by the household members? 
What is the principle type of flooring in your dwelling? 
Table 4: Outcomes used in Principle Component Analysis (PCA) to generate wealth score 
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3 Chapter 3: Cohort Profile 
This chapter is the first of the results chapters but it simply describes the sample and basic 
demographics of the study groups, including results of recruitment, mortality rate, HIV 
prevalence and a brief exploration of the outcomes for the original study groups in the synbiotic 
trial. It also describes missing data, which is largely due to loss to follow up, and presents results 
of questionnaire validity checks. The results in this chapter should give a general background 
profile to the study groups, before moving on to the next chapters which give results specific to 
growth, body composition, physical function and lung function. 
 
3.1 Sample Description 
I recruited 320 living case children in the study. The recruitment flow diagram (Figure 5) shows 
numbers recruited, died and lost to follow-up for case children, starting with the original number 
of admissions during PRONUT study up to current follow up. A sibling control was sought for 
every case child recruited, however not all cases had siblings, some didn’t have any siblings 
within the eligible age range (4-15 years), and some had siblings who were not available or 
declined to take part, hence there is a slight disparity between number of cases and number of 
siblings. A community control was sought for every recruited case child; number of families who 
had an eligible control child but declined to take part was not recorded. Some case children live in 
very rural communities where locating a community control family that would consent was 
difficult. Many potential community control families had no experience of study participation and 
no history linking them to the NRU at QECH, hence they were more difficult to recruit than case 
families. Following recruitment, 11 sibling controls and 11 community controls were excluded 
from analysis as they had been admitted for SAM in their lifetime. 217 sibling controls and 184 
community controls are included in the final analyses.  
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Figure 5: Recruitment flow diagram for case children in the cohort, starting with original recruitment in 
2006 (PRONUT)[88], followed by 1-year follow up (FuSAM)[97], and present follow up (ChroSAM).  
 
The number of children with a valid measure for analysis varies across all the outcomes. Carers 
and participants had the option to consent to some outcome measures but not others, some 
measures are effort-dependent (spirometry and physical function), and some variables required 
more cleaning of implausible results than others. Details of the number of readings removed due 
to data cleaning can be found in each of the relevant results chapters. Spirometry results have a 
particularly complex cleaning process, hence a specific flow diagram for spirometry outcomes can 
be found in Chapter 7. A summary of the number of participants included in analysis for all of 
the main outcomes can be seen in Table 5.   
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 Cases Sibling  
Controls 
Community 
Controls 
Total children 
Recruited 
(reported 
health) 
320 
(309 well, 11 
sick) 
217  
(215 well, 2 sick) 
184 
(182 well, 2 sick) 
721 
HAZ  299 203 159 661 
WAZ 215 94 117 426 
Sitting height  292 198 151 640 
MUAC 302 204 159 664 
Head 
circumference 
302 203 159 664 
Waist 
circumference 
301 203 157 661 
BIA 295 197 151 643 
Skinfold 
thicknesses 
280 187 141 608 
Handgrip 
strength 
298 199 154 651 
iStep exercise 
test 
222 149 126 497 
Accelerometer 
data 
44 36 41 121 
Spirometry 
FEV1Z 
(failed traces) 
199 
(+38 fails) 
142 
(+22 fails) 
121 
(+10 fails) 
462 
Spirometry 
FVCZ 
(failed traces) 
186 
(+51 fails) 
138 
(+26 fails) 
115 
(+16 fails) 
439 
Table 5: Number of participants included in analysis for each of the main outcomes 
3.1.1 Missing data 
It is important to consider whether missing data could be biasing study results. The main reasons 
for missing data in this study are children who died before follow-up, and children who could not 
be located. Minor reasons for missing data specific to each outcome are discussed in the relevant 
results chapters. Missing data due to deaths in the cohort group could result in survivor bias, 
discussed below. Most of the potential bias resulting from missing data cannot be identified 
however it is possible to explore whether there are common factors among the missing data which 
could suggest that their absence may be biasing results. Deaths and loss to follow-up during 
PRONUT and FuSAM studies have already been explored[87]. 
Some variables of those lost to follow up are available from baseline (PRONUT) study. When 
comparing those included (n=320) and those lost to follow up over the whole study period 
(n=190), I found that those lost to follow-up are significantly younger, less likely to be orphans, 
less likely to have parents who have divorced, less likely to have HIV positive mothers and less 
likely to have mothers or fathers with no education. These results suggest that those lost to follow 
up might be more affluent than those included. See numbers in Table 6. Although urban/rural 
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status was not collected, it was noted by the study team that those in rural areas were easier to 
locate than those in more densely populated urban areas as urban dwellers are less likely to know 
their neighbours and more likely to move often due to rent prices. It is possible that those lost to 
follow up are slightly more affluent and more urban.  
3.1.2 Other Bias 
As 46% (476/1024) of the original cohorts are known to have died, survivor bias is an important 
consideration for this study. If those who have died have systematic differences to those who 
survived, our case group could be misrepresenting the long-term effects of SAM. Kerac 
previously explained that those who died between admission and 1 year post-discharge were more 
likely to have marasmus than kwashiorkor, were more wasted and stunted on admission, were 
more likely to be HIV positive and were more likely to have a disability[87]. Cases who have died 
since the 1-year follow up (n=46) are more likely to be HIV positive and previously contracted 
TB than those in the survivors’ case group. They are also more likely to have HIV positive 
mothers, mothers who have died, mothers without secondary education, and shorter and thinner 
mothers. This suggests survivor bias may be masking some of the long-term effects of SAM as 
the most malnourished, least healthy and those with the poorest maternal health have not 
survived.   
Selection bias could also be affecting our community control group as it is possible that those 
who chose to participate differ systematically from those who declined. I cannot assess this as I 
do not have data on those who declined but I can speculate that they may be different in SES or 
health status; it may be that those who chose to participate have had some experience of hospital 
care and were therefore less wary than those who are healthy and therefore never had dealings 
with the QECH.  
Age is an important variable, particularly when calculating anthropometric z scores. Recall error 
is likely to be affecting reported age of the participants; however this only constitutes recall bias 
if it is systematic in one direction or differentially affects one study group over another. As age 
was reported both at admission and during this follow-up for the case group, I could compare the 
reported ages for systematic error. 28/320 cases had a reported age that was more than 6 months 
different to the original reported age; 17 had increased in age since admission and 11 had 
decreased. Although the original age reported at admission is likely to be more accurate as it is 
temporally closer to the child’s date of birth, I ran all analysis with the ChroSAM reported ages as 
any recall error affecting these is likely to equally effect the control’s reported ages as well.    
Lastly, due to the data collectors not being blinded to the case/control status of the participants, 
observer bias could be affecting the results. The data collectors may have unconsciously 
influenced the participants or unconsciously alter measurements, differentially for cases and 
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controls. This is unlikely to have affected anthropometric outcomes as 2 operators had to take 
independent measures; it is also not very relevant for BIA readings which are largely objective 
and also accelerometer data where operators were not present during measurement. Observer bias 
could be relevant for hand grip strength, iStep test and spirometry where varying levels of 
encouragement or subtle subconscious differences in behaviour towards the case children could 
affect their performance differentially to controls.  
3.1.3 Study group Demographic and Health Characteristics 
The background characteristics of the cases, sibling controls and community controls are 
presented in Table 6. The sex ratio and birth order are similar across the groups; the ages of cases 
and community controls are similar but sibling controls are older on average. Regarding clinical 
history, more cases are HIV positive and have a history of TB than controls, and cases are more 
likely to have visited a health clinic in the past 6 months. Regarding other hospital admissions 
beside SAM, this is actually slightly higher for community controls than cases. Perhaps this 
reflects the type of community control recruited i.e. those more likely to seek medical care or 
have medical issues, or perhaps it just reflects the high rates of morbidity among all children in 
the community. 
Education variables are not significantly different across the groups, but cases and siblings come 
from more disadvantaged families than community controls. Cases are more likely to be orphans 
or come from single parent families than community controls and have mothers with smaller 
MUAC and lower BMI. Mothers of SAM survivors are not more stunted than other mothers in the 
community, as might be expected. There is no significant difference in prevalence of poor 
maternal mental health between the cases and controls, but community controls are more likely to 
live in families subject to domestic violence than case children.   
Reported home environment is similar across the groups, but cases come from slightly lower 
socioeconomic background than community controls. Smoking during pregnancy is a risk factor 
for poor growth and greater NCD risk signs in children, however reported foetal tobacco exposure 
in this sample was very low, with less than 1% (4/526) of mothers smoking during pregnancy and 
no significant difference between case and control groups[208].  
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 Cases  
(n=320)  
ChroSAM 
deaths 
(n=46) 
Sibling 
controls 
(n=217) 
Community 
controls  
(n=184) 
Cases Lost to 
Follow Up 
(190) 
Basic 
Demographics 
     
Median age 
/would be age 
(years) 
9.3 (range 7.4 
– 20.1 ) 
10 (range 
8.1 – 16) 
10.9 (range 4 
– 15.6) 
9.1 (range 5.1 
– 15.1) 
 
8 (range 7 - 
19) 
Males (gender) 174 (55%) 
 
28 (57%) 106 (49%) 96 (52%) 108 (57%) 
Median Birth 
Order 
2 (IQR 1-4) 3 (IQR 1-9) 2 (IQR 2-3) 2 (IQR 1-3) 2 (IQR 1-3) 
Clinical 
History  
     
HIV       
  Seropositive 90/320 (28%) 25/46(53%) 9/217 (4%) 5/184 (3%) 44/190(23%) 
  Seronegative  208/320(65%) 20/46 
(43%) 
130/217(60%) 95/184 (52%) 121/190(64%) 
  Unknown   22/320 (7%) 1/46 (2%) 78/217 (36%) 84/184 (46%) 25/190 (13%) 
History of TB 18/317 (5.7%) 4/38 (11%) 1/215 (0.5%) 1/179 (0.6%) 4/173 (2%) 
History of 
pneumonia 
admissions 
10/317 (3%) /// 15/213 (7%) 9/180 (5%) /// 
Ever admitted 
to hospital 
(except SAM) 
70/318 (22%) /// 53/213 (25%) 54/180 (30%) /// 
Visited 
outpatient clinic 
in past 6 months 
115/315 
(37%) 
/// 56/214 (26%) 51/179 (28%) /// 
Education      
School grade 
achieved 
(median) 
2 (IQR 2-3) /// 3 (IQR 1-5) 3 (IQR 2-4) /// 
Didn’t attended 
school this 
year(>5.9yrs) 
21/315 (7%) /// 18/196 (9%) 9/176 (5%) /// 
Receive school 
meals  
206/313 
(66%) 
/// /// 120/173 
(69%) 
/// 
Family       
Mother died 51/303 (17%) 11/30 
(37%) 
 
/// 4/160 (3%) 8/159 (5%) 
Father died 59/286 (21%)  /// 9/151 (6%)  
Orphaned 
 
34/334 (10%) 6/31 (19%) /// 2/160 (1%) 0/190 (0%) 
Parents 
separated 
141/280 
(50%) 
7/14 (50%) /// 59/172 (34%) 25/139(18%) 
Mother HIV 
positive 
83/222 (37%) 10/20 
(50%) 
/// 23/135 (17%) 23/81 (28%) 
Mother’s age 
(median) 
32 (range 18-
62) 
34 (range 
28-47) 
/// 30 (range 19-
50 
/// 
Maternal 
Height cm 
(mean) (SD) 
 
 
156.9 (5.7) 155.5 (3.1) /// 156.4 (5.9) /// 
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Maternal  
MUAC mm 
(mean) (SD) 
271 (39) 260 (21) /// 282 (41) /// 
Mother’s BMI 
(mean) (SD) 
22.9 (4.1) 21.8 (2.3) /// 23.6 (4.3) /// 
Parity~ 
(median)  
3 (IQR 3-5) 3 (2-4) /// 4 (IQR 3-5) /// 
Proportion of 
siblings died 
(mean) (SD) 
0.09 (0.2) 0.4 (0.3) /// 0.04 (0.1) /// 
Mothers victims 
of domestic 
violence 
58/257 (23%) 0/9 (0%) /// 46/135 (34%) /// 
Poor maternal 
mental health¥ 
73/275 (27%) 5/15 (33%) /// 52/155 (34%) /// 
Mother with no 
social support 
13/288 (5%) 0/11 (0%) /// 5/173 (3%) /// 
Home 
environment 
     
Exposed to 
tobacco smoke 
47/317 (15%) 5/35 (14%) /// 30/174 (17%) /// 
Cooking with 
solid fuel in the 
home * 
47/317 (15%) 2/35 (6%) /// 21/174 (12%) /// 
Unimproved 
toilet Ф  
244/315 
(77%) 
20/24 
(83%) 
/// 140/173 
(81%) 
/// 
Socioeconomic 
status 
     
Mother education     
     None 56/309 (18%) 5/14 (35%) /// 22/173 (13%) 13/155 (8%) 
     Primary 121/309(39%) 6/14 (43%) /// 65/173 (38%) 108/155(70%) 
     Secondary  132/309(43%) 3/14 (21%) /// 86/173 (50%) 34/155 (22%) 
Father with no 
education 
39/270 (14%) 3/13 (23%) /// 11/150 (7%) 5/122 (4%) 
Father 
unemployed 
120/255(47%) 6/9 (67%) /// 62/158 (39%) /// 
Lowest wealth 
asset quintile  
67/311 (22%) 3/24 (13%) 48/215 (22%) 30/174 (17%) /// 
Table 6: Characteristics of cases recruited, cases that have died since 1 year follow-up, sibling controls, 
community controls and cases lost to follow up. ~ parity defined as number of children in family alive; ¥ 
poor maternal mental health defined as SRQ score ≥7; * cooking smoke defined as cooking with wood or 
charcoal inside the home; Ф unsanitary toilet defined as open pit latrine or field or bush. /// indicates no 
data, largely because family characteristics for siblings were presumed to be the same as cases 
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3.1.4 HIV 
As HIV is likely to have a large impact on all study outcomes, HIV status in the sample warrants 
further description. Figure 6 shows the proportion of HIV positive, negative and unknown status 
children in each of the study groups and in those who died since 1 year post-discharge.  The 
proportion of HIV positive children in the case group is considerably larger than that in the sibling 
and community control groups, and the proportion with unknown status is considerable in the 
control groups as many families declined to be tested. Of the HIV positive children, 76/104 (70%) 
are taking both Cotrimoxazole (COT) and Antiretroviral medication (ARVs). 11/104 (11%) have 
taken COT but not ARVs, and 6/104 (6%) have never taken COT or ARVs. Of those taking 
ARVs, only 50/76 (66%) report not having missed any doses of ARV in the past 3 months.  A 
small number of families reported problems taking COT (5/87) or problems taking ARVs (6/76); 
reasons for these problems included the child being too sick to go to collect the medication, the 
mother being too busy to collect the medication or the medication being out of stock. Particularly 
for ARVs, problems also included the child refusing the medication, the medication tasting bad 
and/or being difficult to swallow and there being no food to take medication with.    
 
 
Figure 6: Graph showing proportion HIV positive, negative and unknown status children in each of the 
study groups as well as in those who have died since 1 year post-discharge.   
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3.2 Mortality 
This section explores the mortality of the case group across the different follow-up periods. I am 
describing mortality here rather than in the main results section as it is very difficult to conclude 
whether the mortality rate found is higher or lower than the normal population rate without a 
control group; only rough estimates can be made.  
  
 Mortality between the 1 year follow-up (FuSAM) and the present follow-up was not expected to 
be high as mortality rates after 2 years of age generally drop compared to younger children, and 
because so many of the cohort had already died, suggesting that those that remained were the 
healthier ones. Since admission and 1-year post-discharge, a total of 42% (427/1024) of the cohort 
had died. Mortality was highest during initial inpatient treatment where 238 of the 427 deaths 
occurred (56%). Of the 427 deaths, 62% were HIV positive and 17% HIV negative, as previously 
described [97]. After the high mortality on the ward, the death rate has continued to decrease with 
increased time since discharge. Of the 398 children who were found during this 7 year follow-up, 
46 had died since FuSAM (12%). Of the 46 deaths, 25 (51%) were HIV positive, 10 (22%) had a 
disability, and 11 (24%) had neither HIV nor a disability; Appendix 11 shows pie chart of all 
known causes of ChroSAM deaths. Figures 7a and 7b show Kaplan Meier Time-to-death curves; 
they are extended versions of the curves published after the 1-year follow up[97]. The tables 
below the curves show numbers at risk at the beginning of each period. With this denominator 
change, the y-axis is mortality probability rather than percentage. The steep initial slope of the 
curve highlights that probability of death was highest within 1 month of admission, and continued 
to rise until 2 years post-admission. Time-to-death curves by HIV status (Figure 7b) highlight the 
significant adverse impact of HIV; deaths in the HIV negative patients slow significantly soon 
after admission but continued to rise more sharply for those in the HIV positive group, even as 
long as 8 years post-admission. The likely explanation for the step up in deaths around 90 months 
post-admission in recall bias with regard to date of death.  
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The difficulty in analysing mortality is assessing whether those children who died between 1 and 
7 years post-discharge are excess mortality over and above background rates, or whether 
statistically some were going to die anyway. Without following a control group, I can only refer 
to national mortality rates in order to try to estimate this. WHO life tables for Malawi in 2012 
show mortality rate in children aged 1 to 4 years is 0.007, and aged 5 to 9 years is 0.003[209].  
These are age-specific death rates (nMx) where: 
x: exact age at beginning of interval 
M: number of deaths 
n: width of the interval (in years) 
 
 
Age-specific death rate is calculated as: 
The number of deaths in a year to persons between exact ages x and x+n 
The number of person years lived by the population between exact x and x+n in the same year 
 
By focussing on specific years, for example 2011, I calculated how old all the case children would 
be in 2011 (removing any who died before that year) and then calculated the person years for all 
those who were between 5 and 9 years in 2011. Then I divided the number of deaths between ages 
of 5 and 9 in 2011 by the number of person years. However, due to small numbers, there is 
relatively large variation in the number of deaths each year; resulting in mortality rate between 
0.05 and 0.002 from 2008 to 2013. Mean mortality rate across the period is 0.014, significantly 
higher than national rate of 0.003 for that age group; the highest death rate is at the start of the 
period (i.e. 2 years post-discharge). Graph of mortality rate across ChroSAM follow-up years can 
be seen in Appendix 12.  
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Figure 7a: Kaplan Meier time-to-death curve for whole sample since admission with SAM. Curves show 
probability of death, table below graph shows number of children at risk across each period 
	
 
Figure 7b: Kaplan Meier time-to-death curves by HIV status since admission with SAM. Curves show 
probability of death, table below graph shows number of children at risk across each period 
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3.3 Original Synbiotic/Control groups 
The original cohort arose from a randomised control trial testing the benefits of providing 
synbiotics to SAM suffers during treatment (PRONUT study)[88]; the probiotics were found to 
have no effect and therefore the synbiotic group and control group were combined to form this 
cohort. It is prudent to check whether the original synbiotic group remains different to the original 
control group. I explored differences in mortality and nutritional status for the two original 
groupings within the SAM survivors. Time-to-death curves in Figure 8 show that there is still no 
significant difference in survival between synbiotic and original control group.  Equally there is 
no significant difference in HAZ, WAZ and BAZ at 7 years post-discharge between synbiotic and 
original control groups; results in Table 7.  
 
Figure 8: Kaplan Meier time-to-death curves by original synbiotic/control status 
	
	 Original	control	
group	n=131	
synbiotic	group	
n=148	
	 Mean	(SD)	 Mean	(SD)	 Unadjusted	
difference	 (95%	
CI)	
Adjusted	
difference	(95%	CI)	
WAZ	 -1.44	(0.9)	 -1.63	(1.0)	 -0.19	(-0.5,	0.1)	 -0.18	(-0.4,	0.1)	
HAZ	 -1.77	(1.1)	 -1.84	(1.3)	 -0.07	(-0.4,0.2)	 -0.06	(-0.3,	0.2)	
BAZ	 -0.85	(0.9)	 -0.86	(1.0)	 -0.01	(-0.2,	0.2)	 -0.04	(-0.3,	0.2)	
Table 7: Means and differences for WAZ, HAZ and BAZ for the original controls and case groups in the 
PRONUT study.  Adjusted differences include HIV status and SES in the regression model. No differences 
have a p value <0.05.  
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3.4 Questionnaire Repeatability  
Due to constant time pressures and unique requirements of each and every family, repeat 
questionnaires were only completed for 14 participants. I used Cohen’s kappa, a measurement of 
agreement between repeat measures, to assess questionnaire repeatability[210]. Means, kappa and 
kappa interpretation are presented in Table 8 for a range of variables. Kappa is the amount by 
which agreement exceeds chance, divided by the maximum possible amount by which agreement 
could exceed change. Perfect agreement is kappa=1, no agreement is kappa=0. Landis and Koch 
(1977) set cut-off values for kappa in order to define agreement as poor, fair, moderate, good and 
very good[211]. Sex, birth order, history of TB, HIV status, school achievement and sight 
impairments all had perfect or very good agreement between first and second questionnaires. 
Mother’s and father’s occupation had relatively low agreement, likely reflecting a poorly designed 
question with overlapping response options, for example a mother can be both “unemployed” and 
a “housewife”. Questions about children’s behaviour in the Disability screening questionnaire 
only had fair or moderate agreement.    
Variable 
 
Mean (SD) 
1st time 
Mean (SD) 
2nd time 
Kappa 
(k) 
Kappa 
interpretation  
Sex 1.36 (0.5) 1.36 (0.5) 1.00 Perfect agreement 
Birth order 2.21 (1.5) 2.29 (1.5) 0.90 Very good agreement 
Started puberty? 1.92 (0.3) 1.86 (0.4) 0.63 Good agreement 
Number of outpatient 
visits in past 6 months 
1.36 (2.8) 0.43 (0.8) 0.44 Moderate agreement 
History of TB? 2 (0) 2 (0) 1.00 Perfect agreement 
HIV status 1.6 (0.5) 1.3 (0.5) 1.00 Perfect agreement 
Highest level of school 
achievement  
3.43 (2.6) 3.36 (2.6) 0.91 Very good agreement 
Ever experienced 
domestic violence? 
1.4 (0.5) 1.6 (0.5) 0.67 Good agreement 
Fathers occupation 2 (1.5) 1.5 (0.8) 0.23 Fair agreement 
Mothers occupation 3.33 (3.0) 4.67 (3.5) 0.10 Poor agreement 
Does child have 
difficulty seeing? 
1.1 (0.3) 1 (0) 0.91 Very good agreement 
How much difficulty 
does child have 
completing a task? 
1.4 (0.6) 1.3 (0.7) 0.43 Moderate agreement 
How much difficulty 
does child have 
controlling their 
behaviour? 
1.5 (0.8) 1.5 (0.9) 0.27 Fair agreement 
Table 8: Results of questionnaire validity analysis, including means for each repeat, Cohen’s kappa and 
kappa interpretation as published by Landis and Koch[211].  
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4 Chapter 4: Growth and Anthropometric Status 
 
This chapter presents specific methods and results for the first of the four areas of outcome 
presented in this thesis: long term effects of SAM on growth. Following a description of the 
anthropometric methods, the results are presented starting with growth of the whole sample 
followed by the main results comparing growth outcomes of cases to controls. The longitudinal 
results for sibling controls and cases between 1 and 7 years post-discharge are then presented 
followed by an exploration of HIV and growth, factors at admission which predict poor growth 
outcomes and association between reported birth size and growth outcomes.      
	
	
4.1 Chapter-specific Hypotheses 
As mentioned in the Chapter 1: Background, growth is an important determinant of both short- 
and long-term health and quality of life[84, 96]. During the one year follow-up of this cohort, 
survivors were found to be significantly more stunted that their siblings[97], hence linear growth 
is a major outcome being considered during this current follow-up. Additionally, the “Thrifty 
Phenotype” hypothesis postulates that essential growth, such as head and core body, is preserved 
in the place of less-essential growth, such as limbs[40, 110]. Hence another area of exploration for 
this study is analysis of sitting height, leg length and head circumference, as evidence for “Thrifty 
Growth”. Hypothesis one and two relate to the growth outcomes being explored in this chapter, 
and are restated below: 
1. Compared to controls, SAM survivors have impaired linear growth, specifically 
a. Smaller HAZ 
b. Shorter leg length 
c. But preserved head circumference 
 
2. Compared to sibling controls, linear growth velocity is continuing at normal rates 
resulting in no catch-up growth since 1 year post-discharge.  
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4.2 Specific Methods  
4.2.1 Anthropometry 
Weight: weight was measured using Marsden digital medical weighing scales (Marsden 
Weighing Group, UK). The children were measured without their shoes and any heavy clothing, 
standing in the centre of the scales with their hands by their sides. Measurements were recorded to 
the nearest 0.1kg.  
Height: to measure the child and parent’s standing height, a Leicester Height Measure was used 
(Marsden Weighing Group, UK). Shoes and hair ornaments were removed and the participant 
stood straight with their feet flat on floor, their heels against the heel plate and their head 
horizontal in the Frankfurt plane (Figure 9). Prior to recording the measurement, the participant 
was asked to breathe in and then relax. The headboard was adjusted on expiration and 
measurement taken. The measurements were recorded to the nearest 0.1cm.  
 
	
Figure 9: Image illustrating the Frankfurt plane which is used to position the head during height measures 
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Sitting height: The child was seated on the specially designed stool which accommodates the 
base of the Leicester Height Measure and has adjustable foot rests (Image 4). The child’s spine 
and bottom were touching the stadiometer backboard and their feet were on the footrest so that 
their hips were at right angles and their thighs horizontal with the floor. As with standing height, 
the child was asked to breathe in and relax and the measurement was taken while the child 
exhales, recorded to the nearest 0.1cm.  
 
	
Image 4: Specially-designed stool for measuring sitting height; the Leicester Height Measure base fits onto 
the top of the stool for sitting on and there are adjustable foot rests to ensure the child’s thighs are 
horizontal with the floor 
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Head circumference: A Rollfix Hoechstmass measuring tape was used for all circumferences. 
Hair ornaments were removed so that any hair could be compressed close to the skull and the 
child stands with their head in the Frankfurt plane. The tape goes around the head so that it rests 
on the fore head just above the eyebrows, and at the widest point of the curve at the back of the 
head (occipital bone). The measurement was recorded to the nearest 0.1cm. 
 
	
Image 5: Measuring head circumference at a participant’s home (written permission was obtained from 
subjects for all photographs featuring children in this thesis) 
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Lower limb length: this was measured with the child siting on the ‘sitting height stool’ so that 
their feet were resting on the appropriate footrest in order to have their thighs perpendicular to the 
floor. Using the Leicester Height Measure, the feet were placed on the base of the stadiometer and 
the headboard bought down to rest on the child’s right thigh, just above the knee. This measures 
the distance between the top surface of the thigh (above the condyles of the femur and about 4cm 
above the patella) and the bottom of the foot, as seen in Figure 10. The measurement was 
recorded to the nearest 0.1cm. 
 
	
Figure 10: Diagram illustration distance measured for lower limb length, source: CDC anthropometry 
procedures manual[212] 
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Mid-upper arm circumference (MUAC): MUAC was measured using specifically designed 
‘MUAC tapes’ produced by Teaching Aids at Low Cost (TALC). MUAC was measured on the 
left arm, while the arm was straight and relaxed, and the reading recorded to the nearest 1mm. 
The midpoint of the upper arm was located by measuring the distance the acromion process and 
the olecranon process, while the arm was held across the stomach with the elbow bent at 90 ̊.  
 
	
Image 6: Measuring MUAC of a participant at their home using a TALC MUAC tape. 
	
4.2.2 Sample Size Calculations 
As already mentioned, the sample size available for this study was constrained by the number of 
children available from the initial cohort recruitment. Based on actual sample size and using 
evidence from previous studies, I calculated power for the primary outcomes. Statistical power is 
the likelihood of detecting an effect if one does exist; greater power reduces the chance of 
erroneously accepting the null hypothesis when it is actually false (type II error). Sample size was 
calculated using Stata “sampsi” command.  
 
The 1-year FuSAM study found a difference in WAZ of 0.55 and HAZ 1.13 between cases and 
sibling controls[97]. With our sample size for WAZ being 215 cases and 94 siblings, based on the 
difference seen in the FuSAM study, the comparison of the means is powered to 95% with 
significance level at 5%. Our HAZ sample size is also sufficiently powered based on FuSAM 
findings; comparing 299 cases and 213 siblings is powered to 100% at 5% significance level. For 
a more conservative estimate, I used the results of a meta-analysis by Richard et al. comparing 
HAZ of children with an incidence of wasting to those without; they found a range of differences 
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in HAZ, particularly depending on the age of the wasting insult[85]. The mean difference they 
found was 0.75 z scores, which is still detectable at 100% power with our sample size. 
 
4.3 Analysis  
Following brief presentation of the growth for the sample as a whole compared to the global 
norm, the Primary analysis is presented which firstly compared sibling and community controls 
to cases using regression analysis for:  
• Weight 
• Height (including sitting height and leg length) 
• Nutritional z scores (WAZ, HAZ & BAZ) 
• Mid-upper arm circumference (MUAC) 
• Head circumference  
These are all continuous outcomes hence simple and multivariable linear regression analysis was 
used to compare cases and both types of control. WAZ, HAZ and BAZ are the 3 standard 
indicators of nutritional status currently recommended by the WHO, each indicating different 
elements of nutrition and each with its own limitation. Potential confounding factors were 
adjusted for in multivariable linear regression; namely HIV status, age, sex, puberty and SES, 
based on a priori assumptions. A conceptual framework of potential confounders is depicted in 
Figure 4a, Chapter 2. Age and sex are included in multivariable regression analysis of z score 
outcomes as these z scores are generated from an external reference and scores are known to 
change across ages and sex. 
Children with disabilities were considered for exclusion from analysis as some disabilities, such 
as cerebral palsy, can have large impacts on growth. However I decided to keep these children in 
the analysis (where accurate measures could be taken) in order to make the results of this study as 
generalizable to “SAM survivors” as possible. Much SAM does coincide with disability; hence it 
is important to consider the long-term outcomes of all children in the group.  
Analysis of longitudinal WAZ, HAZ and BAZ data for case children and sibling controls also 
forms the second part of the primary analysis. Basic anthropometry of all siblings was measured 
during FuSAM study; by matching birth order I was able to link FuSAM sibling anthropometry to 
the sibling control selected in this follow-up. Some data is missing hence sample size for siblings 
with longitudinal data is 69. Change in nutritional z scores between 1 year and 7 years post-
discharge are calculated for case children only and repeated measures ANOVA was used to 
compare whether z score changes of the cases is significantly different to z score changes of the 
sibling controls. As with any ANOVA, repeated measures ANOVA tests the equality of means; it 
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is used when members of a random sample are measured under a number of different conditions, 
in this case the WAZ, HAZ and BAZ are measured at different follow-up points.  
Secondary analysis considered the impact of HIV and birth weight on growth as well as factors 
at admission which might predict poor growth at 7-years post-discharge, namely severity of 
stunting and wasting at admission, presence of oedema, time taken to recover and age at 
admission for case children only. Using linear regression, cases with different admission 
characteristics were compared to each other and in addition the two groups of cases were also 
compared to the control groups combined. Comparing the outcomes of the cases to each other 
internal is interesting but may not be relevant to the wider community; hence both types of 
comparison were conduct. For example, if the HAZ of those with oedema at admission and those 
without oedema at admission is compared, I may find that one group are significantly more 
stunted than the other. However if I then compare these two groups to the controls, I may find that 
in fact both groups are still more stunted than controls, so the applicable difference of oedema at 
admission compared to other children is minimal.  
4.3.1 Data Cleaning & Z scores 
In order to check for erroneous data among the anthropometric measures, I plotted scatter graphs 
of each variable against age and height, and checked each of the outliers for notes on their paper 
files. Some files had notes confirming or correcting readings, for example noting if a child was 
particularly stunted.  Highly improbable readings without explanation were removed from 
analysis. Following this, WHO Anthro Plus software was used to calculate weight-for-age 
(WAZ), height-for-age (HAZ) and BMI-for-age (BAZ) z scores, based on the WHO 2007 Growth 
Reference for 5-19 year olds (http://www.who.int/growthref/en/). The WHO reference was 
created using Box-Cox power exponential methods on data from 22 countries[213]. These 
references replaced the 1977 National Centre for Health Statistics (NCHS) growth references. As 
the WHO reference was yet to be released, the previous studies of this cohort, PRONUT and 
FuSAM, reported results using the NCHS reference. I have recalculated the z scores using 
admission, discharge and follow-up anthropometry into WHO z-scores in order to compare 
growth across the whole timespan of the cohort. Anthro Plus uses default values (Table 9) to flag 
extreme z scores which may be erroneous. I used these flags to identify further anomalous values, 
and again checked the paper files for notes. Those readings outside of the range in the table, 
without explanation, were removed. Some values beyond this range were allowed to remain in 
analysis as they were verified to be correct. The number of values which needed to be removed 
was low; 3 readings of height were excluded and sitting height had 5 values excluded. Figure 11 
shows two scatter plots for height against weight, before and after data cleaning; outlying values 
were either corrected or removed. 
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Beside anthropometry, date of birth (DOB) is another variable which is fundamental to z score 
calculations. There is no way of checking whether DOB is correct for sibling and community 
control children, however a method of cross checking age and DOB was implemented during data 
collection to try minimise errors. For case children I was able to check that all dates of birth were 
feasible by comparing them against date of admission for malnutrition; no case children had a 
reported DOB post admission date. There were some discrepancies between DOB reported during 
PRONUT study and our follow up, as already discussed in Chapter 3, Section 3.1.2 Bias.  
Indicator Lower SD Upper SD 
WAZ -6 +5 
HAZ -6 +6 
BAZ -5 +5 
Table 9: WHO standards for flag of extreme z score results 
 
Figure 11: Scatter plots of height against weight; left hand plot is before data cleaning, right hand plot is 
after data cleaning. Notably some anomalies have been corrected or removed during cleaning.  
4.3.2 Calculations and Statistics 
Much of the analysis for growth was not of raw anthropometry but rather ratios and relative 
measures. Z scores were used to normalise the data, wherever reference tables were available, as 
described above. Besides z-scores, the following calculations were also applied to anthropometric 
growth data: 
  
• Sitting height percentage = (sitting height / height)*100 
• BMI = weight(kg) / (height(m))2 
• Lower Limb Length Ratio = lower limb length / height 
• Leg Length = height – sitting height 
• Relative Leg Length = height-adjusted standardised residuals of leg length   
Relative leg length was calculated by regressing leg length by sitting height to obtain the 
regression residual. This was then divided by the standard error of the estimate of the regression 
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equation to obtain height-adjusted standardised residuals. This method eliminates the need for z 
scores based on reference tables and the need to divide leg length by height when leg length has 
already been calculated based on height. Raw values of MUAC and head circumference were 
used in this analysis as growth curves show very little increments in either head circumference or 
MUAC from 2 to 11 years of age[214, 215].  
4.4 Results 
4.4.1 Missing Data 
Besides deaths and loss to follow-up (already described in Chapter 3, section 3.1.1), the most 
significant missing data to mention for the growth outcomes is WAZ. WAZ in all children above 
10 years of age is missing as the WHO 2007 growth reference, although range up to 19 years old 
for HAZ and BAZ, only extends to 10 years of age for WAZ.  The WHO states that WAZ is not a 
good indicator in children above 10 years of age as it cannot distinguish between height and body 
mass in an age period where many children are experiencing the pubertal growth spurt and may 
appear as having excess weight using this measure, when in fact they are just tall[213]. There is 
no significant difference in amount of missing WAZ values between cases and community 
control, however there are significantly more missing WAZ values for sibling controls (p<0.001) 
as they are older on average than cases.  
Erroneous data entry or measurements resulted in a very small amount of missing data for some 
anthropometry variables, as did children refusing to cooperate or children not attending the 
hospital appointments. For example, HAZ, had no significant difference in the prevalence of 
missing values between cases and siblings but there were significantly more missing values for 
community controls (p=0.006) due to a greater number of missed hospital appointments among 
community controls.  
For a full table of number of results for each outcome variable see Table 5 in Chapter 3: Section 
3.1 
 
4.4.2 Growth: Whole Cohort 
The distributions of WAZ, HAZ and BAZ for the whole sample are shown in Figure 12. 
Although the sample is normally distributed, the majority of the children, including controls, have 
growth indicators below the global norm (z score 0) based on the WHO 2007 growth reference. 
BAZ is closest to global norm, followed by WAZ and then HAZ. Table 10 shows proportion of 
each group with low (<-2) WAZ, HAZ and BAZ. There was no significant difference in z scores 
between the sexes within the study groups.  
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Histograms for each of the growth outcomes for the cohort as a whole can be found in Appendix 
13. 
 
% with low: Cases Sibling controls Community controls 
WAZ 33% (71/215) 23% (22/94) 21% (24/117) 
HAZ 41% (123/299) 33% (68/203) 25% (39/159) 
BAZ 9% (26/297) 11% (23/203) 8% (12/159) 
Table 10: Proportion of children with low (<-2) WAZ, HAZ and BAZ in each study group 
 
 
 
Figure 12: Frequency distribution for WAZ, HAZ and BAZ for the whole sample 
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4.4.3 Growth of Controls vs Cases 
I hypothesised that cases would have impaired growth as compared to controls due to disrupted 
development during their episode of SAM and subsequent adaptations. Compared to controls, 
even in this group of healthy survivors, children who have had SAM have some compromised 
growth at 7 years post-discharge. 	
Table 11 shows means for each growth measurement and study group, and the results of both 
simple and multivariable linear regression analysis. In summary, the following growth outcomes 
are significantly smaller for cases than both sets of controls in adjusted analysis (p<0.05):  
• weight 
• standing height 
• leg length 
• relative leg length 
• lower limb length ratio 
• HAZ 
• MUAC 
Sitting height percentage is significantly larger for cases than both sets of controls. Interestingly, 
absolute sitting height is not significantly different between cases and controls, even though 
controls are significantly taller.  
There is a marginal difference in WAZ between case children and community controls, but not 
sibling controls after adjusting for potential confounders. There is a significant difference in BMI 
between cases and sibling controls, but when converted to BAZ, there is no significant difference 
between either of the groups. Figure 13 shows box plots for BAZ, HAZ and WAZ between the 3 
groups. There is no significant difference between cases and either of the groups for head 
circumference.    
Results are very similar when comparing HIV negative children only across the study groups, as 
can be seen in table in Appendix 14. There are a few differences worth mentioning; interestingly 
sitting height is significantly larger for both sibling and community controls compared to cases 
when looking at HIV negative children only but sitting height percentage is still significantly 
different between cases and community controls. Sibling controls also have significantly larger 
HAZ than cases when comparing HIV negatives only. These results indicate the negative effects 
that HIV is having on height, sitting height and sitting height ratio of the sibling controls. Case 
also have significantly smaller head circumference than community controls when looking at HIV 
negative children only. Head circumference is actually larger for HIV negative case group but 
confidence interval is smaller, affecting the p value. HIV may be masking some small differences 
in head circumference between cases and community controls due to larger range of measures.  
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Anthropometry	 Cases	 Sibling	 Community	
	 Mean	
(SD)	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)	
P	value	
Adjusted	
difference	
(95%	CI)	
P	value	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)	
P	value	
Adjusted	
difference	
(95%	CI)	
P	value	
Weight	 	 	 	 	 	 	 	
Weight	(kg)	 23.9	
(4.9)	
27.7	
(9.7)	
3.8	*		
(2.5,	5.0)	
<0.001	
1.9	*		
(1.0,	2.7)	
<0.001	
25.4	
(6.6)	
1.4	*	
(2.5,	5.0)	
0.04	
1.5	*		
(0.6,	2.4)	
<0.001	
BMI	 15.2	
(1.4)	
15.7	
(1.9)	
0.5	*	
(0.2,	0.8)	
<0.001	
0.3	*	
(0.0,	0.6)	
0.03	
15.4	
(1.7)	
0.2	
(-0.2,	0.5)	
0.31	
0.2	
(-0.1,	0.5)	
0.23	
Height	 	 	 	 	 	 	 	
Standing	(cm)	 124.9	
(9.0)	
130.3	
(16.8)	
5.3	*	
(3.1,	7.5)	
<0.001	
2.0	*		
(0.6,	3.4)	
0.006	
127.4	
(9.9)	
2.4	*	
(0.1,	4.8)	
0.04	
2.7	*	
(1.2,	4.2)	
0.001	
Sitting		(cm)	 65.2	
(4.4)	
67.4	
(7.6)	
2.2	*	
(1.2,3.2)	
<0.001	
0.6	
(-0.1,1.3)	
0.11	
65.9	
(4.5)	
0.8		
(-0.3,1.9)	
0.18	
0.7	
(-0.1,1.5)	
0.07	
Sitting	Height	%	 52.2	
(1.5)	
51.8	
(1.7)	
-0.4	*	
(-0.7,	-0.1)	
0.004	
-0.3	*	
(-0.6,-0.0)	
0.02		
51.8	
(1.5)	
-0.5	*		
(-0.8,-0.1)	
0.003	
-0.6	*		
(-0.9,-0.0)	
<0.001	
Leg	length	(cm)	 59.6	
(5.5)	
63.0	
(9.6)	
3.1	*	
(1.8,	4.4)	
<0.001	
1.4	*	
(0.5,	2.3)	
0.002	
61.6	
(6.0)	
1.7	*	
(1.8,	4.4)	
0.02	
2.0	*	
(1.0,	3.0)	
<0.001	
Relative	 leg	
length	
39.9	
(18)	
49.6	
(32.9)	
9.7	*	
(5.4,14.0)	
<0.001	
3.1	*	
(0.2,5.9)	
0.04	
44.0	
(19.2)	
4.0	
(-0.7,8.7)	
0.09	
4.1	*	
(1.0,7.2)	
0.01	
Lower	 limb	
length	ratio	
31.0	
(1.6)	
31.6	
(1.8)	
0.6	*	
(0.3,	0.9)	
<0.001	
0.5	*	
(0.1,	0.8)	
0.004	
31.5	
(1.6)	
0.5	*	
(0.1,	0.8)	
0.005	
0.5	*	
(0.1,	0.8)	
0.007	
Growth	Z	scores	 	 	 	 	 	 	
WAZ	 -1.6	
(0.9)	
-1.4	
(1.0)	
0.1	
(-0.1,	0.4)	
0.27	
-0.2	
(-0.5,	0.1)	
0.16	
-1.2	
(0.9)	
0.4	*	
(0.0,	0.5)	
0.002	
0.3		
(-0.0,	0.5)	
0.06	
BAZ	 -0.8	
(0.9)	
-0.8	
(0.9)	
0.03	
(-0.1,	0.2)	
0.71	
0.08	
(-0.1,	0.3)	
0.39	
-0.7	
(0.9)	
0.1	
(-0.0,	0.3)	
0.14	
0.1	
(-0.1,	0.3)	
0.31	
HAZ	 -1.8	
(1.2)	
-1.5	
(1.2)	
0.3	*	
(0.1,	0.5)	
0.01	
0.2	*	
(0.0,	0.4)	
0.04	
-1.3	
(1.1)	
0.5	*	
(0.3,	0.7)	
<0.001	
0.4	*	
(0.2,	0.6)	
<0.001	
Body	circumferences	 	 	 	 	 	 	
Head	(cm)	 51.1	
(2.1)	
52.1	
(2.5)	
0.4	*	
(0.0,	0.7)	
0.04	
0.1		
(-0.3,	0.5)	
0.37	
52.1	
(1.9)	
0.3	
(-0.1,	0.7)	
0.21	
0.3		
(-0.1,	0.8)	
0.12	
MUAC	(mm)	 172	
(20)	
183	
(29.8)	
10.9	*	
(6.7,	15.1)	
<0.001	
5.7	*	
(2.3,	9.1)	
0.001	
178	
(22)	
5.5	*	
(1.0,	10.1)	
0.02	
5.6	*	
(1.9,	9.4)	
0.003	
Table 11: Results of simple and multivariable linear regression analysis, comparing siblings and 
community controls to cases for each growth variable at 7 years post-discharge. Adjusted difference 
includes age, sex, HIV status, SES and puberty in regression model. * indicates p value less than 0.05. 
Sitting height % = sitting height/height*100; Relative leg length = regression residuals for leg length by 
sitting height; Lower limb length ratio = lower limb length/height  
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Figure 13: Box plots showing mean weight-for-age, height-for-age and BMI-for-age z scores for each of 
the 3 study groups: cases, siblings and community controls at 7 years post-discharge.   
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4.4.4 Longitudinal Growth Data 
Using growth data across four time points from admission to 7 years post-discharge for case 
children, results suggest that case children are catching up towards global norms for weight and 
height. The FuSAM study found very little improvement in HAZ from discharge to 1 year post-
discharge, however I have found a large relative improvement in HAZ from 1 year post discharge 
to 7 years post discharge, as seen in Table 12. Conversely, WAZ made large gains in the first 
year post-discharge but has since slowed. BMI-for-age deteriorated from 1 year post-discharge to 
present, due to the large gains in height not being matched by gains in weight. The differences in 
BAZ WAZ and HAZ across 3 time points are depicted as boxplots in Figure 14. Some studies 
have assessed catch up growth by comparing the change in proportion of stunting in the group 
over time[103]; in this study, at 1 year post-discharge 83% (249/299) children were stunted (HAZ 
<-2) while at 7 years post-discharge 41% (123/299) of the case children are stunted. We can 
compare these proportions to sibling controls where 46% (140/302) were stunted in 2006, and 
now 33% (68/203) of siblings are stunted.  
Using “spaghetti” plots focusing on those children who were in the smallest or largest 10% during 
admission, we can see that those starting from lower z scores have greater catch-up growth than 
those starting with less of a deficit. Figure 15 shows 3 spaghetti plots for WAZ, HAZ and BAZ 
across 5 time points: admission, minimum weight on the ward, discharge from OTP programme, 
1 year post-discharge and 7 years post-discharge. Although those with low z score have shown the 
most improvements, there are very few children who have crossed-over from smallest to largest 
and vice-versa. This suggests that those children who were small during admission have exhibited 
catch up growth but still remain relatively small at 7 years post-discharge  
	
	 Mean	 (SD)	
on	ward		
Mean	 (SD)	
discharge	
Mean	 (SD)	1	
year	p.d.	
Mean	 (SD)	7	
years	p.d.	
Difference	
discharge	 -
1year	
Difference	
1year	 	 –	 7	
years	
WAZ	 -3.76	(1.4)	 -2.63	(1.5)	 -1.75	(1.2)	 -1.56	(1.0)	 0.88	 0.19	
HAZ	 -3.24	(1.4)	 -3.31	(1.7)	 -3.28	(1.3)	 -1.82	(1.2)	 0.03	 1.46	
BAZ	 -2.67	(1.7)	 -0.73	(1.4)	 0.65	(1.4)	 -0.85	(0.9)	 1.38	 -1.50	
Table 12: Mean (SD) of WAZ HAZ and BAZ across 4 time points (on the ward, at discharge from OTP, at 
1 year post-discharge and at 7 years post-discharge) (p.d = post-discharge). Difference in z score between 
discharge and 1 year post-discharge, and difference in z score between 1 year post-discharge and 7 years 
post-discharge are also presented.   
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Figure 14: The differences in WAZ, HAZ and BAZ for cases across the 3 time points: at their minimum 
weight on the ward, at 1 year post-discharge and at 7 years post-discharge.   
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A) 	
B) 	
C) 	
Figure 15: Spaghetti plots showing changes in a) WAZ, b) HAZ and c) BAZ for individual children from 
admission, at minimum weight during admission, discharge from OTP programme, 1-year post-discharge 
and 7-years post discharge. This is for the smallest 10% and largest 10% at minimum weight on the ward 
only.  
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4.4.5 Longitudinal Data: Comparing Growth of Cases with Sibling Controls 
As some sibling controls were recruited at 1 year post-discharge, I could compare the changes in 
WAZ, HAZ and BAZ of cases to siblings between 1 year and 7 years post-discharge. Results of 
“repeated measures ANOVA” show that there is both a significant difference in HAZ and BAZ 
within each study group between 1 year and 7 years post-discharge (p<0.001 for both), and more 
importantly, sibling controls have significantly larger HAZ, BAZ and WAZ than cases across the 
time periods (significant difference between the groups) (p <0.001, 0.02 and <0.001 respectively). 
Repeated measures mixed regression models can also be used in place of ANOVA, giving the 
same results; it confirms that the adjusted change in HAZ across the time points was 1.1 z-scores 
greater in cases than sibling controls, and change in WAZ was 0.9 z-scores greater (p<0·001 and 
<0·01 respectively). Figure 16 shows modelled means for HAZ and WAZ allowing us to see how 
means of sibling and case groups have changed between 1 year and 7 year post-discharge follow 
ups. Interestingly mean WAZ for siblings dropped slightly whereas cases have increased. Both 
groups have increased their HAZ though change in HAZ is steeper for cases than controls. It is 
important to note that although CIs on the graphs do overlap, this does not mean there is no 
significant difference between the groups; the CIs are for point estimates, not differences. This 
data suggests that cases are catching up their lost WAZ and HAZ at a faster rate than sibling 
controls.  
 
Figure 16: Modelled means for HAZ and WAZ for siblings and cases at 1 and 7 years post-discharge, 
including 95% confidence intervals. 
83 
	
4.4.6 Impact of HIV on Growth 
HIV has had a significant impact on growth in SAM survivors, particularly affecting the 
prevalence of stunting. Mean values and SD scores for anthropometric growth measures are 
presented in Table 13, stratified by study group and HIV status. Notice that the number of HIV 
positive children in the two control groups is small. The difference between HIV positive and 
HIV negative groups is most notable for HAZ (unadjusted difference -0.60, 95% CI -0.9 to -0.3, 
p<0.001). WAZ, BAZ, sitting height ratio, head circumference and MUAC show no significant 
difference between HIV positive and negative groups. Figure 17 shows mean HAZ for each study 
group stratified by HIV status; notice that HIV positive sibling controls actually have the lowest 
HAZ, which could be evidence of survivor bias.  
	 Cases	 Sibling	Controls	 Community	Controls	
	 HIV	positive	
HIV	
negative	
HIV	
positive	
HIV	
negative	
HIV	
positive	
HIV	
negative	
n	 90	 208	 9	 130	 5	 95	
WAZ	 -1.7	(1.0)	 -1.5	(0.9)	 -1.8	(0.3)	 -1.5	(1.1)	 -1.0	(1.9)	 -1.2	(1.1)	
HAZ	 -2.1	(1.2)	 -1.7	(1.2)	 -2.3	(0.7)	 -1.4	(1.2)	 -1.6	(0.6)	 -1.2	(1.2)	
BAZ	 -0.9	(0.9)	 -0.8	(1.0)	 -0.7	(0.5)	 -0.8	(0.9)	 -0.8	(1.4)	 -0.7	(1.0)	
Sitting	 height	
%	 52.3	(1.4)	 52.2	(1.5)	 52.4	(1.4)	 51.7	(1.7)	 49.8	(3.1)	 51.9	(1.3)	
Lower	 limb	
ratio	 31.0	(1.2)	 31.0	(1.8)	 30.0	(3.2)	 31.7	(1.7)	 32.9	(2.1)	 31.6	(1.1)	
Head	
circumference	
(cm)	
52.0	(1.8)	 51.7	(2.2)	 51.1	(1.2)	 51.9	(2.6)	 52.0	(1.2)	 52.0	(1.9)	
MUAC	(mm)	 174.3	(21)	 171.5	(19)	 168.9	(20)	 183.6	(33)	 171.8	(5.9)	 176.5	(23)	
Table 13: Mean values and SD scores for growth variables by study group and HIV status. Those with 
unknown HIV status are not included. Sitting height % = sitting height/height*100. Lower limb ratio = 
lower limb length/height.   
	
Figure 17: Bar graph showing mean HAZ by study group and HIV status at 7 years post-discharge 
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4.4.7 Predictors of Growth Outcomes 
Lastly, I explored factors at admission which might predict poorer growth outcomes at 7 years 
post-discharge. Table 14 presents raw data (means (SD)) for growth outcomes of children with 
different characteristics at admission.  Further analysis show that small WAZ, HAZ and BAZ at 
admission, no oedema and being older than 2 years at admission are associated with worse growth 
outcomes at 7 years post-discharge. Time taken to recover is not associated with 7-year growth 
outcomes. Reported birth size of cases is also not associated with any long-term growth outcomes 
except head circumference; results of these analyses are presented in more detail below.  
 
Mean (SD) WAZ 
 
HAZ BAZ Sitting 
height % 
Head 
circumferenc 
Degree of wasting at admission     
 Low WAZ <-4 (n=137) -1.85 (1.0) -2.17 (1.3) -1.06 (1.0) 52.3 (1.5) 51.6 (2.0) 
 High WAZ >-4 (n=160) -1.29 (0.9) -1.52 (1.0) -0.67 (0.8) 52.2 (1.5) 52.1 (1.7) 
Degree of stunting at admission     
 Low HAZ (<-3) 
(n=164) 
-1.87 (0.9) -2.28 (1.1) -0.93 (0.9) 52.2 (1.6) 51.7 (1.9) 
 High HAZ (>-3) 
(n=132) 
-1.21 (0.9) -1.23 (1.0) -0.72 (0.9) 52.3 (1.4) 52.1 (1.7) 
Kwashiorkor or wasting      
 Oedema (n=265) -1.49 (0.9) -1.79 (1.2) -0.79 (0.9) 52.2 (1.5) 51.9 (1.8) 
 No oedema (n=54) -1.82 (1.0) -2.00 (1.3) -1.10 (1.0) 52.3 (1.4) 51.8 (2.0) 
Time to recovery      
 <50 days (n=) -1.44 (0.9) -1.75 (1.2) -0.81 (1.0) 52.2 (1.5) 51.9 (1.8) 
 >50 days (n=) -1.76 (1.0) -1.95 (1.2) -0.92 (0.8) 52.4 (1.4) 51.7 (1.9) 
Age at admission      
 <2 years (n=157) -1.53 (1.0) -1.51 (1.1) -0.79 (0.9) 52.4 (1.4) 51.6 (1.9) 
 >2 years (n=142) -1.63 (0.9) -2.17 (1.2) -0.92 (0.9) 52.0 (1.5) 52.1 (1.8) 
Reported birth size      
 Small at birth (n=33) -1.70 (1.0) -1.73 (0.9) -1.10 (1.0) 52.1 (1.6) 50.8 (2.2) 
 Normal size at birth 
(n=332) 
-1.54 (1.0) -1.84 (1.2) -0.82 (0.9) 52.2 (1.5) 52.0 (1.8) 
Table 14: Means and standard deviations for main growth outcomes stratified by characteristics at 
admission 
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4.4.7.1 Degrees of Stunting and Wasting at admission 
Linear regression analysis confirms that degree of nutritional deficiency at admission is predictive 
of some growth measures at 7 years post-discharge, as seen in Table 15. The only exceptions are 
that BAZ during admission does not predict degree of stunting (HAZ) or head circumference 7 
years post-discharge, and neither WAZ, HAZ nor BAZ during admission predict sitting height 
percentage at 7 years post-discharge.  
 
	 	WAZ	during	admission	 	HAZ	during	admission	 BAZ	during	admission	
	 Adjusted	
difference	
(95%	CI)	
P	value	 Adjusted	
difference	
(95%	CI)	
P	value	 Adjusted	
difference	
(95%	CI)	
P	value	
WAZ	7yrs		
post-
discharge			
0.29		
(0.2,	0.4)	
<0.001*	 0.32	
(0.2,	0.4)	
<0.001*	 0.11	
(0.0,	0.2)	
0.009*	
HAZ	7yrs	
post-
discharge			
0.28	
(0.2,	0.4)	
<0.001*	 0.42	
(0.4,	0.5)	
<0.001*	 -0.01	
(-0.1,	0.1)	
0.73	
BAZ	7yrs	
post-
discharge			
0.21	
(0.1,	0.3)	
<0.001*	 0.11	
(0.0,	0.2)	
0.006*	 0.15	
(0.1,	0.2)	
<0.001*	
Sitting	 height	
%	
-0.05	
(-0.2,	0.1)	
0.45	 -0.12	
(-0.2,	0.0)	
0.05	 0.03	
(-0.1,	0.1)	
0.59	
Head	
circumference	
(cm)	
0.34	
(0.2,	0.5)	
<0.001*	 0.34	
(0.2,	0.5)	
<0.001*	 0.13	
(-0.0,	0.3)	
0.07	
Table 15: Results of linear regression analysis assessing associations between nutritional z scores at the 
point of minimum weight during admission and growth outcomes at 7 years post-discharge. Outcome at 7 
years post-discharge is the dependant variable. Regression has been adjusted for HIV status, age, sex and 
SES. * indicates p<0.05. Sitting height % = sitting height/ height *100.  
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4.4.7.2 Oedema 
Presence of oedema at admission is associated with better growth outcomes at 7 years post 
discharge. Those who didn’t have oedema at admission had a worse WAZ, HAZ and BAZ at 
admission, and continued to have a worse HAZ at 1 year post-discharge, as previously discussed 
by Kerac et al[87]. Comparison of mean z scores of cases with and without oedema, as well as 
comparison of these two groups with controls, shows a small shift compared to the previous 
follow up. Those without oedema no longer have significantly lower HAZ at 7 years post-
discharge, but they do have significantly lower WAZ and BAZ. Table 16 shows results of 
multivariable linear regression analysis comparing those admitted with oedema and those 
admitted without to the control group (sibling and community combined). Control groups are 
combined in this instance as larger numbers increase power of the analysis. Results show that 
both oedematous and non-oedematous admissions have significantly larger sitting height 
percentage than controls, but they are not significantly different from one another. There is no 
significant difference between either group and controls for head circumference. It is important to 
remember that oedema is much more prevalent than wasting in this cohort. Figure 18 shows 
spaghetti plots for WAZ and HAZ comparing the oedematous and non-oedematous groups over 
the course of follow up; this highlights that although WAZ in the non-oedema group started 
significantly lower and remains significantly lower, the has been significant catch-up growth in 
both groups. This is also true for HAZ, although the differences are less pronounced.		
	
	 Survivors	with	Oedema	
(n=	265)	
Survivors	without	Oedema	
(n=	54)	
	 Regress	 coef.	 (95%	
CI)	
P	value	 Regress	 coef.	 (95%	
CI)	
P	value	
WAZ	 -0.11	(-0.32,	0.09)	 0.28	 -0.45	(-0.80,	-0.09)	 0.01*	
HAZ	 -0.27	(-0.47,	-0.07)	 0.01*	 -0.43	(-0.80,	-0.06)	 0.02*	
BAZ	 -0.01	(-0.17,	0.15)	 0.90	 -0.40	(-0.69,	-0.10)	 0.01*	
Sitting	height	%	 0.49	(0.21,	0.77)	 <0.001*	 0.51	(-0.00,	1.02)	 0.05*	
Head	circumference	 0.04	(-0.63,	0.70)	 0.91	 0.37	(-0.18,	0.93)	 0.18	
Table 16: Results of linear regression analysis for growth outcomes at 7 years post-discharge comparing 
cases who had oedema at admission and those who didn’t, with controls (siblings and community 
combined), adjusted for HIV and SES. * indicates significant difference.  Sitting height % = sitting 
height/height*100.  
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Figure 18: Spaghetti plots for WAZ and HAZ for those who did and didn’t have oedema at admission, over 
the course of follow up.   
 
4.4.7.3 Time to recovery 
I also assessed whether time taken to recover was associated with long-term growth; I found no 
significant association between time taken to recover and BAZ, WAZ or HAZ at 7 years post-
discharge. Figure 19 shows scatter graphs of WAZ and HAZ at 7 years post-discharge plotted 
against days taken to recover for SAM.   
	
Figure 19: Scatter plots of WAZ and HAZ at 7 years post-discharge against number of days taken to 
recover (admission to discharge from OTP). The regression line is not significant for either graph.  
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4.4.7.4 Age at Admission 
I also assessed whether age at admission had an impact on growth outcomes, and found that HAZ, 
MUAC and BAZ are significantly smaller in children admitted at an older age. WAZ, sitting 
height percentage and head circumference are not affected by the age at admission. Physical 
disability and HIV are associated with older age at admission therefore they are adjusted for in the 
regression model. Low HAZ is also associated with increased age at admission however adjusting 
for HAZ at admission does not remove the significant correlation between age at admission and 
HAZ at 7 years post-discharge. I can therefore conclude that children admitted when they are 
older are more likely to be more stunted on admission and for every month increase in age at 
admission they are likely to be 0.02 z scores more stunted at follow up (p<0.001), regardless of 
how stunted they were at admission.	
Table 17 shows results of multivariable linear regression analysis comparing growth outcomes of 
those who were admitted at or before 24 months and those who were admitted after 24 months to 
controls. This analysis confirms that older admissions have worse HAZ outcomes as those 
admitted after 24 months have significantly lower HAZ than controls, whereas those admitted 
before 24 months do not have a significantly different HAZ to controls. Young admissions seem 
therefore to have caught up to community HAZ levels. Both those admitted before and those 
admitted after 24 months have significantly larger sitting height percentage than controls.  
I considered whether HAZ and age at admission had an n-shaped relationship i.e. the very young 
ones have worse outcomes, and as do the very old ones. However the line graph in Figure 20 
shows that this is not the case; with every categorical increase in age at admission, the mean HAZ 
at follow-up gets worse. There could be an element of survivor bias raising the HAZ of the 
youngest admission category (0-12months), as this group had a significantly heightened risk of 
mortality, and only 33% of this group were alive at 2-years post-admission.  
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	 Survivors	admitted	before	or	
at	24	months	(n=188)	
Survivors	 admitted	 after	 24	months	
(n=172)	
	 Regress	 coef.	 (95%	
CI)	
P	value	 Regress	 coef.	 (95%	
CI)	
P	value	
WAZ	 -0.12	(-0.33,	0.1)	 0.28	 -0.23	(-0.52,	0.06)	 0.12	
HAZ	 -0.03	(-0.26,	0.2)	 0.81	 -0.62	(-0.86,	-0.37)	 <0.001*	
BAZ	 -0.03	(-0.21,	0.16)	 0.76	 -0.14	(-0.34,	0.06)	 0.18	
Sitting	height	%	 0.31	(0.01,	0.61)	 0.04*	 0.58	(0.026,	0.90)	 <0.001*	
Head	circumference	 -0.04	(-0.45,	0.38)	 0.86	 -0.44	(-0.88,	0.01)	 0.05	
MUAC	 -5.15	(-8.79,	-1.52)	 0.01*	 -7.11	(-11.1,	-3.21)	 <0.001*	
Table 17: Results of linear regression analysis comparing growth outcomes of those who were admitted 
before or at 24 months and those who were admitted after 24 months to controls, adjusted for HIV status, 
age, sex, SES and physical disability.  
	
	
	
Figure 20: Line graph showing mean HAZ at ChroSAM 7 year follow-up for each “age at admission” 
category. Percentages next to each point indicate the proportion of that age category that survived SAM 
treatment as a consideration of survivor bias.   
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4.4.7.5 Reported Birth Weight 
Birth weight is often used as an indicator for prenatal nutrition; prenatal nutrition is known to 
have long-term consequences on growth and other health outcomes. Birth weight was not 
routinely recorded in medical documents when the majority of this cohort were born however 
during PRONUT study mothers were asked to give an estimate of the size of their child at birth: 
normal, small or very small. 
I assessed whether estimated size at birth was associated with main growth outcomes at 7 years 
post-discharge. Numbers in the “small at birth” category were small, however I found no 
significant difference between though who were normal size at birth and those who were small or 
very small at birth for WAZ, HAZ, BAZ and sitting height percentage at 7 years post-discharge. 
There was an association between being small at birth and small head circumference in childhood 
(adjusted difference -0.93, 95% CI -1.7 to -0.2, p=0.01). When the two types of birth size are 
compared to controls (Table 18), only those small at birth had significantly smaller BAZ and 
head circumference. Interestingly only those who were normal-large size at birth had significantly 
smaller HAZ and larger sitting height percentage than controls.  
 
	 Normal	size	at	birth	
(n=	288)	
Small	size	at	birth	
(n=	72)	
	 Regress	 coef.	 (95%	
CI)	
P	value	 Regress	 coef.	 (95%	
CI)	
P	value	
WAZ	 -0.06	(-0.3,	0.2)	 0.57	 -0.27	(-0.7,	0.2)	 0.26	
HAZ	 -0.30	(-0.5,	-0.1)	 0.00	*	 -0.25	(-0.7,	0.2)	 0.30	
BAZ	 -0.05	(-0.2,	0.1)	 0.53	 -0.43	(-0.8,	-0.0)	 0.03	*	
Sitting	height	%	 0.46	(0.2,	0.7)	 0.00	*	 0.12	(-0.5,	0.7)	 0.69	
Head	circumference	 -0.17	(-0.5,	0.1)	 0.30	 -1.07	(-1.8,	-0.3)	 0.01	*	
Table 18: Results of linear regression analysis for growth outcomes at 7 years post-discharge comparing 
cases that were reportedly small or very small at birth with those who were normal or large size at birth, 
with controls (siblings and community combined), adjusted for HIV, age, sex and SES. * indicates p<0.05.  
Sitting height % = sitting height/height*100.  
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4.4.8 Summary 
This chapter explored various aspects of growth including weight-for-age, height-for-age, BMI-
for-age, sitting height proportions, leg length and head circumference. Results show that majority 
of the children in the sample are stunted and underweight compared to global norms, however 
SAM survivors are significantly more stunted than both their siblings and children of similar age 
in their community. SAM survivors also have similar sitting height and significantly shorter legs 
than controls, resulting in a significantly larger sitting height percentage. Longitudinal analysis of 
the change in HAZ since 1 year post-discharge suggests that case children are catching up their 
linear growth at a steeper rate than their sibling controls. These results also highlight the 
significant adverse impact that HIV has had on linear growth independently of SAM; however the 
long-term effects of SAM on linear growth are still significantly evident once HIV has been either 
adjusted for or removed from the analysis. Other factors at admission have impacted long-term 
growth; namely small WAZ, HAZ and BAZ at admission, no oedema and being older than 2 
years at admission are associated with worse growth outcomes at 7 years post-discharge. Reported 
birth size of cases is associated with head circumference at 7-years post-discharge, but not other 
growth outcomes. 	
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5 Chapter 5: Body Composition 
This chapter explores the potential effects that SAM could have on long-term body composition. 
Body composition as well as growth is an important component of health; and where growth tells 
us about absolute size, body composition allows for differentiation between fat and lean mass and 
its distribution across the body. Measures of body composition used in this chapter are waist, hip 
and calf circumference, bioelectrical impedance analysis (BIA) and skinfold thickness. Following 
an introduction to previous studies and existing knowledge, body composition methods are 
described and results of analysis presented. Primary analysis compares body composition 
outcomes of cases to controls to assess whether an episode of SAM has had enduring detrimental 
effects in this area; secondary analysis explored predictors of poor body composition in case 
children.  
5.1 Chapter-specific Hypotheses 
As described in the Chapter 1, body composition is a measure of the amount and distribution of 
fat and fat-free mass in the body, as well as the body’s general size and shape. Not only amount of 
fat, but positioning of fat is of great importance to health, particularly NCDs in adulthood [130-
132]. Barker, in his proposal of the “Thrifty Phenotype” hypothesis, suggested that the adaptive 
phenotype during undernutrition favours fat storage, particularly on the core body where 
resources are needed for vital organ function and development, and this phenotype continues post-
malnutrition[29]. Based on this theory and evidence from low birth weight studies, I hypothesised 
the following: 
3. Compared to controls, SAM survivors have an altered body composition, specifically (a) 
greater proportion of central fat to peripheral fat, (b) a lower magnitude of lean mass. 
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5.2 Measuring Body Composition 
There are various ways of measuring body composition, beside the gold standard cadaver 
analysis. Each in vivo technique however makes assumptions as they do not measure body 
composition directly but predict it based on different body properties. Techniques for measuring 
body composition include underwater weighing (densitometry), dual energy x-ray absorptiometry 
(DEXA), anthropometry, bioelectrical impedance analysis (BIA), magnetic resonance imaging 
(MRI) and skinfold thickness. The relative benefits of different techniques have been reviewed in 
detail[216]. No single technique is likely to be optimal in all circumstances therefore this study 
uses a number of different techniques, including anthropometry, skinfold thickness and 
bioelectrical impedance (BIA), selected based on both the reliability of the method and the 
practicalities of what was plausible in the study setting, with the study budget.  
 
Anthropometry measures include calf, hip and waist circumference; waist circumference is 
indicative of core fat whereas hip circumference indicates peripheral fat. Waist/hip ratio is a 
commonly used measure of the amount of core fat in relation to peripheral fat. There is some 
debate as to whether waist/hip ratio or waist circumference is the better predictor of NCDs [217, 
218]. It has also been noted that waist/hip ratio is not always a good measure of central fat if the 
waist girth alone is low; young children can have a small waist girth and still have a high 
waist/hip ratio, yet they do not have high central adiposity[219]. High waist/hip ratio can also be 
as a result of small hip circumference rather than large waist circumference, which is also relevant 
as small hip circumference is associated with higher risk of diabetes, independent of BMI and 
waist circumference[132]. In the absence of age and sex reference data for waist and hip 
circumference, one way of standardising waist and hip circumference measures is to divide by 
height; waist to height ratio is gaining evidence as a good measure of central adiposity[220]. 
Hence it is important to explore all these variables independently as well as in ratio form.     
Skinfold thickness is also a commonly used measure of body fat distribution. It measures the 
amount of subcutaneous fat using callipers, and can be done at various standardized places on the 
body. Again, it is used to distinguish between core and peripheral fat distribution. Skinfold 
thickness of triceps and biceps indicate amount of peripheral fat, and measures of the waist and 
subscapular indicate level of central adiposity. Studies have also correlated skinfold thickness 
measures with impaired functional outputs and NCD risk; for example high subscapular skinfold 
readings are associated with persistent impaired glucose tolerance[221]. Skinfold thickness can be 
an inaccurate and imprecise measure in obese people however in others it is generally thought that 
intra- and inter-observer errors are low compared to between-subject variability. Skinfold 
thickness can be converted into percentage body fat but this is now thought to be relatively 
unreliable; it is now thought that raw values and z-scores based on reference data are the most 
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reliable use of skinfold thickness for determining regional fatness[216]. There is no reference data 
for skinfold thickness in sub-Saharan Africa, but it is possible to create reference data from the 
control children in the study using the LMS method in order to generate skinfold thickness z 
scores[222]. A ratio of core to peripheral skinfold measures can also be used as an indicator of 
core fatness, without the need for reference data, although some adjustment for age is 
recommended[223].   
 
Lastly, BIA can be used to better understand weight as it estimates the proportions of water, fat 
and fat free mass which make up total body weight. BIA is based on the assumption that the body 
is a cylindrical shaped ionic conductor in which the extracellular and intracellular non-adipose 
tissue compartments act as resistors and capacitors, respectively[224]. BIA gives a measure of 
electrical impedance (Z) and its two components: resistance (R) and reactance (Xc). Resistance is 
the opposition offered by the body to the flow of an alternating electrical current, and it is 
inversely related to the water and electrolyte content of tissue. Reactance is related to the 
capacitance properties of the cell membrane, and variations can occur depending on its integrity, 
function, and composition[225]. Many researchers have developed empirical equations for 
predicting total body water (TBW), fat free mass (FFM), body cell mass and body fat content 
using weight, age, sex, race and other variables in addition to resistance and height[226-228]. 
TBW can be calculated using resistance(R), weight, height, sex and age. Once TBW is calculated, 
FFM can be calculated by diving by the “hydration constant”. The equations are based on the fact 
that muscle has higher water content than fat mass; therefore higher TBW equates to higher 
percentage of your weight being composed of FFM. In the absence of a population-specific 
equation and “hydration constant”, it is possible to calculate a proxy for lean mass by dividing 
impedance by height (impedance index). The residuals of BMI regressed on impedance index can 
provide a value proportional to fat mass index. These values do not have units in kilograms like 
actual FFM and FM but are good proximate values[229]. In relation to malnutrition, it is theorised 
that the “thrifty phenotype” will result in children exposed to nutritional insults having less FFM 
than controls due to inhibition of organ growth and muscle mass accumulation, and may also have 
higher FM due to hoarding of central fat. Because BIA does not distinguish between core fat and 
peripheral fat, it is not sure whether total fat mass will be higher in cases or controls in this study.  
 
A common method for analysing BIA data in the absence of a population-specific empirical 
equation is to use isotope dilution methods to validate FFM calculations[216]. Isotopes of 
hydrogen (such as deuterium) can be used to quantify TBW and therefore this method can be used 
to calibrate the calculation of FFM from BIA[230]. However, the isotope mass spectrometry 
required to estimate TBW from isotope dilution is costly and time-intensive, and was not 
budgeted for as part of this study. Additionally, Piccoli (1994 & 2006) believes that isotope 
95 
	
dilution is not accurate enough in clinical settings where patients might have altered hydration 
status. He suggests BIA Vector Analysis (BIVA) as the best way to compare levels of lean mass 
and hydration using BIA data[231, 232]. As impedance is a direct measure of lean and fat mass 
combined, impedance vectors can be used on any population as a stand-alone procedure. This 
method plots R/height against Xc/height, and the arc tangent of Xc/R is called the phase angle. 
Long vectors with a small phase angle (increased R with decreased Xc) are associated with 
malnutrition, whereas short vectors with a small phase angle (decreased R with decreased Xc) are 
associated with fluid overload[232]. I will use this method to compare impedance readings 
between cases and controls.     
 
The measure of ‘Phase Angle’, derived from the relation between the direct measures of 
resistance and reactance can also be analysed as a stand-alone outcome. Its biological meaning 
and pathogenic effects are not completely understood, however phase angle has been interpreted 
as an indicator of body cell mass, cell membrane integrity and water distribution within and 
between cells[233]. It may also be an indicator of function and general health, however this is still 
being explored[234]. There is currently evidence linking low phase angle with malnutrition, lower 
muscle strength and mortality risk in hospitalized patients[235, 236]. It might be that SAM 
survivors have a lower phase angle than control children as their cell integrity, general function 
and health has been disrupted by an insult in early growth and development.  
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5.3 Specific Methods  
5.3.1 Anthropometry  
Waist circumference: The child removed or lifted up any vest/shirt to expose their waist. The 
child stood straight with abdomen relaxed, arms hanging at their side and feet together. The 
operator located the waist by finding the top of the iliac crest. The Rollfix Hoechstmass measuring 
tape was passed around the waist and the reading taken at the end of a normal expiration. 	 
Hip circumference: The child was measured standing and wearing thin clothing or underwear. 
Whilst squatting at the child’s side, the operator found the widest girth of the hips, usually around 
the greatest trochanters of the femur, and passed the measuring tape around this point.  
Calf circumference: The child stood stand straight with their weight evenly distributed over both 
legs. The calf circumference was measured on the right leg, at the widest point of the calf, with 
the measuring tape perpendicular to the long axis of the calf.  
Waist circumference, hip circumference and calf circumference were all measured to the nearest 
0.1cm.   
	
Image 7: Measuring a child’s calf circumference on the right leg  
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5.3.2 Bioelectrical Impedance (BIA) 
BIA was measured on the children using the Quadscan 4000 machine (Bodystat Ltd, UK), as seen 
in Image 8. The Quadscan provides data on impedance, resistance, reactance and phase angle. 
This standard BIA technique, with tetrapolar measurement on a hand and a foot with 50 kHz 
current frequency, provides the best information at a body level because it maximizes the signal-
to-noise ratio and minimizes variability of electric flow path of multi-frequency BIA[231].  
The BIA readings were taken from the right side of the body while the child was lying on their 
back. Follow the manufacturer’s instructions, the child’s hands and feet were washed and dried, 
and their arms were at their side but not touching their sides; their thighs were also not touching 
one another. The electrodes were connected at the wrist, hand, ankle and foot in the positions seen 
in Image 9. A second reading was taken immediately after the first by removing and reattaching 
the electrode leads, but leaving electrode stickers in place. If the two readings varied by more than 
20 ohms, the BIA data were deemed invalid and excluded from analysis.  
 
Image 8: Bodystat Quadscan 4000 being used to measure BIA in Blantyre, Malawi 
  
Image 9: Position of BIA electrode stickers on right hand and right foot 
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5.3.3 Skinfold Thickness  
Skinfold thickness was measured using Holtain Tanner/Whitehouse Skinfold Callipers (Holtain 
Ltd, UK). Skinfold thickness was measured on 4 locations across the body: bicep, tricep, 
subscapular and suprailiac, on the left side of the body. The measurements were conducted 
independently by two operators, as with the other anthropometric measures. The callipers were set 
to zero before each measurement. The location of measurements was marked on the skin with 
eyeliner pencil, and the thumb and forefinger of the left hand were used to elevate a fold of skin 
and subcutaneous fat about 1cm away from the measurement point.  The right hand was then used 
to place the callipers over the skinfold, perpendicular to the long axis of the fold, approximately 
half way between the crest of the fold and the body surface.  The reading was taken once the dial 
of the callipers slowed to an almost stop. Measurements were recorded to the nearest 2mm.  
 
Location of each skinfold measure: 
• Bicep skinfold: a perpendicular line was drawn directly over the humerus and a 
horizontal line was draw at the same place as the MUAC reading (midway between the 
acromion process and the olecranon process), making a cross. 
• Tricep skinfold: a similar cross was made at the back of the arm, also at the point of the 
MUAC reading and directly over the humerus.  
• Subscapular skinfold: the inferior angle at the lower margin of the scapular was located 
and a diagonal line drawn around 1cm out from the shoulder blade corner. A 
perpendicular line to this one was drawn around 1cm from the scapular. 
• Suprailiac skinfold: the operator located the top of the iliac crest (the same location as 
used for waist circumference) and marked this with a horizontal line. A cross was made 
by drawing a vertical line in line with the mid-axillar. The skinfold was grasped just 
above the cross, at a 45 ̊angle, following the natural cleavage of the skin. 
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Image 10: Marking location and measuring skinfold thickness for triceps and biceps 
	
	
Image 11: Marking location and measuring suprailiac and subscapular skinfold thickness 
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5.4 Analysis 
Primary analysis compared sibling and community controls to cases using linear regression 
analysis for:  
• Relative waist circumference, relative hip circumference and calf circumference 
• Tricep, bicep, subscapular and suprailiac skinfold thickness z scores 
• Waist/hip ratio and skinfold thickness ratio 
• Lean mass index and fat mass index proxy derived from BIA impedance readings 
• R/h and Xc/h derived from BIVA 
Potential confounding factors were adjusted for in multivariable linear regression; namely HIV 
status, age, sex, puberty status and SES, based on a priori assumptions. A conceptual framework 
of potential confounders is depicted in Figure 4b, Chapter 2. 
Secondary analysis considered if any factors at admission predict poor body composition at 7-
years post-discharge, namely severity of stunting and wasting at admission, age at admission and 
presence of oedema, as well as reported birth weight, for case children only. I also consider the 
impact of HIV and sex on body composition. 
5.4.1 Data Cleaning 
As with the growth data, I checked for erroneous values among the anthropometric measures by 
plotting scatter graphs of each variable against age and height. Outliers were identified and paper 
files checked for notes, corrections or explanations. Highly improbable readings without 
explanation were removed: 3 waist circumference readings and 1 hip circumference reading were 
removed. No skinfold thickness data was identified as anomalous though checking ranges, ratios 
and scatter plots against weight; this data has a large range making it difficult to identify 
erroneous entries. In order to clean BIA data, the first and second readings were compared, and 
any with a difference greater than 20ohms identified. 2 children had readings which were 
inconsistent and therefore, without being able to conclude which, if any, of the readings was 
correct, both sets of readings were removed from analysis. Scatter plots of BIA readings against 
weight identified no further major anomalies.   
For analysis, an average of the first and second BIA readings was used.    
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5.4.2 Calculations and Statistics  
For body composition, anthropometric measures were not only analysed in their raw state but also 
converted to ratios and relative measures detailed below: 
• Relative waist circumference = waist circumference / height 
• Relative hip circumference = hip circumference / height 
• Waist:hip ratio = waist circumference / hip circumference 
• Skinfold thickness ratio = (subscapular+waist) / tricep  
 
Skinfold z scores using the LMS method  
In the absence of relevant reference data for skinfold thickness, I used “LMSChartmaker” 
software to create an LMS reference table for males and females aged 4-15 years for each 
skinfold measure (bicep, tricep, subscapular and waist) using the data from sibling and 
community controls. The LMS method provides a way of obtaining normalized growth centile 
standards by summarising the changing distribution of a measure (e.g. skinfold thickness) 
according to a covariate (e.g. age). It assumes that the data can be normalized by using a power 
transformation, which stretches one tail of the distribution and shrinks the other, removing the 
skewness. Using data from sibling and community controls, the software calculates the optimal 
power to obtain normality for each age category and the trend is summarized by a smooth (L) 
curve. Trends in the mean (M) and coefficient of variation (S) are also smoothed. The resulting L, 
M and S curves contain the information to draw a centile curve which is used to generate a 
reference table with approximate standard errors for the smoothed centiles for each age category. I 
then used “LMSGrowth” software to calculate skinfold z scores for each child, including cases, 
by entering the child’s age, sex and skinfold readings [222, 237]  
(http://www.healthforallchildren.com/lms-chartmaker-light-download/).  
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Lean mass index 
In order to calculate a proxy for lean mass and total body water, a lean mass index equivalent 
(LMI) was calculated based on impedance index (H2/Z) and height, as described by Wells et al 
2007[229]. Lean mass index is lean mass accounting for height. A value proportional to LMI can 
be obtained by calculating impedance index and then dividing it by height2. This calculation 
results in a value called 1/z; use of 1/z opposed to LMI avoids the need for population-specific 
conversion equations. 1/z is statistically the same as lean mass index but the units are abstract 
rather than in kilograms. The residuals of BMI regressed on 1/z provide a value proportional to fat 
mass index.   
• Impedance index = height2 / impedance   
• 1/z (equivalent to LMI)= (height2 / impedance) / height2    
 
 
BIVA 
Besides 1/z, I also used BIA data in BIA vector analysis (BIVA). Again, in order to avoid 
converting BIA readings into total body water (TBW) using equations which are not suitable for 
this population, BIVA can be used to consider the combined changes in resistance (R) and 
reactance (Xc) on the “RXc” mean graph, where the average of R/h and Xc/h are plotted as line 
segments with the 95% confidence ellipse[231].  This method allows for consideration of 
hydration as well as lean mass, which is not possible using the LMI method described above. It 
requires the following calculations: 
• R/h = resistance / height (m) 
• Xc/h = reactance / height (m) 
 
I used “BIVA Software 2002” created by Piccoli & Pastori (Department of Medical and Surgical 
Sciences, University of Padova, Padova, Italy, 2002) to create my RXc mean graphs with ellipses. 
The software is an Excel file with Visual Basic macros; the means and standard deviations for R/h 
and Xc/h for each study group are entered into the software and it creates the graph[238] 
(http://www.renalgate.it/formule_calcolatori/BIVAguide.pdf).  
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5.5 Results 
5.5.1 Missing Data  
Anthropometry, BIA and skinfold thickness readings were available for almost the whole sample, 
with only a handful of missing readings for each variable. As already mentioned, a few readings 
were removed during data cleaning and other reasons for missing data included children refusing 
to cooperate or children not attending the hospital appointments, as with growth measures. For a 
full table of number of results for each outcome see Table 5 in Chapter 3: Section 3.1. 
 
5.5.2 BIA repeatability  
Routinely, BIA readings were repeated for each child immediately after the first reading, in order 
to highlight and correct any obviously erroneous readings. To test the reliability of the BIA 
machine at different times of the day, I measured a subset of children 2 hours after their initial 
BIA reading and compared the two results. Figure 21 shows scatter plots and Pearson’s 
correlation coefficients for repeat readings of each of the four BIA outcomes. Using this method 
impedance had the highest correlation between repeat readings.  
 
Figure 21: Scatter plots with regression line showing the correlation between repeat readings for each of 
the four BIA outcomes: Impedance, Resistance, Phase Angle and Reactance 
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Using a paired t-test (n=23) which is a comparison of the means, there was no significant 
difference in impedance, reactance, resistance or phase angle across the 2 readings. Using this 
method, reactance was the most robust of the readings with a p value of 0.96 and mean difference 
of just 0.06 ohms between repeats; see results in Table 19.  
Measure (n=23) Mean  
1st reading 
Mean  
2nd Reading 
Mean difference 
(SD) 
95% CI P value 
Impedance 726.0 720.8 5.22 (22.39) -4.5, 14.9 0.28 
Resistance 722.9 704.5 18.43 (62.51) -8.6, 45.5 0.17 
Reactance 67.7 67.6 0.06 (5.28) -2.2, 2.3 0.96 
Phase Angle 5.3 5.4 -0.09 (0.24) -0.19, 0.01 0.09 
Table 19: Results of paired t-test comparing repeat BIA readings in order to assess BIA reading 
consistency. 2nd BIA reading was taken at least 2 hours after the first reading on a subset of children (n=23).  
 
Besides correlation and regression, the Bland-Altman method is an alternative way for analysing 
repeatability[239]. It was proposed as an alternative to these methods as it analyses “agreement” 
between two readings rather than correlation or difference between the means.  Bland-Altman 
graphs plot the difference between reading 1 and reading 2 on the Y axis against the mean of 
reading 1 and reading 2 on the X axis. This X axis (i.e. the means of the readings) represents the 
“true value”. The mean of the differences should be zero for perfect “agreement”. The mean of 
the differences is the same as the mean difference listed in Table 19. Bland and Altman state that 
95% of data points should be within ±2 SD of the mean difference, as this is the “limit of 
agreement”[239]. This is true for all four BIA outcomes (Bland-Altman plots for impedance, 
resistance, reactance and phase angle can be seen in Appendix 15).  
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5.5.3 Body Composition of Controls vs Cases 
5.5.3.1 Calf, Waist & Hip Circumferences and Skinfold Thickness 
I hypothesised that case children would have less peripheral fat (and peripheral mass) than control 
children, and relatively more central fat than control children, based on a similar adaptation seen 
in low birth weight infants. Table 20 shows means by study group for each anthropometric 
measurement, and the results of both simple and multivariable linear regression analysis 
comparing the groups. See Appendix 16 for histograms of all outcomes in this chapter. 
Regression analysis shows that: 
• Calf circumference is significantly smaller for cases than both sibling and community 
controls  
• Cases have smaller relative hip circumference than sibling controls	
• Cases have larger relative waists circumference than community controls	
• Cases have larger waist/hip ratio than community controls due to the smaller hips of the 
cases 
It is also worth noting that, as discussed in the previous chapter, MUAC is significantly smaller 
for cases than controls. These results indicate that cases have less peripheral mass than controls. 
MUAC and other circumferences cannot differentiate between fat and lean mass, however 
skinfold thickness specifically measures fat mass. When using skinfold thickness z scores to 
assess core and peripheral fat levels, the adjusted difference in peripheral fat is similar between 
the groups, except bicep skinfold is slightly larger for sibling controls than cases. Siblings also 
have significantly larger waist and subscapular skinfold thickness, suggesting that siblings have 
both more core and peripheral fat than cases, but skinfold thickness ratio is similar across all the 
groups. 
When considering the HIV negative children only, the results are the same (see table in Appendix 
17) except relative hip circumference which is not significantly different between cases and 
siblings when HIV positive children are removed from analysis. This is due to the HIV positive 
siblings having a significantly larger relative hip circumference than HIV negative siblings. 	
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Anthropometry	 Cases	 Sibling	 Community	
	 Mean	
(SD)	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)	
P	value	
Adjusted	
difference	
(95%	CI)	
P	value	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)	
P	value	
Adjusted	
difference	
(95%	CI)	
P	value	
Peripheral	fat	 	 	 	 	 	 	 	
Calf	
circumference	
(cm)	
23.7	
(2.3)	
25.0	
(3.5)	
1.36	*	
(0.9,	1.9)	
<0.001	
0.62	*	
(0.2,	1.0)	
0.002	
24.3	
(2.4)	
0.59	*	
(0.2,	1.0)	
0.02	
0.49	*	
(0.1,	0.9)	
0.02	
Hip	
circumference		
(cm)	
62.3	
(5.8)	
65.9	
(10.2)	
3.51	*	
(2.1,	4.9)	
<0.001	
1.83	*	
(0.8,	2.8)	
<0.001	
63.7	
(6.9)	
1.34	
(-0.2,	2.8)	
0.08	
1.56	*	
(0.5,	2.7)	
0.001	
Relative	 hip	
circumference	
0.50	
(0.0)	
0.51	
(0.0)	
	0.01	*	
(0.0,	0.0)	
0.02	
0.01	*	
(0.0,	0.01)	
0.04	
0.50	
(0.0)	
0.00	
(-0.0,	0.0)	
0.94	
0.00	
(-0.0,0.0)	
0.66	
Tricep	 skinfold	
thickness	 z	
score	
-0.10	
(1.1)	
0.11	
(0.9)	
0.21	*	
(0.0,	0.4)	
0.04	
0.16	
(-0.0,	0.4)	
0.12	
-0.14	
(1.1)	
-0.04	
(-0.3,0.0)	
0.67	
-0.07	
(-0.3,	0.2)	
0.63	
Bicep	 skinfold	
thickness	 z	
score	
-0.2	
(1.2)	
0.06	
(1.0)	
0.26	*	
(0.1,0.5)	
0.01	
0.23	*	
(0.0,	0.4)	
0.04	
-0.07	
(1.0)	
0.13	
(-0.1,0.4)	
0.23	
0.14	
(-0.1,	0.4)	
0.22	
Core	fat	 	 	 	 	 	 	 	
Waist	
circumference	
(cm)	
56.3	
(4.2)	
57.7	
(6.4)	
1.45	*	
(0.5,	2.3)	
0.002	
0.55		
(-0.2,	1.3)	
0.15	
56.0	
(4.5)	
-0.25		
(-1.2,	0.7)	
0.61	
0.08	
(-0.7,	0.9)	
0.86	
Relative	 waist	
circumference	
0.45	
(0.0)	
0.45	
(0.0)	
-0.01	*	
(-0.01,-0.0)		
0.045											
-0.00	
(-0.0,	0.0)	
0.73	
0.44	
(0.0)	
-0.01	*		
(-0.02,	-0.0)	
0.002	
-0.01	*	
(-0.1,-0.0)	
0.01	
Waist	 skinfold	
thickness	 z	
score	
-0.15	
(1.0)	
0.15	
(1.0)	
0.29	*	
(0.1,0.5)	
0.002	
0.27	*	
(0.1,	0.5)	
0.004	
-0.19	
(1.0)	
-0.04	
(-0.2,	0.2)	
0.67	
-0.05	
(-0.3,	0.5)	
0.69	
Subscapular	
skinfold	
thickness	 z	
score	
-0.20	
(1.1)	
0.13	
(1.0)	
0.33	*	
(0.1,	0.5)	
0.001	
0.30	*	
(0.1,	0.5)	
0.004	
-0.17	
(1.0)	
0.03	
(-0.2,	0.2)	
0.76	
0.02	
(-0.2,	0.2)	
0.82	
Ratio	 of	 core	 to	
peripheral	fat	
	 	 	 	 	 	
Skinfold	
thickness	ratio	
1.7	
(0.4)	
1.8	
(0.4)	
0.04		
(-0.0,	0.1)	
0.31	
0.03		
(-0.1,	0.1)	
0.53	
1.7	
(0.4)	
0.02	
(-0.1,	0.1)	
0.69	
0.03	
(-0.1,	0.1)	
0.50	
Waist/hip	ratio	 0.91	
(0.1)	
0.88	
(0.1)	
-0.02	*	
(-0.03,	-0.0)	
0.001	
-0.01	
(-0.02,	0.0)	
0.07	
0.89	
(0.1)	
-0.02	*	
(-0.03,	-0.0)	
0.006	
-0.02	*	
(-0.0,-0.0)	
0.01	
Table 20: Means and results of simple and multivariable regression analysis for body composition 
anthropometry. Adjusted differences include HIV status, SES, puberty, age and sex in the linear regression 
model. Calf circumference adjusted difference also includes adjustment for presence of a physical 
disability. * indicates p value less than 0.05. Relative hip circumference= hip circumference/height; 
Relative waist circumference= waist circumference/height; Skinfold thickness ratio = (subscapular+waist) / 
tricep 
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5.5.3.2 BIA: Lean Mass Index 
Table 21 shows mean values for each study group for 1/z (LMI equivalent) and BMI regression 
residual from 1/z (fat mass equivalent), as well as results of simple and multivariable linear 
regression analysis between the groups. There is no significant difference in lean mass or fat mass 
between cases and either type of control when assessed by this method. However, in the scatter 
plots of 1/z against age for the 3 study groups (Figure 22), it is clear to see that among the cases 
there are more children with very low LMI (<8) than in the control groups. When conducting 
analysis with HIV negative children only, results are similar except sibling controls have 
significantly more lean mass than cases once HIV positive children are removed from analysis 
(see results in Appendix 17).  
 
	 Cases	 Sibling	 Community	
	 Mean	
(SD)	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)	
	P	value	
Adjusted	
difference	
(95%	CI)		
P	value	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)		
P	value	
Adjusted	
difference	
(95%	CI)		
P	value	
1/z	
(lean	mass)	
9.02	
(1.1)	
9.20	
(1.0)	
0.17	
(-0.0,0.4)	
0.08	
0.13	
(-0.1,0.3)	
0.19	
9.12	
(1.0)	
0.09	
(-0.1,	0.3)	
0.36	
0.04	
(-0.2,0.3)	
0.72	
BMI	 residual	
from	1/z	
(fat	mass)	
-0.15	
(1.2)	
0.28	
(1.8)	
0.43	*	
(0.2,	0.7)	
0.002	
0.22	
(-0.0,	0.5)	
0.08	
-0.08	
(1.6)	
0.10	
(-0.2,	0.4)	
0.67	
0.15	
(-0.1,	0.4)	
0.27	
Table 21: Results of simple and multivariable linear regression analysis; adjusted difference includes HIV 
status, SES, puberty, age and sex in the regression model. * indicates p<0.05. z= impedance.  
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Figure 22: scatter plots of LMI equivalent (1/z) against age for cases, siblings and community controls 
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5.5.3.3 BIA Vector Analysis (BIVA) 
The outcome of BIVA is graphical (Figure 23) and indicates that community controls have more 
lean mass, compared to cases and siblings. It also suggests that cases have less total body water 
than community controls, and even less compared to siblings. In order to adjust for potential 
confounders such as HIV, SES, age, gender and puberty, R/h, Xc/h and phase angle were 
analysed with linear regression. Result presented in Table 22 show that there is a significant 
difference in R/h and phase angle between cases and community controls after adjusting for HIV, 
age, sex, SES and puberty. There is no difference in R/h, Xc/h and phase angle between cases and 
sibling controls after potential confounders are adjusted for. The reduced R/h of the siblings seen 
in the graph (Figure 22) can be largely explained by the difference in age between siblings and the 
other 2 groups; particularly the male siblings, who are significantly older than the cases and more 
hydrated than the other groups. BIVA suggests that cases have significantly less fluid and less 
lean mass than community controls, but similar levels to siblings. Cases have significantly smaller 
adjusted phase angle than community controls (p=0.004), which is associated with lower lean 
mass as well as nutritional and morbidity risk[235]. Results of adjusted analysis are the same 
when excluding HIV positive children from the model (see Appendix 17).  
 
	
Figure 23: Results of BIVA for cases, siblings and community controls 7 years post-discharge 
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	 Cases	
(n=294)	
Sibling	
(n=198)	
Community	
(n=151)	
	 Mean	
(SD)	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)	
P	value	
Adjusted	
difference	
(95%	CI)	
P	value	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)	
P	value	
Adjusted	
difference	
(95%	CI)	
P	value	
R/h	 603.5	
(105.1)	
567.4	
(129.6)	
-36.1	*	
(-56.1,-16.1)	
<0.001	
-11.5	
(-29,5.8)	
0.19	
577.1	
(90.7)	
-26.4	*	
(-48.1,-4.6)	
0.02	
-24.5	*	
(-43,-5.5)	
0.01	
Xc/h	 52.2	
(8.4)	
49.7	
(9.3)	
-2.5	*	
(-4.1,-0.9)	
0.002	
-0.5		
(-2.1,	1.0)	
0.52	
51.5	
(7.8)	
-0.7	
(-2.3,	1.0)	
0.43	
0.3		
(-1.4,	1.9)	
0.75	
Phase	
angle	⁰	
5.0	
(0.7)	
5.1	
(0.7)	
0.1	
(-0.1,0.2)	
0.09	
0.1	
(-0.0,	0.2)	
0.16	
5.1	
(0.5)	
0.1	
(-0.0,0.2)	
0.07	
0.2	*	
(0.1,	0.3)	
0.003	
Table 22: Results of simple and multivariable linear regression analysis; adjusted difference includes HIV 
status, socioeconomic status, puberty, age and sex in the regression model. * indicates p<0.05. R/h = 
resistance/height(m); Xc/h=reactance/height(m) 
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5.5.4 Impact of HIV on Body composition 
HIV is not associated with significant differences in body composition at this age, in contrast to 
its impact on linear growth. Table 23 presents means and standard deviation values for main body 
composition outcomes stratified by HIV status and study group. Note the small numbers of HIV 
positive children in the control groups. For cases only, regressing body composition outcomes by 
HIV status shows no significant difference between HIV positive and HIV negatives for calf 
circumference, skinfold thickness ratio, hip circumference, waist/hip ratio, LMI equivalent, fat 
mass equivalent and R/h. HIV positive children have a significantly higher Xc/h (coef. 2.80, 95% 
CI 0.7 to 4.9, p=0.01) and phase angle (coef 0.18, 95% CI 0.0 to 0.5, p=0.045). This is 
unexpected, as it suggested that HIV positive case children have healthier cell membranes than 
HIV negative children and lower morbidity risk, however there is some evidence that ARV 
therapy can improve BIA outcomes and as all these children are controlling their HIV with 
medication, perhaps this explains their slightly improved body composition[240].     
 
	 Cases	 Sibling	Controls	 Community	Controls	
	 HIV	positive	
HIV	
negative	
HIV	
positive	
HIV	
negative	
HIV	
positive	
HIV	
negative	
N	 89	 198	 9	 125	 4	 92	
Calf	
circumference	 23.6	(2.1)	 23.6	(2.3)	 23.0	(2.2)	 25.1	(3.7)	 23.2	(1.2)	 24.1	(2.3)	
Skinfold	ratio	 1.77	(0.4)	 1.69	(0.4)	 1.62	(0.4)	 1.73	(0.4)	 2.01	(0.4)	 1.76	(0.4)	
Hip	
circumference	 62.1	(5.8)	 62.5	(5.7)	 64.5	(14.2)	 66.0	(11)	 61.4	(4.4)	 63.5	(7.1)	
Waist/hip	
ratio	 0.91	(0.1)	 0.90	(0.1)	 0.89	(0.1)	 0.88	(0.1)	 0.92	(0.1)	 0.89	(0.1)	
1/z	
(lean	mass)	 8.9	(1.0)	 9.1	(1.1)	 8.7	(0.7)	 9.2	(0.9)	 8.9	(0.8)	 9.1	(1.0)	
BMI	 residual	
(fat	mass)	
-0.02	
(1.2)	 -0.20	(1.2)	 0.16	(0.9)	 0.34	(2.0)	 0.03	(1.7)	
-0.10	
(1.8)	
R/h	 615	(118)	 601	(101)	 666	(123)	 569	(130)	 580	(35)	 580	(97)	
Xc/h	 54.3	(9.3)	 51.5	(7.9)	 58.9	(9.3)	 49.8	(9.7)	 51.4	(4.9)	 52.0	(7.4)	
Phase	angle	 5.12	(0.7)	 4.94	(0.67)	 5.09	(0.40)	 5.09	(0.7)	 5.05	(0.48)	 5.14	(0.6)	
Table 23: Means and standard deviations for body composition outcomes stratified by HIV status and study 
group are presented. Those with unknown HIV status are not included. Skinfold thickness ratio= 
(subscapular+waist) / tricep.  
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5.5.5 Body composition and Sex 
There are significant differences in body composition between sexes which are worth 
highlighting. These differences are consistent across the study groups. After adjusting for 
case/control status, HIV and age, there is no significant difference in skinfold thickness ratio or 
phase angle between girls and boys. However, boys have significantly smaller calves than girls 
(coef -0.57, 95% CI -0.8 to -0.2, p<0.001) and smaller hip circumferences (coef -1.85, 95% CI -
2.7 to -1.0, p<0.001) and boys have significantly larger waist/hip ratio than girls (coef 0.03, 95% 
CI 0.02 to 0.04, p<0.001). Boys also have more lean mass (1/z) than girls (coef 0.44, 95% CI 0.3 
to 0.6, p<0.001) and less fat mass (coef -0.30, 95% CI -0.5 to -0.1, p<0.001). Boys have 
significantly lower R/h (coef. -17.0 p=0.02) and lower Xc/h (coef. -1.88, p<0.001) than girls. 
Considering these large sex differences, I conducted a stratified analysis of cases vs controls for 
boys and for girls and found that the differences in body composition between cases and controls 
are more prominent for girls than for boys (result of sex stratified regression analysis can be seen 
in Appendix 18). Waist circumference, waist/hip ratio and phase angle are not significantly 
different between community control boys and case boys, whereas girls are. Conversely, only 
community control boys have significantly lower R/h than cases, girls do not have significantly 
different R/h.   
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5.5.6 Predictors of adverse Body composition in cases 
Lastly, I explored factors at admission which might predict adverse body composition outcomes 
at 7 years post-discharge. Table 24 presents raw data (means (SD)) for some of the main body 
composition outcomes of children with different characteristics at admission.  Further analysis 
shows that low WAZ and HAZ at admission and marasmus rather than kwashiorkor are 
associated with adverse body composition at 7 years post-discharge.  Age at admission and 
reported birth size are not associated with body composition outcomes.    
Mean (SD) Calf 
circumferen 
 
Waist/hip 
ratio 
1/z  (LMI) R/h Phase angle 
Degree of wasting at admission     
 Low WAZ <-4 (n=137) 22.9 (2.2) 0.93 (0.1) 8.90 (1.1) 634 (114) 4.92 (0.8) 
 High WAZ >-4 (n=160) 24.3 (2.1) 0.89 (0.1) 9.13 (1.0) 579 (89.1) 5.05 (0.6) 
Degree of stunting at admission     
 Low HAZ (<-3) (n=143) 23.2 (2.2) 0.92 (0.1) 9.06 (1.1) 618 (98.7) 4.93 (0.7) 
 High HAZ (>-3) (n=157) 24.1 (2.3) 0.89 (0.1) 8.98 (1.1) 592 (110) 5.05 (0.7) 
Kwashiorkor or wasting      
 Oedema (n=265) 23.8 (2.2) 0.90 (0.1) 9.09 (1.0) 594 (94.5) 5.00 (0.6) 
 No oedema (n=54) 22.9 (2.4) 0.92 (0.1) 8.76 (1.2) 649 (138) 4.95 (0.8) 
Age at admission      
 <2 years (n=158) 23.1 (2.0) 0.92 (0.1) 9.03 (1.1) 623 (108) 4.89 (0.6) 
 >2 years (n=145) 24.3 (2.4) 0.90 (0.1) 9.03 (1.1) 583 (98.4) 5.11 (0.7) 
Reported birth size      
 Small at birth (n=24) 22.7 (1.7) 0.90 (0.1) 8.74 (1.1) 635 (82.5) 5.10 (0.5) 
 Normal size at birth 
(n=270) 
23.8 (2.3) 0.91 (0.1) 9.07 (1.1) 600 (108) 4.99 (0.7) 
Table 24: Means and standard deviations for main body composition outcomes stratified by characteristics 
at admission 
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Degree of Wasting and Stunting at admission 
Those with greater stunting or greater wasting at admission have significantly smaller calf 
circumference and phase angle at 7 years post-discharge. They also have significantly larger 
waist/hip ratio and significantly larger R/h at 7 years post-discharge. Those who had a WAZ 
larger than -4 at admission do not have significantly different calf circumference, waist/hip ratio, 
lean mass equivalent, R/h and phase angle to control children.  
Kwashiorkor at admission 
When considering those cases who were admitted with and without oedema 7 years ago, we can 
see that survivors who were admitted without oedema (i.e. marasmus) have a significantly higher 
R/h than controls at 7 years post-discharge, whereas those survivors admitted with oedema have 
similar R/h to controls. This suggests that those who were admitted with marasmus now have 
significantly less fluid and less lean mass than controls, whereas those who were admitted with 
kwashiorkor have similar lean mass and hydration to controls at 7 years post discharge (see 
Figure 24). Additionally, calf circumference is significantly lower in marasmus survivors than 
kwashiorkor survivors and lean mass equivalent (1/z) is lower in marasmus survivors than 
kwashiorkor survivors with borderline significance (p=0.08). Waist/hip ratio and phase angle are 
not significantly different between marasmic and kwashiorkor survivors.  
The body composition differences seen between cases and controls is more pronounced in 
survivors who had marasmus; those who had kwashiorkor seem to have retained a more “normal” 
body composition at 7 years post discharge. This correlates with results in previous chapter which 
showed marasmic survivors to have significantly lower WAZ at 7 years post-discharge than 
kwashiorkor survivors.			
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Figure 24: BIVA results for those children who had oedema at admission, and those that didn’t, and 
community controls, at 7 years post-discharge.    
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5.5.7 Summary 
This chapter explored various aspects of body composition including body circumferences, 
skinfold thickness, and BIA. Results show that SAM-survivors do have some elements of altered 
body composition compared to controls. Cases have smaller calf circumference to controls; they 
also have smaller or same sized relative hip circumference to controls, and larger or same sized 
relative waists to controls. This suggests an unhealthy ratio of core to peripheral mass with cases 
having less peripheral lean mass. However, when it comes to subcutaneous fat, skinfold thickness 
results suggest that although siblings have significantly more subcutaneous fat, the ratio of core to 
peripheral subcutaneous fat is the same as cases. Additionally, when assessing overall fat mass 
using BIA-BMI regression residuals, there is no significant difference between cases and control. 
LMI equivalent as calculated from BIA also shows no difference between cases and controls, 
however when the impedance reading is broken down into resistance and reactance using BIVA 
we find that cases have significantly less fluid and less lean mass than community controls, but 
similar levels to siblings. Cases also have lower phase angle than community controls which is 
associated with nutritional and morbidity risk. These effects are particularly pronounced in 
females at this age, and in those children who were admitted with wasting rather than those with 
kwashiorkor. Adverse body composition is also more evident in those admitted with a greater 
degree of wasting or stunting 7 years ago.  
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6 Chapter 6: Physical Function 
	
This chapter discusses physical function and the potential effects that SAM could have on long-
term physical function. Besides anthropometry and body composition, discussed in previous 
chapters, it is important to explore whether clinical insults are having any impact on everyday 
function such as physical function. Specific areas of physical function discussed here are muscle 
strength, daily physical activity and physical capacity for exercise. This chapter also describes 
the specific methods, analysis and results related to physical function outcomes; primarily 
comparing physical function of cases to controls to assess whether an episode of SAM has had 
enduring detrimental effects in this area. Additionally, I present results exploring the links 
between body composition and physical function, and exploring variables among cases at 
admission that may predict poor physical function at 7 years post-discharge.  
 
6.1 Chapter-specific Hypotheses  
Physical function is the first of my functional outcomes to be explored. For the purpose of this 
study physical function refers to muscle strength and physical fitness, as these are the areas I felt 
were most relevant to SAM-survivors, as well as having important implications for chronic 
diseases in adulthood and major implications for productivity and earning-potential[96, 138]. The 
long-term implications that SAM has had on growth and body composition may well translate to 
important detrimental impacts on physical function. I hypothesised that: 	
4. Compared to controls, SAM survivors have (a) lower levels of physical activity, (b) lower 
physical capacity during an exercise test and (c) weaker hand grip strength. 
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6.2 Specific Methods 
6.2.1 Hand Grip Strength 
Hand grip strength was measured using a “Takei Grip-D” dynamometer device (Japan) which 
measures hand grip strength from 5kg and above. The child held the device in their hand, with 
their elbow by their side and at right angle. The operator often needed to hold the other side of the 
device to steady it. The child then squeezed the device with as much effort as possible and with 
no other movement of their body. Three attempts were made with each hand and any disabilities 
which may interfere with the reading were noted.  
 
Image 12: Takei Grip-D device used to measure hand grip strength in kg 
6.2.2 Physical Activity: Accelerometers 
In order to measure physical activity, the children were required to wear “ActiLife” 
accelerometers (Actigraph Corp, USA) around their waist for at least 48 hours. The device was 
fitted during the first visit to the child’s home, and they were asked to wear the device at all times, 
including when sleeping. The child was asked to attend the hospital appointment wearing the 
device, at which point it was removed and the data downloaded.  
 
Image 13: Three “ActiLife” accelerometers with elastic tape to fit around the children’s waists  
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6.2.3 Physical Capacity: iStep Exercise Test 
The iStep Test is a 10 minute exercise test to assess exercise capacity. The test was developed at 
Great Ormond Street Hospital (GOSH) with the UCL Institute of Child Health (UK) as part of a 
study looking at the development and validation of a “field-friendly” exercise test for children 
with Cystic Fibrosis[151]. It is an externally paced test on a single standard exercise step for 
children aged 6-16 years. The step height should be appropriate for the height of the child 
therefore we had 3 available steps of 15, 20 and 25cm. In order to select the correct step height, 
the child’s lower limb was measured from ankle bone to the knee joint; the length was then 
divided by 2 and rounded down to the closest step height i.e. 33cm lower limb measurement ÷ 2= 
16.5cm → therefore the 15cm step would be used.  
The child was instructed to step up and down in time to the beeps. There are 5 levels to the test; 
each level is 2 minutes long; the test is a total of 10 minutes. The pace of the beeps becomes 
quicker at each level. The child was told that the aim should be to complete the test however if 
there was any point where they felt unwell or not able to carry on, they should stop. The following 
measurements were taken at baseline, during the test, at the end of the test and at one minute after 
the test: 
• Heart Rate (HR) 
• Oxygen saturation 
• OMNI scale (for perceived exhaustion)[241] 
• VAS (visual analogue scale for perceived breathlessness) 
A NONIN PalmSAT 2500 pulse oximeter device (Nonin Medical Inc., USA) was used for 
measuring heart rate and oxygen saturation during the test as it has technology which allows for 
participant movement during measurement. Images of the English and Chichewa versions of 
OMNI and VAS scales can be seen in Appendix 19.  
The main outcomes used in analysis were: highest HR, lowest oxygen saturation, time completed 
of the test, highest HR adjusted for stopping time (HR:Level ratio), drop in HR at recovery  (as % 
of highest HR) and final HR in all those who completed the test.  
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Image 14: iStep exercise test in progress (top photo) followed by 1 minute recovery (bottom photo) 
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6.2.4 Sample Size Calculations 
Due to lack of previous studies with these specific outcomes, it was difficult to calculate required 
sample sizes for most physical function measures. I did find a study for AMA and for hand grip 
strength that compared cases and controls with some relevance to nutrition. Based on our actual 
sample size and using evidence from these studies, I calculated the power of our sample size 
using Stata “sampsi” command. Benefice et al., (1992) found mean AMA of 21.8 (±2.8) in 
normal children compared to 18.7 (±2.9) in children with low WAZ; with AMA outcomes for 279 
cases, 185  siblings and 140 community controls, our analysis is powered to 100% to detect this 
difference[142].  
 
For hand grip strength, a study found a change in grip strength of 2.79kg (±3.11) following 
nutrition supplementation in adult TB patients[242]. Again, our existing sample size is powered to 
100% to detect this difference. However this difference is perhaps larger than I would expect in 
this study as these are adults with a current infection being compared during recovery. Another 
study in adults suggested that a change of more than 6kg is required to be clinically significant in 
adults; the standard deviation was not provided[243]. I could not find a study with the equivalent 
value for children.   
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6.3 Analysis 
Primary analysis compared sibling and community controls to cases using regression analysis 
for:  
• Prevalence of physical disabilities (seeing, hearing, walking) 
• Hand grip strength 
• Arm-muscle area (AMA) 
• Daily physical activity levels (average steps taken per hour) 
• Physical capacity using iStep test 
Logistic regression was used to analyse differences in binary outcomes for physical disabilities 
between the three study groups; both unadjusted odds ratio (OR) and adjusted OR at presented. 
Adjusted OR includes age, sex, HIV status and SES in the model as potential confounders.  
For continuous outcomes (hand grip strength, majority of iStep outcomes and physical activity 
levels), simple and multivariable linear regression analysis was used to compare cases and both 
types of control. Potential confounding factors were adjusted for in multivariable linear 
regression; namely HIV status, age, sex, physical disability and SES, based on a priori 
assumptions. A conceptual framework of potential confounders is depicted in Figure 4c, Chapter 
2. Ordered logistic regression was used to compare time completed of the iStep test as it is a 
categorical ordinal variable and it is not normally distributed.  
Secondary analysis considered if any factors at admission predict poor physical function 7 years 
post-discharge, namely severity of stunting and wasting at admission, age at admission and 
presence of oedema, as well as reported birth weight, for case children only. I also considered the 
impact of HIV on physical function and explore to what extent differences in body size and 
composition (WAZ, HAZ and lean mass) predict physical function.   
6.3.1 Calculations 
As hand grip strength was measured on each hand 3 times, the best reading from either hand was 
used in analysis. AMA was calculated based on the formula proposed by Gurney & Jelliffe as 
follows[244]: 
AMA (cm2) = [MUAC – ((Tricep skinfold * π)]2 / (4 * π))/100 
Accelerometer data can be analysed in a number of ways; one options is to analyse proportion of 
the day spend sedentary or active, however definition of sedentary and active is based on standard 
cut-off points which may not be applicable to Malawian children, hence I decided not to use this 
and to simply use number of steps per hour as my variable for comparing physical activity levels 
between the groups. Steps per hour were calculated as follows: 
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Steps per hour = (total steps record / total minutes wear time) * 60 
Four outcomes were derived from the iStep exercise test with the intention of assessing physical 
exercise capacity. Lowest oxygen saturation during the test and amount of time completed of the 
test, which require no calculations. The other two outcomes, heart rate/level ratio and percent drop 
in heart rate at 1 minute recovery, were calculated as follows: 
Heart rate: Level ratio = highest heart rate / highest test level completed 
Drop in HR at 1 minute recovery (%) = (heart rate at recovery / highest heart rate) *100 
6.4 Results 
6.4.1 Missing Data & Data Quality 
Almost all of the sample have hand grip strength readings (298 cases, 200 siblings and 154 
controls) and iStep test readings; the reason for a few missing results is either physical disability 
or illness (such as malaria) at the time of data collection.  
Unfortunately, there is a lot of missing accelerometer data. There are a number of reasons for this. 
Firstly, not all children were asked to wear accelerometers largely due to the logistics of charging 
them at a computer. When I was not present in Malawi, the data team could not charge and 
initiate accelerometers as only 1 person can have access to the software and charging hub. 
Secondly, as hospital appointments were made at the family’s convenience, accelerometers were 
only offered to those with a gap of at least 48 hours between home and hospital visits. 
Additionally, of those who were asked to wear accelerometers, some refused as they didn’t like 
the look of them; most often this was due to the accelerometers being red in colour which is 
associated with blood and witchcraft in Malawi hence carrying negative associations in some 
communities. Others explained that they didn’t want everyone to see their child wearing them, or 
they just didn’t understand what they did and therefore were wary of them. Of the 156 children 
who were offered accelerometers and agreed to wear them, 121 actually wore them for at least a 
short time after the study team left. Of these 121, 78 wore them for more than 500 minutes in a 
day for 2 days and therefore had enough data for analysis.   
For a full table of number of results for each outcome variable see Table 4 in Chapter 3: Section 
3.1. 
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6.4.2 Physical function of Controls vs Cases 
6.4.2.1 Physical Disability 
Table 25 shows results of logistic regression analysis for hearing, sight and walking disabilities, 
comparing the 2 control groups to the cases. Once adjusted for potential confounders, there is no 
significant difference in odds of having difficulty seeing between cases and controls; cases are 
more likely to have difficulty hearing than siblings. OR of having difficulty walking is 
significantly lower for community controls than cases, but not different for sibling controls. There 
could be an element of selection bias here as mothers with disabled children in the community 
control group may be less likely to agree to attend a hospital appointment due to the added 
logistical difficulties. Additionally, when searching for a community control in the village, 
families who were approached who have a child with a disability may have assumed that he/she 
was not eligible and therefore not volunteered that child.  
	 Cases	
(n=	313)	
Sibling	
(n=209)	
Community	
(n=175)	
	 %	 %	 Unadjusted	
OR	(95%	CI)	
P	value	
Adjusted	OR	
(95%	CI)	
P	value		
%	 Unadjusted	
OR	(95%	CI)	
P	value	
Adjusted	OR	
(95%	CI)	
P	value	
Difficulty	
seeing	
0.06	 0.04	 -0.54	
(-1.4,	0.3)	
0.21	
-0.45		
(-1.4,	0.5)	
0.35	
0.06	 -0.12	
(-0.9,	0.7)	
0.77	
0.16	
(-0.7,	1.1)	
0.73	
Difficulty	
hearing	
0.17	 0.07	 -1.02	*	
(-1.6,	-0.4)	
<0.01	
-0.84	*	
(-1.5,-0.2)	
0.02	
0.13	 -0.33	
(-0.9,	0.2)	
0.23	
-0.08	
(-0.7,	0.6)	
0.81	
Difficulty	
walking	
0.04	 0.02	 -0.79	
(-1.9,	0.3)	
0.17	
-1.20	
(-2.5,	0.1)	
0.08	
0.01	 -2.02	
(-4.1,	0.0)	
0.05	
-2.20	*	
(-4.4,	-0.0)	
0.049	
Table 25: Percentage of each study group with a physical disability, and odds ratios (OR) comparing 
controls to cases generated using logistic regression analysis. Adjusted OR includes age, sex, HIV status 
and SES as potential confounders in the regression model. * indicates p value <0.05 
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6.4.2.2 Hand grip strength, Physical Activity & Physical Capacity   
I hypothesised that, compared to controls, SAM survivors would have lower levels of physical 
activity, lower physical capacity during an exercise test and weaker hand grip strength. The mean 
values for each outcome as well as results of simple and multivariable regression analysis 
comparing hand grip strength, physical activity levels and physical capacity between controls and 
cases are presented in Table 26. Histograms for each outcome can be found in Appendix 20.  
Average steps per day for the sample as a whole was 14,667 based on children wearing the device 
for more than 11 hours per day. Results show that cases take on average 239 fewer steps per hour 
than their sibling controls and 54 fewer steps per hour than community controls; however results 
of the regression analysis show that these differences did not reach the cut-off for significance. 
Post hoc sample size calculations show that the test is currently only powered to 18% and to 
achieve 90% power, based on the current means of the cases and community controls, sample size 
would need to be around 320 per group. However the difference between the cases and 
community controls is 0.13 standard deviations and difference between cases and siblings is 0.58 
standard deviations, which is large in biological terms. This suggests there may be a difference in 
physical activity levels between ex-SAM cases and controls. When comparing HIV negative 
children only, siblings take significantly more steps than cases in both unadjusted and adjusted 
analyses (see table of result for HIV negative children only in Appendix 21). Age was not 
significantly associated with physical activity levels.   
Community controls have significantly stronger hand grip strength than cases. Siblings also have 
stronger hand grip strength than cases using simple linear regression; after adjusting for age 
differences and other potential confounders (sex, HIV status and SES), the difference is decreased 
but still significance (p=0.005). When comparing HIV negative children only, sibling and 
community controls have significantly stronger hand grip strength than cases, using both simple 
and multivariable regression models (Appendix 21). Community controls and siblings also have 
significantly larger AMA than cases.  
Physical capacity results based on outcomes from the iStep exercise test show some adjusted 
significant differences between cases and community controls. A larger proportion of sibling and 
community controls completed the exercise test than cases and community controls have 0.47 
higher log-odds than cases of completing more minutes of the exercise test with marginal 
significance after adjusting for potential confounders (p=0.07) (Table 27). Community controls 
are therefore marginally less likely to opt out of the test before the end. In addition, despite 
completing few minutes of the exercise test, there is no significant difference in highest heart rate 
between the groups (Table 25). This suggests that the HR of community controls did not rise as 
much as cases, relative to the amount of exercise they completed. Lastly, community controls 
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have a significantly greater drop in HR during 1st minute of recovery than cases, indicating that 
their HR recovers more quickly than cases. This is presented as a percentage of their highest HR. 
For sibling controls, there is no adjusted significant difference in physical capacity outcomes, 
however the result are trending in the same direction as those of community controls. Neither 
siblings nor community controls have a significantly different “lowest oxygen saturation” than 
cases, indicating that oxygen diffusion during exercise is similar across the groups. This suggests 
that lung function in terms of oxygen diffusion has been unaffected by SAM; further lung 
function results are presented in Chapter 7. There was no difference in “perceived tiredness” or 
“perceived breathlessness” between cases and controls, nor in the final heart rate when comparing 
only those who completed the test. All the physical capacity results remain true when comparing 
HIV negative children only (see table in Appendix 21).    
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	 Cases	 Sibling	 Community	
	 Mean	
(SD)	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)		
P	value	
Adjusted	
difference	
(95%	CI)		
P	value	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)		
P	value	
Adjusted	
difference	
(95%	CI)		
P	value	
Muscle	Strength	
Hand	 grip	
strength	(kg)	
n=	652	
12.7	
(6.3)	
14.8	
(7.9)	
	
2.05	*	
(1.2,	2.9)	
<0.001	
1.01	*	
(0.3,	1.7)	
0.005	
13.8	
(3.9)	
1.39	*	
(0.4,	2.4)	
0.005	
1.68	*	
(0.9,	2.4)	
<0.001	
AMA	(cm2)	 18.9	
(4.5)	
21.1	
(6.3)	
2.15	*	
(1.2,	3.1)	
<0.001	
1.07	*	
(0.3,	1.8)	
0.007	
20.1	
(4.6)	
1.21	*	
(0.6,	2.3)	
0.02	
1.41	*	
(0.6,	2.3)	
0.001	
Physical	Activity	
Steps	per	hour	
n=78	
859.8	
(280)	
1001	
(298)	
141.5		
(-10.1,	293)	
0.07	
144.5	
(-37,	325)	
0.12	
884.5	
(224)	
24.6	
(-116,	166)	
0.73	
-6.72	
(-185,	172)	
0.94	
Physical	Capacity	(iStep	outcomes,	n=778)	
Baseline	HR	 99.9	
(15.1)	
98.6	
(15.4)	
-1.29	
(-4.5,1.9)	
0.43	
-0.23	
(-3.6,3.2)	
0.89	
99.1	
(14.4)	
-0.76	
(-4.1,2.6)	
0.66	
-1.0	
(-4.6,2.5)	
0.57	
Highest	HR	 154.8	
(21.9)	
156.7	
(20.9)	
1.82	
(-2.7,6.3)	
0.43	
-0.47	
(-5.3,4.4)	
0.85	
159.5	
(19.5)	
4.22	
(-0.5,9.0)	
0.08	
4.24	
(-0.9,9.3)	
0.10	
HR:Level	
Ratio	~log	
52.2	
(35.2)	
45.6	
(28.9)	
-0.10		
(-0.2,	0.0)	
0.06	
-0.08	
(-0.2,	0.0)	
0.19	
45.7	
(27.3)	
-0.09	
(-0.2,	0.0)	
0.10	
-0.11	
(-0.2,	0.0)	
0.07	
Lowest	O2	
saturation	
93.4		
(4.9)	
93.7	
(4.9)	
0.37	
(-0.6,	1.4)	
0.47	
0.73	
(-0.4,	1.8)	
0.19	
93.8		
(3.8)	
0.45		
(-0.6,	1.5)	
0.40	
0.29	
(-0.9,	1.4)	
0.63	
HR	 at	 1	 min	
recovery	
113.6	
(18.6)	
112.9	
(19.1)	
-0.73	
(-4.9,3.4)	
0.73	
0.74	
(-3.8,	5.3)	
0.75	
110.9	
(18.1)	
-2.70	
(-7.1,1.7)	
0.23	
-1.35	
(-6.1,	3.4)	
0.58	
Drop	 in	 HR	 at	
recovery	 	 (as	%	
of	highest	HR)	
72.6	
(10.8)	
70.9	
(10.9)	
-1.71	
(-4.1,	0.6)	
0.15	
-0.24	
(-2.8,	2.4)	
0.86	
68.6		
(10.0)	
-3.95	*	
(-6.5,	-1.4)	
0.002	
-3.37	*	
(-6.1,	-0.7)	
0.01	
Final	HR	
(if	 test	 was	
completed)	
157.5	
(18.6)	
n=125	
157.6	
(18.1)	
n=90	
0.09	
(-4.9,	5.1)	
0.97	
0.87	
(-4.9,	6.7)	
0.77	
153.8	
(17.8)	
n=78	
-3.70	
(-8.9,	1.5)	
0.16	
-2.19	
(-8.0,	3.6)	
0.46	
Table 26: Mean (SD) and results of simple and multivariable linear regression analysis for hand grip 
strength and steps per hour for controls vs cases. Adjusted difference includes age, sex, HIV status and SES 
as potential confounders in the regression model. * indicates significant difference i.e. p value <0.05. HR = 
Heart Rate. ~ indicates that natural log of the raw value is being used 
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	 Cases		 Siblings	 Community	
	 %	
completed	
test		
(10	mins)	
%	
completed	
test		
(10	mins)	
Unadjusted	
log-odds		
(95%	CI)		
P	value	
Adjusted	
log-odds		
(95%	CI)		
P	value	
%	
completed	
test		
(10	mins)	
Unadjusted	
log-odds		
(95%	CI)	
P	value	
Adjusted	
log-odds				
(95%	CI)		
P	value	
Time	
completed	
of	iStep	
59%	
(124/210)	
69%	
(92/134)	
0.47	*	
(0.0,	0.9)	
0.04	
0.27		
(-0.2,	
0.8)	0.29	
68%	
(77/113)	
0.47		
(-0.0,	0.9)	
0.05	
0.47	
(-0.0,	
1.0)	
0.07	
Table 27: Result of ordered logistic regression comparing time completed of the iStep test for siblings and 
community controls with cases. Adjusted difference included age, sex, HIV status and SES in the regression 
model.  
	
	
6.4.3 HIV and Physical Function 
Interestingly, after adjusting for case/control status, HIV has no significant impact on hand grip 
strength, AMA, physical activity or physical capacity (time completed of iStep test). 
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6.4.4 Effect of Body Size and Composition on Physical Function 
6.4.4.1 Body Size: WAZ and HAZ 
We know from the previous section that cases have significantly weaker hand grip, smaller AMA 
and marginally lower physical capacity than community controls, is this only because they are 
shorter and lighter than controls?  
Firstly, is there an association between weight/height and physical function? Table 28 shows that 
as WAZ and HAZ increase, hand grip strength also increases significantly. Equally, AMA 
increases very slightly but significantly with increase in WAZ, HAZ and BAZ. However, physical 
capacity (in the form of time completed of the iStep test) is not associated with WAZ, HAZ or 
BAZ. Results for steps per hour have not been presented as sample size is too small, especially for 
stratification 
 
 Hand grip strength 
(kg) 
Unadjusted 
difference (95% CI) 
AMA (cm2) 
Unadjusted 
difference (95% CI) 
Time completed of 
iStep (minutes) 
Unadjusted log-odds  
(95% CI) 
WAZ 0.10 * (0.07, 0.12)  0.001* (0.00, 0.01) 0.13 (-0.1, 0.4) 
HAZ 0.05 * (0.03, 0.07) 0.001 * (0.00, 0.01) 0.12 (-0.0, 0.3) 
BAZ 0.01 (-0.00, 0.02) 0.001 * (0.00, 0.01) 0.61 (-0.1, 0.3) 
Table 28: Results of regression analysis of functional outcomes against anthropometric indicators for the 
cohort as a whole. * indicates significant difference i.e. p value <0.05   
	
Distinguishing between the effects of a previous episode of SAM and the effects of a child’s 
current WAZ and HAZ is very difficult, as they are very much interlinked. Age is also a potential 
confounder as it is associated with both WAZ/HAZ and physical function outcomes (older 
children tend to have lower WAZ and HAZ). However, if I compare cases who have HAZ >-1 
(n=153) to controls who also have HAZ >-1 (n=167) whilst adjusting for age, we see no 
significant difference in physical capacity, but non-stunted cases still have significantly lower 
hand grip strength (coef -1.1, p=0.04) and AMA (coef -158, p=0.02) than non-stunted controls. If 
I consider cases with WAZ >-1.5 (n=96) compared to controls with WAZ >-1.5 (n=117) adjusting 
for age, I find no significant difference in hand grip strength, AMA or physical capacity. These 
results suggest that weight, specifically continued low weight in cases, is playing a large role in 
the difference in physical function between cases and controls. See Figure 25 for boxplots of 
AMA and grip strength stratified by study group and WAZ category.  
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Figure 25: Box plots for hand grip strength and AMA stratified by study group and WAZ category. Wasted 
defined as WAZ<-1.5 
	
6.4.4.2 Lean Mass 
There is a significant positive association between hand grip strength, AMA, time completed of 
iStep and lean mass (measured either using LMI or R/H). Interestingly, there is also an 
association between steps per hour and lean mass, indicating that lean mass as assessed by BIA 
may be a good measure of physical activity (results in Table 29). Causality i.e. whether more lean 
mass results in greater physical function or vice versa, cannot be deduced from this data.  
 Hand grip 
strength (kg) 
Unadjusted 
difference  
(95% CI) 
AMA (cm2) 
Unadjusted 
difference  
(95% CI) 
Time completed 
of iStep 
(minutes) 
Log-odds 
(95% CI) 
Steps per hour 
Unadjusted 
difference  
(95% CI) 
LMI 0.75 * (0.4, 1.1)  189.2 * (151, 228) 0.31 * (0.1, 0.5) 88.59 *(35,141) 
R/H -0.03 * (-0.0, -0.0) -3.69 * (-3.9, -3.4) -0.01 *(-0.0, -
0.0) 
-0.67* (-1.2, -
0.1) 
Xc/H -0.25 * (-0.3, -0.2) -30.1 * (-34, -25) -0.04* (-0.1, -
0.0) 
-7.38 (-14.9, 0.2) 
Table 29: Results of regression analysis of functional outcomes against lean mass indicators for the cohort 
as a whole.   
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6.4.5 Associations between Physical Function Measures 
There is a significant positive correlation (after adjusting for age and sex) between: 
• Hand grip strength and physical capacity (p=0.004) 
• Hand grip strength and AMA(p<0.001) 
There is no significant association between physical activity and any of the other physical 
function measures, however sample size for physical activity is small. There is also no significant 
correlation between AMA and physical capacity; however there is an association between 
physical capacity and calf circumference (log-odds 0.18, 95% CI 0.1 to 0.3, p<0.001).   
6.4.6 Predictors of Poor Physical Function in Cases 
In order to identify any factors at admission that may predict poor long-term physical function a 
variety of potential predictors were explored, comparing within the case group. Any predictors 
that were identified as potentially significant where explored further by comparing the two types 
of cases to controls (siblings and community controls combined).  
Table 30 shows adjusted difference within the case group for hand grip strength, AMA and time 
completed of iStep test comparing various potentially predictive factors. Results for steps per hour 
have not been presented as sample size is too small, especially for stratification. Those cases that 
were severely stunted or severely wasted at admission have weaker handgrip strength, smaller 
AMA but no difference in physical capacity at 7 years post-discharge. However it is important to 
remember that those severely stunted and wasted at admission continue to be more stunted and 
wasted at follow up, which is likely impacting on result as mentioned above.  
Those who were admitted with oedema have similar handgrip strength and similar physical 
capacity to those admitted without oedema, but oedematous admissions have larger AMA than 
marasmic admissions at follow-up. This is in line with BIVA results presented in previous chapter 
that show marasmic admissions continuing to have less lean mass at follow up, whereas 
kwashiorkor survivors now have similar levels of lean mass to controls.  
There is no significant difference in hand grip strength, AMA or physical capacity when 
comparing HIV status, sex and reported birth weight, within the case group. There is no 
significant difference between those admitted before 24 months and those admitted after for 
handgrip strength or AMA. Interestingly, those admitted after 24 months completed significantly 
more minutes of the exercise test, despite having worse growth outcomes.  
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Potential Predictors  Adjusted difference 
Hand grip strength  
(95% CI) 
Adjusted difference  
AMA 
(95% CI) 
Adjusted Log odds 
Time completed  
(95% CI) 
Stunted at admission 
(HAZ <-3) 
-0.98 * 
(-1.9, -0.0) 
-86.2  
(-196, 23.8) 
0.24  
(-0.3, 0.8) 
Wasted at admission 
(WAZ≤-4) 
-1.16 * 
(-1.9, -0.4) 
-148.8 * 
(-241, -56.5) 
-0.43 
(-1.0, 0.1) 
Oedema at admission 0.55 
(-0.5, 1.6) 
141.0 * 
(16.4, 266) 
0.06 
(-0.7, 0.8) 
HIV negative vs 
positive 
-0.03 
(-0.9, 0.8) 
3.35 
(-97.5, 104) 
-0.27 
(-0.8, 0.3) 
Females vs males 0.75 
(-0.0, 1.5) 
-20.2 
(-111.7, 71.3) 
-0.16 
(-0.7, 0.4) 
Normal vs low birth 
weight 
-0.14 
(-1.6, 1.3) 
-85.3 
(-250.6, 79.9) 
0.03 
(-0.9, 1.0) 
Admitted ≤2 yrs vs >2 
yrs 
0.07 
(-0.9, 1.1) 
-48.0 
(-164, 67.9) 
1.07 * 
(0.3, 1.8) 
Table 30: Results of linear regression and ordered logistic regression analysis comparing 
characteristics at admission within the case groups adjusted for age, sex, HIV status and SES 
When compared to controls (siblings and community combined) both oedematous and marasmic 
admission have lower hand grip and AMA than controls; equally both those severely stunted at 
admission, those less stunted at admission, those severely wasted at admission and those less 
wasted at admission have lower hand grip, AMA and time completed of iStep than controls. For 
age at admission, both younger admissions and older admissions have significantly lower hand 
grip and AMA than controls, but only those admitted before 24 months completed significantly 
fewer minutes of the iStep test (log odds -0.49, p=0.04 (adjusting for age and HIV status). There 
is no significant difference in time completed of the iStep test for those admitted after 24 months 
(log odds -0.24, p=0.36)  
133 
	
6.5 Summary 
This chapter explores 3 main areas of physical function: muscle strength, physical activity and 
physical capacity. Results show no consistent difference for reported physical disabilities between 
cases and controls. Cases have significantly smaller AMA than both sibling and community 
controls, as well as weaker hand grip strength. Cases may have lower physical capacity than 
community controls as their heart rate recovers significantly more slowly following the exercise 
test. There is no significant difference in oxygen saturation between cases and controls during 
exercise. Cases are less physically active than controls (steps per hour) however sample size is too 
small to be conclusive. Interestingly, after adjusting for case/control status, HIV has no significant 
impact on hand grip strength, AMA, physical activity or physical capacity. Weight and height do 
affect hand grip strength and AMA but not physical capacity; results suggest that catching up 
height does not mitigate the long-term effects of SAM on physical function, however catching up 
weight does. Lean mass as measured by BIA is an important indicator of physical function as it is 
significantly associated with all outcomes in this chapter. Greater stunting and greater wasting at 
admission are associated with worse muscle strength and lower AMA 7 years post-discharge, 
likely due to the continued deficits in WAZ and HAZ in these patients. Marasmic admissions, 
rather than those who had kwashiorkor, continue to have lower AMA however this doesn’t seem 
to have affected muscle strength or physical capacity.   
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7 Chapter 7: Lung function 
	
This chapter introduces lung function and specifically the potential effects that SAM could have 
on long-term lung function. Continuing on from the previous chapter which explored physical 
function, lung function is another important functional outcome and could also indicate the health 
of vital organs in general. This chapter also describes the specific methods related to lung 
function outcomes, analysis and lung function results. Methods and results from this chapter have 
been presented at European Respiratory Society (ERS) conferences in 2014 and 2015.   
 
 
7.1 Chapter-specific Hypotheses  
Lung development including alveologenesis, lung size and gas-exchange surface area occurs 
between gestation and early childhood[32, 163]. An insult to growth and development during any 
of these time periods could feasibly damage lung function. There is already evidence that 
intrauterine insults, nutritional and other, can result in poor lung function and increased risk of 
asthma in childhood and heightened risk of COPD in adulthood[32]. Based on this evidence, I 
hypothesised that:   
5. Compared to controls, SAM survivors have impaired lung function; namely  
a. reduced Forced Expiratory Volume in 1 second (FEV1) 
b. reduced Forced Vital Capacity (FVC) 
c. and/or reduced FEV1/FVC ratio z scores. 
Additionally, those who suffered SAM at a younger age (<2 years) have greater lung 
function impairments.  
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7.2 Measuring Lung Function 
Spirometry testing is the most common method of measuring lung function. Although it does not 
assess all aspects of lung function, it does assess the volume and flow of air that can be inhaled 
and exhaled. The main outcomes are: 
• Forced expiratory volume in 1 second (FEV1) 
• Forced vital capacity (FVC)  
• FEV1/FVC ratio 
• Forced expiratory flow (FEF) 
• Mean forced expiratory flow during 25-75% FVC (FEF25-75). 
The FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre; FVC is 
the total amount of air expelled from the lungs after a maximal inhalation. The FEV1 is reduced in 
both obstructive and restrictive lung disease; these two categories of lung disease are 
differentiated using FEV1/FVC ratio as FVC is only reduced in restrictive disorders. In asthma 
for example, an obstructive lung disorder, the FEV1 is usually decreased but the FVC is normal 
hence the FEV1/FVC ratio is decreased. Both obstructive and restrictive lung function patterns 
could be relevant to SAM survivors. FEF is the speed of the air coming out of the lung during the 
middle portion of a forced expiration; it has recently been suggested that FEF25-75 is a more 
sensitive measure of obstructive small airways disease[245].	   
Other lung function tests include gas diffusion tests which measure amount of oxygen or carbon 
dioxide in the blood stream; body plethysmography which measure total lung capacity and 
residual volume using a plethysmograph booth which measures pressure changes as you breath; 
and exercise tests which measure lung diffusion capabilities by monitoring blood oxygen 
saturation during exercise.  
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7.3 Specific Methods 
7.3.1 Anthropometry 
Chest circumference: this was measured after the child had removed clothing from the chest, and 
stood with their hands by their side. The tape was passes around the chest, 2cm below the arm pit 
but always above the nipple. The tape should be horizontal with the floor and the measurement 
taken during a normal exhale; this measurement sometimes included protruding shoulder blades 
depending on the child’s chest shape.  
Chest width: this was measured at the same level as chest circumference, using body callipers. 
The child stood with relaxed shoulders and with their hands on their hips while the measurement 
was taken from the child’s back.  
Chest depth: this was measured using the same body callipers as with chest width, and the 
reading was taken at the same level as both chest width and chest circumference. The child stood 
with their hands by their sides and can be approached with callipers from either side. It was 
important that the callipers were horizontal with the floor as this could often be difficult with 
certain shoulder blade shapes. 
7.3.2 Spirometry 
The spirometry testing was done using an NDD Easy On-PC spirometer (NDD Medical, 
Switzerland). “FVC (exhale only)” test was used. This device was chosen as it connects directly 
into a PC or laptop, making it highly portable and it has an ultrasonic flow head which allows for 
easy calibration in the form of zero flow verification. It also has the added benefit of displaying 
spirometry-related incentives (i.e. children’s computer games) to encourage optimal exhalations, 
as spirometry is an effort-dependant test. Effort, as well as skill, is also required from the operator 
of the test to encourage maximal effort from the children; I undertook 2 weeks of training at Great 
Ormond Street children’s hospital in London by a team from the Institute for Child Health in 
order to learn how best to conduct spirometry tests with children. I then passed this training on to 
select members of the Malawian study team. We also shadowed the Blantyre Health Study team 
who were undertaking spirometry in Malawian adults in order for us to learn appropriate 
Chichewa translations for common spirometry instructions.   
7.3.2.1 Contraindications 
A questionnaire regarding contraindications and confounding factors was administered to the 
parent or guardian of the child prior to conducting spirometry, including questions regarding 
abdominal aneurysm, recent pneumothorax, asthma, eczema, environmental smoke exposure and 
history of respiratory illness. These questions were developed based of questions from “American 
Thoracic Society’s ATS-DLD-78C respiratory questionnaire” and UCL’s “SLIC” study 
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questionnaire[246, 247]. Spirometry was not attempted if the child had any one of the following 
contraindications: 
• abdominal aneurysm 
• recent heart attack 
• current respiratory infection 
• recent pneumothorax 
• haemoptysis 
• any recent surgery 
 
7.3.2.2 Spirogram Acceptability and Grading 
During the spirometry test, acceptability of traces was assessed as to know when to stop testing. 
Ideally the testing finished when there were 3 repeatable readings, however this was not always 
possible. The operator never ended the test on the best attempt in case the child could improve 
further. In most cases, at least 6 spirometry traces were recorded for each child; in some cases as 
many as 25 spirometry attempts were done by one child. 
The criteria for acceptability of individual spirometry traces are listed below. Figure 26 gives an 
example of an acceptable and an unacceptable trace. Although the NDD software automatically 
rejects unacceptable traces and selects the child’s best result for export, this process is not perfect 
and needs to be checked. Inappropriate traces were discounted and acceptable ones included by 
the operator. I also checked all spirometry data each week and Jane Kirkby (senior respiratory 
physiologist, UCL Respiratory Section IIIP), who was blinded to the study groups, checked at 
least 10% of results each month, amending acceptable and unacceptable inclusions. The final 
spirometry outcomes are based on the best attempt of all the “acceptable” traces.  
Criteria for acceptable spirometry traces: 
• Free from artefact i.e. 
o Coughing 
o Glottis closure 
o Early termination or cut-off 
o Leak 
o Obstruction of the mouth piece (tongue or biting) 
• Effort must be maximal throughout 
• Exhale start should be strong 
• Back extrapolated value should be <5% of FCV 
• Exhale should last at least 3 seconds or plateau in the volume-time curve 
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Following this quality control process, quality grades were applied to the data for each child based 
on repeatability of accepted traces (see Table 31 for grades and repeatability criteria). The criteria 
for repeatability of the spirometry curves was based on  “ATS/ERS task force: standardisation of 
lung function testing” by Miller et al. adapted slightly for children to accept a 10% difference 
between spirograms in accordance with guidelines used by Kirkby et al [248, 249]. This grading 
system allows one to distinguish between a child who has a poor spirometry reading but only one 
acceptable trace, and another who has a poor spirometry reading with multiple acceptable, similar 
traces to back it up, proposing that better grades are more likely to be a true reflection of lung 
function than lower grades.  
  
 
 
 
 
 
 
 
 
 
 
Table 31: Quality Control Grading for Spirometry 
	 	
Grade FEV1 or FVC 
A 3 acceptable trials within 5% or 100mL 
B 2 acceptable trials within 5% or 100mL 
C 2 acceptable trials within 10% or 150mL 
D One acceptable trial 
F Fail: No acceptable trials 
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a) 
	
b) 
	
Figure 26: Examples of a) acceptable and repeatable spirometry traces b) unacceptable traces 
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7.3.3 Sample Size Calculations 
Sample size for this study was difficult to calculate as reference ranges for Malawian children do 
not yet exist. Based on a common clinical difference in lung function of 0.5 z scores (standard 
deviation 1.0), I calculated that sample size needed to be 85 in each group to detect this 
difference. A follow-up study of lung function in Nepal based their sample size calculation on US 
data from children in the National Health and Nutrition Examination Survey III[250, 251] and 
suggested that only a 0.2 z score difference should be expected between groups. To detect this 
difference and based on our sample size of 199 cases and 142 siblings, our sample is only 
powered to 44% and analysis of community controls (n=121) is powered to 35%.  
 
Image 15: Study children undertaking spirometry testing on the NDD Easy-On PC spirometer during the 
data collection in Blantyre 	
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7.4 Analysis 
Primary analysis compared sibling and community controls to cases using regression analysis 
for:  
• Chest anthropometry 
• Main spirometry outcomes: FEV1, FVC and FEV/FVC ratio z scores 
As these are all continuous outcomes, simple and multivariable linear regression analysis was 
used to compare cases and both types of control. Potential confounding factors were adjusted for 
in multivariable linear regression; namely HIV status, sitting height, puberty status and SES, 
based on a priori assumptions. Age and sex were also included in anthropometry outcomes as 
they have not been converted to z scores. A description of how potential confounders were 
selected for inclusion is provided below.  
Secondary analysis considered impact of various other factors on spirometry outcomes including 
HIV status, wealth, sex and effect of being in a “SAM” household. I also explored if any factors 
at admission were predictive of poor lung function 7 years post-discharge, namely severity of 
stunting and wasting at admission, HV status, age at admission and presence of oedema, as well 
as reported birth weight, for case children only. Besides linear regression, Students t test and Chi 
squared testing were also used in some analyses in this Chapter to assess association when only 
two groups are involved and/or if both variables are categorical. 
7.4.1 Data Cleaning 
As with growth data, I check for erroneous values among the anthropometric measures by plotting 
scatter graphs of each variable against age, height and weight. Outliers were identified and paper 
files check for notes, corrections or explanations. Impossible readings without explanation were 
removed: 2 chest circumference readings. No chest width or chest depth data were removed. I 
removed spirometry data for 1 child due to implausibility; this result was at the extreme high end 
of z scores for age and height and was not repeatable; it was most likely the result of the operator 
or another older child demonstrating an attempt.  
7.4.2 Calculations and Statistics  
The analysis of spirometry data focused on the most widely used spirometry outcomes: FEV1, 
FVC, and FEV1/FVC ratio. For all children with grade A-D spirometry results, the best acceptable 
spirometry reading was used to calculate z scores based on child’s age, height, sex and ethnicity 
using Quanjer et al., (2012) Global Lung Function Initiative (GLI) reference data [252]. The GLI 
reference was derived from healthy individuals between ages of 3 and 95, including Caucasian, 
African-American, North East Asian and South East Asian ethnicities. Z scores were computed 
for Malawian children using the African-American only reference data (called GLI-Black). There 
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is currently no specific spirometry reference for Malawi or Southern Africa; one small study 
considered spirometry outcomes in Malawian children and showed them to be lower than both 
Caucasian and conventional Black reference data, however because I am comparing cases to 
controls, the appropriateness  of the reference equation to Malawian children in general is less 
important [253]. The applicability of the GLI-Black equation for these Malawian children was 
investigated in a separate study, abstract and poster of which can be seen in Appendix 22.  
The following calculations were applied to the anthropometry data:  
• Sitting height percentage = (sitting height / height )*100 
• Relative chest circumference = chest circumference / height 
  
7.4.3 Adjusting for Potential Confounders 
Potential confounding factors were adjusted for in multivariable linear regression; namely HIV 
status, age, sex, puberty and socio-economic status (SES). These variables are highly likely to be 
confounders as they are closely linked to SAM and likely linked to lung function; hence they were 
controlled for regardless of statistical significance. For exploring the association between SAM 
and spirometry outcomes, further potential confounders including previous respiratory infection, 
sitting height percentage, reported asthma, maternal education level and household smoke were 
considered. There is evidence that up to 35% of those with COPD in low and middle income 
countries developed the disease after exposure to biomass fuel combustion, hence this is an 
important consideration[254]. Previous respiratory infections are also important to consider as 
evidence shows they are closely linked to COPD in later life, however the direction of causality is 
not yet clear[32, 73]. One confounder that I was not able to adjust for is birth weight, as this is not 
known for the majority of study participants, though is known to have significant effects on later 
lung function[73]. Lung function is also closely linked to sitting height because, although z scores 
account for overall height, they do not account for differences in torso height specifically, which 
is likely to be more closely related to lung volume. A conceptual framework of all these potential 
confounders is depicted in Figure 4d, Chapter 2. Table 32 shows consideration of all these 
potential confounders in relation to FEV1, FVC and FEV1/FVC z scores; previous respiratory 
infection, maternal education level and household smoke exposure are not associated with 
spirometry outcomes, hence were not included in multivariable linear regression as potential 
confounders. Reported Asthma is only significantly associated with FEV1/FVC ratio. It is worth 
mentioning that only 1.7% of our sample cook with a clean fuel and only 1.5% do not cook on an 
open fire, hence there is likely to be little variation in cooking smoke exposure across the sample. 
Sitting height percentage is positively associated with both FEV1Z and FVCZ therefore it is 
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included in multivariable regression analysis when comparing lung function outcomes between 
groups in this chapter.    
 
 FEV1Z FVCZ FEV1/FVC Z 
 Adjusted difference 
(95% CI) 
Adjusted difference 
(95% CI) 
Adjusted 
difference (95% 
CI) 
HIV positive -0.51 * (-0.8, -0.2) -0.43 * (-0.7, -0.1) -0.22 (-0.5, 0.1) 
Age (years) -0.12 * (-0.2, -0.1) -0.09 * (-0.1, -0.0) -0.08 * (-0.1, -0.0) 
Started puberty 0.30  (-0.2, 0.8) 0.30   (-0.2, 0.8) 0.11 (-0.3, 0.5) 
SES 0.10 * (0.0, 0.2) 0.08 * (0.0, 0.1) 0.02 (-0.0, 0.1) 
History of pneumonia  0.22   (-0.2, 0.7) 0.16  (-0.3, 0.6) 0.08 (-0.3, 0.5) 
Reported asthma -0.13  (-0.5, 0.3) 0.11  (-0.3, 0.5) -0.38 * (-0.7, -0.0) 
Maternal education  
(2ndary vs none) 
-0.02  (-0.4, 0.3) 0.02  (-0.3, 0.40 -0.16 (-0.5, 0.2) 
Cooking with solid 
fuel in the home 
0.30  (-0.0, 0.6) 0.27 (-0.1, 0.6) -0.02 (-0.3, 0.3) 
Sitting height 
percentage 
0.15 * (0.1, 0.2) 0.12 * (0.1, 0.2) 0.06 * (0.0, 0.1) 
Table 32: Results presented for linear regression analysis of each potential confounder for FEV1, FVC and 
FEV1/FVC z scores. Results are all adjusted for study group (i.e. case/control status). * indicates p<0.05 
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7.5 Results 
7.5.1 Missing Data 
Spirometry was attempted by 532/721 (74%) children in the study (see flow diagram in Figure 
27). 189 children did not attempt spirometry for the following reasons: 
• Child was less than 6 years old (only applies to sibling controls) (n=19)  
• Child was too unwell (e.g. malaria or a current respiratory infections) (n=36)  
• Child didn’t attend the hospital appointment because they didn’t want to or they 
lived too far away (n=95) 
• Child has a physical and/or cognitive disability (n=39) 
For a full table of number of results for each outcome variable see Table 4 in Chapter 3: Cohort 
Profile. 
 
 
Figure 27: Flow diagram showing recruitment of cases, siblings and community controls for spirometry 
outcomes 
145 
	
In order to explore any “response bias” caused by this missing data, Table 33 shows results of a 
Student’s t-test comparing age and anthropometry data for those who did vs those who didn’t 
attempt spirometry testing. There is no significant difference in WAZ, HAZ, BAZ or sitting 
height percentage between the 2 groups. There is also no difference in HIV status or gender 
balance between the two groups. There is however a significantly higher proportion of children 
with disabilities in the “didn’t attempt” group (7% vs 1%) (Chi squared 20.4, 1 d.f, p<0.001), and 
the “didn’t attempt” group are slightly but significantly younger, which is as expected as age was 
an exclusion criterion (p=0.02).  
There is also a significant relationship between those who attempted spirometry and study group; 
the odds of attempting spirometry are 1.8 (p<0.001) for siblings compared to cases, and 1.5 
(p=0.05) for community controls compared to cases. This is likely due to the higher prevalence of 
disability in the case group; of the 45 with disabilities who couldn’t attempt spirometry 43 were 
cases, 2 were siblings and 0 were community controls.   
 Didn’t do 
spirometry 
Mean (SD)  
Did 
spirometry 
Mean (SD)   
Mean 
difference 
(95% CI) 
p value 
Age (years) 9.6 (2.3) 10.0 (2.1) -0.4 (-0.7, -0.1) 0.02 * 
WAZ -1.4 (1.0) -1.4 (1.0) -0.1 (-0.4, 0.1) 0.3 
HAZ -1.7 (1.3) -1.6 (1.2) -0.1 (-0.3, 0.2) 0.5 
BAZ -0.7 (1.0) -0.8 (0.9) 0.1 (-0.1, 0.3) 0.4 
Sitting height 
percentage (%) 
52.1 (1.8) 52.0 (1.5) 0.2 (-0.1, 0.5) 0.2 
Table 33: Mean (SD) and results of Student t-test for those who did attempt spirometry vs those who did 
not (continuous variables only). * indicates p<0.05 
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7.5.2 Data Quality 	
Of 532 children with spirometry results, 364 had repeatable data (Grade A-C) for both FEV1 and 
FVC (see Table 34 for breakdown of data quality by study group). The overall fail rate was 12% 
(64/532) (Grade F). Grade F data was excluded from analysis. 14% (72/532) achieved Grade D (1 
acceptable trace) for FEV1 and 12% (62/532) for FVC. There is no statistically significant 
relationship between being a case or control and spirometry quality grade achieved (A-C, D or F) 
(chi-square with 4 degree of freedom FEV1= 5.33, p= 0.3; FVC = 8.52, p=0.07).  
 Ex-SAM Case 
n=237 
Sibling 
Control 
n=164 
Community 
Control 
n=131 
FEV1 & FVC 
repeatable (A-C) 
146 (62%) 116 (71%) 102 (78%) 
Symptomatic 13 (5%) 4 (2%) 4 (3%) 
FEV1 only 15 (6%) 5 (3%) 6 (5%) 
FVC only 2 (1%) 1 (0.6%) 0 
Grade D 25 (11%) 16 (10%) 9 (7%) 
Fail 34 (14%) 20 (12%) 10 (8%) 
Fail & symptomatic 2 (1%) 0 0 
Exclude:Implausable  0 1 (0.6%) 0 
Table 34: Break-down of quality control information by study groups 
 
Children with reported coughs/colds (‘symptomatic’), self-reported asthma, cooking with solid 
fuel in the home or history of pneumonia and those with grade D data were reviewed to ascertain 
if they could bias our results. Figure 28 shows that both symptomatic and Grade D children have 
FEV1 and FVC z scores evenly spread throughtout the range of results i.e. they are not at the 
extremes of the z scores. Table 35 summaries the mean (SD) z scores for quality data (grade A-C) 
and grade D data, sympotmatic data and children with history of respiratry illness; linear 
regression analysis revealed no statistical group differences in FEV1, FVC nor FEV1/FVC z 
scores between children with grade D data/symptomatic/history of pnuemonia/self-reported 
asthma/cooking smoke in home, and quality data. There is however a significant difference in 
FEV1 and FVC z scores between those with a history of TB and quality data (FEV1Z Coeff -0.91, 
p<0.001; FVCZ Coeff -1.1, p<0.001). Inclusion of grade D and symptomatic data in the final 
analysis therefore does not bias the results and has been included; those with a history of TB have 
been excluded from analysis. Inclusion of grade D and symtomatic data is inline with some 
previous studies[255] . 
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Figure 28: The distribution of FEV1 (left) and FVC (right) z scores for all quality results and those which 
came from Grade D children (green triangles) and symptomatic children (cold/flu symptoms) (red 
diamonds).  
 
 
 
 Grade A-C 
(n=364) 
Grade D 
 (n=50) 
Symptomatic 
(cough/cold)  
(n=23) 
History of 
pneumonia 
(n=25) 
Self-
reported 
Asthma 
(n=28) 
History of 
TB 
(n=11) 
Cooking 
with solid 
fuel in the 
home 
(n=51) 
FEV1 z-
score 
-0.4 (1.0) -0.4 (1.1) -0.7 (1.3) -0.2 (1.3) -0.5 (1.0) -1.3 (1.7) -0.2 (0.9) 
FVC z-
score 
-0.3 (1.0) -0.4 (1.2) -0.2 (1.2) -0.2 (1.2) -0.2 (0.8) -1.3 (1.7) -0.1 (0.9) 
FEV1/FVC 
z-score 
-0.2 (0.9) 0.1 (0.9) -0.9 (1.0) -0.2 (1.0) -0.6 (1.3) -0.6 (1.3) -0.3 (0.8) 
Table 35: Mean (SD) FEV1, FVC and FEV1/FVC z scores for acceptable quality data (Grade A-C) versus 
grade D data, symptomatic children, children with a history of pneumonia, history of TB, cooking smoke in 
the home and those with self-reported asthma. The results indicate that all these groups have similar mean z 
scores to acceptable data, except those children who have a history of TB.  
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7.5.3 Anthropometry 
As stated in Chapter 4: Growth, case children are significantly more stunted and have larger 
sitting height percentage than both sets of controls. Table 36 shows results of simple and 
multivariable linear regression analysis comparing chest anthropometry of cases and control 
groups; results indicate no significant adjusted difference in chest size or torso height, apart from 
chest width which is significantly larger for controls than cases. This information indicates that 
although cases are shorter for their age than controls, their sitting height and chest size is largely 
preserved when compared to sibling and community controls.  Histograms for each variable can 
be found in Appendix 23.  
 
Anthropometry	 Cases	
(n=302)	
Sibling	
(n=	202)	
Community	
(n=158)	
	 Mean	
(SD)	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)		
P	value	
Adjusted	
difference	
(95%	CI)		
P	value	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)		
P	value	
Adjusted	
difference	
(95%	CI)		
P	value	
Chest	 width	
(cm)	
19.1	
(1.5)	
19.9	
(2.6)	
0.81	*	
(0.5,	1.2)	
<0.001	
0.39	*	
(0.1,	0.7)	
0.005	
19.3	
(1.7)	
0.28	
(-0.1,	0.7)	
0.16	
0.34	*	
(0.0,	0.6)	
0.02	
Chest	 depth	
(cm)	
14.4	
(1.4)	
14.9	
(2.0)	
0.49	*	
(0.2,	0.8)	
0.001	
0.20	
(-0.0,	0.4)	
0.11	
14.5	
(1.5)	
0.09	
(-0.2,	0.4)	
0.55	
0.17	
(-0.1,	0.4)	
0.21	
Chest	
circumference	
(cm)	
60.8	
(4.8)	
62.8	
(7.8)	
1.99	*	
(0.9,	3.1)	
<0.001	
0.68	
(-0.1,	1.5)	
0.09	
61.3	
(5.4)	
0.55	
(-0.6,	1.7)	
0.35	
0.82	
(-0.0,	1.7)	
0.06	
Sitting	 height	
(cm)	
65.2	
(4.4)	
67.4	
(7.6)	
2.2	*	
(1.2,3.2)	
<0.001	
0.6	
(-0.1,1.3)	
0.11	
65.9	
(4.5)	
0.8		
(-0.3,1.9)	
0.18	
0.7	
(-0.1,1.5)	
0.07	
Chest	
circumference/
height		
0.49	
(0.0)	
0.48	
(0.0)	
-0.00	
(-0.0,	0.0)	
0.13	
-0.00	
(-0.0,	0.0)	
0.56	
0.48	
(0.0)	
-0.01	*	
(-0.0,	-0.0)	
0.04	
-0.00	
(-0.0,	0.0)	
0.13	
Table 36: Results of simple and multivariable linear regression analysis for chest anthropometry across the 
3 study groups. Adjusted difference includes age, sex, HIV status, SES and puberty. * indicates p<0.05.  
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7.5.4 Spirometry  
7.5.4.1 Checking lung function z scores   
As raw spirometry data was converted to z scores using African-American reference data, I firstly 
checked that conversion of raw values into z scores was adequately accounting for differences in 
age and height. Figure 29 and Figure 30 show scatter plots for both raw FEV1 and FVC as well 
as z scores for control children only; Figure 28 shows spirometry values plotted against age, 
figure 29 shows spirometry values plotted against height. As you can see from these figures, both 
age and height are associated with FEV1 and FVC as expected, and the z score conversion 
adequately removes any association.  
 
	
Figure 29: Scatter plots showing raw FEV1 and FVC values against age on the left side, with FEV1 and 
FVC z scores against age on the right side. This is for control data only to indicate adequate accounting for 
age by the z score conversions.  
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Figure 30: Scatter plots showing raw FEV1 and FVC values against height on the left side, with FEV1 and 
FVC z scores against height on the right side. This is for control data only to indicate adequate accounting 
for height by the z score conversions.  
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7.5.4.2 Lung function of the whole cohort 
The sample as a whole is normally distributed for FEV1Z and FVCZ but has a slight off-set 
compared to the reference data for a healthy population (expected mean (SD) 0 (1)). Although the 
standard deviation for our sample as a whole is 1.1 for FEV1Z and 1.0 for FVCZ, which is a credit 
to the data quality, the means are slightly below reference mean of 0 (FEV1Z -0.44; FVCZ -0.29). 
Histograms for spirometry outcomes can be seen in Appendix 23.  
When considering the sample as a whole, FEV1Z and FVCZ are positively and significantly 
associated with HAZ, WAZ and sitting height percentage, suggesting that underweight and 
stunted children have worse spirometry outcomes, particularly those with a relatively smaller 
sitting height.   
7.5.4.3 Lung Function and HIV status 
This analysis looks at the HIV status for the sample as a whole. There is a significant difference in 
FEV1 and FVC z scores between HIV positive and negative children (FEV1Z regression coef: -
0.5, p= 0.001 and FVCZ regression coef: -0.4, p= 0.009). The boxplot in Figure 31 shows the 
significant reduction in mean FEV1 z score for HIV positive children compared to the HIV 
negative group. HIV does not significantly affect FEV1/FVC ratio z score (p=0.216) because 
FEV1 and FVC are reduced in equal proportions. This indicates that HIV results in a more 
restrictive lung defect pattern.   
 
 
Figure 31: Boxplots of FEV1 Z (left) and FVCZ (right) for HIV negative and HIV positive groups.  
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7.5.4.4 Lung Function and Wealth quintile  
This analysis looks at the wealth for the sample as a whole. Those in the bottom three wealth 
quintiles have significantly worse FEV1 and FVC z scores than those in the top two quintiles 
(mean difference FEV1Z -0.30, p<0.01; FVCZ -0.26, p=0.012). FEV1/FVC z score is unaffected 
by wealth quintile. This suggests that poorer children have a slightly more restrictive lung 
function pattern than wealthier children, although clinically the difference is small. Wealth itself 
cannot directly affect lung function but must be an indicator of other environmental factors. The 
bar graph in Figure 32 shows FEV1 z score for each of the wealth quintiles (1 is poorest, 5 is 
richest), highlighting that although there is a statistically significant difference between the wealth 
quintiles, the difference in z scores is small.   
 
	
Figure 32: Boxplot showing FEV1Z for each wealth quintile for the whole sample. Wealth score is an 
asset-based score derived from Demographic Health Survey questions; score 1 is the poorest and score 5 is 
the richest within the sample.  
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7.5.4.5 Lung Function and Sex 
This analysis looks at the sex for the sample as a whole. There is no significant difference in 
proportion of each sex between the case and control groups, however there is a significant 
difference in FEV1 and FVC z score between the two sexes, across the whole sample (see Figure 
33). Females have significantly worse FEV1 and FVC z scores than males (mean difference 
FEV1Z -0.28 p=0.004 and FVCZ -0.25 p= 0.015), but no difference in FEV1/FVC z score between 
the sexes. This holds true when using linear regression to adjust for HIV status, SES, sitting 
height ratio and puberty. There is no significant difference in age, wealth or HIV status between 
the sexes. Females therefore appear to have a more restrictive lung function pattern than males 
(reduced FEV1 and FVC and no difference in FEV1/FVC). Although we have already seen that 
living with a tobacco smoker and cooking with solid fuel in the home do not significantly affect 
spirometry outcomes in this study, differential exposure to cooking smoke between the sexes 
could still be a reasonable explanation for the difference in spirometric score.  
Using sex stratified analysis, there is no significant difference in FEV1 or FVC z scores for males 
exposed and unexposed to household cooking smoke. However there is a marginal significant 
difference for females exposed to household smoke having worse FEV1Z than unexposed girls 
(coef, 0.50, p=0.058). FVC and FEV1/FVC z scores are not significantly different in girls exposed 
to household smoke.    
Other explanations for this sex difference that I have explored include delayed puberty in 
Malawian girls resulting in poor adherence to the African-American reference data differentially 
for girls, and differences in body composition between sexes affecting lung function. If delayed 
puberty was affecting the fit to the reference data for girls there would be no sex difference in the 
younger group (<9 years), however the sex difference remains (FEV1Z unadjusted difference 
0.44, p<0.01; FVCZ unadjusted difference 0.37, p=0.02), so this is an unlikely explanation. 
Regarding body composition, previous studies have found greater lean mass to be associated with 
better spirometry outcomes, and greater fat mass with poorer spirometry [256-258]. The females 
in this cohort have significantly less lean mass and significantly more fat mass than the males; 
LMI is positively associated with FEV1Z and FVCZ (FEV1Z coef. adjusted for case/control status 
0.30, p<0.01; FVCZ coef adjusted for case/control status 0.31, p<0.01) whereas fat mass is 
negatively associated with FEV1/FVC z ratio (FEV1/FVCZ difference adjusted for case/control 
status -0.07, p=0.03). This could therefore be another explanation for sex differences in 
spirometric results.  
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Figure 33: Box plots showing mean FEV1, FVC and FEV1/FVC z scores for both sexes and each study 
group. Females (in pink) have consistently lower FEV1Z and FVCZ than males across all 3 study groups. 
FEV1/FVC ratio is unaffected by sex 
n=	
	 females	 males	
Cases	 98	 103	
Siblings	 76	 66	
community	 51	 70	
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7.5.4.6 Lung function at Household level  
When comparing households (i.e. cases and siblings VS community controls), there is no 
significant difference in FEV1Z or FVCZ, with either unadjusted or adjusted regression analysis: 
FEV1Z adjusted difference between case/sibling households and community households is 0.08 
(95% CI -0.1 to 0.3) p=0.47. FVCZ is 0.15 (-0.1, to 0.4) p=0.19. FEV1/FVCZ is -0.20 (-0.4 to 0.0) 
p=0.06 (adjusted for HIV status, SES and puberty status). Community control households actually 
have a lower FEV1/FVCZ ratio than cases and sibling control households with marginal 
significance.  
7.5.4.7 Lung function and SAM; Cases vs Controls  
I hypothesised that case children would have poorer FEV1 and FVC than sibling and community 
control children due to disrupted lung development during their SAM episode. Figure 34 shows 
bee swarm plots for four spirometry z score outcomes for each of the study groups. The plots 
show an apparent similarity in z scores between the cases and control groups. Simple and 
multivariable regression analysis for spirometry outcomes confirms that there is no significant 
difference in FEV1, FVC and FEV1/FVC z scores between case and control groups. Results are 
presented in Table 37. There is no significant difference between the groups both when including 
all the data, and when exclude Grade D data, and when adjusting for HIV status, sitting height 
ratio, SES and puberty as potential confounders. This also holds true when comparing known HIV 
negatives only across the groups, as well as stratified analysis by sex (see Tables in Appendix 24 
and 25).  
Also in Table 37 are means and unadjusted/adjusted differences for raw values of FEV1, FVC and 
FEV1/FVC. The main analysis for this outcome was always intended to be with z scores, however 
due to the large height difference between cases and controls, it is important to consider these raw 
values. The important difference between these adjusted values and the z scores is that the 
volumes are adjusted for sitting height only, rather than over-all height which could be falsely 
inflating z scores due to stunting in the legs. Sibling controls do have significantly larger FEV1 
even after adjustment, and interestingly, if sitting height is replaced by height in the regression 
model, the significant difference between cases and siblings for FEV1 is lost. However there is no 
significant difference in raw volumes for FVC, nor for any of the outcomes between cases and 
community controls. Sitting height ratio varies with age, hence the difference in age between 
cases and siblings could be affecting these results. This suggests that cases have preserved 
spirometry volumes compared to controls even when only adjusting for sitting height rather than 
overall height.  
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Figure 34: Bee swarm plots illustrating lung function z scores for each of the 3 study groups: cases, 
siblings and community controls. There is no significant difference in spirometry outcomes between the 3 
groups. 
 
	 Cases	
(n=199)	
Sibling	
(n=	140)	
Community	
(n=121)	
	 Mean	
(SD)	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)		
P	value		
Adjusted	
difference	
(95%	CI)		
P	value	
Mean	
(SD)	
Unadjusted	
difference	
(95%	CI)	
P	value	
Adjusted	
difference	
(95%	CI)		
P	value	
FEV1	(litres)	 1.26	
(0.3)	
1.55	
(0.7)	
0.30	*		
(0.2,	0.4)	
<0.001	
0.07	*	
(0.0,	0.1)	
0.009	
1.33	
(0.34)	
0.10	
(-0.0,	0.2)	
0.07	
0.04		
(-0.0,	0.1)	
0.12	
FVC	(litres)	 1.45	
(0.3)	
1.77	
(0.6)	
0.33	*		
(0.2,	0.4)	
<0.001	
0.05		
(-0.0,	0.1)	
0.09	
1.54	
(0.4)	
0.10		
(-0.0,	0.2)	
0.07	
0.06	
(-0.0,	0.1)	
0.054	
FEV1:FVC	 0.88	
(0.1)	
0.89	
(0.1)	
0.01	
(-0.0,	0.0)	
0.30	
0.02	*	
(0.0,	0.0)	
0.012	
0.87	
(0.1)	
-0.01		
(-0.0,	0.0)	
0.29	
-0.01	
(-0.0,	0.0)	
0.54	
FEV1	Z	score	 -0.47	
(1.1)	
-0.48	
(1.0)	
-0.02	
(-0.2,	0.2)	
0.88	
-0.11	
(-0.4,	0.1)	
0.40	
-0.34	
(1.1)	
0.13	
(-0.1,	0.4)	
0.30	
0.01	
(-0.3,	0.3)	
0.94	
FVC	Z	score	 -0.32	
(1.0)	
-0.38	
(1.1)	
-0.06	
(-0.3,	0.2)	
0.61	
-0.21	
(-0.5,	0.1)	
0.12	
-0.15	
(1.1)	
0.17	
(-0.1,	0.4)	
0.17	
0.04	
(-0.2,	0.3)	
0.77	
FEV1:FVC	 Z	
score	
-0.21	
(0.9)	
-0.15	
(0.9)	
0.06	
(-0.1,	0.3)	
0.54	
0.14	
(-0.1,	0.4)	
0.25	
-0.37	
(1.0)	
-0.16	
(-0.4,	0.1)	
0.14	
-0.16	
(-0.4,	0.1)	
0.21	
Table 37: Results of simple and multivariable linear regression analysis for four main spirometry outcomes 
across the 3 study groups. The first 3 rows are raw spirometry outcomes, the subsequent 3 rows are z scores 
based on GLI reference data.  Adjusted difference includes sitting height, HIV status, SES and puberty. Age 
and sex are also included as potential confounders for variables not in z score format. * indicates p<0.05.  
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7.5.5 Predictors of Lung Function in Case Group 
I also explored whether factors which differed between the cases at admission could predict poor 
spirometry outcomes at 7 years post-discharge. There is no difference in spirometry outcomes 
when comparing degree of wasting or degree of stunting at admission within the case group. 
Presence of oedema at admission also has no effect on spirometry outcomes. Reported birth 
weight (i.e. mother reported child to be born “normal or big” or “small” has also no association 
with spirometry outcomes in the case group. However, age at admission is negatively associated 
with spirometry outcomes. Additionally, I also explored whether sex, wealth and HIV are factors 
associated with spirometry outcomes; HIV and sex are significantly associated.  
Mean differences for these predictors of poor lung function are presented in Table 38.  
Potential Predictors  Mean difference 
FEV1Z  
(95% CI) 
Mean difference 
FVCZ  
(95% CI) 
Mean difference 
FEV1/FVC Z ratio 
(95% CI) 
Stunted at admission 
(HAZ <-3) 
0.09 (-0.1, 0.3) -0.06 (-0.3, 0.2) 0.07 (-0.2, 0.3) 
Wasted at admission 
(WAZ≤-4) 
0.19 (-0.1, 0.5) -0.10 (-0.4, 0.2) 0.46* (0.2, 0.7) 
Oedema at admission -0.18 (-0.6, 0.2) -0.14 (-0.5, 0.2) -0.28 (-0.6, 0.1) 
HIV negative vs 
positive 
0.55* (0.2, 0.9) 0.50* (0.2, 0.8) 0.16 (-0.1, 0.4) 
Poorest vs Richest SES -0.10 (-0.4, 0.2) -0.08  (-0.4, 0.2) -0.07 (-0.3, 0.1) 
Females vs males -0.31* (-0.6, -0.0) -0.26 (-0.6, 0.0) -0.04 (-0.2, 0.1) 
Normal vs low birth 
size 
-0.01 (-0.5, 0.5) 0.06 (-0.5, 0.6) -0.00 (-0.5, 0.5) 
Admitted ≤2 yrs vs >2 
yrs 
-0.47* (0.1, 0.7) 0.32* (0.0, 0.6) 0.08 (-0.2, 0.4) 
Table 38: Results of Student t test comparing predictors of poor long-term FEV1, FVC and FEV1/FVC z 
scores in SAM survivors (case group only). * indicates p<0.05 
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7.5.5.1 Lung Function and Age of SAM admission  
I would like to explore this outcome further. I hypothesised that those children admitted with 
malnutrition at an earlier age would likely have more of a deficit in lung function than those 
admitted at an older age, due to the greater likelihood of disrupted lung development, however 
that is not the case, hence this warrants further exploration. The mean age of admission of our 
case group who had technically acceptable spirometry is 2.4 years (n=237). FEV1 and FVC z 
scores are significantly associated with age of admission; FEV1/FVC ratio z score is not affected. 
As seen in Table 39, for each year increment in age of admission, FEV1 is 0.15 z score’s worse, 
therefore suggesting that being admitted at an older age is indicative of worse lung function 7 
years later, the opposite of our hypothesis. Although 0.15 z scores is statistically significant, this 
is not clinically significant.  
 
When I compared those admitted on or before 2 years and those admitted after with the control 
group, we see that despite the older admission being more stunted with smaller chest 
circumference than controls, their spirometry z scores are not significantly different to controls in 
either age group (see Table 40). This is therefore inconclusive.  
 
Lung function measure 
vs age at admission 
Unadjusted difference 
(95% CI) p value 
Adjusted difference 
(95% CI) p value 
FEV1 z-score -0.22 * (-0.3, -0.1)  
<0.001 
-0.15 * (-0.3, -0.1) 
0.004 
FVC z-score -0.20 * (-0.3, -0.1) 
<0.001 
-0.15 * (-0.2, -0.0) 
0.004 
FEV1:FVC z-score -0.06   (-0.1, 0.0) 
0.14 
-0.05    (-0.1, 0.1) 
0.36 
Table 39: Simple and multivariable linear regression of lung function z scores against age at admission 
(years) (cases only). Adjusted difference includes sitting height percentage, HIV status, SES and puberty. * 
indicates p<0.05 
 
	 Survivors	admitted	before	or	
at	24	months	(n=106)	
Survivors	 admitted	 after	 24	months	
(n=94)	
	 Regress	 coef.	 (95%	
CI)	
P	value	 Regress	 coef.	 (95%	
CI)	
P	value	
HAZ	 -0.03	(-0.26,	0.2)	 0.81	 -0.62	(-0.86,	-0.37)	 <0.001*	
Sitting	height	%	 0.31	(0.01,	0.61)	 0.04*	 0.58	(0.026,	0.90)	 <0.001*	
Chest	circumference	 -0.16	(-1.0,	0.7)	 0.71	 -1.34	(-2.2,	-0.5)	 0.003	*	
SES	 0.05	(-0.2,	0.3)	 0.71	 -0.05	(-0.3,	0.2)	 0.73	
FEV1Z	 0.03	(-0.2,	0.3)	 0.80	 -0.12	(-0.4,	0.2)	 0.39	
FVC	Z	 0.09	(-0.2,	0.4)	 0.53	 -0.10	(-0.4,	0.2)	 0.50	
FEV1:FVC	Z	 -0.02	(-0.3,	0.2)	 0.85	 -0.01	(-0.3,	0.3)	 1.0	
Table 40: Results of linear regression analysis comparing growth and spirometry outcomes of those who 
were admitted before or at 24 months and those who were admitted after 24 months to controls, adjusted for 
HIV status, SES, puberty and physical disability. Spirometry outcomes are also adjusted for sitting height 
ratio.  Sitting height ratio and chest circumference are also adjusted for age and sex as they are not z score 
calculations. * indicates p<0.05 
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7.5.6 Summary 
Malawian children in this cohort have surprisingly robust lung function compared to African-
American data. Characteristics significantly associated with poor spirometry outcomes in this 
group are:  
• HIV positive status 
• Low SES 
• Female gender 
This data suggests that SAM has had little impact on long-term lung function. There is no 
difference in FEV1, FVC or FEV1/FVC z scores between cases and either type of control. SAM 
survivors who are HIV positive or admitted at an older age (>24 months) have poorer lung 
function at 7 years-post discharge than other SAM survivors. Those who were more wasted at 
admission, more stunted at admission, admitted with oedema or reportedly low birth weight have 
no significant deficit in long-term lung function. The implications of these results are discussed in 
Chapter 8.  
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8 Chapter 8: Discussion 
 
 
This PhD set out to explore the long-term (7-year) outcomes of an episode of SAM, with 
particular focus on growth, body composition, physical function and lung function. In addition, it 
explored further risk factors for SAM survivors, such as age at admission, and considered the 
effects of HIV on the main outcomes. Following a description of the cohort in Chapter 3, the 
results of these analyses have been presented in Chapter 4-7. In this chapter I discuss the results 
for each of the main outcomes: growth, body composition, physical function and lung function, 
and place them in the context of existing knowledge from other studies. I also discuss emerging 
topics of importance including effects of HIV on the main outcomes and focus on age at admission 
as an interesting predictor of adverse outcomes following SAM. The chapter finishes with a 
discussion of the overall picture of adverse outcomes following SAM and the implications of the 
results for science, programmes and policy.    
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8.1 Summary of Hypotheses and Results 
1. Initial Hypothesis: Compared to controls, SAM survivors have impaired linear growth, 
specifically (a) HAZ (b) shorter leg length but (c) preserved head circumference 
Results: Impaired growth in SAM survivors compared to both sibling and community 
controls was observed; SAM survivors had (a) lower HAZ than community controls and 
sibling controls (b) shorter relative leg length and larger sitting height percentage than 
both types of controls but (c) preserved head circumference. Additionally, cases had 
lower WAZ than community controls. 
2. Initial Hypothesis: Compared to sibling controls, linear growth velocity is continuing at 
normal rates resulting in no catch-up growth since 1 year post-discharge.  
Results: SAM survivors had greater growth velocity than sibling controls, resulting in 
significant catch-up growth between 1 and 7 years post-discharge, contrary to the original 
hypothesis.  
3. Initial Hypothesis: Compared to controls, SAM survivors have an altered body 
composition, specifically (a) greater proportion of central fat to peripheral fat, (b) a lower 
proportion of lean mass. 
Results: SAM survivors were observed to have some elements of altered body 
composition compared to controls; (a) MUAC, calf, waist and hip circumferences 
indicated that SAM survivors have greater proportion of central to peripheral mass, 
however skinfold thickness did not suggest that this was as a result of differences in 
subcutaneous fat distribution, (b) circumference results as well as BIVA results indicate 
that cases do have a lower proportion of lean mass than controls.   
4. Initial Hypothesis: Compared to controls, SAM survivors have (a) lower levels of 
physical activity, (b) lower physical capacity during an exercise test and (c) weaker hand 
grip strength. 
Results: Compared to controls, SAM survivors were observed to have (a) lower levels of 
physical activity, however, the sample size was too small to be conclusive; (b) the only 
evidence of lower physical capacity is their slower HR recovery than community controls 
(c) they have weaker hand grip strength and lower arm muscle area (AMA).  
5. Initial Hypothesis: Compared to controls, SAM survivors have impaired lung function 
(namely reduced FEV1, FVC and/or FEV1/FVC ratio z scores). Additionally, those who 
suffered SAM at a younger age have greater lung function impairments.  
Results: Contrary to all aspects of this hypothesis, SAM survivors had similar FEV1, 
FVC and FEV1/FVC ratio z scores to controls. Younger SAM sufferers did not have 
greater lung function impairments; older SAM sufferers actually have significantly poorer 
lung function than younger admissions (<24 months).  
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8.2 Growth 
25% of community controls were stunted and 21% were underweight; this is high considering that 
the community controls were intended to be a “healthy” comparison group. Malawi DHS for 2012 
presents nutritional status for children under 5 only, showing that 47% of 5 year olds are stunted 
and 13% are underweight[98]; data on nutritional status of children older than 5 years is not 
available. The WHO would classify the community control group as having “medium” levels of 
stunting and “high” levels of underweight; sibling controls would classify as both high stunting 
(33%) and high underweight (23%), and ex-malnourished cases would be classified as “very 
high” for both (41% stunting, 33% underweight)[259].   
These results show that SAM survivors are more likely to be underweight and stunted after 
recovery than children in their community, even as long as 7 years post-discharge. Being 
underweight or wasted is associated with short-term nutrition deprivation whereas stunting is 
associated with chronic undernutrition[260]. Results showing that ex-malnourished cases have a 
significantly lower WAZ than community controls but not significantly different to sibling 
controls suggests that access to nutrition remains low for case children at a household level. SAM 
survivors are more stunted than both their community and sibling controls suggesting that this is 
not a household issue but directly related to the SAM admission. It was hypothesized that this 
would be the case based on findings by Kerac et al., that case children were significantly more 
stunted than their siblings at 1 year post-discharge[97]. Richard et al., also found that previously 
wasted children were more likely to be stunted at 2 year of age using longitudinal data from 8 
cohort studies[85]. It is also thought that it is difficult to catch-up stunting after the first “1000 
days” of life (conception to two years)[92], although this has been disputed[93]. The link between 
wasting and stunting is complex and has been a topic of some recent discussion[261]. I have 
found that children who have been severely wasted are more likely to be stunted in late childhood. 
Stunting has known long-term consequences; namely poor cognitive function, lower earning 
potential and poor reproductive health[84].  
The stunting of SAM survivors can be accounted for largely by shorter limbs than community and 
sibling controls. The proportion of height accounted for by sitting height is greater in SAM 
survivors than controls, suggesting that torso growth has been preserved and limbs compromised, 
potentially as a result of the SAM episode. Leg length in relation to height is considered an 
indicator of the quality of the environment for growth during infancy and childhood[113]. These 
results could indicate that SAM children undertake “brain-sparing growth” or have adapted a 
“thrifty phenotype” where growth of vital organs has been spared and less vital growth, such as 
limb length, compromised [29, 30]. This is supported by the preservation of head circumference 
of SAM survivors compared to controls. Birth weight could be a significant confounder in this 
study, which we do not have accurate data for, however only 9% of surviving cases were reported 
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to be small or very small at birth. The pattern of growth seen by these SAM survivors may have 
significant implications for adult health; sitting height percentage has been associated with 
cardiovascular disease (CVD) and diabetes in adulthood, and short limb length is associated with 
higher adult blood pressure[121, 123, 124]. Additionally, evidence from LBW cohorts (Helsinki 
cohort and the Hertfordshire studies) found that low WAZ and BAZ at 1 year of age were more 
strongly associated with heart disease than LBW or low WHZ at birth[262]. This suggests that 
postnatal nutrition plays a larger role in risk of heart disease than prenatal nutrition, although it is 
important to remember that birth weight is only a crude measure of foetal nutrition. This study 
therefore adds some preliminary evidence to the theory that SAM in childhood may be 
contributing to the inexplicably high levels of chronic diseases in developing countries[95].     
It’s not all bad news for this cohort. There is some evidence to suggest that the growth pattern of 
these SAM survivors might be changing. Kerac et al., saw a large improvement in WAZ between 
discharge and 1 year post-discharge, but almost no change in HAZ. In the following 6 years, we 
have found that the SAM survivors have made a very small improvement in WAZ but large 
improvements in HAZ. In order to minimise effects of “regression to the mean”, we compared the 
growth of cases to sibling controls between 1 and 7 years post-discharge and found that cases are 
indeed catching up HAZ at a steeper rate than their sibling controls. The gap in HAZ between the 
SAM survivors and their siblings is closing. There has been much conflicting data regarding the 
possibility of catch-up growth in stunted children, partly due to studies using different definitions 
of “catch up growth” (e.g. catching up to community levels or global levels) and different study 
end points[103, 104, 107]. One recent study found that both growth faltering and catch up growth 
could occur between ages of 8 and 15 year, concluding that child growth and development is a 
dynamic process which offers continued opportunities and sustained risks for children after the 
first 1000 days[263].  The same study also found that those children who caught up their HAZ to 
their community norm suffered less of a cognitive deficit than those who didn’t catch up, although 
this is not consistent across all studies[264]. This suggests that there may be opportunity to 
mitigate some of the long-term effects of stunting if it is somewhat reversed by adulthood; i.e. 
there are opportunities for intervention even after the first “1000 days”.  Our study suggests that 
the Malawi SAM survivors are on track to catch-up some of their linear growth; biologically there 
is also still an opportunity for reversal of sitting height percentage as well as growth plates are yet 
to have fused[93]. These results, along with the findings from a few other African cohorts, 
challenge the conventional view in the literature that catch-up growth after early childhood is 
difficult and seldom observed [107, 265, 266]. Some papers offer emerging evidence that puberty 
provides an even greater window of opportunity for catch up growth[93, 267], although Adair et 
al., found puberty to also be a period of missed opportunity where growth faltering can occur and 
gains in height-for-age during childhood can be lost[103]. Whether these SAM survivors will 
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continue to be more stunted than their community and have adverse body proportions after 
adolescence is yet to be seen.  
 
Exploring risk factors which predict adverse long-term growth outcomes offers some 
opportunities for considering potential interventions. Kerac et al., found disability and HIV to be 
significant risk factors in post-SAM survival[97]. They also found that children admitted with 
marasmus (rather than kwashiorkor) had worse WAZ and HAZ both at admission and at 1 year 
post-discharge. This study found that HIV continues to be a risk factor for poor outcomes, namely 
survival, stunting and short relative leg length. This study also found that marasmus survivors 
continue to have significantly lower WAZ than kwashiorkor survivors however their HAZ is no 
longer significantly different, and their sitting height percentage and head circumference are also 
no different. It seems therefore that marasmus survivors are still more prone to being underweight 
but otherwise have similar growth to kwashiorkor survivors. Survivor bias cannot be the 
explanation for the continued differences in WAZ as risk of death during treatment was also 
higher in non-oedematous children. There are no apparent long-term effects on growth relating to 
how quickly patients recover from SAM. 
We found that the most significant risk factor for long-term growth impairments was age at 
admission. These results suggest that the older a child is at admission, the worse their HAZ, 
MUAC and BAZ will be at 7 years post-discharge. It appears that as children get older, possibly 
as they move beyond the “first 1000 days”, their growth becomes canalized and less able to make 
good a severe insult. This emphasises the need for early intervention and active case-finding in 
young children so that SAM can be prevented as they grow older. In this aspect, our data supports 
the concept that first 1000 days is an integral time for intervention, as the capacity for recovery is 
greater in those who has SAM at <2 years of age. These results found that catch-up growth is 
possible after the first “1000 days” however if the insult occurs after the first 1000 days, the 
catch-up ability is much more limited.  Nutrition interventions that go beyond the first 1000 days 
in order to prevent SAM in children older than 2 years could therefore also help to reduce ultimate 
levels of stunting. For children older than 2 years who do suffer an episode of SAM, it could be 
argued that there is a greater need for nutrition interventions in this group of survivors as their 
capacity to recover without intervention is more limited, although we have seen that some catch-
up growth is possible. The most obvious nutrition intervention for children >2 years, particularly 
in adolescence, is effective school feeding programmes.  
In summary, this study suggests that SAM survivors are at higher risk of being stunted, but that 
some linear catch-up growth is possible. Although it is clear that prevention is far better than cure, 
interventions, such as school feeding, which capitalise on this catch-up ability and promote linear 
growth, especially during adolescence, could make use of the “second window of opportunity” to 
165 
	
reduce stunting, correct adverse body proportions and thereby potentially reduce subsequent 
chronic diseases risks in adulthood.     
 
8.3 Body Composition 
SAM survivors were observed to have some elements of adverse body composition compared to 
controls, including lower peripheral mass, a larger waist circumference, a smaller hip 
circumference and significantly less lean mass, as measured by BIVA. MUAC, calf, waist and hip 
circumferences indicated that SAM survivors have greater proportion of central to peripheral 
mass, however skinfold thickness did not suggest that this was as a result of differences in 
subcutaneous fat distribution. Waist/hip ratio indicates a small difference in gluteo-femoral to 
core fat distribution. Skinfold thickness specifically compares limb subcutaneous fat to core 
subcutaneous fat. The lack of difference between cases and controls for this outcome could be 
because proportions of FM are likely to be very low for majority of cases and controls in this 
population, although comparison of body composition outcomes to other populations is made 
difficult by the lack of relevant reference data. Had cases and controls had the opportunity to 
accumulate some FM, perhaps they we would see differential distribution across limbs and core. 
This will likely only be a relevant consideration once Sub-Saharan Africa makes the nutrition 
transition associated with economic development and urbanisation. Another explanation is that 
skinfold thickness ratios have poor statistical validity; it has been said that as the relationship 
between limb and torso skinfolds is not linear, dividing one skinfold by another is a problematic 
way of assessing relative fat distribution[219].  
	
Although BIA cannot measure distribution of fat mass, it does give an indication of overall FM 
levels which appear to be similar across the study groups. The reduction in lean mass of the cases 
(even after adjusting for their shorter height) but preservation of fat mass levels is a similar 
pattern seen in childhood of low birth weight infants[67]. Studies of Indian infants have found 
infant weight gain is positively associated with later lean mass but not fat mass, indicating that 
poor infant growth constrains later lean mass[268]. Disruptions to lean mass in early life are 
predicted to reduce the capacity for homeostasis, and increase the risk of chronic degenerative 
diseases in adulthood[96]. Additionally, peripheral fat and peripheral lean mass, which appear 
diminished in these SAM-survivors, are thought to be protective again CVD, particularly hip 
circumference [132, 269]. Peripheral lean mass also has implications for physical function. 
Although circumferences suggest that siblings have more lean mass, particularly peripheral lean 
mass, than cases, BIA data suggests no difference in amount of lean mass, fluid and fat mass for 
these two groups. Either household levels of undernutrition mean there is no difference in levels 
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of lean mass between cases and siblings, or larger standard deviation of BIA readings, perhaps 
due to larger age range in siblings means that although r/h of siblings is lower on average, it does 
not meet the cut off for significance.     
 
When considering the results of BIVA, we can summarise that, as mentioned in Chapter 5, long 
vectors with a small phase angle (increased R with decreased Xc) are associated with 
malnutrition, whereas short vectors with a small phase angle (decreased R with decreased Xc) are 
associated with fluid overload[231]. This suggests that our cases are still relatively more 
malnourished and have less fluid than community controls. Lower levels of fluid can be explained 
by cases having lower proportion of “high hydration” tissues than controls[270]. Muscle mass is a 
high hydration tissue, and as cases have less lean mass, smaller MUAC and smaller calf 
circumference, this likely explains their lower fluid levels. We also observed sexual dimorphism 
with greater lean mass in boys and greater fat mass in girls; this is in line with a multitude of 
previous studies [67, 271-273]. When stratifying analysis of cases vs controls by sex some 
differences in body composition are only present when comparing control girls to case girls. 
Although a rough measure of puberty was adjusted for, I believe this reflects the difference in 
body composition and fat accumulation which happens earlier in girls than boys[274].  
 
As well as less lean mass and less fluid, BIA tells us that cases have a significantly lower phase 
angle (PA) than community controls. Phase angle is thought to be a measure of cell health, where 
higher values reflect higher cellularity, better cell membrane integrity and better cell function, as 
well being as an indicator of general health and nutritional status [235, 275, 276]. Some studies 
have found it useful in identifying malnutrition, particularly in discriminating between different 
forms of underweight with regard to low fat and low lean mass[235, 277]. However, some studies 
have found PA to be unreliable in identifying malnutrition and morbidity depending on the “cut-
off” value used[278, 279]. There is currently no universally accepted cut off value for “low PA”, 
particularly in children. Kyle et al., suggests PA of <5 in men and <4.6 in women as cut off for 
high nutritional risk in adults. One study of PA in a small number of hospitalised children in 
Japan suggested that most malnourished children have a PA <3.2[280]. The mean phase angle for 
each of our study groups (5.0, 5.1 and 5.1) is therefore relatively “healthy”. Only four children in 
this sample had a PA<3.2, two were cases and 2 were community controls. 
 
Lastly, when considering predictors of adverse body composition in SAM survivors, the most 
notable factor for discussion is marasmus vs kwashiorkor. The results suggest that those who 
were admitted with marasmus now have significantly less fluid and less lean mass and lower PA 
than controls, whereas those who were admitted with kwashiorkor have similar fluid and lean 
mass to controls. Kwashiorkor survivors have therefore attained a “normal” body composition 
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relative to their community whereas marasmus survivors have not. This correlates with 
significantly lower WAZ of marasmus survivors. Could it be possible that oedema develops in 
some severely malnourished children as a mechanism to protect against loss of lean mass and 
resultant long-term implications? Or is kwashiorkor an “early warning system” is some children, 
in which case we can infer that earlier intervention results in fewer long-term implications and 
should therefore be policy norm. Why some children develop kwashiorkor and others marasmus 
is still not known and warrants further study. 		
	
In summary, this study suggests that SAM survivors have less lean mass than community 
controls, and less peripheral lean mass than both community and sibling controls. Peripheral mass 
is protective against some NCDs and has implications for physical function. Cases also have 
lower phase angle than community controls which is indicative of nutritional and morbidity risk, 
although very few children have PA to qualify them as “malnourished”. Marasmus survivors are 
at particular risk of long-term adverse body composition.  
8.4 Physical Function 
Compared to controls, SAM survivors were observed to have lower levels of physical activity 
however sample size was too small to be conclusive; cases had poorer HR recovery from the 
exercise test than community control, but not sibling controls; and cases had weaker hand grip 
strength and lower arm muscle area (AMA). 
Community controls age 8-9 years had mean hand grip strength of 11.9kg, this was significantly 
lower than mean grip strength of 8-9 year olds from one study in USA (17.5kg)[281]. Hand grip 
strength of cases was even lower. A number of other studies have developed reference ranges for 
hand grip strength, however they use a variety of different units including newtons and 
kilopascals, making comparison difficult[142, 282]. For AMA, Benefice et al., found 10-12 year 
olds Senegalese school children had AMA of 18.4cm2; our community controls have a larger 
mean AMA of 23.3cm2 in this age group, despite having a similar height[142]. Perhaps due to 
changes in nutrition across Africa since 1992, the Senegalese data is now out of date. Deficiencies 
in grip strength and AMA observed in case children compared to controls is not surprising 
considering deficits in HAZ, WAZ and lean mass also observed. However it is still important to 
note that these deficits in growth are severe enough to have functional implications. Additionally 
weak hand grip strength is associated with all-cause early mortality, nutritional risk and risk of 
NCDs, and it is being promoted as a non-invasive indicator of mortality risk[159]. These results 
have also highlighted the importance of healthy weight gain for SAM survivors, as better WAZ 
was associated with better muscle strength.  
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Regarding physical activity, it is disappointing that a combination of logistical issues and non-
compliance resulted in a small sample size, with a large standard deviation. However differences 
in standard deviation are large in biological terms and suggest cases may have lower physical 
activity levels than controls. Mean steps per day of the cohort overall were roughly in line with 
European levels which estimate 8-10 year old children to take 12,000 to 16,000 steps/day (1000-
1330 steps per hour)[283]. European girls are thought to take fewer steps than boys which is also 
observed in our case data; European teenagers take fewer steps than children, although this 
doesn’t seem to hold true for our Malawian data. A further study is required to investigate 
whether there is a true deficit in long-term physical activity is SAM survivors, as this could have 
serious implications for NCDs in adulthood, especially as the nutrition transition of the country 
progresses. This study has been able to identify the required sample size of around 300 per group 
for a future study.  
For physical capacity, cases completed similar minutes of the exercise test as sibling and 
community controls. Their maximum heart rate was not significantly different to controls but their 
heart rate was significantly slower to recover than community controls. This may suggest a small 
difference in physical capacity between cases and community controls, although they do not have 
the marked drop in oxygen saturation or raised heart rate seen in cystic fibrosis patients for whom 
the exercise test was originally designed[151]. I must also acknowledge that the operators of the 
iStep test were not blinded to the study group status of the children, hence potentially differential 
encouragement from operators could have affected the time at which the children decided they 
were too tired to continue. 
Based on the range of evidence for physical function outcomes discussed here, it seems likely that 
SAM survivors have worse long-term physical function compared to children in their community. 
Considering this and the known anabolic effect of exercise on muscle growth, an intervention 
which combines both nutrition for better accumulation of weight, particularly lean mass, and 
physical activity for building strength and physical capacity, could have large benefits for the 
long-term health of SAM-survivors. A few studies have considered physical activity interventions 
during immediate SAM recovery, with promising results. Viteri et al., explored the role that 
exercise played on the growth of malnourished weanling rats, discovering that physically active 
animals grew more in length and weight than their inactive counterparts in both the well-
nourished and malnourished groups[284]. Human studies have also concluded that malnourished 
children recovered faster in centres with playgrounds than in smaller centres, and one study found 
children recovering from oedematous SAM in Guatemala who were encouraged to do “active” 
play 6 weeks post-SAM showed similar clinical improvement to the control group but had 
significantly greater linear growth after 5 weeks of intervention; they also grew more in lean body 
mass as well as having higher creatinine-height index (0.97 ±0.12, vs 0.89 ±0.09, P < 0.05) 
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indicating greater muscle mass and protein repletion[154, 285]. These studies suggest that 
moderate but persistent exercise enhance catch-up growth post-SAM. Authors suggest that the 
mechanism may be mediated by endocrine factors that promote the growth of long bones, such as 
growth hormone and insulin-like growth factors, which are stimulated by physical exercise. 
Others have argued that very little exercise is required to stimulate bone growth[154]. Lean mass, 
which is significantly lower in cases, is not only an outcome of physical function but also an 
important predictor of physical work capacity in later life and could be the likely explanation for 
the deficiencies in physical function seen in these SAM-survivors[286]Based on our evidence that 
SAM survivors are more stunted, have weaker hand grip strength and potentially lower physical 
activity levels and lower physical capacity, an intervention which encourages exercise in SAM 
survivors could be beneficial in a variety of aspects.		
Regarding risk factors at admission, those who were admitted with oedema have similar handgrip 
strength and similar physical capacity to those admitted without oedema, but oedematous 
admissions have larger AMA than marasmic admissions, at follow-up. This result correlates with 
higher levels of lean mass observed in kwashiorkor survivors by BIA data. This suggests that it is 
not always quantity of muscle that affects muscle strength; perhaps both quantity and quality are 
important. Also interesting is the lack of impact observed by HIV status on these functional 
outcomes. Most children who are known to be HIV positive (84%) reported taking treatment, 
either Cotrimoxazole or antiretroviral therapy (ARVs), although some did report problems with 
taking their medication; perhaps this high coverage of treatment is mitigating the functional 
impacts of HIV; although the same cannot be said for lung function.    
 
8.5 Lung Function 
Contrary to our hypothesis, no evidence was found that suggests SAM survivors have poor lung 
function compared to sibling or community controls. The quality of the results is unlikely to be an 
issue with standard deviation of z score values very close to 1, and with overall fail rate for 
spirometry results of 12% (64/532), which is in line with results from studies conducted in expert 
settings in developed countries[255].  
The mean spirometry z scores achieved by this cohort are within 0.5 z scores of the reference 
values for black children in USA. Malawian boys have especially robust results with mean FEV1Z 
of -0.31 (95% CI -0.4 to -0.2) and mean FVCZ of -0.17 (95% CI -0.3 to -0.0). It is difficult to 
compare our results to other Malawian studies due to use of different reference ranges, however 
our results appear closer to the reference range used than results in other studies. A study of 
children with sickle cell disease in Blantyre, Malawi ( median age 11.7 years) found  mean z 
scores of −1.64 (95% CI −2.04 to −1.23) for FEV1 and −1.49 (95% CI −1.90 to −1.09) for 
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FVC[287], based on an international reference for Black children by Wang et al[288]; although 
these were not healthy children. A study of 514 Malawian primary school children found FEV1 z 
score of -1.0 and FVC of -0.7 using a European reference range with a scaling factor for black 
ethnicity[253]. They state that their z scores are slightly lower than spirometry results found in 
Sudanese and Libyan children, but similar to Nigerian, Tanzanian and Jamaican children[289-
293]. Their results are similar, although slightly worse than those found in our cohort; however 
the use of a standard scaling factor for black ethnicity (-1.3 z scores) cannot be as accurate as 
comparing to actual data from black children. I chose not to use the reference data generated from 
the Malawian primary school study as numbers are relatively small, the children’s age is rounded 
to a whole number and the reference values are generated only on height, rather than height and 
age.   
The apparent absence of any impact from SAM on spirometry outcomes is surprising, particularly 
given the deficits in WAZ, HAZ and hand grip strength seen in the case group compared to the 
community controls. Our result suggest that while the overall volume of the lungs may be smaller 
in SAM survivors, it is proportional to their body size (height) and there is no evidence of lung 
function quality defects. Evidence from animal models, as well as some human studies in India, 
show that postnatal malnutrition can disturb lung function in the form of qualitative change 
beyond an effect on lung size [176, 294, 295]. Animal models can be conclusive in stating that 
early postnatal malnutrition affects lung development, and this has impacts on lung function; 
however human studies can only conclude that there is a correlation between lung function and 
current nutritional status. Our data also confirms this. However, the reason for the correlation 
cannot be deduced from these results, and interestingly we have observed that an episode of SAM 
with associated stunting and muscle weakness is not enough to have an impact on lung function. 
Perhaps the correlation of WAZ and HAZ with lung function exists due to confounding with 
prenatal malnutrition, very early postnatal malnutrition or other poor environmental factors 
including recurrent infections. Our evidence suggests that a severe nutritional insult between the 
ages of 6 months and 2 years does not have qualitative effects on lung development beyond 
effects on lung size. Even children admitted after 2 years of age, although sustaining a greater 
impact on growth and lower lung function, their lung function is still not significantly lower than 
control children, after adjusting for HIV (p=0.24 and 0.20 for FEV1Z and FVCZ respectively). 
A study of Indian children (6-12 years) found that although weight-for-age affected lung function 
(peak expiratory flow rate) height-for-age had little effect. They hypothesise that low WAZ 
affects lung function due to its negative effect on muscle function, but that past or chronic 
malnutrition does not affect lung function even though it affects somatic growth[175]. Our 
evidence suggests that SAM and subsequent stunting have not had a qualitative impact of lung 
function which could be due to the preservation of sitting height among stunted children. These 
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SAM survivors, despite their significantly reduced HAZ, have similar sitting height to controls 
and significantly larger sitting height percentage. Additionally, FEV1 and FVC z scores are 
positively associated with sitting height percentage. It would be interesting to see whether catch-
up in HAZ, presumably limb growth, which our SAM survivors are currently undertaking, results 
in decreased spirometry z scores. This knowledge would help unpick the complexities of stunting, 
lung size and lung quality.  
When exploring predictors of poor lung function, we see that HIV has a significant impact. There 
is emerging data for HIV positive adults suggesting an increased prevalence of chronic lung 
disease, including both chronic airflow obstruction and restrictive lung disease [296-298]. Studies 
have also shown odds of airflow obstruction were increased >3-fold among HIV-infected adult 
individuals in USA, although smoking and drug use are contributing factors in these 
populations[299]. Very few studies have considered effect of HIV on lung function in children. 
Despite the significant impact of HIV on lung function in this cohort, we did not observe any 
impact of HIV on physical function. We did find that although there is no association between 
having a history of pneumonia and HIV status, the odds of having a history of TB are 8 times 
higher in HIV positive children than negative children (95% CI 3.2 to 19.7); additionally those 
with a history of TB have significantly lower FEV1 and FVC z scores, although those with a 
history of TB were excluded from final analysis. HIV positive children are also significantly more 
stunted than HIV negative children although there is no difference in sitting height percentage 
between HIV positive and HIV negative groups. It could be a combination of repeat infections, 
such as TB, and chronic malnutrition due to greater calorie requirements that have already 
reduced lung function in HIV positive children, despite widespread management with medication.  
The last significant variable associated with lung function to discuss is sex. Females have 
significantly lower FEV1 and FVC than males in this study, suggesting a more restrictive lung 
function pattern. I explored whether this was a result of differences in adherence to the reference 
data between the sexes. As lung function increases linearly with age until the adolescent growth 
spurt at about age 10 years in girls and 12 in boys[288], it could be that delayed puberty known to 
occur in malnourished populations could result in a divergence from the reference data around the 
age of 10 years in females[300]. This would mean the difference between the sexes would only 
become apparent around the age of 10, and this is not the case as presented in Chapter 7. I also 
explored lung function, sex and body composition as studies looking at older European adults 
have found that a larger proportion of FM is associated with worse lung function and more lean 
mass is associated with better lung function[257]. One paper looking at cystic fibrosis in children 
found that more lean mass meant better lung function; they also found that more fat mass meant 
better lung function but not significantly so[256]. Males in our cohort have more lean mass than 
girls (based on LMI and BIVA), and less fat mass, particularly peripheral fat mass. LMI is 
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positively associated with FEV1Z and FVCZ whereas fat mass is negatively associated with 
FEV1/FVC z ratio; hence this could be an explanation for differences in spirometry between the 
sexes.  
Zverev et al., who conducted the study of spirometry in primary school children in Malawi 
(discussed above) also found significantly lower FEV1 and FVC in females than in males, 
however they do not discuss why this might be[253]. The other option for this difference is 
differential exposure to household air pollution. There is evidence that household air pollution can 
lead to respiratory infections and chronic lung disease; women and children are particularly 
susceptible to the toxic effects of pollution and are exposed to the highest concentrations[301]. 
Whether girls in Malawi as young as 9 years have greater exposure to cooking smoke than boys 
the same age is not known; our questionnaire asked about cooking smoke in the home but it did 
not ask specifically who helps with the cooking or whether girls experience greater exposure than 
boys. However, this is another possible explanation for spirometry sex differences. Further study 
is certainly needed in this area, as well as further exploration of the effects of HIV on lung 
function in children.		
8.6 HIV 
HIV is an important potential confounder and/or effect modifier in this research project. HIV 
increases ones risk of SAM (the exposure) and is likely to increase ones risk of some adverse 
outcomes, such as stunting for example[302, 303]. This cohort, as well as others, have seen that 
severely malnourished children with HIV infection have an increased risk of mortality compared 
with their HIV-uninfected counterparts[97, 304]. The extension of the time-to-death curves, 
stratified by HIV status (Figure 5b, Chapter 3), highlight the significant adverse impact of HIV on 
post-SAM survival. Probability of death in the HIV negative patients plateaus around 6 months 
after admission whereas the probability of death in the HIV positive group doesn’t begin to 
plateau until around 2 years post-admission, and even then it continues to rise very gently, even as 
long as 8 years post-admission. The risk of death in the HIV positive group is also made evident 
by the change in proportion of HIV positive children in the sample over time since admission (see 
Figure 35). 
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Figure 35: Bar graph showing percent HIV positive and HIV negative children in the case group of the 
cohort from ward admission to latest follow-up 7 years post-discharge.   
	
A 2009 study has considered the differences between HIV positive and negative children during 
SAM recovery and 4 months post-SAM treatment; they found increased mortality in the HIV 
infected group during treatment, but for those who survived there was no difference in weight 
gain or subscapular and triceps skinfolds during nutrition rehabilitation, nor  weight-for-height z 
score or MUAC at follow-up[305]. Our results concur with these findings as I observed no 
significant difference in WAZ, BAZ, MUAC, calf, hip and waist circumference between HIV 
positive and HIV negative SAM survivors 7-years post-discharge. I also found no difference in 
skinfold thickness, skinfold thickness ratio, fat mass, AMA, hand grip strength and physical 
capacity for these 2 groups. As already mentioned, most children who are known to be HIV 
positive in this cohort (n=104) reported taking treatment, either Cotrimoxazole (COT) (n=11) or 
antiretroviral therapy (ARVs) (n=76). Six had never taken either medication and some did report 
problems with taking their medication (n=7). There was no difference in HAZ between those 
taking COT only and those taking ARVs. However, I have observed some important effects of 
HIV despite the high coverage of treatment, namely greater stunting, less lean mass as measured 
by BIVA, and worse lung function (more restrictive pattern). HIV positive SAM survivors also 
reported more difficulty seeing than HIV negative SAM survivors, but no difference in reports of 
difficulty hearing or walking.  
When considering the impact of HIV across the groups, not just in SAM survivors, the HIV 
positive sibling controls have some of the worst outcomes, resulting in a significant difference in 
HAZ, LMI, BIVA, FEV1Z, FVCZ and greater difficulty seeing and hearing than HIV negative 
children. The HIV positive sibling controls, although numbers were low (n=9), have lower HAZ 
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and LMI than HIV positive case children. This could be an indication of survivor bias; if survival 
of HIV positive children during SAM treatment was to improve, we may see even greater 
differences in long-term stunting and lack of lean mass among survivors.     
8.7 Kwashiorkor vs Marasmas    
This study has found that kwashiorkor survivors (those who had oedema at admission) generally 
have better long-term outcomes than those who didn’t have oedema at admission. These results 
found that kwashiorkor sufferers have better survival, significantly higher WAZ, BAZ, lean mass, 
lower R/h, larger calf circumference and larger AMA than marasmic survivors at follow-up. 
Differences in body composition between kwashiorkor and marasmic survivors are particularly 
pronounced; kwashiorkor survivors have no deficits in body composition compared to controls 
whereas marasmic survivors still have less lean mass, higher R/h and smaller calf circumference 
than controls. Handgrip strength, physical capacity and lung function were not different between 
kwashiorkor and marasmic survivors at follow-up.   
These results are a little surprising as kwashiorkor is usually found to have a higher case fatality 
rate than marasmus in many areas[11]. I found only one study that had compared outcomes for 
marasmus vs kwashiorkor at follow-up: a study in Barbados found no difference in long-term IQ 
between marasmus and kwashiorkor survivors, both were equally lower than community controls 
at 11 years of age[306].   
Deciphering the long-term differences between kwashiorkor and marasmus survivors found in 
this study is difficult due to the ongoing knowledge gaps around the pathogenesis of kwashiorkor.  
Ever since Cicely Williams described the entity known as kwashiorkor in 1935 while working in 
west Africa, there has been much debate on its causes[11, 306]. Some have suggested that 
kwashiorkor is related to low dietary protein and/or antioxidant intake; Manary et al  (2000) found 
increased oxidative stress in kwashiorkor sufferers compared to marasmus, suggesting that 
oxidative damage to proteins and other biologic targets plays a role in the clinical manifestations 
of kwashiorkor[307]. However a study in 2005 examined the impact of an antioxidant cocktail as 
a possible preventive treatment for kwashiorkor in children in Malawi and found no protective 
effect suggesting that antioxidants might not play a central decisive role as originally 
proposed[308]. Another more recent theory is that differences in gut microbiome may be a causal 
factor in kwashiorkor development suggested by a study that transplanted faecal matter from 
kwashiorkor patients into mice and found that this combined with a low protein diet saw marked 
weight loss and perturbations in amino acid and carbohydrate metabolism[309]. 
The results described in this thesis suggest that kwashiorkor is protective against some of the 
long-term adverse outcomes of SAM; WAZ was not as low for kwashiorkor children at admission 
and this maintenance of weight seems to have protected against subsequent low WAZ, low lean 
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mass and low calf circumference and arm muscle in later years. We should remember that the bar 
for admission is much lower for kwashiorkor patients than marasmic patients as presence of any 
oedema results in admission regardless of WHZ or MUAC qualifications. I believe the most 
likely explanations for the better outcomes of kwashiorkor survivors is that the presence of 
oedema worked as an “early warning system” for SAM suffers in Malawi where treatment was 
initiated before further wasting was encountered. It is important to note that oedema was much 
more prevalent than wasting in this cohort; at admission 70% (697/1006) of the group had 
oedema, at the 7 year follow-up 83% (265/320) of the survivors had oedema at admission. The 
definitions of kwashiorkor and SAM could also be affecting these results as bilateral oedema can 
be seen in other acute illnesses besides SAM which could have resulted in some misdiagnoses of 
SAM. 
If oedema did indeed result in earlier treatment and subsequent better long-term outcomes, this 
supports further advocacy for initiation of earlier SAM treatment for all patients, not just those 
with kwashiorkor, in order to prevent some of the long-term effects.  
8.8 Age at Admission 
Based on existing evidence for the DOHaD hypothesis, it is infants who are undertaking a large 
amount of vital and irreversible development, that are more likely to be affected by a nutritional 
insult than older children. We know that the window of “phenotypic plasticity”, i.e. the ability of 
a single genotype to produce more than one alternative form of morphology, physiological state, 
and/or behaviour in response to environmental conditions, is a finite period[79]. Plant and animal 
studies have shown that the window for phenotypic adaption to the environment varies greatly 
across species and can either be very narrow or very wide[80, 310, 311]. How large the window is 
in humans is not known; as humans are born at a relatively advanced state in development, it 
could be that the plasticity period which influences later health stops relatively close to birth[81]. 
Additionally, the “first 1000 days” concept suggests that nutritional deficits, specifically stunting, 
can accumulate before the 2nd birthday, and after which point HAZ is relative fixed, neither 
catching up nor faltering more[92]. Age of insult therefore seems a highly relevant factor when 
exploring the long-term effects of SAM; it seems likely that those who suffered SAM at an earlier 
age (i.e. before 2 years), suffered greater disruption to their development and are more likely to 
have adopted phenotypic changes. I therefore explored effects of age of SAM insult on each of 
the long-term outcomes. 
 
The median age of admission for SAM survivors in this study was 24 months (range 6-168 
months). Although these results have shown that SAM does have long-term effects on a variety of 
outcomes, I did not observe an increase in detrimental effects in those admitted <2 years of age, 
contrary to existing theories. There was no difference between those admitted before they were 2 
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years and those admitted after on long-term WAZ, sitting height percentage, head circumference, 
waist, hip and calf circumference, skinfold thickness ratio, AMA, hand grip or time completed of 
exercise test. Those admitted >2 years are more likely to be HIV positive and more likely to have 
a physical disability; hence these factors were adjusted for as potential confounders during 
analysis. Older admissions also started with greater levels of stunting at admission. It is less 
common for children >2 years to be admitted with SAM hence these children are likely to have 
had some additional complications.  
 
I did however observe that children who were admitted with SAM >2 years had some greater 
deficits in growth, lean mass and lung function. HAZ, BAZ, MUAC, LMI, FEV1Z and FVCZ are 
significantly smaller in children admitted at an older age, and R/H is significantly larger in older 
admissions. My results therefore found that children admitted when they are older are more likely 
to be more stunted on admission and for every month increase in age at admission they are likely 
to be 0.02 z scores more stunted at follow up (p<0.001), regardless of how stunted they were at 
admission. Mortality results also suggest that older admissions are more likely to die than younger 
admission; although this is a U-shaped relationship with very young admissions (<1 year) also at 
greater risk of mortality. When compared with controls, the difference in HAZ and lean mass is 
only significantly lower in those admitted >2 years of age, suggesting that SAM admissions <2 
years have caught up their HAZ and lean mass to community levels by 7 years post-discharge. 
Richard et al., in their meta-analyses also found that older children have less catch-up than 
younger children, but because their study end-point was the same age for all children rather than a 
set number of years since the insult they could not conclude whether this was related to the 
children’s catch-up ability or the fact that older children had had less time to catch up.   
 
Although my finding that older admissions have some more detrimental outcomes than younger 
ones is contrary to my original hypothesis, it does confirm a number of other existing theories. 
The “First 1000 days” theory states that most stunting is accumulated during conception to 2 
years; this is therefore an important period of plasticity for growth and development in which 
good nutrition is paramount. These results concur with the high plasticity of the first 1000 days 
period, however with more of an emphasis on opportunity for catch-up rather than opportunity for 
insult. In contrast, those acquiring SAM in later childhood appear to have minimal plasticity and 
therefore less capacity for rectifying a poorer quality phenotype. Although the older admissions 
began with a lower HAZ than younger ones and have undertaken some catch-up growth, they 
have caught up less height than that gained by the “already relatively taller” younger admissions. 
These results emphasise the need for early nutritional intervention and active case-finding of 
moderate acute malnutrition (MAM) and SAM in younger children, to give them the best chance 
for full recovery. If we miss this window, the chances of long-term growth, body composition and 
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lung function deficits are increased. Interventions which particularly identify and treat 
malnutrition in the first 6 months of life could result in significantly fewer stunted children and 
adults. Identification and treatment of malnutrition in infants is currently lacking in evidence[88]. 
Additionally, sanitation, health and nutrition interventions that go beyond the first 1000 days and 
strive to prevent acute malnutrition is children > 2 years should also be a priority for improving 
long-term outcomes.  
 
8.9 The Overall Picture 
The aim of this study was to explore long-term (7 year) outcomes of severe acute malnutrition on 
growth, body composition, and functional outcomes in children. The results suggest that there are 
long-term adverse effects of an episode of SAM, particularly with regard to growth, body 
composition and physical strength. There are few studies that have considered post-SAM 
outcomes, particularly for longer than 18 months and using the current definitions of SAM, as 
concluded by a recent literature review[86]. Our study shows that SAM survivors continue to be 
at slightly higher risk of mortality many years after admission; the time-to-death curves suggest 
that the majority of mortality risk for SAM survivors in during the first 2-years post-admission; 
the probability of death has now plateaued for the group of survivors as a whole but it may still be 
rising very slightly in the HIV positive group.  
 
However, there are also some signs of recovery, for example in their growth. There is some 
evidence to suggest that their growth pattern might be changing. Kerac et al., saw a large 
improvement in mean WAZ between discharge and 1 year post-discharge, but almost no change 
in HAZ[97]. In the following 6 years, we have found that the SAM survivors have made a very 
small improvement in WAZ but large improvements in HAZ. We compared the growth of cases 
to sibling controls between 1 and 7 years post-discharge and found that cases are indeed catching-
up HAZ at a steeper rate than their sibling controls. These results also suggest that SAM-survivors 
do not have lasting disruption to all of their major body systems as sitting height, lung function 
and head circumference are not significantly different to sibling or community controls. It 
therefore appears that DOHaD does not affect SAM-survivors in the same way seen in low birth 
weight infants[29]. Although it is also worth noting that community controls are not so healthy 
themselves: they have higher number of overall hospital admissions than cases. This likely 
reflects the high levels of morbidity in the community and may be diminishing what we are able 
to see in terms of the long-term effects of SAM.  
 
Another reason why SAM survivors may have different long-term outcomes to LWB infants 
might be because this group of SAM survivors have remained thin. The DOHaD theory explains 
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that LBW infants are susceptible to weight gain once exposed to a higher fat diet, and 
additionally, they have a diminished ability to cope with the heightened “metabolic load”[126, 
312]. This is not currently a consideration for SAM survivors in this cohort and may be the reason 
why their vital organ function, such as lung function, appears unaffected. However, gain in weight 
is a strong possibility for this group, based on the current trends in many African countries 
towards escalating prevalence of obesity and sedentary behaviour, as well as imported unhealthy 
foods[313, 314]. As economic development proceeds, these SAM survivors may be exposed to a 
higher ‘metabolic load’ in adulthood due to increasing BMI, exposing their poorer homeostatic 
capacity[312].  
 
Although weight gain since discharge has been minimal in these SAM survivors, height gain has 
been significant. The catch-up growth seen in this cohort suggests that the “first 1000 days” is not 
the only time that reversal of nutritional insults is possible, however result showing that older 
SAM admissions have worse outcomes confirm that <2 years is the optimal window for reversing 
insults. Catch-up of linear height is generally thought to be a good thing. However, we know that 
when undernutrition during development is followed by improved nutrition, many animals and 
plants conduct accelerated or compensatory growth, which has costs. One theory is that a higher 
rate of cell division causes more rapid shortening of telomeres which hastens cell death and organ 
degradation[315]. It is difficult to separate the costs of the insult and the costs of the 
compensatory growth, however some now believe that catch up growth is more detrimental than 
the original insult. Catch-up growth can be defined as either gain in height-for-age or gain in 
weight-for-height; evidence of the adverse long-term effects in weight-for-height is currently 
more conclusive than that for gain in height-for-age[316]. There are some studies presenting the 
risks of rapid gain in HAZ; LBW infants who gained substantial height by 7 years of age had 
higher risk of coronary heart disease in adulthood[45]. This could be due to excess metabolic 
demands placed on organs which are either small or have fewer but larger cells following catch-
up growth[40]. Could this be a consideration for SAM survivors? Their lung function may be 
healthy now, but will it continue to be so if they catch-up more height? “Rapid catch-up” is 
usually defined as an increase >0.66 z scores[317]; these SAM survivors not only had a change in 
WAZ of 1.13 z scores during SAM treatment, but also a change of 1.07 WAZ since discharge. 
HAZ changed very little during treatment and up until 1 year post-discharge however it has 
increased on average 1.46 z scores by 7 years post-discharge. I explored whether time taken to 
recover (i.e. time taken to achieve discharge weight) affected long-term growth outcomes and 
found no association. Despite the generally negative implication of catch-up growth, a study in 
Guatemala found that acquisition of length in first 3 years of life in a stunted population was not 
associated with increases in fat mass or abdominal fat[318]. Another study found that partial 
reversal of stunting in stunted children resulted in better cognitive function[263]. Stunting also 
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has its own host of associated risks[96]. Hence, in the absence of evidence that catch-up growth 
from stunting has adverse long-term implication, immediate benefits of catch-up currently 
outweigh potential long-term effects. Some could even argue that catch-up of linear growth will 
not mitigate the effects of DOHaD as the damage has already been done by the nutritional insult. 
These results have only given us a snap-shop during mid-childhood into some of the effects of 
SAM. Whether these effects, negative or negligible, will endure, diminish or grow beyond 
adolescence and into adulthood can only be speculated, and requires further follow-up. As with 
conclusions from LBW studies, the greatest policy message from these results in the importance 
of prevention rather than cure.    
 
“They are as sick that surfeit with too much as they that starve with nothing.”  
William Shakespeare, Merchant of Venice 
8.9.1 Strengths and Limitations  
Strengths: Many of the strengths of this study lie within the original cohort; it is a unique cohort 
which as far as we know is one of the largest SAM cohorts in the region. There is also extensive 
baseline data on the case children during admission, discharge and at 1 year post-discharge which 
this study made use of. The follow-up rate in the study is excellent with relatively little loss to 
follow-up considering the 7 year gap since recruitment, and the difficult nature of locating 
participants in a setting with no addresses or communication technology. There is no evidence of 
bias due to loss to follow-up, the cases and community controls are well matched regarding basic 
demographics, data regarding most potential confounders was collected and adjusted for and the 
sample size for both cases and controls was more than adequately powered for all but one of the 
main analyses.  
Limitations: There are some limitations to this study which should be mentioned. We do not 
have accurate data for birth weight, a key potential confounder; although we have a rough gage 
for case children, we do not have any information on birth weight for sibling and community 
controls. This information was not routinely recorded when most of these children were born and 
carers recollections are likely to be unreliable with children this age. We also do not have 
longitudinal growth data for the community control group who were only recruited at this phase 
of follow-up. Although sample size is very good for other outcomes, it is not sufficient to detect a 
significant difference for physical activity. In addition, data collectors were not blinded to the 
study group status of the children due to risk of data recording errors, however there were few 
measurements which could be affected by subjectivity. Lastly, BIA data was not calibrated with 
isotope dilution data, as is the gold standard, due to budget limitations, however BIVA offers a 
good alternative.  
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8.9.2 Causality 
It is worth mentioning a caution regarding causality. Causality cannot be confirmed using an 
observational study design, however some of the criteria of causality outlined by Austin Bradford-
Hill, which have been widely adopted by epidemiologists, have been met by these study 
results[319]. The strength of the association between SAM and the effected outcomes is robust 
and consistent. They are also generally consistent with hypotheses generated based on existing 
pre-natal and early life evidence. There is a biological gradient as the age of admission has a 
graded impact on outcomes. And lastly, it is biologically plausible and coherent with some current 
knowledge. Not all the criteria are met; severity of SAM does not exhibit a dose-dependent 
response on the outcomes, and the temporal sequence of the association cannot be confirmed as 
we do not know body composition or physical function of the cohort prior to SAM.	8.9.3 Generalisability 	
It is important to comment that these results are not wholly generalizable to all SAM sufferers. 
Firstly, survivor bias is an important consideration in this study as 46% (476/1024) of the cohort 
are known to have died. In cohorts where more SAM sufferers survive, results could be quite 
different. Survivor bias has been implicated in another study that followed-up survivors of SAM, 
stating that discharged SAM survivors had better WAZ and HAZ than sibling controls for this 
reason[91]. SAM survivors do not have significantly better results to controls in any of the 
outcomes studies here however survivor bias could be diminishing some of the long-term effects. 
Survivor bias may be most evident in the HIV positive SAM survivors who have an even higher 
rate of mortality and who have better HAZ and lean mass outcomes than HIV positive sibling 
controls.    
Secondly, this cohort was started when inpatient treatment was recommended for all SAM cases, 
and cases were identified using NCHS reference data. The reference data and SAM treatment 
protocol has since changed; a more inclusive WHO reference standard has been introduced and 
community management of acute malnutrition (CMAM) is now widely used[320]. This could 
mean that SAM sufferers of today are receiving earlier treatment and will therefore experience 
fewer long-term effects, or conversely CMAM could be facilitating a higher survival rate which 
could result in more long-term adverse effects as the most affected children who would previously 
have died are now surviving. A long-term follow-up of a CMAM cohort is required to assess 
generalisability to this group. 
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8.10 Study Implications 
	
8.10.1 Scientific & Programme Implications 
This study has added new evidence to existing scientific knowledge; namely: 
• An episode of SAM can have long-term implications 
• Catch-up of linear growth post-SAM does occur, even without intervention or change of 
environment 
• Growth patterns observed in previous DOHaD studies do seem to affect SAM survivors 
in the form of “brain-sparing” growth and limb-compromising growth; however the long-
term effects do not exactly match those seen in LBW infants  
As well as confirming some hypotheses, this study has also generated more questions requiring 
further research; namely: 
• Does linear catch-up growth continue during puberty? Or does growth faltering occur at 
this stage? 
• Can nutrition interventions in adolescence improve linear catch-up growth in stunted 
children? 
• Are there increased risks of NCDs for SAM survivors who catch-up their linear height? 
• Does lung function remain relatively good after puberty, even if catch up growth occurs? 
• Is there any long-term effect of SAM on gut microbiome in this cohort? 
• Is physical activity (measured by accelerometers) significantly lower in long-term 
survivors of SAM compared to controls (required sample size ~300 per group)? 
• Can physical function interventions post-SAM or in adolescence improve physical 
strength and capacity of SAM survivors?  
• How would a physical function intervention be delivered in different cultural and 
economic situations?  
Potential Interventions: The	results	of	this	study	have	highlighted	better	prevention	of	SAM,	reversal	of	stunting,	increase	in	lean	mass	and	improvements in physical strength and capacity 
as potential aims for interventions in order to ultimately improving long-term outcomes in SAM 
survivors. With adolescence being a time of significant developmental transition, setting the stage 
for adult health, this seems one optimal time for implementation of these interventions in SAM 
survivors[93]. A recent review highlights that interventions to promote physical activity, healthy 
lifestyle, improved access to nutritious and healthy foods, as well as sexual and reproductive 
health, have successfully improved health outcomes in young adolescents generally[321]. 
Delivering these interventions in schools has been evaluated and deemed effective, however more 
182 
	
novel methods such as use of social media and information technologies, cash transfers, social 
protection, and micro-finance initiatives could also be promising methods of delivering health and 
nutrition interventions to adolescents[321]. Future research should focus on confirming long-term 
effects, identifying suitable interventions to prevent or reverse long-term effects, and develop 
sustainable and cost-effective delivery methods for interventions. 
Following future research, there could also be some changes made to SAM treatment programmes 
in order to mitigate some of the long-term effects observed. Ideas at this stage include active case 
findings and CMAM treatment for infants <6 months with MAM or SAM, and better follow-up 
care post-SAM, including health monitoring with health messaging and personalised advice as 
this population are at higher risk of mortality, nutrition supplementation and physical activity 
interventions, particularly for older admissions who have worse outcomes.  
 
 
8.10.2 Policy Implications  
Although policy is not purely developed on scientific evidence, results of scientific studies should 
play a role in developing future policy[322]. The results of this study have implications for future 
policies across the areas of child nutrition, adult health particularly NCDs, and wider nutrition-
specific and development areas such as agriculture and sanitation. The over-arching policy 
message that can be gleaned from these results is the need for a focus not only on the mortality 
outcomes of SAM but the morbidity outcomes too; the emphasis shift from “surviving” to 
“thriving” which has gathered pace in other areas of child health need also be applied to SAM. 
Although the SDGs have highlighted the importance of tackling SAM, the lasting effects are not 
yet recognised. These results support the need to include SAM in policies concerning the long-
term implications of malnutrition; many initiatives, such as SUN Movement (Scaling Up 
Nutrition), have their focus purely on the long-term effects of stunting. The role that SAM plays 
in the pathogenesis of stunting, as well as its own long-term implications, should be recognised.  
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8.11 Conclusions  
	
Overall, my PhD research has shown that there are some long-term implications of an acute 
episode of SAM in the areas of growth, body composition and physical function. Deficits in HAZ, 
lean mass and grip strength are most notable in their potential health implications. Lung function, 
sitting height, head circumference and fat distribution measured by skinfold thickness appear 
unaffected by SAM at this age and while the SAM survivors remain thin. Catch up of linear 
growth has occurred since discharge, suggesting growth interventions post-“first 1000 days” can 
still be effective. However as children get older, an episode of SAM can have greater detrimental 
effects, emphasising the need to take every precaution to prevent SAM in children >2 years, as 
well as working to identify and treat children <2 years as early as possible. Other interventions to 
consider for SAM survivors may be further nutrition supplementation and/or physical fitness for 
building of lean mass and strength. It is important to note that adolescence is a time of significant 
developmental transition so it will be interesting to study the long-term effects of SAM after this 
time.  
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Appendix 1: Information Sheet and Consent Form 
You will be given a copy of this information sheet. 
Title of 
Project:   
Chronic Disease Outcomes following Severe Acute Malnutrition (ChroSAM 
study) – a prospective cohort study 
This study has been approved by the Ethics 
Committee [Project ID Number]: P.02/13/1342 
Name, Address and Contact 
Details of Investigator: 
Natasha Lelijveld 
 c/o  Malawi-Liverpool-Wellcome Trust Clinical Research 
Programme 
Telephone 0996 283155 
We would like to invite you to participate in this research project.  
WHAT IS THE RESEARCH ABOUT? 
Severe Malnutrition is a major problem for children in Malawi and many other similar 
countries. Lots of people known about the risks of death following malnutrition. However, 
children who survive can also experience problems with their future health. Some of these 
problems might even last into adult life. Possible problems include effects on growth, 
development, school achievement and health of the body (e.g. heart, lungs, physical 
fitness/strength). In this research we want to understand what the long term effects of 
malnutrition are. We will do this by comparing children who have been malnourished with 
those who have not (siblings and neighbours). We hope that the results of this research will 
help us and others to improve the treatment of malnutrition in the future so as to minimise any 
harmful long term effects. Your contribution to the research is therefore very valuable. 
 
WHAT DOES THE RESEARCH INVOLVE: (There are two parts to this research) 
PART (1) will take place at your home. We would like to ask you some questions about your 
child and your family. We would also like to take some weight, height and arm/head 
circumference measurements to see how your child is growing and how his/her health is (show 
blood pressure cuff and oxygen sats machine). We would also like to measure your (mother’s) 
weight, height and blood pressure.   
We are doing all this to help us understand how children are doing and what are possible 
reasons why some children are doing better and others doing not so well after malnutrition.  
PART (2) will take place at Queen Elizabeth Hospital Malawi. The aim of this is do some more 
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detailed tests. We will arrange a visit on a mutually convenient day. You will be one of several 
children visiting for the same project and will be asked to arrive by 9am. We will ask some more 
questions and do some more tests (blowing into a machine to test how well his/her lungs are 
working; doing some more measurement of the body; checking his/her fitness). We would also 
like to take a blood sample which will tell us about any other health problems he/she may have. 
Part of this will be stored for possible future analysis. The visit will take about 2 hours – food 
and transport expenses will be provided.  
 
With both parts of the assessment, we will let you know if we find any health problems and will 
advise you on what you can do / where you can go for treatment. 
 
ABOUT TAKING PART IN RESEARCH 
You should only participate if you want to; choosing not to take part will not disadvantage you 
or your child in any way. Before you decide whether you want to take part, it is important for 
you to understand what the project involves and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like more information.  
It is up to you to decide whether to take part in both, or one part of this study, or not at all. You 
also do not have to answer any questions that you are not comfortable with. If you decide to 
take part you are still free to withdraw at any time and without giving a reason.   
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Please complete this form after you have read the Information Sheet and/or listened to an explanation about the 
research.  
Title of Project:   
Chronic Disease Outcomes following Severe Acute Malnutrition 
(ChroSAM study) – a prospective cohort study 
This study has been approved by the Ethics 
Committee [Project ID Number]: 
- P.02/13/1342 
Thank you for considering to take part in this research.  The person organising the research must 
explain the project to you before you agree to take part. 
(for ex-MOYO children only) This is a follow-up to previous research that you have been involved 
with on MOYO ward, Queen Elizabeth Hospital.  
If you have any questions arising from the Information Sheet or explanation already given to 
you, please ask the researcher before you decide whether to join in.  You will be given a copy of 
this Consent Form to keep and refer to at any time. 
I understand that if I decide at any other time during the research that I no longer wish to 
participate in this project, I can notify the researchers involved and be withdrawn from it 
immediately. 
I consent to the processing of my personal information for the purposes of this research study.  I 
understand that such information will be treated as strictly confidential. 
Carer’s Signature or thumbprint                             Child / adolescent signature or thumbprint  
(if aged <18 and able to respond concerning participation Î assent to take part) 
I  …………………………………………................ AND       I, ……………………………………………………………….. 
agree that the research project named above has been explained to me to my satisfaction and I 
agree to take part in  a) part 1  b) part 2 of the study. (circle appropriately)  
The notes written above and the Information Sheet about the project have been read to me and 
I understand what the research study involves. 
Signed:                                                                       
Date: :  
Researcher’s Signature. I  …………………………………………………………………….. 
confirm that I have carefully explained the purpose of the study to the participant and that 
consent is freely given  
Signed:                                                                       
Date:   
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Appendix 2: Letter from School explaining absence 
 
Ms Natasha Lelijveld 
Malawi Liverpool Wellcome Trust 
College of Medicine 
PO Box 30096 
Chichiri 
Blantyre 3 
 
Dear Head Teacher,  
This is a letter to inform you that the child ………………………………………………………………………… 
(name) will be missing 1 day of school on ……………… of ……………………. (date) as he/she is taking 
part in a medical research project called ChroSAM. This is related to a previous admission that 
the child had to Queen Elizabeth Central Hospital, Blantyre, in 2006/2007.  
The research is taking place at the same Queen Elizabeth Central Hospital. It is hoped that the 
results of this research project will help the children of Malawi through better management of 
illnesses. 
The ChroSAM project has been approved by College of Medicine Ethical Research Committee. 
Should you have any queries regarding this research project, please feel free to contact the 
Ethical Research Committee, quoting project number P.02/13/1342, on the following telephone 
numbers: 
01877 245 /  01877 291 
We would like to thank you very much for your understanding and thank you for supporting this 
project.  
Kind Regards 
 
Natasha Lelijveld 
 
……………………………………. 
Project Coordinator 
0996 283155 
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Appendix 3: Ethical approval certificate COMREC 
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Appendix 4: Ethical approval letter UCL REC 
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Appendix 5: Gantt Chant of study timing 
 2013 2014 2015 2016 
 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 
Planning              
Ethical 
Approval 
            
UK-based 
training 
(anthropometry 
and spirometry) 
            
Literature 
Review 
            
Questionnaire 
development 
            
Recruiting study 
nurses and field 
workers 
            
Team training & 
piloting 
            
Data             
Recruitment & 
Data Collection 
            
Quality Control             
Data Analysis             
Dissemination              
Writing up 
thesis 
            
Dissemination 
of results 
(conferences) 
            
Dissemination 
of results 
(journal articles) 
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Appendix 6: Paper versions of data collection forms (forms B, C, H, I, and J) 
 
Appendix 7: Questionnaires (forms A, D, E and K) (English versions) 
  
Form C. Family Anthropometry. ChroSAM Study.
Participant ID
Participant Initials
Interview Date
C1
C2
C3
PID
PIN
INTDT
-
/ / 2 0
C4
C5
C6
C7
Mother Anthropometry
(must be biological mother)
Weight
MUAC
Height (standing)
Sitting Height
D D M O N Y Y
MHT
MWGT
MMU
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined
MUAC (mm)
C5 MMU_FIN
1 2 3
.
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined
Height (cm)
1 2 3
C6 MHT_FIN
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined Sitting
Height (cm)
1 2 3
C7 MSHT_FINMSHT
If anthro not done, use
following codes in place of
'Weight':
*Dead = 666.6
*Alive but not available = 555.5
*Alive but out = 444.4
 (coming back)
Page 1
A -moyo child
B -siBling control
C -Community conrol
Y Y
Mother's Date of Birth
Is Mother alive?
Mothers Date of Death
(if died)
/
Yes No Don't know
/
C4 MDOB
MLIV
MDOD
C4
C4
Enter 999 if
don't know
0695303961
Form C. Family Anthropometry. ChroSAM Study.
Participant ID
Participant Initials
C8
C9
PID
PIN
-
C10
C11
C12
C13
Page 2
1 2 3
Sitting Height
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined Sitting
Height (cm)
C13 FSHT_FIN
Father Anthropometry
(Must be biological Father)
Weight
MUAC
Height (standing)
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined
MUAC (mm)
C11 FMU_FIN
1 2 3
.
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined
Height (cm)
C12 FHT_FIN
1 2 3
*Dead = 666.6
*Alive but not available = 555.5
*Alive but out = 444.4
 (coming back)
FWGT
FMU
FHT
FSHT
A/B/C
Father's Date of Birth
Is Father alive?
Father's Date of Death
(if died)
/
Yes No Don't know
/
Enter 999 if
don't knowFDOB
FLIV
FDOD
C10
C10
C10
7688303960
Form C. Family Anthropometry. ChroSAM Study.
Participant ID
Participant Initials
C14
C15
PID
PIN
-
C16
C17
C19 1WGT
1MU
1HT
C20
Page 3
1st Born Anthropometry
(Unless Moyo/Control Child)
Weight
MUAC
Height (standing)
Operator 1 Initials
Operator 2 Initals
1 2 3
Combined
MUAC (mm)
C20 1MU_FIN
1 2 3
.
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined
Height (cm)
1 2 3
C21 1HT_FIN
*Died = 666.6
*Not Applicable = 777.7
*Alive but not available = 555.5
*Alive but out = 444.4
 (coming back)
*Less than 2 years = 222.2
Month and Year of Birth
If died, year of death
/1DOB
1DOD
M M M Y Y Y Y
Y Y Y Y
Sex
If moyo child,
write MMM in place
of Month of birth
and do not
complete. If Sib
control write SSS.
If community
control write CCC
C18 1SEX Male Female
A/B/C
C21
NKIDS How many children are therein the family? (alive)
(children must all have the
same mother)
C16
Don't need to measure if child is
less than 2 years.
0715303964
Form C. Family Anthropometry. ChroSAM Study.
Participant ID
Participant Initials
C23
C24
PID
PIN
-
C25 2DOB
C26 2DOD
C28
2MUC29
2HT
Page 4
Weight
MUAC
Height (standing)
Operator 1 Initials
Operator 2 Initals
1 2 3
Combined
MUAC (mm)
C29 2MU_FIN
1 2 3
.
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined
Height (cm)
1 2 3
C30 2HT_FIN
2nd Born Anthropometry
(Unless Moyo or Control child)
*Died = 666.6
*Not Applicable = 777.7 (ie no
 second born)
*Alive but not available = 555.5
*Alive but out = 444.4
  (coming back)
*Less than 2 years = 222.2
Month and Year of Birth
If died, year of death
/
2WGT
C30
M M M Y Y Y Y
Y Y Y Y
C27 2SEX Sex Male Female
If moyo child,
write MMM in place
of Month of birth
and do not
complete. If Sib
control write SSS.
If community
control write CCC
A/B/C
2262303963
Form C. Family Anthropometry. ChroSAM Study.
Participant ID
Participant Initials
C32
C33
PID
PIN
-
C35
C36
C37
C39
Page 5
3rd Born Anthropometry
(if not Moyo or Control child)
Weight
MUAC
Height (standing)
Operator 1 Initials
Operator 2 Initals
1 2 3
Combined
MUAC (mm)
C38 3MU_FIN
1 2 3
.
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined
Height (cm)
1 2 3
C39 3HT_FIN
*Died = 666.6
*Not Applicable = 777.7 (ie. no
 third born)
*Alive but not available = 555.5
*Alive but out = 444.4
 (coming back)
*Less than 2 years = 222.2
Month and Year of Birth
If died, year of death
/C34
M M M Y Y Y Y
Y Y Y Y
3DOB
3DOD
3WGT
3MU
3HT
Sex Male Female
3SEX
C38
If moyo child,
write MMM in place
of Month of birth
and do not
complete. If Sib
control write SSS.
If community
control write CCC)
A/B/C
4154303965
Form C. Family Anthropometry. ChroSAM Study.
Participant ID
Participant Initials
C41
C42
PID
PIN
-
C43
C45
C46
C47
Page 6
C44
4th Born Anthropometry
(unless Moyo or Control child
Weight
MUAC
Height (standing)
Operator 1 Initials
Operator 2 Initals
1 2 3
Combined
MUAC (mm)
C47 4MU_FIN
1 2 3
.
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined
Height (cm)
1 2 3
C48 4HT_FIN
*Died = 666.6
*Not Applicable = 777.7 (ie no
 4TH born)
*Alive but not available = 555.5
*Alive but out = 444.4
  (coming back)
*Less than 2 years = 222.2
Month and Year of Birth
If died, year of death
/
M M M Y Y Y Y
Y Y Y Y
Sex Male Female
If moyo child,
write MMM in place
of Month of birth
and do not
complete. If Sib
control write SSS.
If community
control write CCC)
4DOB
4DOD
4SEX
4WGT
4MU
C48 4HT
A/B/C
3749303964
Form C. Family Anthropometry. ChroSAM Study.
Participant ID
Participant Initials
C50
C51
PID
PIN
-
C52
C53
C54
Page 7
Weight
MUAC
Height (standing)
Operator 1 Initials
Operator 2 Initals
1 2 3
Combined
MUAC (mm)
C56 5MU_FIN
1 2 3
.
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined
Height (cm)
1 2 3
C57 5HT_FIN
*Died = 666.6
*Not Applicable = 777.7 (ie no
 5TH born)
*Alive but not available = 555.5
*Alive but out = 444.4
  (coming back)
*Less than 2 years = 222.2
Month and Year of Birth
If died, year of death
/
M M M Y Y Y Y
Y Y Y Y
Sex Male Female
If moyo child,
write MMM in place
of Month of birth
and do not
complete. If Sib
control write SSS.
IF community
control write CCC
5th Born Anthropometry
(unless Moyo or Control child
5DOB
5DOD
5SEX
C55
C56
C57 5HT
5MU
5WGT
A/B/C
0456303966
Page 8
Form C. Family Anthropometry. ChroSAM Study.
Participant ID
Participant Initials
C59
C60
PID
PIN
-
6th Born Anthropometry
(Unless Moyo/Control Child)
C61
Weight .
*Died = 666.6
*Not Applicable = 777.7 (ie no
 6TH born)
*Alive but not available = 555.5
*Alive but out = 444.4
  (coming back)
*Less than 2 years = 222.2
Month and Year of Birth
If died, year of death
/
M M M Y Y Y Y
Y Y Y Y
Sex Male Female
If moyo child,
write MMM in place
of Month of birth
and do not
complete. If Sib
control write SSS.
IF community
control write CCC)
C62
C63
C64
6DOB
6DOD
6SEX
6WGT
MUAC
Height (standing)
Operator 1 Initials
Operator 2 Initals
1 2 3
Combined
MUAC (mm)
C65 6MU_FIN
1 2 3
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined
Height (cm)
1 2 3
C66 6HT_FIN
C65
C66
6MU
6HT
A/B/C
4569303965
Form C. Family Anthropometry. ChroSAM Study.
Participant ID
Participant Initials
C68
C69
PID
PIN
-
7th Born Anthropometry
(Unless Moyo/Control Child)
C70
C71
C72
C73
Month and Year of Birth
If died, year of death
/
M M M Y Y Y Y
Y Y Y Y
Sex Male Female
If moyo child,
write MMM in place
of Month of birth
and do not
complete. If Sib
control write SSS.
IF community
control write CCC)
7DOB
7DOD
7SEX
Weight .
*Died = 666.6
*Not Applicable = 777.7 (ie no
 7TH born)
*Alive but not available = 555.5
*Alive but out = 444.4
  (coming back)
*Less than 2 years = 222.2
MUAC
Height (standing)
Operator 1 Initials
Operator 2 Initals
1 2 3
Combined
MUAC (mm)
C74 7MU_FIN
1 2 3
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined
Height (cm)
1 2 3
C75 7HT_FIN
C74
C75
7WGT
7MU
7HT
Page 9
A/B/C
8312303965
Form C. Family Anthropometry. ChroSAM Study.
Participant ID
Participant Initials
C77
C78
PID
PIN
-
8th Born Anthropometry
(Unless Moyo/Control Child)
Month and Year of Birth
If died, year of death
/
M M M Y Y Y Y
Y Y Y Y
Sex Male Female
If moyo child,
write MMM in place
of Month of birth
and do not
complete. If Sib
control write SSS.
IF community
control write CCC)
C79
C80
C81
C82
8DOB
8DOD
8SEX
Weight .
*Died = 666.6
*Not Applicable = 777.7 (ie no
 8TH born)
*Alive but not available = 555.5
*Alive but out = 444.4
  (coming back)
*Less than 2 years = 222.2
MUAC
Height (standing)
Operator 1 Initials
Operator 2 Initals
1 2 3
Combined
MUAC (mm)
C83 8MU_FIN
1 2 3
Operator 1 Initials
Operator 2 Initals
1 2 3
.
Combined
Height (cm)
1 2 3
C84 8HT_FIN
page 10
8WGT
8MU
8HT
C83
C84
A/B/C
6838303966
Form H. Chronic Diseases. ChroSAM study.
H1
H2
PID
PIN
Participant ID
Participant Initials
-
Blood pressure(child)
Mother's Blood pressure
Oxygen saturation (%)
Is the child left or right-handed?
Hand grip strength LEFT
Hand grip strength RIGHT
Any technical difficulties
which may affect the results?
Hand Grip Strength
H3
H4
H5
H6
H7
H8
H9
MBP
BP
SpO2
LHRH
GRPL
GRPR
TECH
/
/
%
Right Left
. . .
Attempt 1 Attempt 2 Attempt 3
Best score on LEFT:
.
LBEST
. . .
Attempt 1 Attempt 2 Attempt 3
Best score on RIGHT:
.
RBEST
Yes No
If yes, please specify on Master form Z
Operator Initials
Interview Date / /INTDT
OPIN
H10
H11
D D M M M Y Y
Participant ID =
HMIS number
followed by
A -moyo child
B -siBling control
C -Community onrol
A/B/C
Page 1 of 2
1326241931
Bioelectrical Impedance Analysis (BIA)
Impedance (Z) at 50khz
Reading 1:
Resistance (R) at 50khz
Reactance (Xc) at 50khz
.
Phase angle at 50khz
.
Impedance (Z) at 50khz
Reading 2:
Resistance (R) at 50khz
Reactance (Xc) at 50khz
.
Phase angle at 50khz
.
Form H. Chronic Diseases. ChroSAM study.
Participant ID
Participant Initials
-
BIAZ
BIAR
BIAPA
BIAXc
BIAZ
BIAR
BIAXc
BIAPA
H14
H17
H18
H19
H20
H21
H22
H23
H24
Accelerometers
Accelerometer Given? Yes NoACEL
H25
If yes, device number:ACELD
H12
H13
H15
Test Number (reading 1)
Test Number (reading 2)
BIAN1
BIAN2
H16
A/B/C
Page 2 of 2
5962241931
Form I. Hospital-Only Measures. ChroSAM study.
Participant ID
Participant Initials
I1
I2
PID
PIN
-
I3
I4
I5
I6
Date of Hospital visit / /
D D M M M Y Y
Skinfold thickness
Left Biceps (FRONT)
(mm)
SFBOP1
SFB0P2
Operator 1 Initials I4SFB_FINCombined Biceps
Skinfold
.
Operator 2 Initials
1 2 3
1 2 3
Left Triceps (BACK)
(mm)
Operator 1 Initials I5SFT_FINCombined Tricep
Skinfold
.
Operator 2 Initials
1 2 3
1 2 3
SFTOP1
SFTOP2
L Subscapular (shoulder)
(mm)
Operator 1 Initials
I6SFS_FIN
Combined
Subscapular
Skinfold
.
Operator 2 Initials
1 2 3
1 2 3
SFSOP1
SFSOP2
SFWOP1
L Suprailiac (waist)(mm)
Operator 1 Initials
I7SFW_FIN
Combined
Subscapular
Skinfold
.
Operator 2 Initials
1 2 3
1 2 3
SFWOP2
I7
Participant ID =
HMIS number
followed by
A -moyo child
B -siBling control
C -Community conrol
A/B/C
INTDT
Page 1 of 2
4676212963
Form I. Hospital-Only Measures. ChroSAM study.
Participant ID
Participant Initials
-
I8
I9 PIN
PID
If the answer is yes to any of the above (I17-I20), do NOT perform
spirometry. Report to a clinician (ie. Dr Kerac or Dr Vostij).
Spirometry
Any cough/cold/flu at the moment?
(according to carer) Yes No Dont know
Any cough observed?
Operator InitialsI10 OPIN
SPIC1I11
Any runny nose observed?
Yes No
Yes No
SPIC2
SPIC3
I12
I13
Does child have any of the following contraindications?
(ask carer)
Chest pain? Yes No
Heart problems? Yes No
Yes No
Yes No
Yes No
Surgery or hospital
admission in past month?
Current chest infection?
Coughing blood?
Spirometry test done?
Add any additional notes to Master form Z
Yes No
I17
I18
I19
I20
I21
I22
SPIC4
SPIC5
SPIC6
SPIC7
SPIC8
SPI
Does mother or father have any of the following:
Asthma?
Wheeze?
Allergies?
I14
I15
I16
FAMAS
FAMWH
FAMAL
Yes No Dont know
Yes No Dont know
Yes No Dont know
Tick Form Z Checklist when Bloods, Retina photos, MRI scan, Ultrasound
and Salivery Cortisol done.
Page 2 of 2
6957212967
Participant ID
Participant Initials
Operator Initials
-
Does child have any of the following contraindications?
(ask carer)
Any technical difficulty which would
inhibit test?
If yes, specify on Master form Z
Yes No
Step height
Heart problems?
Lung problems?
Asthma but no inhaler?
Mental or physical impairment which
prevents cooperation?
If the answer is yes to any of the above, do not perfrom I step test
Yes No
Yes No
Yes No
Yes No
15CM 20CM 25CM
Form J. I-Step Test. ChroSAM study.
J1
J2 PIN
PID
J3 OPIN
J4 STPC1
J5 STPC2
STPC3
STPC4
STPC5
J6
J7
J8
J9 STPH
J10
J11
J12
Level 1 1 min
2 min
LEVEL TIME SpO2 % Heart Rate(BPM)
OMNI
(0-10)
VAS
(0-10)
Level 2 3 min
4 minJ13
5 min
6 min
J14
J15
J16
J17
Level 3
Level 4 7 min
8 min
J10B Base Line 00
A/B/C
Page 1 of 2
4531243428
Level 5 9 min
10 min
LEVEL TIME SpO2 % Heart Rate
(BPM)
OMNI
(0-10)
VAS
(0-10)
1 Min
Recovery
Participant ID
Participant Initials
-
Form J. I-Step Test. ChroSAM study.
J18
J19 PIN
PID
Test completed?
Number of
completed levels
Total time
completed
Reasons for
stopping the test
J20
J21
J22
J23
1 Min
Recovery
Yes NoSCOMP
J24 SLEVE
.
MIN.SECS
Inability to maintain rhythm
Sudden pallor
Drop in SpO2 >10% from resting
Too breathless
Excessive coughing
Loss of coordination
Declined to continue
Light headedness
Not Applicable
J26 SSTOP
J25 STIME
Oxygen Saturation:
(%)
Lowest recording
Heart Rate:
(BPM) Highest recording
OMNI scale (0-10): Highest recording
J27
J28
J29
SOXL
SHRH
SOMH
Page 2 of 2
VAS (0-10): Highest recordingJ30 SVAH
9189243422
Form A. Basic Information. ChroSAM study.
Participant ID
Participant Initials
Operator Initials
Date of visit
A1
A2
A3
A4
PID
PIN
OPIN
INTDT
-
/ /
D D M O N Y Y
A5
A6
A7
Child's reported age
Date of Birth
Check that age and year of birth agree.
Sex Male Female
A8
Birth Order
AGE
DOB
Outcome of visit
/
M O N Y Y Y Y
1st (ie. oldest)
2nd
3rd
4th
5th
6th
7th
8th
Other
SEX
BRTH
OUTCA9
Child seen (1)
Child not seen: but info reliable (2)
Child not seen: info may be unreliable (3)
Unsuccessful search (4)
Information may be unreliable when given by a friend or neighbour
rather than by a close family member.
A10 CARQ Which carer is
answering these
questions?
Mother (1)
Father (2)
Grandmother  (3)
Aunt (4)
Uncle (5)
Neighbour (6)
Other family (7)
Other non-family (8)
Dont know (99)
A -moyo child
B -siBling control
C -Community conrol
years
Y Y
Page 1 of 7
1205617350
Form A. Basic Information. ChroSAM study.
Participant ID
Participant Initials
A11
A12
PID
PIN
-
A13
A14
Who is the main
carer?CARM
How is the child
now (or when last
seen)?
Child died (1) (See A15 and A16)
Child well (2) (proceed to A17)
Child sick (3) (proceed to A17)
Don't know (99) (proceed to A17)
If died, where
did they die?A15
WELL
POD Home (1)
Hospital MOYO (2)
Hospital QECH/PSCW (3)
Hospital other (4)
Dont know (99)
A16 DOD Date of final outcome
(ie. Date of death or
date last known to be
alive)
/ /
D D M M M Y Y Y Y
If day or month unknown, enter 9 in
its place
Include CAUSE OF DEATH and any other notes on Master Checklist Z
If child has died, proceed to Form E, F and G
If child is alive, continue below:
A17 PUBE Has child startedpuberty? (ie. pubic
hair/periods)
Yes No Dont know
A18 RESAM
Any episodes of
SAM.. since we first
met you at Moyo /
ever(controls)?
Yes (see questions A19 to A27)
No (proceed to A28)
Dont know (proceed to A28)
A19 KWAS
Any episodes of
Kwashiorkor/
swelling?
A/B/C
Yes No
If yes, when?
' 'Y Y Y Y Y Y Y Y Y Y Y Y
If more that 3 times, write how many times on Form Z
Mother (1)
Father (2)
Grandmother  (3)
Aunt (4)
Uncle (5)
Neighbour (6)
Other family (7)
Other non-family (8)
Dont know (99)
A19
KWAS1
Page 2 of 7
5092617358
Form A. Basic Information. ChroSAM study.
Participant ID
Participant Initials
A20
A21
PID
PIN
-
A22
A23
Any episodes of
wasting / getting
thin?
Did child get
medical attention? Yes No Dont know
MEDSAM
WAST
A24
A25
A26
A27
NRUSAM How many times
admitted to NRU
(inpatient)?
99 = dont know
How many times had
RUTF/OTP only (CTC)?CTCSAM 99 = dont know
How many times given
advice, multivits/
other, without RUTF?
99 = dont knowADVSAM
How many times referred
to SFP alone?
99 = dont knowSFPSAM
A28 INPAT Number of inpatient
admissions ever (not SAM) If zero, skip
A32 and A33
A29
A30
INPAT1 Number of inpatient
admissions in the last 1
year (not SAM)
OUTPA Number of outpatient
visits in last 6 months
(not SAM)(exclude
routine visits such as
ART, OTP)
A31
A32
Ever admitted with
pneumonia/ chest
infection?
Yes No Dont know
If yes, at what age? ,
Y Y M M
Fill in with
99, if unknown
PNEU
PNAGE
A33 ASMA Has child ever beendiagnosed with asthma? Yes No Dont know
e.g. Health centre or
clinic)
A/B/C
' 'Y Y Y Y Y Y Y Y Y Y Y Y
Yes No
If yes, when?
If more than 3 times, specify how many times on form z
A22 WAST1
Page 3 of 7
6548617355
Form A. Basic Information. ChroSAM study.
Participant ID
Participant Initials
A34
A35
PID
PIN
-
Has the child ever
had TB?
A36 TB Yes No Dont know
A37 TBYR
If yes, year
diagnosed with
TB? Y Y Y Y
A38
A39
A40
If Yes - see
question A37-A40
If No/dont know -
proceed to A41
Were other
children in the
family
screened?
Yes No Dont know
TBFAM
TBTRT How many months
did child have
treatment for?
If not treated, enter 00
TB6M If treatment was
less than 6
months, why?
Still taking treatment
Other (specify on Form Z)
Dont know
Has child ever been
diagnosed with any of
the following? (tick
all that apply)
Eczema or skin allergies (1)
Wheeze (2)
Persistent Cough (3)
Other health problems (4) (Specify on Form Z)
None (5)
A41 HLTH
A42
A43
HIVT Has child ever had
a HIV test? Yes No Dont know
HIV What is the
child's HIV
status
If no/dont know, skip
to A43
R (Positive) (1)
NR (Negative) (2)
Dont know (99)
Prefer not to say (88)
Is a (re)test needed?
A44 HIVRT
A45 If yes, what was
done?
HIVRT1
Yes No
Retest done, R (1)
Retest done, NR (2)
Counselled and referred for test (3)
Refused test (4)
Yes if test was done before 18months of age, or if never tested
A/B/C
Page 4 of 7
3941617359
Form A. Basic Information. ChroSAM study.
Participant ID
Participant Initials
A46
A47
PID
PIN
-
A48
Only ask questions A48 - A60 if child is HIV reactive.
If non-reactive or never tested, skip to question A61.
Has child ever had
COTRIMOXAZOLE
PROPHYLAXIS? (1 daily
dose)
Yes No Dont know
COT If No/ Dont
know, skip to
A52
A49
A50
A51
COTDS If yes, when
did child have
last dose?
Today
Yesterday
2 days ago
3-7 days ago
1 week -1 month ago
More than 1 month ago
Never since MOYO
Dont know
If yes, where
got CoT from
(since MOYO)?
COTWH CoT clinic QECH
Health centre
Other
Dont know
Any problems
taking daily
CoT? (see codes)
COTPR
A52 ARV Has child ever had
ARVs? (2 daily
doses)
Yes (1) (see A53 - A60)
No, never (2) (proceed to A61)
No, not eligible (3) (proceed to A61)
Dont know (99) (proceed to A61)
A53 ARVDT Date started
ARVs / /
D D M O N Y Y Y Y
If day/month unknow, fill with 99
A/B/C
Page 5 of 7
8375617355
Form A. Basic Information. ChroSAM study.
Participant ID
Participant Initials
-A54
A55
PID
PIN
A56
A57
A58
ARVST Still taking
ARVs?
Yes No Dont know
ARVDS
If No/ Dont
know,
proceed to
A60
When did child
last take their
medication?
Today (1)
Yesterday (2)
2 days ago (3)
3-7 days ago (4)
1 week -1 month ago (5)
More than 1 month ago (6)
Never since MOYO (7)
Dont know (99)
ARVMS When did child
last miss a
dose?
Missed today or within last week (1)
Missed dose 1-2 weeks ago (2)
Missed dose 2-4 weeks ago (3)
Missed dose 1-3 months ago(4)
Missed nothing last 3-12 months (5)
Dont know (99)
A59 ARVWH Where got
ARVs from?
QECH (1)
Health centre (2)
Other (3) (Specify on Form Z)
Dont know (99)
A60 Were there anyproblems taking
ARVs? (see codes)
ARVPR
End of HIV questions
A/B/C
Page 6 of 7
1777617354
Medical action
following visit?
Study action
following visit?
No medical intervention required (1)
Medical advice given (2)
Medical action recommended (3) (specify on Z)
Agreed to attend hospital 'base' appointment (1)
Declined to attend 'base' appointment (2)
Arranged to visit the home on a different date (3)
Form A. Basic Information. ChroSAM study.
Participant ID
Participant Initials
-A61
A62
PID
PIN
MEDAC
STAC
A63 What is highest level of
school achievement for this
child?
Did this child attend
school at any time during
this past year?
00= None Primary:
01= S1
02= S2
03= S3
04= S4
05= S5
06= S6
Secondary:
09= F1
10= F2
11= F3
12= F4
13= F5
14= F6
99= Don't Know07= S7
08= S8
A64
A65
A66
SCHA
SCHB
A/B/C
Yes No Dont know
Page 7 of 7
7013617353
Form D. Family Characteristics. ChroSAM study.
Patient ID
Patient Initials
-
PID
PIN
D1
D2
D3
D4
Are the biological parents still
married/together?
What is main occupation of main
female carer (use codes)
What is main occupation of main
male carer? (use codes)
D5 PTGT
Yes No Don't know Not Applicable
MOCC
FOCC
01= mlimi/ganyu
02= employee
03= family business
04= self employed
05= employer
06= worked before,but
now seeking work
07= worked before, not
looking for work
08= never worked
before, but looking
09= never worked,
not looking
10= housewife
11= student
12= other
99= dont know
Codes:
Can mother/female carer read?
(use test sentance below)
Can father/male carer read?
(use test sentance below)
Yes, can read whole sentence (1)
No, can't read (2)
Can read only part of sentence (3)
Reportedly can read, but not present (4)
Don't know (99)
MLIT
D6
FLIT
D7
D8
D9
Operator Initials
Interview Date / / 2 0
OPIN
INTDT
D D M O N Y Y
Participant ID =
HMIS number
followed by
A -moyo child
B -siBling control
C -Community onrol
A/B/C
Yes, can read whole sentence (1)
No, can't read (2)
Can read only part of sentence (3)
Reportedly can read, but not present (4)
Don't know (99)
The child is reading a
book
Farming is hard work
The child is reading a
book
Farming is hard work
Y Y
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Form D. Family Characteristics. ChroSAM study.
Patient ID
Patient Initials
-
PID
PIN
A/B/C
Highest level of education
acheived by mother/female carer?
(use codes)
Highest level of education
acheived by father/ male carer?
(use codes)
0= None Primary:
01= S1
02= S2
03= S3
04= S4
05= S5
06= S6
Secondary:
09= F1
10= F2
11= F3
12= F4
13= F5
14= F6
15= University/other
higher
16= Technical College
99= Don't Know
07= S7
08= S8
MED
FED
D10
D11
D12
Please ensure PRIVACY before asking the following question:
(If privacy is not possible, skip question and move to next form)
Tell the mother: "I am now going to ask you some questions about other
important aspects of a womans life. You may find some of these questions
very personal, however, let me assure you that your answers will be
completely confidential and will not be told to anyone else"
Yes (1)
No (2)
No answer / won't say (88)
From the time you were 15, has any
one hit you, slapped you, kicked
you, or done anything else to hurt
you physically?
VIOL
If yes, who has hurt
you in this way?
Sister/brother (1)
Daughter/Son (2)
Mother/ Step-Mother(3)
Father / Step Father (4)
Teacher (5)
Mother in Law (6)
Father in Law (7)
Current husband /partner (8)
Previous husband/partner (9)
Police/Soldier (10)
Employer/Worker (11)
Other (12) (Specify on Z)
D13 VWHO
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Form D. Family Characteristics. ChroSAM study.
Patient ID
Patient Initials
-
PID
PIN
A/B/C
Are there any members of the
household who have been sick for
at least 3 months in the past 12
months? (ie. too sick to work or
do normal activities)
D14 Yes No Don't KnowSICK
If No/Don't
know, skip
to question
D22 (next
page)
During the last 12 months, has your
household recieved any medical
support for the sick person? Such
as medical care or medicine which
you did not have to pay for.
Yes No Don't Know
D15 MEDSP
During the past 12 months, has your
household recieved any emotional or
psychological support for the sick
person? Such as companionship,
counseling from a trained
counselor, or spiritual support,
which you didnt have to pay for.
Yes No Don't KnowD16 EMOSP
During the past 12 months, has your
household recieved any material
support for the sick person? Such
as clothing, food or financial
support, which you didnt have to
pay for.
Yes No Don't Know
MATSPD17
During the past 12 months, has your
household recieved any social
support for the sick person? Such
as help with housework, training
for a caregiver, or legal services,
which you didnt have to pay for.
Yes No Don't KnowSOCSPD18
What age is the sick person?SICAGD19
If older than 18,
skip to question
D22 (next page)
In the last 12 months, did
your household receive any
support for the sick child's
schooling? Suck as allowance,
free admission, books or
supplies, which you didnt have
to pay for.
Yes No Don't Know
D20 SCHSP
Specify type of school support below, if applicable:
D21
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Form D. Family Characteristics. ChroSAM study.
Patient ID
Patient Initials
-
PID
PIN
A/B/C
D22
D23
Kodi pali munthu wofunikila m'moyo mwanu amene
mungathe kugawana naye nkhawa zanu ndi chisangalalo
chanu?
If 'yes', who is
that person?
D26 Does (participant child)
have a blanket?
Does (participant child)
have a pair of shoes?
Does (participant child)
have atleast 2 sets of
clothes?
How many meals did
(participant child)
eat yesterday?
Does (participant child)
receive school meals?
D27
D28
D29
D30
Yes No Don't Know
Yes No Don't Know
Yes No Don't Know
Yes No Don't Know
BLKT
SHOE
CLOTH
MEAL
SCHME
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Yes No
Amuna anu (husband) (1)
Wachibale wina (family member) (2)
Mzanu (friend) (3)
Zina (other) (specify on z) (4)
MSS1
MSS2
D24 MSS3 Kodi mumapeza mtendere wa mumtima kuchokera
ku abale anu?
I am now going to ask you some questions about the support you get from
you friends and family:
Yes No
Kodi mukhonza kudalira anzanu zinthu zikavuta? Yes NoD25 MSS4
1591190826
Form E. Household and SE Status. ChroSAM
PID
PIN
OPIN
Patient ID
Patient Initials
Operator Initials
E1
E2
E3
-
These questions are regarding the home of the main carer / the place
where the child usually stays:
E4
E5
E6
E7
E8
E9
Is the house... Owned
Rented
Other
Dont know
RENT
ROOM
How many sleeping rooms are there? (excl.
bathroom/storerooms/garage)
How many people usually sleep in the house
together?
MEMB
In the dwelling is there:
Electricity
A radio
A bicycle
A motorbike
A car or truck
A paraffin lamp
(other than Koloboyi)
ELEC
RADIO
BIKE
MBIKE
KOLO
LAMP
OXCA
TV
E10
E11a
E12
E13 An oxcart
A television
A cellphone
Yes No Dont know
Yes No Dont know
Yes No Dont know
Yes No Dont know
Yes No Dont know
Yes No Dont know
Yes No Dont know
Yes No Dont know
Yes No Dont know
E14
CELL
LPHON
BED
E15
E16 A telephone
(landline)
A bed with a mattress
A sofa set
A table and chair(s)
Yes No Dont know
Yes No Dont know
Yes No Dont know
Yes No Dont know
A refridgerator Yes No Dont know
Yes No Dont know
E17
E18
E19
E20
E21
SOFA
TABL
FRID
WATCH
Participant ID =
HMIS number
followed by
A -moyo child
B -siBling control
C -Community conrol
A/B/C
A Koloboyi Yes No Dont know
E11 CAR
A watch
A motocycle Yes No Dont knowE21a MOTO
1825158460
Do members of the household work
their own agricultural land?
Patient ID
Patient Initials
-
Form E. Household and SE Status. ChroSAM
E22
E23
E24
E25
PID
PIN
FARM Yes No Dont know
What is the principal household
source of drinking water?
Pipe inside dwelling (1)
Pipe outside dwelling /to yard (2)
Protected borehole/well (3)
Public tap (4)
Traditional public well (5)
River/canal/lake (6)
Tanker Truck (7)
Bottled water (8)
Rainwater (9)
Cart with small tank (10)
Don't know (99)
WATE
E27
E28
E26 Do you do anything to make the
water safer to drink?
WATES
Boil
Add Bleach/Chlorine/ Water Guard
Strain through a cloth
Use water filter (ceramic/sand/etc)
Solar disinfection
Let it stand and settle
Other (specify on Form Z)
No, Nothing
Don't know
What is the principle type of
toilet facility used by household
members?
Own (exclusive) flush
Shared flush toilet
Ventilated (VIP) latrine
Pit latrine with slab
Pit laterine without slab/open pit
Bush or field
Other
Dont know
WC
How many households,
including yours, use this
toilet facility?
99 = Don't Know
WCNO
A/B/C
1689158468
What is the principle type of
flooring in your dwelling?
Tiles/cement/carpet/vinyl (1)
Wood or planks or brocken bricks (2)
Dirt, sand or dung (3)
Other (9) (specify on Z)
Dont know (99)
What is the principle type of
roofing in your dwelling?
Cement (1)
Wood planks or Cardboard (2)
Iron and tiles (3)
Iron sheets (4)
Natural materials (palm/thatched) (5)
Other (9)
No roof (6)
Dont know (99)
Patient ID
Patient Initials
-
Form E. Household and SE Status. ChroSAM
E29
E30
PID
PIN
FLOR
ROOF
Do any members of the
household have a bank
account?
In the past 12 months, has anyone
come into your house to spray the
inside walls against mosquitos?
How many mosquito nets that can
be used while sleeping does your
house have?
00 = NONE
99 = Don't know
E31
E32
E33 BANK Yes No Don't Know
Yes No Don't KnowE34
E35
SRAY
NETS
A/B/C
0451158464
Form E. Household and SE Status. ChroSAM
Patient ID
Patient Initials
-
E36
E37
PID
PIN
E38
E39
E40
Does anyone ever smoke
tobacco in the home?
Daily (1)
Weekly (2)
Monthly (3)
Less than once a month (4)
Never (5)
SMOK
If yes, who?
(tick all
that apply)
Did the mother smoke during
preganacy?
Yes No Dont knowMSMOK
What type of fuel does your
household MAINLY use for
cooking?
E41
What type of stove/fire
is used for cooking?
Open fire (1)
Stove without chimney/flute (2)
Stove with chimney/flute (3)
E42 STOV
Mother(1)
Father(2)
Grandparent (3)
Sibling (4)
Child (study) (5)
Other (6)
SMOKW
E43 COOKIN Where is the cooking
usually done? In the house (1)
In a separate building(2)
Outside (3)
A/B/C
If never, skip to Question E40
COOK
Electricity (1)
LPG/Natural Gas (2)
Biogas (3)
Kerosene (4)
Coal, Lignite (5)
Charcoal (6)
Wood (7)
Staw/Shrubs/Grass (8)
Animal Dung (9)
Other (10) (Specify on Z)
7204158467
Form K. Family Health History. ChroSAM study.
Participant ID
Participant Initials
Interview Date
-
/ / 2 0
D D M O N Y Y
Operator Initials
Tested for HIV?
If test - HIV status?
Is mother taking
ARVs?
If not tested, note why on Master form Z
Mother HTC
Never Tested (2)
Tested (1)
Don't Know (99)
Prefer not to say (88)
R (positive) (1)
NR (Negative) (2)
Dont know (99)
Prefer not to say (88)
No (2)
Yes (1)
On waiting list (3)
Not eligible (4)
Started but now stopped (5)
Don't know (99)
Participant ID =
HMIS number
followed by
A -moyo child
B -siBling control
C -Community conrol
A/B/CPID
PIN
INTDT
OPIN
K1
K2
K3
K4
K5
K6
K8
MHIVt
MHIV
Specify Any other health problems on Master form z
Yes No Dont know
MHLT
If NR, skip
to K8
Has mother been very sick for
atleast 3 months in past year?
ie. too sick to work or do normal
activities?
K7 MARV
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8273431851
Form K. Family Health History. ChroSAM study.
Participant ID
Participant Initials
-
Father HTC
Tested for HIV?
If test, HIV status
Is Father taking
ARVs?
If not tested, note why on Master form Z
Never Tested (2)
Tested (1)
Don't Know (99)
Prefer not to say (88)
R (positive) (1)
NR (negative) (2)
Dont know (99)
Prefer not to say (88)
No (2)
Yes (1)
On waiting list (3)
Not eligible (4)
Started but now stopped (5)
Don't know (99)
Specify any other health problems on Master form Z
K10
K11
K12
K13
K14
K15
FHIV
FHIVt
FARV
Yes No Dont know
If NR, skip
to K15
Has Father been very sick for
atleast 3 months in past year?
ie. too sick to work or do normal
activities?
FHLT
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8278431856
First Born -Health
(unless Moyo or control child)
Ever had Kwash or Marasmus?
Number of hospital
admissions in last year
Never (2)
NRU admission (1)
CTC (3)
Given multivit/ drugs only (4)
Advice only (5)
Nil Rx (6)
SFP (7)
Note any other health problems or hospital admissions details on
Master Form Z
Form K. Family Health History. ChroSAM study.
Participant ID
Participant Initials
-
K16
K17
PID
PIN
K18 SAM1
K19
K20
HOS1
K21
Is this the Moyo or
control child?
Yes No
2nd Born -Health
(unless Moyo or control child)
Ever had Kwash or Marasmus? Never (2)
NRU admission (1)
CTC (3)
Given multivit/ drugs only (4)
Advice only (5)
Nil Rx (6)
SFP (7)
Number of hospital
admissions in last year
Note any other health problems or hospital admissions details on
Master Form Z
Is this the Moyo or
control child?
Yes No
If yes,
skip to
next child
If yes,
skip to
next child
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SAM2
HOS2
6857431857
Form K. Family Health History. ChroSAM study.
Participant ID
Participant Initials
-
K22
K23
PID
PIN
K24 SAM3
K25 HOS3
SAM4
HOS4
K26
K27
3rd Born -Health
(unless Moyo or control child)
Ever had Kwash or Marasmus? Never (2)
NRU admission (1)
CTC (3)
Given multivit/ drugs only (4)
Advice only (5)
Nil Rx (6)
SFP (7)
Number of hospital
admissions in last year
Note any other health problems or hospital admissions details on
Master Form Z
4th Born -Health
(unless Moyo or control child)
Ever had Kwash or Marasmus? Never
NRU admission
CTC
Given multivit/ drugs only
Advice only
Nil Rx
SFP
Number of hospital
admissions in last year
Note any other health problems or hospital admissions details on
Master Form Z
Is this the Moyo or
control child?
Yes No
If yes,
skip to
next child
Is this the Moyo or
control child?
Yes No
If yes,
skip to
next child
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Form K. Family Health History. ChroSAM study.
Participant ID
Participant Initials
-
K28
K29
PID
PIN
K30 SAM5
K31 HOS5
SAM6K32
HOS6K33
5th Born -Health
(unless Moyo or control child)
Ever had Kwash or Marasmus? Never (2)
NRU admission (1)
CTC (3)
Given multivit/ drugs only (4)
Advice only (5)
Nil Rx (6)
SFP (7)
Number of hospital
admissions in last year
Note any other health problems or hospital admissions details on
Master Form Z
6th Born -Health
(unless Moyo or control child)
Ever had Kwash or Marasmus? Never
NRU admission
CTC
Given multivit/ drugs only
Advice only
Nil Rx
SFP
Number of hospital
admissions in last year
Note any other health problems or hospital admissions details on
Master Form Z
Is this the Moyo or
control child?
Yes No
If yes,
skip to
next child
Is this the Moyo or
control child?
Yes No
If yes,
skip to
next child
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Form K. Family Health History. ChroSAM study.
Participant ID
Participant Initials
-
K34
K35
PID
PIN
K36 SAM7
K37 HOS7
SAM8K38
K39 HOS8
7th Born -Health
(unless Moyo or control child)
Ever had Kwash or Marasmus? Never (2)
NRU admission (1)
CTC (3)
Given multivit/ drugs only (4)
Advice only (5)
Nil Rx (6)
SFP (7)
Number of hospital
admissions in last year
Note any other health problems or hospital admissions details on
Master Form Z
8th Born -Health
(unless Moyo or control child)
Ever had Kwash or Marasmus? Never (2)
NRU admission (1)
CTC (3)
Given multivit/ drugs only (4)
Advice only (5)
Nil Rx (6)
SFP (7)
Number of hospital
admissions in last year
Note any other health problems or hospital admissions details on
Master Form Z
Is this the Moyo or
control child?
Yes No
If yes,
skip to
next child
Is this the Moyo or
control child?
Yes No
If yes,
skip to
next child
Page 6 of 6
1440431850
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Appendix 8: Maternal mental health SRQ 
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Maternal Mental Health: SELF REPORTING QUESTIONNAIRE - ENGLISH  
Now I am going to ask you some questions about the thoughts and feelings that you have experienced over the 
last 4 weeks. You should answer yes or no to each question. If you are not sure, give the answer that is closest to 
how you have been feeling. If you do not understand a question please ask and I can give you an example of 
what the question means. 
 
1 Do you often have headaches?  Yes No 
2 Is your appetite poor? Yes No 
3 Do you sleep badly? Yes No 
4 Do your hands shake? Yes No 
5 Do you feel nervous tense or worried? Yes No 
6 Are you easily frightened? Yes No 
7 Is your digestion poor? Yes No 
8 Do you have trouble thinking clearly? Yes No 
9 Do you feel unhappy?  Yes No 
10 Do you cry more than usual? Yes No 
11 Do you find it difficult to enjoy your daily activities? Yes No 
12 Do you find it difficult to make decisions? Yes No 
13 Is your daily work suffering? Yes No 
14 Are you unable to play a useful part in life? Yes No 
15 Have you lost interest in things? Yes No 
16 Do you feel that you are a worthless person?  Yes No 
17 Has the thought of ending your life been on your mind?  Yes No 
18 Do you feel tired all the time? Yes No 
19 Do you have uncomfortable feelings in your stomach? Yes No 
20 Are you easily tired? Yes No 
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Appendix 9: Disability screening questionnaire 
  
B. Unicef/Washington Group Questions (to be reported by parents)  
Is the child 2 years or above? Yes O No O
If YES, Proceed below, if NO, SKIP to Section D (Rehab) 
Children aged 2-17 years
1a) Does [name] wear glasses or contact lenses Yes O No O
[if child wears glasses] 
1b) Does [name] have difficulty seeing, when wearing his/her glassses?
[if child does NOT wear glasses] 
1c) Does [name] have difficulty seeing?
Children aged 2-17 years
2a) Does [name] use a hearing aid? Yes O No O
If YES go to question 2b
If NO go to question 2c
[if child uses a hearing aid] 
2b) Does [name] have difficulty hearing, when using his/her hearing aid(s)?
[if child does NOT use a hearing aid] 
2c) Does [name] have difficulty hearing?
Children aged 2-17 years
Children aged 5- 17 years
Children aged 2 -4 years
5a) Does [name] have difficulty understanding you?
6a) Do you have difficulty understanding what your child wants?
Children aged 5-17 years
Children aged 2-3 years
Children aged 3-17 years
Children aged 5-17 years
8) Compared with children of the same age, does [name] have 
difficulty remembering things that they have learned? 1 2 3 4 5 6
3 4 5 6
5
5 6
5b) Compared with children of the same age and using [his/her] 
usual language, does [name] have difficulty understanding other 
people? 
1 2 3 4 5
6
6b)Compared with children of the same age and using [his/her] 
usual language, does [name] have difficulty being understood by 
other people?
1 2 3 4
5 6
1 2 3 4 5 6
6
6
4) Compared with children of the same age, does [name] have 
difficulty with  self-care such as feeding or dressing him/herself?
  
1 2 3 4 5 6
3) Compared with children of the same age, does [name] have 
difficulty walking? 1 2 3 4 5
Dont 
Know Refused
No 
difficulty
Some 
difficulty
A lot of 
difficulty
Cannot do 
at all
Dont 
Know Refused
1 2 3 4 5 6
RefusedDont Know
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
No 
difficulty
Some 
difficulty
A lot of 
difficulty
7b) Compared with children of the same age, does [name] have 
difficulty learning to do new things? 1 2
No 
difficulty
Some 
difficulty
A lot of 
difficulty
Cannot do 
at all
Cannot do 
at all
1 2 3 4
7a) Compared with children of the same age, does [name] have 
difficulty learning the names of common objects?  1 2 3 4
Children aged 5-17 years
Children aged 2-4 years
Children aged 5-17 years
Children aged 2-5 years
Children aged 2-12 years
Children aged 13-17 years
6
14b) Compared with children of the same age, does [name] have 
difficulty doing things with other children? (Include things that 
children usually do together.) 1 2 3 4 5
6
14a2) Compared with children of the same age, does [name] have 
difficulty playing with other children? 1 2 3 4 5 6
14 a1) Compared with children of the same age, does [name] have 
difficulty playing with toys or household objects? 1 2 3 4 5
6
13) Does [name] have difficulty getting along with children of 
[his/her] age? 1 2 3 4 5 6
12) Compared with children of the same age, does [name] have 
difficulty accepting change to plans or routine? 1 2 3 4 5
Refused
5 6
6
11) Compared with children of the same age, does [name] have 
difficulty completing a task? 1 2 3 4 5 6
10b) Compared with children of the same age, how much difficulty 
does [name] have controlling [his/her] behaviour? 1 2 3 4 5
No 
difficulty
Some 
difficulty
A lot of 
difficulty
Cannot do 
at all
Dont 
Know
2 3 4 5
Less
1
10a) Compared with children of the same age, how much does 
[name] kick, bite or hit other children or adults? (Either provoked or 
unprovoked) 1 2 3 4
6
The same More A lot more Dont Know Refused
9) Compared with children of the same age, how much does [he 
/she] worry or feel  sad?
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Appendix 10: Validating wealth quintiles; graph of mean HAZ for each quintile  
 
Appendix 10: graph showing mean height-for-age z score (HAZ) for children in each of the 5 wealth 
quintiles. Wealth quintiles were devised from asset data using Principle component analysis (PCA); 
quintile 1 in lowest socioeconomic status and quintile 5 is the highest  
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Appendix 11: Pie chart showing cause of death for 46 ChroSAM deaths 
 
 
Appendix 11: pie chart showing cause of death for 46 “ChroSAM” deaths 
 
 
Appendix 12: Line graph showing mortality rate across ChroSAM follow up period 
 
 
Appendix 12: death rate across ChroSAM follow-up period, with line in orange showing WHO life 
tables normal rate for this age group (5-9 years) in Malawi 
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Appendix 13: Histograms of growth outcomes 
Weight 
 
Height 
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Growth z scores 
 
Body Circumferences 
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Appendix 14: Table of results comparing growth outcomes for HIV negative children only 
Anthropometry HIV-
Cases 
HIV- Sibling HIV- Community 
 Mean 
(SD) 
Mean 
(SD) 
Unadjusted 
difference 
(95% CI) 
Adjusted 
difference 
(95% CI) 
Mean 
(SD) 
Unadjusted 
difference 
(95% CI) 
Adjusted 
difference 
(95% CI) 
Weight        
Weight (kg) 24.0 
(5.0) 
28.0 
(9.7) 
4.0 *     
(2.5, 5.4) 
2.0 *     
(1.1, 3.0) 
25.4 
(6.6) 
1.4              
(-0.1, 2.9) 
1.5 *       
(0.6, 2.5) 
BMI 15.2 
(1.5) 
15.8 
(1.9) 
0.6 * 
(0.3, 0.9) 
0.3 * 
(0.1, 0.6) 
15.4 
(1.7) 
0.2 
(-0.2, 0.5) 
0.2 
(-0.1, 0.5) 
Height        
Standing (cm) 125 
(8.7) 
130.7 
(16.8) 
5.5 * 
(3.0, 7.9) 
2.1 *  
(0.7, 3.5) 
127.4 
(10.1) 
2.2  
(-0.4, 4.7) 
2.5 * 
(1.0, 4.0) 
Sitting  (cm) 65.3 
(4.3) 
67.6 
(7.6) 
2.3 * 
(1.1, 3.4) 
0.8 * 
(0.0, 1.5) 
66.0 
(4.6) 
0.7  
(-0.5,1.9) 
0.8 * 
(0.0, 1.6) 
Sitting Height 
% 
52.2 
(1.5) 
51.8 
(1.7) 
-0.4 * 
(-0.7, -0.1) 
-0.2  
(-0.5, 0.0)  
51.8 
(1.4) 
-0.4 *  
(-0.7,-0.1) 
-0.5 *  
(-0.8,-0.2) 
Leg length (cm) 60 
(5.4) 
63.2 
(9.7) 
3.2 * 
(1.7, 4.6) 
1.4 * 
(0.4, 2.3) 
61.5 
(6.0) 
1.5  
(-0.1, 3.0) 
1.7 * 
(0.7, 2.7) 
Relative leg 
length 
40.5 
(17) 
50.5 
(32.9) 
10.0 * 
(5.2, 14.8) 
3.5 * 
(0.6, 6.5) 
44.1 
(19.4) 
3.6 
(-1.5, 8.8) 
4.1 * 
(1.0,7.2) 
Lower limb 
length ratio 
31.0 
(1.7) 
31.7 
(1.7) 
0.6 * 
(0.3, 1.0) 
0.5 * 
(0.2, 0.8) 
31.4 
(1.5) 
0.4 * 
(0.0, 0.7) 
0.4 * 
(0.1, 0.7) 
Growth Z scores       
WAZ -1.5 
(0.9) 
-1.4 
(1.0) 
0.1 
(-0.1, 0.4) 
-0.2   
(-0.5, 0.1) 
-1.2 
(1.0) 
0.3 * 
(0.1, 0.5) 
0.2 * 
(0.0, 0.5) 
HAZ -1.7 
(1.2) 
-1.5 
(1.2) 
0.2  
(-0.0, 0.4) 
0.2 * 
(0.0, 0.5) 
-1.3 
(1.1) 
0.4 * 
(0.2, 0.7) 
0.4 * 
(0.1, 0.6) 
BAZ -0.8 
(1,0) 
-0.8 
(0.9) 
0.03 
(-0.2, 0.2) 
0.08 
(-0.1, 0.2) 
-0.7 
(0.9) 
0.14 
(-0.1, 0.3) 
0.11 
(-0.1, 0.3) 
Body circumferences       
Head (cm) 51.8 
(1.9) 
52.2 
(2.2) 
0.4 * 
(0.0, 0.8) 
0.2  
(-0.1, 0.6) 
52.1 
(1.9) 
0.3 
(-0.1, 0.7) 
0.4 *  
(0.0, 0.7) 
MUAC (mm) 172 
(19) 
184 
(30) 
12.3 * 
(7.6, 17.0) 
7.0 * 
(3.5, 10.5) 
178 
(22) 
6.5 * 
(1.5, 11.5) 
6.6 * 
(2.9, 10.3) 
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Appendix 15: Bland-Altman plots of “agreement” for repeat BIA readings 
Impedance: 
 
Bland-Altman plot for Impedance: Mean difference is 5.2 (middle line); limits of agreement (±2 SD from 
mean difference) is -50.0 to 39.6 (top and bottom line). 95% of data plots should lie within limits of agreement.  
Resistance: 
 
Bland-Altman plot for Resistance: Mean difference is 18.4 (middle line); limits of agreement (±2 SD from 
mean difference) is -143.0 to 106.6 (top and bottom line). 95% of data plots should lie within limits of 
agreement.  
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Reactance: 
 
Bland-Altman plot for Reactance: Mean difference is 0.06 (middle line); limits of agreement (±2 SD from 
mean difference) is -10.6 to 10.5 (top and bottom line). 95% of data plots should lie within limits of agreement.  
Phase Angle: 
 
Bland-Altman plot for Phase Angle: Mean difference is -0.09 (middle line); limits of agreement (±2 SD from 
mean difference) is -0.4 to 0.6 (top and bottom line). 95% of data plots should lie within limits of agreement.  
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Appendix 16: Histograms of Body composition outcomes 
Peripheral fat 
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Core Fat 
 
Ratios of Core to Peripheral Fat 
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Appendix 17: Table of results comparing body composition outcomes for HIV negative children 
only 
Anthropometry Cases Sibling Community 
 Mean 
(SD) 
Mean 
(SD) 
Unadjusted 
difference 
(95% CI) 
Adjusted 
difference 
(95% CI) 
Mean 
(SD) 
Unadjusted 
difference 
(95% CI) 
Adjusted 
difference 
(95% CI) 
Peripheral fat        
Calf 
circumference 
(cm) 
23.7 
(2.3) 
25.1 
(3.5) 
1.44 * 
(0.9, 2.0) 
0.80 * 
(0.4, 1.2) 
24.3 
(2.4) 
0.62 * 
(0.0, 1.2) 
0.66 * 
(0.2, 1.1) 
Hip 
circumference  
(cm) 
62.4 
(5.8) 
65.9 
(10.0) 
3.49 * 
(2.0, 5.0) 
1.57 * 
(0.5, 2.6) 
63.8 
(7.0) 
1.32 
(-0.3, 3.0) 
1.28 * 
(0.2, 2.4) 
Relative hip 
circumference 
0.50 
(0.0) 
0.50 
(0.0) 
 0.01  
(-0.0, 0.0) 
0.0  
(-0.0, 0.01) 
0.50 
(0.0) 
0.00 
(-0.0, 0.0) 
0.00 
(-0.0,0.0) 
Tricep skinfold z 
score 
-0.07 
(1.1) 
0.10 
(0.9) 
0.17  
(-0.0, 0.4) 
0.15 
(-0.1, 0.3) 
-0.12 
(1.1) 
-0.04 
(-0.3,0.2) 
-0.04 
(-0.3, 0.2) 
Bicep skinfold z 
score 
-0.23 
(1.1) 
0.05 
(1.0) 
0.29 * 
(0.1,0.5) 
0.25 * 
(0.0, 0.5) 
-0.05 
(1.0) 
0.18 
(-0.0,0.4) 
0.16 
(-0.1, 0.4) 
Core fat        
Waist 
circumference 
(cm) 
56.2 
(4.2) 
57.8 
(6.5) 
1.65 * 
(0.6, 2.7) 
0.64  
(-0.2, 1.4) 
56.0 
(4.6) 
-0.13  
(-1.2, 1.0) 
0.08 
(-0.8, 0.9) 
Relative waist 
circumference 
0.45 
(0.0) 
0.44 
(0.0) 
-0.00  
(-0.01, 0.0)            
-0.00 
(-0.0, 0.0) 
0.44 
(0.0) 
-0.01 *  
(-0.01, -0.0) 
-0.01 * 
(-0.1,-0.0) 
Waist skinfold z 
score 
-0.17 
(1.0) 
0.16 
(1.0) 
0.33 * 
(0.1,0.5) 
0.31 * 
(0.1, 0.5) 
-0.17 
(1.0) 
0.01 
(-0.2, 0.2) 
-0.02 
(-0.2, 0.2) 
Subscapular 
skinfold z score 
-0.23 
(1.1) 
0.12 
(1.0) 
0.35 * 
(0.1, 0.6) 
0.32 * 
(0.1, 0.5) 
-0.16 
(1.0) 
0.08 
(-0.1, 0.3) 
0.06 
(-0.2, 0.3) 
Ratio of core to 
peripheral fat 
      
Skinfold 
thickness ratio 
1.7 
(0.4) 
1.8 
(0.4) 
0.07  
(-0.0, 0.1) 
0.04  
(-0.0, 0.1) 
1.7 
(0.4) 
0.03 
(-0.1, 0.1) 
0.03 
(-0.1, 0.1) 
Waist/hip ratio 0.90 
(0.1) 
0.88 
(0.1) 
-0.02 * 
(-0.03, -0.0) 
-0.01 
(-0.02, 0.0) 
0.89 
(0.1) 
-0.02 * 
(-0.03, -0.0) 
-0.02 * 
(-0.0,-0.0) 
Lean Mass Index       
1/z 
(lean mass) 
9.07 
(1.1) 
9.22 
(1.0) 
0.15 
(-0.1,0.3) 
0.22 * 
(0.02, 0.4) 
9.13 
(1.0) 
0.06 
(-0.2, 0.3) 
0.07 
(-0.1,0.3) 
BMI residual 
from 1/Z 
(fat mass) 
-0.20 
(1.2) 
0.98 
(1.8) 
0.49 * 
(0.2, 0.8) 
0.18 
(-0.1, 0.4) 
-0.09 
(1.6) 
0.12 
(-0.2, 0.4) 
0.12 
(-0.2, 0.4) 
BIVA       
r/h 599 
(100) 
563 
(128) 
-36.3 * 
(-58, -15) 
-16.7 
(-34, 0.3) 
577 
(91.8) 
-21.9  
(-45, 1.1) 
-24.5 * 
(-43,-6.5) 
xc/h 51.3 
(7.8) 
49.3 
(9.1) 
-2.1 * 
(-3.7,-0.4) 
-1.1  
(-2.7, 0.4) 
51.5 
(7.8) 
0.19 
(-1.6, 2.0) 
0.06  
(-1.5, 1.7) 
Phase angle ⁰ 4.9 
(0.6) 
5.1 
(0.7) 
0.14 * 
(0.0,0.3) 
0.07 
(-0.0, 0.2) 
5.1 
(0.5) 
0.17 * 
(0.0,0.3) 
0.18 * 
(0.1, 0.3) 
Appendix 17: result of simple and multivariable linear regression analysis for HIV negative and 
unknown children only for body composition anthropometry outcomes comparing siblings and 
community controls to cases. Adjusted includes age, sex, puberty and SES 
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Appendix 18: Body composition outcomes stratified by sex (Adjusted for age, HIV, SES, and puberty 
status) 
Cases 
Girls n=134 
Boys n=169 
Siblings 
Girls n=106 
Boys n=98 
Community 
Girls n=56 
Boys n=65 
 Mean (SD) Mean (SD) Unadjusted 
difference 
(95% CI) 
Adjusted 
difference 
(95% CI) 
Mean (SD) Unadjusted 
difference 
(95% CI) 
Adjusted 
difference 
(95% CI) 
Calf circumference       
Girls 23.9 (2.3) 25.3 (4.0) 1.36 * 
(0.6, 2.1) 
0.61 * 
(0.0, 1.2) 
24.6 (2.8) 0.70 
(-0.2, 1.6) 
0.51  
(-0.1, 1.1) 
Boys  23.5 (2.3) 24.8 (3.0) 1.30 * 
(0.7, 1.9) 
0.56 * 
(0.0, 1.1) 
24.0 (2.0) 0.50 
(-0.1, 1.1) 
0.46 
(-0.1, 1.0) 
Waist circumference       
Girls 55.9 (4.6) 57.6 (7.3) 1.66 * 
(0.2, 3.1) 
0.70 
(-0.4, 1.8) 
55.4 (4.9) -0.48 
(-2.1, 1.1) 
-0.21 
(-1.5, 1.1) 
Boys  56.6 (3.9) 57.9 (5.4) 1.32 * 
(0.2, 2.4) 
0.38 
(-0.6, 1.4) 
56.6 (4.1) -0.01 
(-1.2, 1.1) 
0.31 
(-0.7, 1.3) 
Hip circumference       
Girls  62.9 (6.1) 66.7 (12) 3.74 * 
(1.5, 6.0) 
1.79 * 
(0.2, 3.4) 
65.2 (7.9) 2.24 
(-0.2, 4.7) 
1.77 * 
(0.0, 3.5) 
Boys 61.9 (5.5) 65.0 (8.6) 3.13 * 
(1.5, 4.8) 
1.72 * 
(0.5, 3.0) 
62.4 (5.6) 0.46 
(-1.3, 2.2) 
1.14 
(-0.2, 2.5) 
Waist/hip ratio       
Girls 0.89 (0.1) 0.87 (0.1) -0.02 * 
(-0.03, -0.0) 
-0.01 
(-0.0, 0.0) 
0.86 (0.1) -0.03 * 
(-0.1, -0.0) 
-0.02 * 
(-0.04,-0.0) 
Boys 0.92  (0.1) 0.90 (0.1) -0.02 * 
(-0.03, -0.0) 
-0.01 
(-0.0, 0.0) 
0.91 (0.1) -0.01 
(-0.02, 0.0) 
-0.01 
(-0.0, 0.0) 
Skinfold ratio        
Girls  1.70 (0.4) 1.75 (0.4) 0.05 
(-0.1, 0.2) 
0.07 
(-0.0, 0.2) 
1.70 (0.4) -0.00 
(-0.1, 0.1) 
0.04 
(-0.1, 0.2) 
Boys 1.73 (0.4) 1.76 (0.5) 0.03 
(-0.1, 0.1) 
-0.00 
(-0.1, 0.1) 
1.77 (0.4) 0.04 
(-0.1, 0.2) 
0.04 
(-0.1, 0.2) 
1/z (lean mass)       
Girls 8.86 (0.9) 8.91 (0.8) 0.05 
(-0.2, 0.3) 
0.07 
(-0.2, 0.3) 
8.84 (0.8) -0.02 
(-0.3, 0.2) 
-0.04 
(-0.3, 0.2) 
Boys 9.16 (1.2) 9.51 (1.0) 0.35 * 
(0.1, 0.6) 
0.29 
(-0.2, 0.6) 
9.37 (1.0) 0.21 
(-0.1, 0.5) 
0.12 
(-0.2, 0.4) 
BMI residual (fat mass)      
Girls -0.06 (1.3) 0.47 (2.2) 0.53 *  
(0.1, 1.0) 
0.30  
(-0.1, 0.7) 
0.09 (1.9) 0.14 
(-0.4, 0.7) 
0.26 
(-0.2, 0.7) 
Boys -0.22 (1.1) 0.08 (1.1) 0.30 * 
(0.0, 0.6) 
0.10 
(-0.2, 0.4) 
-0.23 (1.1) -0.01 
(-0.3, 0.3) 
0.03 
(-0.3, 0.3) 
R/h        
Girls 567 (130) 585 (137) -25.3  
(-55, 4.1) 
-5.78 
(-30, 19) 
586 (98) -24.5 
(-57, 8.3) 
-20.5 
(-48, 6.9) 
Boys 610 (98) 548 (119) -49.8 * 
(-77, -22) 
-21.0 
(-46, 4.1) 
569 (84) -28.8  
(-58, 0.1) 
-26.7 * 
(-53, -0.3) 
Xc/h         
Girls 52.8 (8.9) 51.5 (9.3) -1.39 
(-3.7, 0.9) 
0.86 
(-1.3, 3.0) 
52.5 (7.4) -0.34 
(-2.9, 2.2) 
1.26 
(-1.2, 3.7) 
Boys  51.7 (8.0) 47.8 (9.0) -3.92 * 
(-6.0, -1.8) 
-1.96 
(-4.1, 0.2) 
50.6 (8.0) -1.06 
(-3.3, 1.2) 
-0.55 
(-2.8, 1.7) 
Phase angle        
Girls  4.98 (0.7) 5.14 (0.7) 0.16 
(-0.0, 0.3) 
0.19 * 
(0.0, 0.4) 
5.12 (0.5) 0.15 
(-0.0, 0.3) 
0.26 * 
(0.1, 0.5) 
Boys  5.01 (0.7) 5.04 (0.7) 0.03 
(-0.1, 0.2) 
-0.02 
(-0.2, 0.1) 
5.10 (0.5) 0.09 
(-0.1, 0.3) 
0.13 
(-0.0, 0.3) 
259 
 
 
Appendix 19: Images of the English and Chichewa versions OMNI and VAS scales 
OMNI: 
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OMNI:  
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VAS: 
 
 
  
0                   10 
 Visual Analogue Scale 
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Appendix 20: Histograms of Physical activity outcomes 
Arm muscle area (AMA), Hand grip strength and Steps per hour 
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iStep Outcomes 
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Appendix 21: Table of results comparing physical activity outcomes for HIV negative children 
only 
 HIV-
Cases 
n=210 
HIV- 
Siblings 
n=206 
HIV- 
Community 
n=175 
 Mean 
(SD) 
Mean 
(SD) 
Unadjusted 
difference 
(95% CI) 
Adjusted 
difference 
(95% CI) 
Mean 
(SD) 
Unadjusted 
difference 
(95% CI) 
Adjusted 
difference 
(95% CI) 
Muscle Strength       
Hand grip 
strength (kg) 
n= 550 
12.3 
(3.8) 
14.6 
(6.8) 
2.26 * 
(1.3, 3.3) 
1.03 * 
(0.3, 1.7) 
13.8 
(3.9) 
1.47 * 
(0.4, 2.5) 
1.66 * 
(0.9, 2.4) 
AMA (cm2) 1877.4 
(440) 
2170.1 
(728) 
292.6 * 
(176, 410) 
152.8 * 
(63.4,242) 
2038.8 
(529) 
161.3 * 
(35.1, 288) 
165.8 * 
(68.6, 263) 
Physical Activity       
Steps per hour 
n=63 
839.9 
(292) 
1017.4 
(296) 
177.5 * 
(5.5, 350) 
202.3 * 
(16.5,388) 
860.6 
(213) 
20.76 
(-143, 184) 
60.84 
(-122, 234) 
Physical Capacity 
(iStep outcomes)(n=778) 
      
time 
completed 
(minutes)~log 
7.64 
(3.2) 
8.45 
(2.8) 
0.17~ * 
(0.0, 0.3) 
0.10~ 
(-0.0, 0.2) 
8.39 
(2.7) 
0.14~ * 
(0.0, 0.3) 
0.14~ *  
(0.0, 0.3) 
Baseline HR 100.3 
(14.8) 
98.5 
(15.7) 
-1.81 
(-5.3, 1.7) 
-0.67 
(-4.2, 2.8) 
99.2 
(14.6) 
-1.14 
(-4.8, 2.5) 
-1.50 
(-5.1, 2.1) 
Highest HR 154.4  
(20.3) 
157.7 
(20.5) 
3.34 
(-1.4, 8.1) 
1.15 
(-3.7, 6.0) 
159.0 
(19.9) 
4.58 
(-0.4, 9.5) 
4.47 
(-0.4, 9.4) 
Lowest o2 
saturation 
93.6 
(4.7) 
93.8 
(5.0) 
0.25 
(-0.8, 1.3) 
0.79 
(-0.3, 1.9) 
93.7 
(3.9) 
0.12  
(-1.0, 1.2) 
0.30 
(-0.8, 1,4) 
HR at 1 min 
recovery 
112.7 
(17.7) 
113.3 
(19.4) 
0.68 
(-3.8, 5.1) 
1.13 
(-3.5, 5.8) 
111.2 
(18.0) 
-1.46 
(-6.2, 3.2) 
-1.50 
(-6.2, 3.1) 
Drop in HR at 
recovery  (as % 
of highest HR) 
72.49 
(10.3) 
70.64 
(10.6) 
-1.85 
(-4.3, 0.6) 
-0.78 
(-3.4, 1.8) 
68.86 
(9.9) 
-3.62 * 
(-6.3, -1.0) 
-3.69 * 
(-6.3, -1.1) 
Appendix 21: mean (SD) as well we result of simple and multivariable linear regression analysis for 
comparing physical function outcomes by study group for HIV negative children only. ~ indicates that 
natural log of the raw value is being used 
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Appendix 22: Poster exploring relevance of GLI equation for our data 
Selecting a spirometry control group for Malawian children
J Kirkby1 N Lelijveld1,2 S Lum1 M Kerac3,2 J Stocks1 
1 University College London; 2 Malawi-Liverpool Wellcome Trust; 3 London School of Hygiene and Tropical Medicine
Introduction:
Lung Function is an important marker of chronic 
disease in developing countries, but interpreting 
results can be challenging.  
Aim: To determine whether the GLI-Black 
spirometry reference equation (Quanjer, ERJ 
2012) is appropriate for use in Malawian children.
j
Conclusions:
• Despite large height and weight differences between UK-BA and Malawian children, sit/stand 
height ratio was similar and spirometric differences were small, with no evidence of obstructive 
lung disease from the FEV1/FVC ratio suggesting relative preservation of lung and airway size.
• Although the GLI-Black equation fitted the Malawian children reasonably well, interpretation of LF 
in developing countries with secular changes in somatic growth will be enhanced by recruiting 
local controls.
Methods: 
• Identical anthropometry and spirometry were 
undertaken in healthy children participating in:
1) The ‘Chronic Disease Outcomes following 
Severe Acute Malnutrition’ (ChroSAM) study 
(Blantyre, Malawi)
2) The ‘Size and Lung Function in Children’ 
(SLIC) study (London, UK)
• Training and quality control conducted by the 
same physiologist.
• Malawian and UK-Black African (UK BA) 
spirometry data were expressed as z-scores 
using the GLI-Black equation.
• Anthropometry z-scores were calculated with 
the WHO2007 equations.
UK:Black
African
Malawi Mean Diff (UK-
Malawi) (95% CI)
n (% male) 460 (39%) 193 (49%)
Age (years) 8.7 (1.6) 9.1 (1.5) -0.5 (-0.7;-2.0)
Height z-score 1.2 (1.1) -1.2 (1.0) 2.4 (2.2; 2.6)
Weight z-score 1.0 (1.0) -1.2 (1.3) 2.2 (2.0; 2.4)
BMI z-score 1.0 (1.2) -0.7 (0.9) 1.7 (1.5; 1.9)
Sit/stand ht (%) 51.8 (1.6) 52.0 (1.6) -0.2 (-0.5;0.1)
FEV1 z-score -0.01 (0.9) -0.34 (1.0) 0.3 (0.2; 0.5)
FVC z-score 0.24 (1.0) -0.23 (1.0) 0.5 (0.3; 0.6)
FEV1/FVC z-score -0.32 (1.0) -0.15 (1.0) -0.3 (-0.4;-0.2)
Table 1: Comparison of UK Black African and Malawian 
control children
Funding support: Wellcome Trust
• The proportion of acceptable results 
was similar in both groups (71-76%).
• In comparison to UK BA children, 
Malawian children were:
 Significantly lighter, shorter and 
lower BMI
 FEV1 and FVC were significantly 
lower in the Malawian controls 
• The spirometric deficits were not as 
extreme as those observed for height 
and weight.
• There was no significant difference in 
sit/stand height ratio (Table 1).  
Results:
Figure 1: Spirometry results in UK Black African and Malawian control children
j.kirkby@ucl.ac.uk
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Appendix 23: Histograms of Lung function outcomes 
 
Anthropometry outcomes: 
 
Histograms of sitting height, chest circumference, chest depth and chest width; these outcomes are 
analysed in Chapter 7: Lung Function  
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Spirometry Outcomes: 
 
Histograms of spirometry outcomes FEV1, FVC FEV1/FVC and FEF25-75 z scores; these outcomes are 
analysed in Chapter 7: Lung Function  
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Appendix 24: Table of results comparing lung function outcomes for HIV negative children 
only 
  HIV- 
Cases 
(n=146) 
HIV- Sibling 
 (n=136) 
HIV- Community 
 (n=114) 
 Mean 
(SD) 
Mean 
(SD) 
Unadjusted 
difference 
(95% CI) 
Adjusted 
difference 
(95% CI) 
Mean 
(SD) 
Unadjusted 
difference 
(95% CI) 
Adjusted 
difference 
(95% CI) 
FEV1 (litres) 1.26 (0.3) 1.55 
(0.5) 
0.29 * (0.2, 
0.4) 
0.05 (-0.0, 
0.1) 
1.34 
(0.3) 
0.08 (-0.0, 
0.2) 
0.03 (-0.0, 
0.1) 
FVC (litres) 1.45 (0.3) 1.78 
(0.6) 
0.32 * (0.2, 
0.4) 
0.03 (-0.0, 
0.10 
1.55 
(0.4) 
0.10 (-0.0, 
0.2) 
0.05 (-0.0, 
0.1) 
FEV1:FVC 0.88 (0.1) 0.89 
(0.1) 
0.01 (-0.0, 
0.0) 
0.02 * (0.0, 
0.0) 
0.87 
(0.1) 
-0.01 (-0.0, 
0.0) 
-0.01 (-0.0, 
0.0) 
FEV1 Z score -0.32 
(1.0) 
-0.51 
(1.0) 
-0.18 (-0.4, 
0.1) 
-0.19 (-0.4, 
0.1) 
-0.31 
(1.1) 
0.01 (-0.2, 
0.3) 
-0.02 (-0.3, 
0.2) 
FVC Z score -0.19 
(0.9) 
-0.41 
(1.0) 
-0.22 (-0.5, 
0.0) 
-0.26 * (-0.5, 
-0.0) 
-0.13 
(1.0) 
0.06 (-0.2, 
0.3) 
0.03 (-0.2, 
0.3) 
FEV1:FVC Z 
score 
-0.16 
(1.0) 
-0.14 
(0.9) 
0.02 (-0.2, 
0.3) 
0.10 (-0.1, 
0.3) 
-0.34 
(1.0) 
-0.18 (-0.4, 
0.1) 
-0.18 (-0.4, 
0.1) 
Appendix 24: Adjusted for SES, sitting height and puberty, raw litres also adjusted for age and sex  
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Appendix 25: Table of results comparing lung function outcomes stratified by sex 
Cases 
Girls n=92 
Boys n=108 
Siblings 
Girls n=74 
Boys n=67 
Community 
Girls n=56 
Boys n=65 
 Mean (SD) Mean (SD) Unadjusted 
difference 
(95% CI) 
Adjusted 
difference 
(95% CI) 
Mean (SD) Unadjusted 
difference 
(95% CI) 
Adjusted 
difference 
(95% CI) 
FEV1 (litres)       
Girls 1.22 (0.3) 1.52 (0.5) 0.30 *  
(0.2, 0.4) 
0.07 * 
(0.0, 0.1) 
1.34 (0.4) 0.12  
(-0.0, 0.2) 
0.09 * 
(0.0, 0.2) 
Boys  1.29 (0.3) 1.58 (0.7) 0.30 * 
(0.2, 0.4) 
0.06 
(-0.0, 0.1) 
1.33 (0.3) 0.04 
(-0.1, 0.2) 
0.01 
(-0.1, 0.1) 
FVC (litres)        
Girls 1.41 (0.3) 1.74 (0.5) 0.33 * 
(0.2, 0.5) 
0.06  
(-0.0, 0.1) 
1.53 (0.4) 0.12 
(-0.0, 0.3) 
0.09 *  
(0.0, 0.2) 
Boys  1.48 (0.3) 1.82 (0.6) 0.33 *  
(0.2, 0.5) 
0.04 
(-0.1, 0.1) 
1.56 (0.4) 0.07  
(-0.1, 0.2) 
0.04 
(-0.1, 0.1) 
FEV1:FVC        
Girls 0.88 (0.1) 0.89 (0.1) 0.00 
(-0.0, 0.0) 
0.01 
(-0.0, 0.0) 
0.88 (0.1) -0.00 
(-0.0, 0.0) 
0.00 
(-0.0, 0.0) 
Boys  0.87 (0.1) 0.89 (0.1) 0.01 
(-0.0, 0.0) 
0.03 * 
(0.0, 0.1) 
0.86 (0.1) -0.01 
(-0.0, 0.0) 
-0.01 
(-0.0, 0.0) 
FEV1 Z score       
Girls -0.64 (1.1) -0.66 (0.8) -0.02 
(-0.3, 0.3) 
-0.14 
(-0.5, 0.2) 
-0.40 (1.1) 0.24 
(-0.1, 0.6) 
0.17  
(-0.2, 0.6) 
Boys  -0.32 (1.1) -0.30 (1.1) 0.03 
(-0.3, 0.4) 
-0.08 
(-0.5, 0.3) 
-0.29 (1.2) 0.04 
(-0.3, 0.4) 
-0.15 
(-0.5, 0.2) 
FVC Z score       
Girls -0.46 (1.0) -0.50 (0.9) -0.03 
(-0.3, 0.3) 
-0.21 
(-0.6, 0.1) 
-0.27 (1.0) 0.19 
(-0.1, 0.5) 
0.10 
(-0.3, 0.5) 
Boys  -0.20 (1.0) -0.25 (1.2) -0.06 
(-0.4, 0.3) 
-0.22 
(-0.6, 0.2) 
-0.05 (1.1) 0.14 
(-0.2, 0.5) 
-0.04 
(-0.4, 0.3) 
FEV1:FVC Z score       
Girls -0.23 (0.9) -0.25 (0.9) -0.02 
(-0.3, 0.3) 
0.04 
(-0.3, 0.4) 
-0.30 (0.9) -0.07 
(-0.4, 0.2) 
-0.04 
(-0.4, 0.3) 
Boys  -0.20 (0.9) -0.03 (0.9) 0.17 
(-0.1, 0.5) 
0.26 
(-0.1, 0.6) 
-0.44 (1.1) -0.24 
(-0.5, 0.1) 
-0.25 
(-0.6, 0.1) 
Appendix 25: Adjusted for SES, HIV status, sitting height and puberty, raw litres also adjusted for age 
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Appendix 26: Glossary of Terms 
Ẅ BIA: Bioelectrical Impedance Analysis (BIA) is a technique used for measuring body 
composition. It uses the principle that electric current flows at different rates through the body 
depending upon its composition of fat and water. It therefore uses measures of Resistance and 
Reactance (together known as Impedance) along with height to estimate total body water, fat 
mass and lean mass.   
Ẅ BIVA: BIA Vector Analysis (BIVA) is a method used for analysing BIA data without the 
need for population-specific conversions equations. BIVA allows for comparison of lean 
mass and hydration levels using BIA data. Comparing impedance values directly does not 
allow for differentiation between high lean mass and high hydration. However BIVA plots the 
two components of impedance (resistance (R) and reactance (Xc)) as a vector on a graph 
allowing for differentiation between hydration and lean mass. The arc tangent of the vector 
graph equates to the phase angle. Long vectors with a small phase angle (increased R with 
decreased Xc) are associated with malnutrition, whereas short vectors with a small phase 
angle (decreased R with decreased Xc) are associated with fluid overload.  
Ẅ BMI: Body Mass Index (BMI) is a simple index of weight-for-height that is commonly used 
to classify underweight, overweight and obesity in older children and adults. It is defined as 
the weight in kilograms divided by the square of the height in metres (kg/m2). The WHO 
defines BMI<18.5 as underweight and BMI ≥ 25 as overweight.  
Ẅ CMAM: Community-Based Management of Acute Malnutrition (CMAM) is a methodology 
for active-case finding and treatment of acute malnutrition in the community. The 
introduction of Ready-to-Use-Therapeutic Foods (RUTF) enabled the development of 
CMAM as RUTF can easily be administered at home by care-givers. The majority of acute 
malnutrition cases found can be treated as outpatient cases using RUTF; only those cases with 
presence of nutritional oedema, loss of appetite or other concurrent illnesses need to be 
admitted for inpatient treatment. The CMAM model was developed by Valid International 
and has been endorsed by WHO and UNICEF.  
Ẅ COPD: Chronic Obstructive Pulmonary Disease is a group of lung diseases characterized by 
chronic inflammatory obstruction of lung airflow that interferes with normal breathing and is 
not fully reversible. The more familiar terms 'chronic bronchitis' and 'emphysema' are no 
longer used, but are now included within the COPD diagnosis.  
Ẅ DOHaD: The developmental origins of health and disease theory (DOHaD) is a multi-
disciplinary field of research that examines how environmental factors during the phase of 
developmental plasticity (i.e. prenatal or early postnatal life) interact with genotypic variation 
to change the capacity of the organism to cope with is environment in later life, often 
resulting in adult diseases.  
Ẅ FEV1: Forced expiratory volume in one second is the volume of air exhaled during the first 
second of a forced expiratory manoeuvre. 
Ẅ FEV1/FVC: Forced expiratory volume in one second (FEV1) expressed as a proportion of the 
forced vital capacity (FVC) is the fraction of the total that is exhaled in the first second. It is 
the index of the speed of expiratory airflow. It is calculated by using the largest FEV1 and the 
largest FVC, even if they are not from the same curve. A low FEV1/FVC is associated with 
airways obstruction 
Ẅ FVC: Forced Vital Capacity is the maximal volume of air which can be exhaled forcefully 
after maximal inspiration. NOTE: The vital capacity is the amount of air that can be exhaled 
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by an individual after taking the deepest breath possible, whether or not the air is exhaled 
forcefully (FVC) or slowly (VC).  
Ẅ Impedance: Impedance (Z) is the degree to which a medium slows or stops an electrical 
current. When referred to as an outcome from BIA, high impedance indicates low water 
tissues such as adipose. Muscle has about 75% water, so it has low impedance. It is measured 
in Ohms.  
Ẅ Kwashiorkor:  Kwashiorkor is a form of severe acute malnutrition (SAM) characterised by 
too much fluid in body tissues which causes swelling under the skin (called oedema). It 
usually begins in the legs, but can involve the whole body, including the face. An enlarged 
abdomen, irritability, yellow hair, drowsiness and patches of inflamed or peeling skin may 
also be present. If the condition is left untreated, it can be fatal. The word derives from the 
Ghanaian language meaning “weaning sickness” as it often presents in children around the 
age of weaning. The exact physiological causes behind kwashiorkor are still unknown. 
Children with kwashiorkor are considered to have “complicated SAM” and must therefore be 
treated as inpatients in health facilities.  
Ẅ Lean mass index (LMI): Lean mass, usually calculated from BIA readings, can be converted 
to LMI by diving it by the square of height (lean mass (kg) / height (m)2). Lean mass 
calculated from BIA is not adjusted for body size, hence LMI provide a discrete measure of 
relative lean mass, expressed in the same kg/m2 units as BMI. When an appropriate 
conversion equation is not available to convert BIA readings into lean mass (kg), a useful 
“LMI equivalent” can be calculated simply by dividing 1/Resistance (R).  
Ẅ Low Birth Weight (LBW): LBW is most commonly defined as an infant weighing less than 
2500g at birth; this can include infants born early. A more specific term now commonly used 
is “small for gestational age” which takes preterm births into account.  
Ẅ MAM: Moderate Acute Malnutrition (MAM) is characterised by moderate wasting defined 
by a weight-for-height indicator between -3 and -2 z-scores of the WHO international growth 
standard, or by a mid-upper arm circumference (MUAC) between 11.5cm and 12.5cm. If 
MAM is not treated, it can develop further and become “severe acute malnutrition” (SAM). 
MAM can be treated with RUTF in the community. 
Ẅ Marasmus: Marasmus is one form of severe acute malnutrition characterised by muscle mass 
loss. The term marasmus is derived from the Greek word marasmos, which means withering 
or wasting.   
Ẅ Non-Communicable Diseases (NCDs): these are a group of medical conditions or diseases 
that are non-infectious or non-transmissible. NCDs often refer to chronic diseases which last 
for long periods of time and progress slowly. The 4 main types of NCDs are cardiovascular 
diseases (like heart attacks and stroke), cancers, chronic respiratory diseases (such as chronic 
obstructed pulmonary disease and asthma) and diabetes. Some people might be surprised to 
learn that NCDs now disproportionately affect low- and middle-income countries where 
nearly three quarters of NCD deaths – 28 million – occur.  
Ẅ Phase angle: this is a derived measure obtained from the relation between the direct measures 
of resistance and reactance. It is useful because it does not depend on any conversion 
equations. It is thought to reflect cell wall health however its exact biological meaning and 
pathogenic effects are not completely understood.  
Ẅ Physical activity:  this is a measure of how physically active someone is during their 
everyday life; it is technically defined as a body movement that requires energy expenditure 
however the measure of interest is usually how much it varies in amount, length and/or 
intensity.     
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Ẅ Physical capacity: an individual’s physical capacity, also known as exercise capacity, is 
measured by their ability to endure exercise and/or the maximum workload achieved during 
the exercise period. Physical capacity provides information on the functioning of several body 
systems, including circulation, cardiovascular, pulmonary, muscle action and neural function; 
small deficits in one or some of these areas may only be observed during strenuous effort such 
as exercise 
Ẅ Reactance: (Xc) this is a component of impedance. It is a measure of the amount of current 
which a medium can SLOW. For example, cell membranes can store the current for a short 
period of time, and this slows it down – if it can store, it is called a Capacitor. At low 
frequencies (50khz), cell membranes are Resistors (current can’t pass through) hence 
reactance only makes up 5% of impedance  
Ẅ Resistance: (R) this is a component of impedance. It is a measure of the amount of current 
which a medium can STOP. Water has very low resistance hence the less water in the body, 
the more resistance. Resistance makes up around 95% of impedance 
Ẅ RUTF: Ready-to-Use-Therapeutic Food is a treatment prescribed for malnutrition sufferers. 
It requires no preparation, no cooking and no addition of water so it is ready-to-use and is 
fortified with vitamins and minerals; it is usually made of a peanut paste mixed with dry milk 
products, high in calories to encourage weight gain. It’s invention transformed malnutrition 
treatment as mother’s can give RUTF to their children at home without the need for 
admission to health centres if they have no complications. 
Ẅ SAM: Severe acute malnutrition is defined by a very low weight for height (below -3z scores 
of the median WHO growth standards); by low MUAC (<11.5cm); by visible severe wasting, 
or by the presence of nutritional oedema. SAM is the most dangerous form of malnutrition; if 
left untreated, it can result in death. Until 2006, the recommendation was to refer these 
children to hospital to receive therapeutic diets along with medical care. Treatment 
recommendations have now changed following the advent of “ready to use therapeutic foods” 
(RUTF) which allows the management of SAM in the community for those children above 
the age of 6 months and without medical complications. 
Ẅ Skinfold thickness ratio: skinfold thickness is a measure of subcutaneous fat levels; the ratio 
is intended to assess relative levels of core to peripheral subcutaneous fat levels. Core 
skinfold measures include subscapular and suprailiac sites whereas peripheral sites are biceps 
and triceps. Skinfold thickness ratio is most commonly calculated by adding the subscapular 
to suprailiac reading and diving this by the tricep reading  
Ẅ Spirometry: (meaning “the measuring of breath”) is the most common of the pulmonary 
function tests, measuring lung function. Specifically it measures the amount (volume) and/or 
speed (flow) of air that can be inhaled and exhaled. It can be used to diagnose asthma, COPD 
and other conditions that affect breathing.  
Ẅ The LMS method: The LMS method provides a way of obtaining normalized growth centile 
standards by summarising the changing distribution of a measure (e.g. skinfold thickness) 
according to a covariate (e.g. age). It assumes that the data can be normalized by using a 
power transformation, which stretches one tail of the distribution and shrinks the other, 
removing the skewness. Using a range of “normal” measurements across within an age 
bracket, the method calculates the optimal power to obtain normality and the trend is 
summarized by a smooth (L) curve. Trends in the mean (M) and coefficient of variation (S) 
are also smoothed. The resulting L, M and S curves contain the information to draw a centile 
curve which is used to generate a reference table with approximate standard errors for the 
smoothed centiles for each age category. This then allows for comparison of one child’s 
measurements to the group “norm” for that age category,  
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Ẅ Wasting: wasting is a form of severe acute malnutrition; it can also be referred to as 
Marasmus. Wasting is characterised by a loss of muscle mass, usually assessed by 
anthropometry; weight-for-height and mid-upper arm circumference (MUAC) are the 
measures recommended by the WHO.  
 
 
